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Abstract 
Introduction 
This is a study of the negotiation of benefits in HIV biomedical prevention trials. It 
took place at a very dynamic period in HIV prevention research, 2009-2012, during 
which there were positive efficacy results from six large, randomised controlled trials 
of HIV prevention interventions.  
 
This study presents evidence on how benefits to participants are negotiated in efficacy 
trials of biomedical HIV prevention technologies. It re-considers debates about 
obligations to trial participants in the light of the positive trial results and asks how 
partially effective HIV prevention modalities impact on these debates. 
Methods 
Empirical 
The empirical components of the study comprise: 
• a survey of principal investigators who conducted HIV prevention trials  
• 14 in-depth interviews with principal investigators; and  
• additional data collection from document analysis and  personal 
communications. 
Descriptive statistics were calculated for survey responses, and interview data were 
analysed thematically from a symbolic interactionist perspective.  
Normative 
The normative component focuses on four big-picture issues:  
 Whether there is ethical justification for antiretroviral (ARV)-based prevention 
in HIV endemic areas; 
 How the positive HIV prevention trial results – which demonstrate partial 
efficacy – affect (or should affect) future HIV prevention research; 
 The implications of incorporating newly validated technologies into the 
standard of prevention; and 
 Whether PrEP should become the comparator arm in HIV prevention trials 
from now on. 
Results 
Procedural norms have developed regarding some aspects of standard of prevention. 
There are differences however regarding whether standards of prevention should be 
basic or optimal, and whether or when new interventions should be added.  
Access to ARV for seroconverters, usually through partnerships, has also become a 
norm, and some principal investigators also reported a strong obligation towards those 
‘screened out’ of trials – volunteers with pre-existing HIV infection. The importance 
of various forms of ancillary care provision was recognised and negotiation of this 
care helped establish the research project as part of a healthcare continuum.  
Post-trial access provisions were in place for all the interventions that had successful 
efficacy results. There were significant differences in both the duration and the 
timeliness of actual post-trial provision, however. 
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Conclusion 
 
Partially effective interventions pose problems for enduring post-trial access as by 
definition, they raise questions about ‘how good is good enough’ for implementation 
within particular epidemic settings. A similar dilemma is faced with regard to 
standard of prevention. The key question facing HIV prevention research is how to 
test new experimental interventions in the context of partially effective interventions. 
Ongoing research into new intervention is crucial, but reducing HIV incidence in trial 
populations is a legitimate goal. Hence, it is time to include a proven biologically 
effective intervention as an active comparator in HIV prevention trials. The goals of 
HIV prevention research must be to find the most effective ways of using existing 
tools and to establish the effectiveness of new tools. An active comparator balances 
the need to protect participants with the need to develop new interventions. 
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Preface 
The idea for this thesis was born in the Hotel Ashok, New Delhi, India at the 
Microbicides conference in February 2008. In a cross-track session entitled, 
When clinical trials end: Challenges, experiences and lessons learned, principal 
investigator Lut van Damme spoke about the end of the cellulose sulphate 
microbicide trial. She began with an account of receiving the phone call from 
the chair of the Data Safety Monitoring Board and learning that – once again – 
the experimental product was associated with harm, and the trial would have to 
close prematurely. ‘Once again’, because Lut was also the principal investigator 
of an earlier microbicide efficacy trial that tested the product nonxynol-9, which 
had been found to enhance HIV acquisition in the trial population some seven 
years earlier. 
Lut spoke frankly about the emotional impact of that phone call, the sense of 
déjà vu, her deep concern for the participants, and incredulity that such a thing 
could happen again despite the raft of safety studies the product had been gone 
through prior to large-scale efficacy testing. Then she recounted how the 
standard of care in this second trial – in particular the access to antiretrovirals 
for seroconverters – had been designed to ensure that the women had access to 
optimised prevention, and that anyone who acquired HIV on the trial would 
have access to life-saving therapy. This was delivered not in the spirit of self-
justification, but as a kind of forensic examination of whether the trial had 
succeeded in minimising harms in the event of a worst-case scenario. 
I don’t recall whether Lut herself contrasted the care in the cellulose sulphate 
trial to the lack of access that women who acquired HIV had in the earlier 
nonoynol-9 study, or whether I made that connection in my head. What 
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impressed me was her sense of moral conviction – that research into a new HIV 
prevention options for women remained an imperative, and the risk this entailed 
for vulnerable participants had to be mitigated.  
The importance of optimal standards of care was the message I took away, 
together with a desire to understand more about the ways that principal 
investigators approached standard of care issues, and how their personal 
experiences and convictions shaped this.  
This thesis is a study of ethical issues in the standards of care in HIV biomedical 
prevention research, with a specific focus on the benefits for participants – the 
standard of prevention, ancillary care and post-trial access. The key informants 
are principal investigators, who are key decision makers in the research 
hierarchy, but who nevertheless operate within a highly controlling system of 
regulation, competition and funding constraints. 
The community of principal investigators of HIV prevention trials is a small 
one, and its members evince an overwhelming commitment to the goal of 
developing effective, user-friendly HIV prevention modalities. 
Initially I intended to triangulate the principal investigator perspectives, gleaned 
through interviews, surveys and personal communications, with a parallel set of 
data collected from members of ethics committees who reviewed HIV 
prevention trials. Unfortunately the response rate from ethics committee 
members was so low that this was unfeasible within my time constraints. 
When I began this thesis in mid-2009, male circumcision was the only ‘new’ 
technology for prevention of sexual HIV transmission, and a series of seemingly 
promising interventions had produced negative results. Shortly afterwards 
however there were positive results from a vaccine trial, a microbicide trial, pre-
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exposure prophylaxis trials and a treatment-as prevention trial. As a 
consequence of this dynamic environment, important normative issues about the 
future direction of HIV prevention research were thrown into the spotlight. 
Being immersed in these issues and deeply concerned about the outcomes of the 
ensuing debates, I responded in the series of normative papers that accompany 
the empirical chapters. As a result of publishing in the area that I was 
conducting empirical research, my relationship with some participants was 
altered, in that I was not viewed as a neutral interviewer but as someone 
associated with specific arguments about standards of care. While this affected 
the tenor of some interviews, I think its impact was in some ways positive. 
Those who disagreed with some of the arguments made had the opportunity to 
make their views more forcefully, and certainly one informant did so. 
In terms of research contribution, I designed the surveys and the semi-structured 
interview format, obtained ethics approval from the University of Sydney, 
conducted the interviews and analysed both interview and survey data. I was the 
principal author of all the published papers in this thesis, and I gratefully 
acknowledge the intellectual input of my primary supervisor Chris Jordens, who 
co-authored two of the published papers and a third that is under review. My 
involvement with the debates around standards of prevention also facilitated 
productive collegiate relationships with John Kaldor, who co-authored two 
published articles with me, and Morenike Folayan, Catherine Hankins, Jeremy 
Sugarman, Sheena McCormack, Gita Ramjee and Mitchell Warren, with whom 
I co-authored another. 
Like the principal investigators interviewed, I too share the conviction that HIV 
prevention research is a moral enterprise and there is an imperative to expand 
the range of prevention options so that people at disproportionate risk of HIV 
acquisition can protect themselves, and people living with HIV can protect their 
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sexual partners. Condoms, while necessary, are insufficient to provide protection 
for the myriad of ways that people connect sexually, and find themselves at risk 
of HIV acquisition. The field has reached a turning point – partially effective 
prevention interventions have been established and licensed in some places, and 
not in others. What happens next is that the field has to decide how these 
developments affect future research. This thesis, I hope, can play a part in those 
deliberations. 
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Part 1, Chapter 1 
 
 
Introduction 
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Organisation of the Thesis 
 
In recent years, HIV biomedical prevention has become a fast-moving field with 
a series of successive and at times unexpected trial results. These results have 
had a profound impact on thinking about the goals for future research and how 
that research should be conducted. In order to respond in a timely fashion to the 
debates engendered by new data, this is a thesis-by-publication. It comprises a 
series of published papers, papers accepted for publication and papers submitted 
for publication, which are linked into a unified whole. 
These papers have been published throughout my candidature, and hence reflect 
the state of knowledge at the time of publication. This is noted at the beginning 
of chapters as appropriate. 
The thesis broadly follows the traditional research reporting style, including a 
Background, Overview of Methods, Results and Summary and Conclusions. 
There is no separate Discussion section, as each of the papers has a lengthy 
discussion section of its own. Conclusions are drawn from these in the final 
section of the thesis. 
 
In addition to material intended for publication, there are two short chapters that 
report findings of surveys undertaken with principal investigators who 
conducted HIV prevention trials and members of ethical review committees who 
reviewed these trials. This preliminary research provided background to focus 
the in-depth qualitative interviews. 
Each chapter can be read as complete in its own right, and has references at the 
end. Published material will use the referencing style of the journal for which it 
was accepted. A complete alphabetical list of all references cited in the thesis is 
provided at the end of the thesis. 
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Part 1: Introduction and background 
 
Part I has two chapters. The first introduces the issues and debates surrounding 
standards of prevention and care in HIV prevention research and describes the 
rapidly evolving evidentiary context in which this research took place. This is 
followed by an overview of the methods used in the thesis, which are also 
detailed in each of the empirical papers. It then includes the chapter Because we 
can: Clashes of perspective over obligation in the failed PrEP trials, which 
provides an historical account of the standard of care issue in HIV prevention 
research in the late1990s and how the unresolved issues re-emerged in the early 
to mid 2000s, when a series of HIV prevention trial sites were closed due to 
community concerns over the adequacy of the benefits they were providing to 
participants. 
Part II: Empirical results 
 
Part II is the empirical results section, which has five chapters. It begins with 
two short chapters that report the results of the preliminary questionnaire-based 
research that was undertaken with principal investigators of HIV prevention 
research and members of ethical review committees that reviewed it. The next 
three chapters are papers that draw on the empirical data from the in-depth 
interviews. Firstly there is Ethics of medical care and clinical research 
published online in the Journal of Medical Ethics Nov 22, 2012. This paper is 
based on informants’ discussions of their perception of their role and 
responsibilities, and in particular discusses the issue of whether or not trial 
investigators have a ‘doctor-like’ duty of care to research participants. Secondly 
there is Standard of prevention in the real world: a qualitative study of principal 
investigators in HIV biomedical prevention trials, accepted for publication by 
AJOB Primary Research on February 26, 2013. This discusses how principal 
investigators determine appropriate standards of prevention when conducting 
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HIV prevention trials, and how the narrow aims and obligations of a research 
study sit within the broader context of disease burden and inequitable access to 
health care in the resource-poor world. Finally there is Mind the gap: An 
empirical study of post-trial access in HIV biomedical prevention trials, which 
has been submitted to Developing World Bioethics (under peer review). This 
paper provides a comprehensive empirical account of post-trial access to 
products shown to be successful in recent HIV prevention trials, together with 
provisions for antiretroviral access for trial participants who acquire HIV 
infection. In particular it considers the role of the researcher as an advocate for 
access in instances where government and regulatory authorities are slow to 
recognise the obligation. 
Part III: Normative issues 
 
Part III is the normative results section, and has four chapters. It begins with 
Ethics of ARV-based prevention: PrEP and treatment-as-prevention, accepted 
for publication in Developing World Bioethics on January 10, 2013. This paper 
explores the moral basis of two different forms of ARV-based prevention – pre-
exposure prophylaxis and treatment-as-prevention – in the context of limited 
global resources that result in people who need ARV for their own health 
lacking access.  This is followed by How good is ‘good enough’: when should 
new HIV technologies should become standard of care? published in The 
American Journal of Bioethics,2012 12(6):21-30. This chapter questions the 
evidentiary standards set by regulators in resource-rich countries that delay 
access to modestly effective products that could have major public health 
impact, particularly for women generalised epidemics with limited power to 
negotiate condom use. The third chapter is Ethical considerations in 
determining standard of prevention packages for HIV prevention trials: 
Examining PrEP, accepted for publication in Developing World Bioethics on 
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January 10, 2013. This chapter looks at the ethical, scientific and logistical 
negotiations that would be required in order to include PrEP as the new standard 
of prevention. The fourth and final chapter, taking into account the issues 
discussed in previous chapters, makes an argument that PrEp should be not the 
new universal standard of prevention, but the comparator against which new 
experimental interventions are measured. This chapter, It’s time: The case for 
PrEP as an active comparator in HIV biomedical prevention trials, has been 
submitted to The American Journal of Bioethics but is still under review. 
Part IV Summary and conclusions 
 
Part IV is the summary and conclusions, which draws together the main issues 
in the thesis – the normative ethical conflict over ethical standards and the 
evidentiary debate over when and how new interventions are established as 
‘good enough’ to constitute new standards of prevention and/or care. These are 
considered in the light of the different ways that informants perceive their roles 
with regard to different aspect of the ‘standards of care’ – from prevention 
packages for participants to post-trial access.  
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Introduction 
Background 
In 2011, an estimated 2.5 million people acquired HIV, bringing the global 
estimate of people living with HIV to 34 million.  Eight million of these are on 
antiretroviral therapy, but another seven million require immediate treatment to 
which they do not have access. Of the 19 million remaining, they too will 
require treatment within the next six to ten years. While the global incidence of 
HIV is declining, the number of people living with HIV, and needing treatment, 
will continue to rise (UNAIDS 2012).  
HIV prevention is a global priority, with the elimination of HIV transmission as 
the aspirational target – ‘Getting to zero’ – set by UNAIDS. Preventing new 
infections is critical to sustaining current treatment levels and working towards 
universal access. 
 
Why prevention research is important 
HIV prevention research remains imperative because, while the last five years 
have delivered some new, partially effective prevention interventions, there is no 
vaccine. Non-vaccine prevention interventions have benefits but also 
disadvantages, including problems with cost, acceptability, high adherence 
requirements (daily use or use at every coital act), levels of efficacy, and/or lack 
of ability to be controlled by the receptive sex partner. Until there is a highly 
effective, cheap and accessible intervention that does not require ongoing 
adherence and is suitable for both receptive and insertive sex partners, HIV 
prevention research will remain a high global priority. 
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The established ethical debates/issues concerning prevention research 
There is a set of well established ethical issues in HIV prevention research. The 
overarching one is the ‘standard of care’ in clinical trials. The key point of 
contention is whether the standard of care for participants in a clinical trial 
should be the best proven prevention/treatment intervention for the illness that 
the trial addresses, or whether the standard may vary according to the setting in 
which the trial takes place. On closer examination, however, the ‘standard of 
care’ issue in HIV prevention trials actually covers a set of related issues 
including the following:  
o Standard of prevention – the prevention package provided to all participants 
in an HIV prevention trial; 
o Choice of comparator arm – whether an experimental intervention is 
measured against a placebo or an active comparator; 
o Ancillary care – care that is provided to trial participants beyond that which 
is required for the effective conduct of the trial; and 
o Access to antiretrovirals – whether or not participants who acquire HIV 
while on an HIV prevention trial are provided with access to ARV. 
 
In addition to the issues that fall under ‘standard of care’, four other issues have 
become foci of ethical discourse: 
o Community involvement/consultation – whether affected local communities 
are given the opportunity to have meaningful input into the design and 
implementation of research;  
o Whether drug/intervention addresses a health priority in the country or 
countries in which the trial occurs; 
o Contribution to health infrastructure – whether or how the trial contributes to 
local health infrastructure; 
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o Post-trial access – whether or not trial participants are assured access to 
products shown to be effective through the research. 
Standard of care obligations in research are complex and multi-factorial as they 
straddle the health gap between the optimal access to healthcare that can be 
provided in a research study and real-life healthcare access and infrastructure 
constraints faced by the communities in which the research takes place. Accordingly 
standard of care is a major focus of international ethical guidance on research ethics. 
 
Guidelines 
Overview of current international guidance structures 
There is no lack of authoritative normative guidance for international research 
ethics. The problem is that there are multiple sets of ethical guidance that 
propose different normative standards. The following is an overview of 
influential guidelines that pertain to HIV prevention research, with brief 
accounts of their history and key features. 
 
Declaration of Helsinki 
The initial iteration of the Declaration of Helsinki was drafted in 1964. It is a 
general guide to research ethics by the World Medical Association (WMA). The 
WMA formed after the Nuremberg Doctors’ Trials specifically to articulate and 
protect the ethics of the medical profession. Codifying research ethics in the 
Declaration of Helsinki was an important aspect of that charter. The Declaration 
drew on the 10 points articulated in the Nuremberg Code and tied them in with 
physicians’ obligations under the Declaration of Geneva (1948). It has since 
been revised six times, most recently in 2008. The 1996 revision articulated that 
the ‘best proven’ intervention should be used as a control, and that a placebo 
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control should not be used when a proven effective intervention existed. This 
clause attracted a great deal of attention in the 1997 when controversy erupted 
concerning research practices in HIV biomedical mother-to-child prevention 
research. A subsequent revision in 2000 removed the ‘best proven’ clause 
regarding placebo. The term ‘best proven’ was replaced with ‘current’, and a 
clause was added stipulating that trial participants should have post-trial access 
to the successful products of research to which they contributed. In 2002 a 
footnote was added specifying appropriate use of placebos that excluded HIV 
prevention trials (‘serious or irreversible harm’), and in 2008 a new revision 
strengthened protections for vulnerable participants with regard to access to  
products proven beneficial in research and limitations on use of placebos. 
The Common Rule (US Federal regulations) 
The Common Rule refers to the set of federal regulations that govern federally 
funded clinical research in USA.  Despite the Declaration of Helsinki, there 
were a swathe of public scandals in the 1960s over research studies that violated 
the principles of informed consent and minimisation of harm to research 
subjects. These were documented in a famous article by Henry Beecher (1966). 
Several years after Beecher’s article, the now-notorious Tuskegee study (1937 to 
1972) came to public attention. This trial withheld effective treatment from its 
study population of African American men in order to observe the natural 
history of syphilis.  The Tuskegee exposé was the catalyst for sweeping reform 
in the United States, and it led to the National Research Act of 1974 and, 
subsequently, federal regulations regarding human experimentation in 1981.  
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CIOMS 
The Council for International Organizations of Medical Sciences (CIOMS) is a 
non-profit non-government organisation set up in 1949 by the World Health 
Organization and UNESCO (the United Nations’ Educational, Scientific and 
Cultural Organisation). CIOMS developed the International Ethical Guidelines 
for Biomedical Research Involving Human Subjects in 1993, and revised them in 
2002. These guidelines were intended to assist developing countries to define 
national policies on the ethics of biomedical research involving humans, to 
apply ethical standards in local circumstances, and to establish or improve 
ethical review mechanisms. The 2002 revision was catalysed by bitter 
disagreements within biomedicine and biomedical ethics about whether it is 
acceptable to use placebos in research when proven effective therapy exists. 
 
UNAIDS/WHO  
The UNAIDS/WHO guidelines specifically address the issues relating to HIV 
prevention trials, unlike more the general guidance offered by the Declaration of 
Helsinki (human subject research generally), or CIOMS (international human 
subject research). The UNAIDS/WHO initially published a guidance document 
on ethical considerations in HIV preventative vaccine research in 2000, based on 
consultations with a wide range of stakeholders. The document stipulates 
minimum ethical standards such as informed consent, use of placebos and access 
to ARV for seroconverters in vaccine trials. In 2007, a new guidance document, 
Ethical Considerations in Biomedical HIV Prevention Trials, was produced in 
concordance with a new policy that foregrounded universal access to ARV for 
people with HIV. The 2007 guidance document sets higher standards for 
research than the preceding document: it specifies that people who seroconvert 
during a trial must have access to ARV regimens ‘from among those 
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internationally recognised as optimal’, that the standard of prevention for all 
participants should be ‘state of the art’, and that post-trial access to effective 
products should be provided for trial participants and other high risk 
communities. In 2012, an extra guidance point was added.  
 
HIV Prevention Trials Network (HPTN) 
The HPTN guidelines are specific to HIV prevention research, like those of the 
UNAIDS/WHO but, unlike the latter, they are produced specifically by a US-
based research network which is a subsidiary of the National Institutes of Health 
(NIH). Authors Stuart Rennie and Jeremy Sugarman define the HPTN 
guidelines as being more deliberately pragmatic that those of the 
UNAIDS/WHO. The guidelines divide ethical goals into ‘obligatory’ and 
‘aspirational’ categories. They also define ‘inequity’ as differences in access to 
healthcare between research participants and people in the local population in 
which the trial is situated, rather than differences in access to healthcare between 
populations on a global scale (e.g. between the developing world and the 
wealthier nations—which is the comparison used by those who advocate a 
universalist, global perspective). They claim that providing an array of ‘state-of-
the-art’ risk reduction methods that are not available outside the trial in specific 
contexts could constitute undue inducement to participate (Rennie and 
Sugarman 2010, 811). 
The HPTN document also provides guidance on aspects of research not detailed 
in the UNAIDS/WHO document, including specifying processes of community 
engagement, building capacity and partnerships.  
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Other national/international guidelines 
In addition to international guidelines produced by international non-
government organisations, there are guidelines or authoritative reports on 
international research ethics produced by national and regional bodies. These 
include the US National Bioethics Advisory Commission (NBAC 2001), the 
UK’s Nuffield Council on Bioethics (2002, 2005), the European Group on 
Ethics in Science and New Technologies (EGE) and the Council of Europe’s 
Steering Committee on Bioethics (CDBI). Some institutions also have specific 
guidance, such as the UK’s Medical Research Council’s (MRC) Guidance on 
Provision of ART in developing countries issues, May 2003. 
 
International Conference on Harmonisation Good Clinical Practice 
Guidelines (ICH-GCP) 
The ICH-GCP is a set of international standards with a much broader scope than 
research ethics alone. The standards govern the design, conduct, performance, 
monitoring, auditing, recording, analysis, and reporting of clinical trials, in order 
to ensure scientific quality and protection of the wellbeing of study participants.  
Adherence to GCP is mandated by many national regulatory systems (ICH-GCP 
1996). 
 
The positive trials 
This study took place at a very dynamic period of HIV prevention research, 
2009-2012 during which positive efficacy results were reported from six large, 
randomised controlled trials (RCTs) of HIV prevention interventions. One of 
these trials tested a candidate vaccine, RV144, while the other five tested three 
different, but related, preventive strategies that use antiretroviral drugs in 
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different ways. The CAPRISA 004 trial evaluated the topical use of tenofovir as 
a vaginal microbicide; the iPrEx, Partners PrEP and TDF 2 trials evaluated the 
efficacy of pre-exposure prophylaxis using either tenofovir alone or 
emtricitabine/tenofovir combined; and the HPTN 052 trial evaluated the efficacy 
of treatment-as-prevention (i.e. treating HIV positive people with ARV earlier 
than medically required in order to prevent transmission to sexual partners).  
These trials added to existing evidence that medical male circumcision is 
partially effective in reducing the rate of  HIV transmission from women to men. 
 
Of these six new results, the vaccine trial RV144 is the least significant with 
regard to its implications for the conduct of other studies, as its biological 
efficacy was both modest (below the threshold at which the country in which it 
was held, Thailand, would consider licensure) and contested, so it may be due to 
chance.  
 
The methods and results of each of these trial is summarised below. 
 
RV144 
In October 2009, results of the RV 144 vaccine trial in Thailand were published. 
The investigators concluded that the vaccine lowered the rate of infection by 
31.2% in the trial population of 16,402 people, based on a modified intent-to-
treat analysis (an analysis that groups all participants according to the arm to 
which they were randomised, regardless of whether or not they remained in the 
trial and were vaccinated with active product or placebo according to schedule) 
(Rerks-Ngarm, Pitisuttithum and Nitayaphan et al. 2009). There is some 
controversy over the robustness of this finding, however, as the per-protocol 
analysis (which excludes any participant who was not fully vaccinated) returned 
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a lower level of efficacy and was below the level of statistical significance 
(Gilbert et al. 2011.) 
 
CAPRISA 004 
In July 2010 the first ever positive microbicide results was reported. The product 
was a vaginal gel that contained 1% tenofovir – the same antiretroviral drug 
used in PrEP trials. The microbicide reduced HIV acquisition by 39% overall, 
with higher adherers (women who used the gel 80% of the time) achieving 54% 
efficacy (Abdool Karim et al. 2010). CAPRISA 004 was not designed as a full 
scale efficacy trial, however. It included only 889 participants in the final 
analysis rather than several thousand, and it was not statistically powered to 
provide the level of evidence usually required by regulatory authorities to 
license a product (Abdool Karim et al 2010). Such studies are called phase IIb 
trials (as distinct from phase III efficacy trials), or ‘proof of concept’ (Bass 
2004). 
 
iPrEx 
The first positive PrEP results were reported just four months after CAPRISA 
004, in November 2010. The experimental intervention was TDF/FTC taken 
orally each day. This was found to reduce  HIV acquisition by 44% (Grant et al 
2010). As in the CAPRISA 004 trial, high adherers (measured by blood levels of 
drug) achieved greater protection: an efficacy figure of 73% to 90% is cited for 
those who took their pills at least 90% of the time (Grant et al 2012; Anderson et 
al 2012). 
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Treatment as prevention: HPTN 052 
The strongest impact on HIV acquisition to date was seen in HPTN 052, a study 
in serodiscordant couples that tested the impact of earlier access to ARV for the 
positive partner. In couples randomised to receive immediate ARV, the negative 
partners were 96 % less likely to acquire HIV than in partnerships where 
treatment for the HIV positive member was delayed until his or her immune 
system showed signs of damage (CD4 counts falling below 250) (Cohen et al 
2011).   
 
Partners PrEP 
The reduction in HIV acquisition seen in the Partners PrEP trial was 75%, which 
approximately matched the high adherers in iPrEx. Partners PrEP, reported eight 
months after iPrEx, was conducted in serodiscordant heterosexual couples in 
Kenya and Uganda (i.e. couples where one person has HIV and the other does 
not). It was a three arm trial, with participants randomised to TDF/FTC, TDF 
alone or placebo. The TDF/FTC combination showed the highest reduction in 
HIV acquisition, while the TDF alone arm showed 67% reduction (Baeten et al. 
2012). 
 
Botswana PrEP (TDF2) 
A slightly lower level of efficacy for TDF/FTC was seen in the Botswana PrEP 
study – a 63% reduction in HIV acquisition. This study compared TDF/FTC to 
placebo in a study population of heterosexual men and women. A separate 
analysis aimed at differentiating between efficacy in high adherers compared 
with low adherers, which excluded HIV acquisitions in people on the active 
drug who had not taken their pills for 30 days or more when seroconversion 
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occurred, showed a 78% reduction (Thigpen et al. 2012). The Botswana PrEP 
results were reported at the same time as the Partners PrEP trial. 
 
Other relevant research with positive findings 
PACTG 076 
The first evidence that ARV could be used to prevent HIV transmission was 
published in 1994 (Connor, Sperling and Gelber et al. 1994). The study, known 
as PACTG076, reduced transmission from HIV infected mothers to their infants 
by two thirds, using the single antiretroviral drug AZT during pregnancy and 
delivery, administering the drug to infants after delivery for six weeks, and 
replacing breast milk with formula. This study, which was conducted in the US 
and France, transformed the care of HIV positive pregnant women in high 
income countries. The regimen was criticised as being unachievably costly and 
complex for use in low income countries, however. The ethical furore that 
ensued as a result of mother-to-child transmission studies in low income 
countries proceeding as if there was no proven effective intervention will be 
discussed in detail in Part 1 Chapter 2.  
  
Male circumcision 
After the mother-to-child trials, and before any ARV-based prevention strategy 
was proven effective, male circumcision was shown to reduce the rate of HIV 
transmission from women to men. Three separate randomised controlled trials 
showed that the ancient practice of surgical removal of the foreskin of the penis1 
had a protective effect of around 55% in heterosexual men living in countries 
 
1 Circumcision to prevent HIV transmission is medical procedure, as distinct from traditional practices, as serious 
safety problems related to the ritual form of circumcision. 
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with generalised epidemics (Auvert et al. 2005; Bailey et al. 2007; Gray et al. 
2007).  
 
Post-exposure prophylaxis (PEP) 
Post-exposure prophylaxis (PEP) was instituted in medical settings (needle stick 
injuries and the like), following a case-control study published in 1997 that 
showed an 81% reduction in HIV acquisition associated with PEP (Cardo et al. 
1997).  Randomised controlled trials were never conducted for either medical or 
sexual exposure, as to randomise a person to placebo given the evidence that 
could be extrapolated from peri-natal trials (in particular Wade, Birkhead, 
Warren et al. 1998) was deemed neither feasible nor ethical (van den Berg, 
Lindenburg and Coutinho 2010, 324; Poynten et al. 2012).  
 
Other relevant trials with negative findings 
FEM-PrEP 
Amidst the positive trial results of biomedical HIV prevention in 2010-11, one 
trial bucked the trend. Fem-PrEP, a trial of combination TDF/FTC in women at 
high risk of HIV from the African countries, was prematurely halted by its Data 
Safety Monitoring Board (DSMB) due to futility in April 2011 (CDC April 11 
2011). DSMBs are independent, expert groups who are charged with reviewing 
data at pre-ordained intervals (or in response to unexpected adverse events) to 
ensure participant safety and adherence to the trial protocol.  
 
The DSMB determined after an interim analysis that the trial would not be able 
to demonstrate efficacy if it continued for the pre-ordained time. Why this PrEP 
result differs from the two other PrEP studies that involved heterosexual women 
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(Partners PrEP and Botswana PrEP) is considered to be at least in part due to 
very low adherence on the study (Van Damme et al. 2012). 
 
VOICE 
Final results of the VOICE trial (also known as MTN 003) were presented on 
March 4, 2013. The findings were all negative – that is, none of the three 
interventions tested were found to be effective in the trial population: 
combination oral PrEP (TDF/FTC), TDF-only oral PrEP, and tenofovir gel 
(vaginally delivered, using a different dosing strategy to CAPRISA 004). The 
failure was attributed to low adherence to all interventions on the trial: on 
average, less than 30% of women randomised to each of the intervention arms 
had detectable blood levels of the respective drugs (29% for 
tenofovir/emtricitabine, 28% for oral tenofovir, and 22% for tenofovir gel). 
 
VOICE tested the three different prevention strategies against matched placebo 
(both an oral and a vaginal placebo were used). It was a phase IIb study rather 
than a full scale phase IIIb efficacy trial, powered to show efficacy of more than 
25% of the study products, with efficacy of less than 25% the null hypothesis 
(Protocol v 2 December 31 2010, 10.3, p. 9). 
 
In 2011, two of the three active arms of the VOICE trial were stopped due to 
futility2. This judgement was made by the DSMB on the basis that these 
particular active arms could not show efficacy even if they proceeded. 
 
 
2 ‘Futility’ in this context meaning that the control arm and the intervention arm have nearly identical 
results, and even if the trial continued a statistically significant difference between the two would 
likely not occur. 
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The VOICE trial is endpoint-driven, with its final endpoint being 217 HIV 
infections in the study population. Under the protocol, the DSMB was to review 
data when 25%, 50% and 75% of these 217 seroconversions occurred.  
 
Earlier negative trials: microbicides and diaphragm 
Before 2007 there was a raft of failures of new technologies designed to prevent 
sexual transmission of HIV, and some interventions were found to enhance HIV 
acquisition. 
 
The first failed trial in the microbicides field was a trial of nonoxynol-9, a 
spermicide that had showed promising anti-HIV activity. The product was 
evaluated in a population of sex workers, but it was halted prematurely by its 
DSMB in 2000 when more HIV infections were observed in the active 
(experimental) arm of the trial than the placebo arm. It was found that frequent 
use of the product increased the risk of HIV infection by disrupting the vaginal 
epithelium (van Damme et al. 2002).  
 
Following the nonoxynol-9 results, several other microbicide candidates were 
tested for efficacy, including Savvy, Carraguard, cellulose sulphate (CS), 
Buffergel and Pro 2000. The Savvy trial was halted in 2006 when the HIV 
incidence in the trial population was significantly lower than expected. The 
DSMB determined that the trial could not reach a result (i.e. it was deemed 
‘futile’).  
 
Two parallel trials of the microbicide cellulose sulphate were halted in 2007, 
when an interim analysis showed that results in one of the trials were trending 
towards the nonoxynol-9 pattern – that is, increased seroconversions in the 
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active product arm suggested that the product was increasing than decreasing the 
risk of infection. While in the final analysis this trend was not statistically 
significant, the researchers concluded that the product may have caused harm, 
and research on the product ceased (van Damme et al. 2008). 
 
Following the premature closure of the four preceding microbicide trials, the 
fact that the Carraguard study was completed in full was considered a victory in 
itself, despite the fact that the product, while safe, did not show any efficacy 
(Skoler-Karpoff et al. 2008). 
 
The run of negative results was continued by the MIRA (Methods for Improving 
Reproductive Health in Africa) trial, which tested whether the diaphragm 
provided protection from HIV acquisition for women living in South Africa and 
Zimbabwe. The trial showed no additional protective effect from the diaphragm, 
though the authors suggest that some effect may have been seen with a different 
trial design or higher levels of adherence to the study product (Padian et al. 
2007). 
 
A small proof-of-concept study, HPTN 035, tested two candidate microbicides 
Buffergel and PRO2000, with results released in February 2009. Buffergel was 
ineffective, but PRO 2000 appeared to be about 30% effective (MTN 2009). In 
December 2009, however, results of a much more robust trial MDP 301 also 
testing PRO 2000 showed no impact on HIV acquisition (AVAC 2009).  
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Previous vaccine trials 
Prior to RV144, two candidate vaccines failed to show efficacy in large-scale 
trials. The first was rgp120, a vaccine based on the envelope protein of HIV. 
Two variants of rgp120 were trialled in different populations in the early 2000s 
– gay men, men who have sex with men and so-called ‘high risk’ women in 
Europe and North America tested the variant designed for subtype B (Flynn et 
al. 2005), while a Thai trial tested a variant based on prevalent Thai subtype B/E 
in injecting drug users (Vanichseni et al. 2004).  
 
Despite neither of these trials testing rgp120 showing efficacy, the rgp120 
vaccine formed part of the subsequent ‘prime/boost’ vaccine strategy, RV 144, 
that produced the borderline result described on page 17. The RV 144 trial 
essentially used two different vaccines in sequence – rgp 120 and an ALVAC 
vaccine based on a canary pox vector – each of which aimed to stimulate 
different aspects of the immune system. 
 
A different vaccine strategy, aimed at producing cell-mediated immunity was 
tested by the pharmaceutical company Merck. This trial, known as the STEP 
study, used a human adenovirus as a vector and had sites in the Americas, 
Europe and Australia. It not only failed to show efficacy, but uncircumcised men 
and those with pre-existing immunity to the vector (adenovirus 5) were more 
likely to become infected than those on placebo, suggesting the vaccine 
enhanced infection in these populations (Buchbinder, Mehrotra & Duerr 2008).  
 
A second efficacy trial of this vaccine (Phambili) ceased recruitment following 
on the STEP results. It was conducted in South Africa, and only 801 of the 
projected 3000 people were enrolled at the time recruitment closed.   
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PrEP trials prior to 2010 
In the early 2000s, four trials of tenofovir-only pre-exposure prophylaxis (PrEP) 
were commenced in Africa and Asia. One trial had sites in Ghana, Cameroon 
and Nigeria, while the other three were limited to sites in a single country: 
Thailand, Cambodia and Malawi.  By 2006, the two trials in Cambodia and 
Malawi had closed, as had two of the sites (Cameroon and Nigeria) in the 
international African study (Page-Shafer et al. 2005; Haire 2011). The 
international study produced a statistically non-significant result in 2007 
(Peterson et al 2007), while the Thai study went ahead despite serious ethical 
objections, and is still ongoing at the time of writing (March 2013) (Chua et al. 
2005). 
 
The controversy over the early PrEP trials centred on two key issues in the 
conduct of HIV prevention research: whether or not host communities are 
meaningfully engaged in research so that they can have input into research 
design and implementation, and the putative obligation of researchers and 
sponsors to ensure access to ARV for seroconverters. 
 
These issues are discussed in full in Part 1 Chapter 2, Because we can: Clashes 
of perspective over research obligation in the failed PrEP trials. This situates 
the PrEP trials in the historical context of the vertical transmission debates of the 
1990s, where there was protracted disagreement over the use of placebos despite 
the existence of a proven intervention. It then discusses how research practice 
has been influenced by the dramatic improvement in the clinical management of 
HIV from 1996 onwards, and the treatment access movement. 
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Context - vulnerability to HIV infection 
HIV prevention trials are conducted in HIV negative individuals from high 
incidence populations, the majority of which are in low to middle-income 
countries in Africa (and to a lesser degree, Asia) that have generalised HIV 
epidemics. A smaller proportion of high incidence populations are drawn from 
countries with epidemics that are concentrated with populations that face a 
disproportionately high risk of HIV acquisition, such as in gay men and other 
men who have sex with men, and injecting drug users. 
 
The HIV prevention trial context is one in which participants are vulnerable to 
risks of a structural, social and medical nature (Abdool Karim and Abdool 
Karim 2012). Structural risks include the disproportionate risk of HIV which 
renders them eligible for trial participation. Social risks include being identified 
with a stigmatised infection that is associated with other stigmatised identities 
such as homosexuality or sex work. Medical risks include harm caused by the 
product under investigation. Benefits for participants can include better general 
medical care (either directly or through referrals), improved access to HIV 
prevention interventions, improved access to antiretroviral therapy (ARV) if 
HIV is acquired, strengthened medical and research infrastructure at community 
level, and post-trial access to proven products.  
 
The level at which benefits are provided to participants, who is responsible for 
providing which benefits, and whether benefits should be provided to 
participants alone, the trial community more broadly, or somewhere in between, 
are issues contested at the theoretical level. They are also vexed at 
implementation level, because regulatory constraints, funding limitations and 
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feasibility confounders all affect both what is possible and what is deemed 
desirable within a trial. 
 
 
Aims/Research questions 
This study aims 
 To gather evidence about how benefits to participants are negotiated in 
efficacy trials of biomedical HIV prevention technologies. 
 To re-consider the debates about obligations to trial participants in the light 
of the positive trial results (what are the ethical issues in HIV prevention 
research in the age of partially effective HIV prevention modalities?) 
 To understand how principal investigators and ethics committees navigate 
this territory, and how experience in conducting HIV prevention trials shapes 
views on how they should be conducted in the future 
 To explore the factors that affect how and when positive research findings 
are implemented; and 
 To account for any ethical issues that emerge in the empirical investigations 
that are not present in the current normative literature. 
 
Methods 
This study addressed HIV prevention efficacy trials (phase IIb or III) that took 
place between 2000 and 2011. It has both empirical and normative components. 
 
Empirical components of the study 
In all, 28 efficacy trials of biomedical HIV prevention (either phase III or IIb) 
were identified between 2000 and 2011through the Current Controlled Trials 
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and clinical trials.gov databases. Principal investigators and first authors of key 
publications were contacted by email and invited to participate in the study by 
completing the questionnaire, and/or participating in a semi-structured 
interview. 
 
Surveys 
Principal investigators and first authors of key publications were contacted by 
email and invited to participate in a survey. The survey was a preliminary form 
of data collection that aimed to make initial contact with principal investigators 
and gather general information about standards of care. 
 
Members of ethical review committees that had reviewed phase IIb or phase III 
HIV prevention trial were also contacted by email and invited to participate in a 
survey. Originally this survey too was intended as a preliminary form of data 
collection that would provide guidance for in-depth qualitative interviews. 
Accessing and recruiting REC personnel proved slow and unproductive. Many 
REC chairs did not respond at all, and those that did respond indicated that they 
were either ineligible or unwilling to participate. No single individual agreed to 
be interviewed, so this aspect of the study was abandoned in order to meet 
timelines.  
 
In addition, the response to the REC survey was extremely poor – out of 69 
eligible RECs, responses were received by only 15 eligible respondents and only 
11 completed the survey. Due to this low response, survey results will not be 
published, however the survey instrument and responses are available in 
Appendix D. 
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Interviews 
I interviewed 14 principal investigators from the 28 trials identified. Between 
them they had worked on more than 20 HIV prevention trials. Both men and 
women were included in the sample. Of the principal investigators interviewed, 
two were ‘in-country’ investigators, which means that they headed the study at a 
particular trial site, but did not have oversight of the trial as a whole. The 
remaining 12 informants oversaw whole trials and in some cases networks of 
HIV prevention trials. Most of these informants had been a principal investigator 
or a senior member of the research team on more than one study.  
 
All of the interviews were conducted by the author. Nine interviews were 
conducted by telephone and five were conducted face-to-face. The study was 
reviewed and approved by the ethics committee of the University of Sydney. 
Data were coded using N-Vivo 9 software and analysed thematically. 
 
Data were analysed from a symbolic interactionist perspective, in which 
interviews are understood not as mirror images of an objective reality (the 
positivist view), but as accounts of experience through which participants in the 
interview purvey their understandings of the social world under investigation 
(the ‘world’ of the HIV prevention trial). 
 
Additional data collection 
Ongoing email contact was established with principal investigators of HIV 
prevention trials (including some who did not consent to be interviewed), and 
information was exchanged about specific aspects of their respective studies, 
with particular regard to post-trial access issues. Trial protocols were obtained 
where possible, research network websites were checked regularly and 
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correspondence established with trial-related public relations personnel. 
Advocacy networks including AVAC (AIDS Vaccine Advocacy Coalition), the 
International Rectal Microbicides Advocates (IRMA) and the former Global 
Campaign for Microbicides (GCM, now defunct), were also sources.  
 
Normative component 
The normative component of the study focuses on four “big-picture” issues.  
 
The first normative issue is whether there is ethical justification for antiretroviral 
(ARV)-based prevention in HIV endemic areas. The answer to this cannot be 
assumed, given limited health budgets, difficulties with targeting ARV-based 
prevention, adherence issues and the interconnectedness of ARV-based 
prevention and treatment. Seven million people who require ARVs cannot 
access them, so there is an argument that ARV should not be used as prevention 
until all who require treatment have assured access.  
 
If ARV-based prevention is not ethically justifiable, or if only some forms of it 
are justifiable and others are not, this raises a serious issue for HIV prevention 
research. If ARV-based prevention is justifiable, then there is an argument that it 
should be provided, particularly in jurisdictions where the right to health is 
explicitly stated. This issue is explored in Part 3 Chapter 1, Ethics of ARV-based 
HIV prevention: treatment-as-prevention and PrEP. This paper investigates the 
rights claims of uninfected people for access to ARVs for prevention, and 
whether moral claims justify the provision of ARV therapy to those who do not 
yet clinically require treatment as a way of reducing HIV transmission risk. It 
compares the application of PrEP and treatment-as-prevention strategies using a 
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public health stewardship model developed by the Nuffield Bioethics Council 
and the Beauchamp and Childress principles approach (1994).  
 
 The second normative issue is how the positive HIV prevention trial results – 
which demonstrate partial efficacy – affect (or should affect) future HIV 
prevention research. The key issue is what level of evidence is required to 
disturb equipoise, and whether or not the urgency with which interventions are 
required has an impact. This is discussed in Part 3 Chapter 2, How good is 
“good enough”? The case for varying standards of evidence according to need 
for new interventions in HIV prevention.  
 
The third normative issue is whether the newly-validated modality of pre-
exposure prophylaxis (PrEP) should be now become standard of prevention. The 
implications are discussed with respect to normative guidance, scientific 
rationale, policy and considerations regarding affected communities. These 
questions are considered in Part 3 Chapter 3, Ethical considerations in 
determining standard of prevention packages for HIV prevention trials: 
Examining PrEP.  
 
The fourth normative issue is whether PrEP should become the comparator arm 
in HIV prevention trials from now on. This is discussed in Part 3 Chapter 4, 
which considers different sets of normative research ethics guidelines and the 
moral imperative to ensure that there are not double standards between low-to-
middle and high income countries, with regard to where PrEP should sit in the 
current standard of care.  
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Results 
Empirical 
Three key publications, together with chapters outlining the survey results, form 
the basis of the empirical results. 
Standard of prevention in the real world: A qualitative study of principal 
investigators in HIV biomedical prevention trials 
This chapter looks at how principal investigators on HIV prevention studies 
determine appropriate standards of prevention. It builds on previous work 
mapping standards of care in HIV prevention trials by investigating how 
decisions were arrived at, in addition to reporting what was decided. The 
analysis shows that there is no ethical consensus about the standard of 
prevention among principal investigators, and that rational arguments are used 
to support disparate positions. 
 
Ethics of medical care and clinical research: A qualitative study of principal 
investigators in biomedical HIV prevention research: This chapter is a response 
to Miller and Brody’s (2003, 2007) critique of the ‘therapeutic obligation’ in 
research. It considers whether the views of the principal investigators are 
compatible with the proposition that there is a “doctor-like” duty of care to 
research participant. It finds that these particular researchers do admit this 
obligation, though it is limited by the nature of the research, the depth of the 
relationship between research and participant, and the capacity of the research 
site. The paper concludes that the therapeutic orientation in HIV prevention 
trials appears to be indivisible from competent research practise by making 
concrete and appropriate benefits available to trial participants and their 
communities, which support rather than compete with local infrastructure. 
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Mind the gap: An empirical study of post-trial access in HIV biomedical 
prevention trials: This chapter provides an empirical, descriptive account of 
post-trial access to successful biomedical HIV prevention interventions and 
ARV for seroconverters. It elucidates the constraints that trial investigators face 
in when securing ‘post-trial’ access and analyses the procedural problems that 
beset the implementation of normative frameworks on post-trial obligations 
outlined in guidance documents. Finally recommendations are made as to how 
the other critical actors – sponsors and governments/regulators – should 
contribute to securing this benefit. 
 
Normative 
Ethics of ARV-based HIV prevention: Treatment-as-prevention and PrEP 
This chapter argues that the use of ARV for prevention is ethically justified, 
despite imperfect global access to drugs for those in clinical need, and that there 
are sound moral reasons for implementing both PrEP and treatment-as-
prevention. The determination of which ARV-based HIV prevention strategy is 
ethically preferable in particular settings maybe complex and must take into 
account both public health and interpersonal considerations.  
 
How good is “good enough”? The case for varying standards of evidence 
according to need for newiInterventions in HIV prevention 
This chapter argues that the judgments of evidentiary standards are not value-
neutral. It discusses two of the recent positive trials (CAPRISA 004 and iPrEx) 
as case studies. It first considers the question of whether equipoise still exists 
regarding the respective interventions (tenofovir gel and emtricitabine/tenofovir 
PrEP). It then addresses the question of whether the regulatory decision to 
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require further confirmatory trials, which will potentially delay access to 
scientific innovation to the people who are most urgently in need of it. 
  
Ethical considerations in determining standard of prevention packages for HIV 
prevention trials: Examining PrEP 
This chapter outlines arguments concerning the inclusion of newly established 
ARV-based HIV prevention interventions as standard of prevention in HIV 
prevention trials from multiple perspectives.  It argues that there is a clear need 
to incorporate stakeholders in a robust discussion to determine the appropriate 
trial design for each study population. 
 
It’s time: The case for PrEP as an active comparator in HIV biomedical 
prevention trials  
This chapter argues that in light of evidence that treatment-as-prevention, PrEP 
and circumcision are effective in preventing HIV acquisition, it is no longer 
ethically appropriate to design HIV prevention without securing access to these 
interventions, particularly as each of these strategies has been approved by a 
regulatory authority or in a normative guideline. Given that many important 
scientific questions about the optimal use of existing prevention technologies 
that remain to be answered, however, this chapter also argues that PrEP should 
form the comparator against which new experimental HIV prevention 
technologies should be tested. 
 
Conclusions 
This thesis addresses critical issues in the ethics of HIV prevention trials. The 
experience of the failed PrEP trials in the early 2000s demonstrates the need for 
meaningful community collaboration with researchers in order build trust and 
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produce better outcomes for the communities who participate in research. I 
argue in favour of ARV-based prevention using a range of modalities, not 
restricted to either treatment-as-prevention or PrEP alone, on the grounds that 
different individuals and populations have different prevention needs. The high 
bar set for product licensure is questioned in the context of generalised 
epidemics, based on the modelled impact of less effective strategies in high 
incidence areas and the moral right of people to make use of technology to 
protect their health. 
 
This thesis catalogues differences in scope, duration and timeliness of post-trial 
access to effective products of research, so that lessons can be learned about the 
effective mechanisms for distribution of newly validated products, and the role 
of principal investigators in advocating for justice in this respect is 
acknowledged. 
 
Despite the current consensus on the basic prevention package (condoms, 
counselling and STI treatment)3 there remains serious disagreement as to 
whether packages should be optimised or basic, linked to national guidelines or 
universal standards. This has potential to result in ethical stalemate or double 
standards in an age where new partially effective HIV prevention technologies 
are licensed for use in some countries only, as we now see in the case of PrEP. 
The argument that PrEP should now be added to the prevention package for all 
experimental interventions, while attractive in terms of distributive justice, is 
defeated by the spectre of drug-drug interactions while antiretroviral-based 
 
3 Voluntary medical male circumcision, as will be shown, has not been universally offered to date in 
trials with eligible participants (HIV negative, heterosexually active, uncircumcised men from 
countries with generalised epidemics).  
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interventions remain the most promising, and by the  issues of scale it would 
necessarily involve.  Accordingly, I propose that PrEP should be used as a 
universal comparator until there is a more effective and user-friendly biomedical 
intervention for HIV negative people. 
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Overview of empirical methods 
 
There were four components to the empirical data collection: 
1. Surveys of principal investigators (PIs) who had conducted phase IIb or III HIV 
biomedical prevention research between 2000 and 2011; 
2. A survey of members of ethics committees who had reviewed phase IIb or III 
trials of HIV biomedical prevention research between 2000 and 2011; 
3. In depth semi-structured interviews with PIs who had conducted phase IIb or III 
HIV biomedical prevention research between 2000 and 2011; 
4. Additional data collection through email communications. 
 
Principal investigator survey 
The survey was a preliminary form of data collection intended to make initial 
contact with principal investigators, to gather general information about standards 
of care, and to identify ethical review committees eligible to participate in the 
survey of ethics committee members.  
 
Principal investigator eligibility 
PIs were considered eligible for the study if, between 2000 and 2011, they had 
conducted a phase IIb or III trial of a biomedical intervention that was designed to 
prevent sexual transmission of HIV.  
 
To identify the study population, I searched the Current Controlled Trials and 
clinical trials.gov databases for trials that were conducted between 2000 and 2011 
using the term ‘HIV prevention’. I then sorted through the search results to identify 
phase III or IIb trials that evaluated the efficacy of biomedical interventions 
designed prevent sexual transmission of HIV. Twenty-eight trials met these 
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criteria. Principal investigators (PIs) and first authors of key publications from 
these trials were contacted by email and invited to participate in the study by 
responding to an online survey and/or participating in an in-depth interview. 
 
Principal investigator recruitment 
Eligible PIs were contacted by email and sent information forms and a link to the 
online survey. Potential participants were also followed up in person at 
international conferences (Microbicides 2010 in Pittsburgh, International AIDS 
Society in Rome and Microbicides 2012 in Sydney) and through mediated email 
introductions and recommendations provided by colleagues. Each eligible PI was 
sent at least one reminder email.  
 
Principal investigator questionnaire design 
 The questionnaire was designed using SurveyMonkey Select software.  The 
conceptual framework was based on categories established in a seminal ‘standards 
of care’ mapping study (Heise, Shapiro and West Slevin 2008).  The questionnaire 
was piloted online with two staff members and three students at the Centre for 
Values Ethics and the Law in Medicine (VELiM) and went live in May 2010. 
Initial responses from eligible PIs highlighted some further difficulties with the 
questionnaire design, particularly the requirement that people repeat the 
questionnaire several times depending on the number of trials they had conducted. 
Accordingly, the study was re-designed and piloted again with two members of the 
ethics committee of ACON (formerly known as the AIDS Council of NSW) and 
two staff members from the Kirby Institute. Following feedback, further alterations 
were made to the format, the wording, and the sequence of questions, and 
provision was made within the questionnaire to report on more than one study. 
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Because it was difficult to recruit PIs to the study, those who responded to the 
initial questionnaire were not asked to complete the revised one, and results of both 
the initial survey and the revised survey are reported. The survey used a multiple 
choice format, with some questions allowing a single response and others allowing 
more than one, depending on the nature of the question. In many cases, a free text 
field was also provided for further comment. Descriptive statistics in the form of 
simple frequencies were calculated for responses to closed-ended questions, and 
summaries were compiled for free-text responses where they were provided. 
 
Data collected from both the initial survey and the revised, final survey are 
reported alongside each other. I have noted when the survey questions differed. 
Where difference makes the two sets of results incommensurable, they are reported 
separately. 
 
Ethics committee member surveys 
The survey of ethics committee members was also intended as a preliminary step 
for in-depth qualitative interviews. Accessing and recruiting ethics committee 
personnel proved slow and unproductive, however. The interviews were therefore 
abandoned. Fifteen eligible participants began the online survey, and eleven 
completed it, from a potential 69 eligible RECs. This response is too low to merit 
publishing the results. 
 
Principal investigator interviews 
Forty-two principal investigators and first authors of key publications from these 
trials were identified, contacted by email, and invited to participate in a semi-
structured interview. Two were uncontactable. Repeated invitations were sent in 
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order to recruit investigators who had worked on multiple studies. Potential 
participants were also followed up in person at international conferences 
(Microbicides 2010 in Pittsburgh, International AIDS Society in Rome and 
Microbicides 2012 in Sydney) and through mediated email introductions and 
recommendations provided by colleagues. Each eligible PI was sent at least one 
reminder email. Some eligible individuals did not respond, some declined, and one 
agreed to an interview but was subsequently uncontactable. 
 
Fourteen principal investigators from the 28 trials identified were interviewed, who 
between them had worked on more than 20 HIV prevention trials. Both men and 
women were included in the sample. Of the principal investigators interviewed, 
two were ‘in-country’ investigators, meaning that they headed the study at a 
particular trial site, but did not have oversight of the trial as a whole. The 
remaining 12 informants oversaw whole trials and in some cases networks of HIV 
prevention trials. Most of these informants had been a principal investigator or a 
senior member of the research team on more than one study.  
 
I personally conducted and coded all of the interviews. Nine interviews were 
conducted by telephone and five were conducted face-to-face. The study was 
reviewed and approved by the ethics committee of the University of Sydney. Data 
were coded using N-Vivo 9 software and analysed thematically. 
 
Data were analysed from a symbolic interactionist perspective, in which interviews 
are understood not as mirror images of an objective reality (the positivist view), 
but as accounts of experience through which participants in the interview purvey 
their understandings of the social world under scrutiny - the ‘world’ of the HIV 
prevention trial (Miller and Glasner 2004). 
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The interviews were conducted from May 2010 to March 2012, a period during 
which five of the nine successful HIV biomedical prevention trials had positive 
findings (CAPRISA 004, iPrEx, HPTN 052, Partners PrEP and TDF-2). In several 
cases, the positive trial results were known by the informant but not by the 
interviewer.  
 
Where interview data were factual (as distinct an expression of an opinion), facts 
were verified against other sources, such as protocols if available and trial 
websites.  
 
Additional data collection 
Ongoing email contact was established with principal investigators of HIV 
prevention trials (including some who did not consent to be interviewed), and 
information exchanged regarding specific aspects of their respective studies, with 
particular regard to post-trial access issues.  
 
Principal investigators (PI) of the nine HIV prevention trials that reported positive 
efficacy findings were contacted by emails for fact-checking and to supply 
additional information.  This group included PIs who had been interviewed and 
those who had not. In one instance the PI referred me to another senior member of 
the research team for further details. 
 
PIs who had not been interviewed were engaged in email exchanges on post-trial 
access issues. Of the nine positive trials, two PIs did not respond either to requests 
for an interview or to provide email comments. In these cases (the RV144 vaccine 
trial and the Orange Farm circumcision trial), information about post-trial access 
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plans was sourced from pre-trial documents and post-trial access meeting minutes 
provided by AVAC (AIDS Vaccine Advocacy Coalition) and by a trial-related 
public relations officer. 
 
 Trial protocols were obtained where possible; research network websites were 
checked regularly, and correspondence established with trial-related public 
relations personnel. Information was also gleaned from advocacy networks 
including AVAC (AIDS Vaccine Advocacy Coalition), the International Rectal 
Microbicides Advocates (IRMA) and the former Global Campaign for 
Microbicides (GCM, now defunct.  
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Abstract 
 
This article examines the relationship between bioethics and the therapeutic standards in HIV 
prevention research in the developing world, focusing on the closure of the pre-exposure 
prophylaxis (PrEP) trials in the early 2000s. I situate the PrEP trials in the historical context 
of the vertical transmission debates of the 1990s, where there was protracted debate over the 
use of placebos despite the existence of a proven intervention. I then discuss the dramatic 
improvement in the clinical management of HIV and the treatment access movement, and 
consider how these contexts have influenced research practice. I argue that as HIV prevention 
trials oblige researchers to observe the rate at which vulnerable people under their care 
acquire HIV, there is an obligation to provide antiretroviral treatment to seroconverters and 
other health care benefits that fall within the scope of researchers’ entrustment, both to avoid 
exploitation and to enact reciprocal justice. I argue against propositions that the obligations to 
provide specific benefits are vague, fall only upon researchers and sponsors, and create 
injustices by privileging the few over the many. Finally, I contend that the realisation of a 
broader standard of care in HIV prevention research broadens the role of research from being 
a simple tool to produce knowledge to a complex intervention that can play a part in the 
reduction of health disparities. 
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Introduction 
 
This article focuses on the closure of the pre-exposure prophylaxis (PrEP) trials in the early 
2000s and reflects on how the issues of justice and exploitation in clinical research played out 
in a context where HIV treatment activism had affected the landscape of possibility.  
 
It is my contention that unresolved issues concerning the obligations of HIV prevention 
researchers to research participants resurfaced in the context of the PrEP trials. The issue 
debated in the late 1990s was the use of placebo controls in vertical transmission research, 
which left the research community divided as to the nature and scope of researcher 
obligation. The issues that arose in the PrEP trials are closely related: concerning ancillary 
care, compensation for harm and access to antiretroviral therapy for seroconverters. Rather 
than being another academic debate, however, communities became actively engaged in the 
question of what clinical research could, or should, offer to participants. 
 
The PrEP controversy erupted seven years after the exposé in the New England Journal of 
Medicine about mother-to-child (vertical) HIV transmission trials which were placebo-based 
despite the existence of a proven intervention.1  
 
                                                            
1 P. Lurie & S.M. Wolfe. Unethical Trials of Interventions to Reduce Perinatal Transmission of the Human 
Immunodeficiency Virus in Developing Countries. N Engl J Med 1997; 337: 853-856; M. Angell. The Ethics of 
Clinical Research in the Third World. N Engl J Med 1997; 337: 847-849. 
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PrEP – pre-exposure prophylaxis – is an HIV prevention strategy, as yet unproven, that 
involves the use of antiretroviral medication prior to exposure to prevent HIV infection.2 This 
article looks at three PrEP trials that came to international attention: one that was to be 
conducted in Cambodia in a population of female sex workers; a second at three sites in 
Africa: Ghana, Nigeria and Cameroon, in a population of women at high risk of HIV 
infection; and a third in Thailand in injecting drug users. By 2005, the Cambodian trial and 
two of the three African trial sites had closed due to community objections to the conduct of 
the research, and activists were raising serious concerns about the Thai study. While there 
were differences in the specific issues at the respective sites the overwhelming concerns were 
access to treatment and/or prevention interventions, and medical care as part of the research 
package.3 
 
Both the failed PrEP trials and the earlier placebo-controlled vertical transmission trials raise 
important ethical questions for researchers. What obligations do researchers have to 
participants? What role does context and circumstance play in determining obligation? How 
do ideas of fairness and reciprocity play out in the context of limited research funding and 
inadequate national health systems? I will argue that the researcher is obliged to protect the 
best interests of the research participants, insofar as these interests fall within the scope of the 
                                                            
2 E. Mills et al. Designing Research in Vulnerable Populations: Lessons from the HIV Prevention Trials that 
Stopped Early. Br Med J 2005; 331: 1403-1406. 
3 E. Mills et al. Media Reporting of Tenofovir Trials in Cambodia and Cameroon. BMC International Health 
and Human Rights 2005; 5 no. 6.  
Available at: http://www.biomedcentral.com/1472-698X/5/6 [Accessed 13 Jan 2010]. 
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research study and to the extent that logistics allow. This obligation, arising from the 
imperative to avoid exploitation and grounded in reciprocal justice, should take precedence 
over the production of knowledge and potential benefits that may flow from this knowledge. 
In the case of HIV prevention studies, this may necessarily involve investment in 
infrastructure to facilitate treatment access post-trial. While this arguably increases the 
burdens placed upon researchers, it situates the production of knowledge appropriately within 
a relationship of care for the subject, rather than divorcing the research context from the 
clinical context. 
 
The debate over placebo controlled vertical transmission trials  
The issue of therapeutic standards in HIV prevention research came into sharp focus in 1997, 
when the New England Journal of Medicine published an article by Lurie and Wolfe,4 which 
condemned a series of clinical trials in the developing world as unethical. The basis of their 
criticism was that interventions to prevent vertical (mother-to-child) transmission of HIV 
were being tested against placebo controls, despite the existence of a proven regimen 
established in 1994, known as the ‘076 regimen’, named after the landmark trial ACTG076.5 
Their critique was supported by an editorial by Marcia Angell,6 which compared the vertical 
                                                            
4 Lurie & Wolfe, op. cit. note 1. 
5 E.M. Connor et al. Reduction Of Maternal-Infant Transmission Of Human Immunodeficiency Virus Type 1 
with Zidovudine Treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 
1994; 331: 1173-1180. 
6 Angell, op. cit. note 1. 
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transmission trial to the infamous Tuskegee experiment, which denied African American men 
access to proven syphilis treatment in order to study the natural history of the disease.  
 
The practice of testing a new therapy against placebo when a proven therapy exists was 
explicitly proscribed by the Declaration of Helsinki (the ‘Declaration’),7 an international 
document providing guidance on research ethics. The Declaration of Helsinki was adopted in 
1964 by the World Medical Association and periodically updated. It is a descendent of the 
Nuremberg Code of 1949, which defined guidelines for the ethical conduct of human 
research in the aftermath of the trials of the Nazi doctors, but is somewhat more liberal than 
that code in its definitions of permissible research.8  
 
Because the 1996 Declaration explicitly stated that placebo-controlled trials where proven 
interventions exist were unethical, it came under intense scrutiny and was subject to a number 
of revisions, which have been dealt with elsewhere.9 In the wake of this scrutiny, there 
ensued an international debate about research standards and the role of guidelines. The debate 
                                                            
7 World Medical Association (WMA). 1996. Declaration of Helsinki 1996. Ferney-Voltaire, France: WMA. 
Available at: http://www.jcto.co.uk/Documents/Training/Declaration_of_Helsinki_1996_version.pdf  [Accessed 
22 Sept 2010] 
8 B. Loff & J. Black. The Declaration of Helsinki and Research in Vulnerable Populations. Med J Aust 2000; 
172: 292-295; H. Wolinsky. The Battle of Helsinki.  EMBO Rep 2006; 7: 670-672. 
 
9 See for example, R. Macklin. After Helsinki: Unresolved Issues in International Research. Kennedy Inst Ethics 
J 2001; 11: 17-36. 
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centred upon the themes of exploitation, the obligations of researchers to trial participants, 
the need for research to be responsive to the needs of the developing world and the 
requirement for scientific rigour.10 These issues were not resolved,11 and they resurfaced in a 
different guise with regard to the ethical design of the PrEP trials. 
 
The HIV treatment revolution and its impact  
 
While the ethical debate over placebo-controlled trials in the developing world was raging in 
the journals, the landscape of HIV treatment (for those who could afford it) was being 
transformed in the clinics of the developed world. Research first presented in 1996, and 
consolidated in the years immediately following, radically changed the perception of 
HIV/AIDS as a terminal illness in wealthy countries. It was shown that HIV replication could 
be effectively suppressed using combination antiretroviral therapy (ART), and that this 
appeared to halt and even reverse immune damage in people with HIV. Although initial 
optimism about the possibility of a cure turned out to be misplaced, the prediction that HIV 
                                                            
10 Angell, op. cit. note 1; Lurie & Wolfe, op. cit. note 1; R. Levine. The Need to Revise the Declaration of 
Helsinki. N Engl J Med, 1999; 341: 531-534; H.E. Varmus & D. Satcher. Ethical Complexities of Conducting 
Research in Developing Countries. N Engl J Med 1997, vol. 337:1003-1005. 
11  Macklin, op. cit. note 9. 
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infection could become another chronic manageable condition has arguably come to pass – 
for some people and to some extent.12 
 
By July 2000, at the International AIDS Conference in Durban, South Africa, the stark 
injustice of people dying of AIDS in the developing world while people lived indefinitely 
with HIV in the resource rich world was palpable. Treatment access had become the most 
significant political issue.13 The drug pricing policies and intellectual property regimes that 
made treatment inaccessible for the majority of people living with HIV became the news 
story from this conference, rather than some biomedical breakthrough.14 
 
Only two antiretroviral drugs were listed on the World Health Organization’s (WHO) 
essential drug list in 2000 and these were both listed for prevention rather than treatment 
(AZT and nevirapine - both to prevent vertical transmission). Even Bactrim, the basic 
                                                            
12 K. Bhaskaran. Changes In The Risk Of Death After HIV Seroconversion Compared with Mortality in the 
General Population. JAMA 2008; 300: 51-59; The Antiretroviral Therapy Cohort Collaboration. Life 
Expectancy of Individuals on Combination Antiretroviral Therapy in High-Income Countries: A Collaborative 
Analysis of 14 Cohort Studies. Lancet 2008; 372: 93-299. 
13 See for example, B. Whyte. Nelson Mandela Calls for Unity at the XIIIth International AIDS Conference in 
Durban, South Africa. B World Health Organ 2000; 78 (9): 1169. Available at 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2560854/pdf/0042-9686_78_9_1169a.pdf [Accessed 21 Feb 
2010]. 
14 N. Geffen.2000. What Happened in Durban? A South African Perspective. The Body September/October. 
Available at: http://www.thebody.com/content/art13213.html [Accessed 21 Feb 2010]. 
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antibiotic used to prevent two common opportunistic infections in people with AIDS, was 
grossly underutilised in Africa.15 
 
Five major pharmaceutical companies announced a partnership with UNAIDS to reduce 
drugs costs for Africa at the Durban conference,16 but this news was greeted by activists with 
‘caution and scepticism’, due to concerns that such programs would come with complicating 
conditions that could prevent access to generic antiretrovirals.17 
 
By 2003, the treatment access movement that had begun at the grass roots and non-
governmental organization (NGO) levels went mainstream. The WHO announced its ‘3 by 5’ 
                                                            
15 South African Department of Health. 2000. Report on the 13th International AIDS Conference, Durban, 9 – 
14 July 2000: Summary Report of Major Issues, Conclusions and Recommendations. Pretoria, South Africa: 
South African Department of Health: section 7.3. Available at: http://www.doh.gov.za/aids/docs/13conf00.html 
[Accessed 21 Feb 2010]. 
AIDS Coalition to Unleash Power (ACT-UP) New York. 2000. WHO Sold Out to Big Pharma. New York, NY: 
ACT-UP New York. Available at: http://www.actupny.org/reports/durban-who.html [Accessed 3 Mar 2010]; 
D.G. McNeill. 2000. Agencies Urge Use of Affordable Drug for H.I.V. in Africa. New York Times (online) 6 
April. Available at: http://www.nytimes.com/2000/04/06/world/agencies-urge-use-of-affordable-drug-for-hiv-
in-africa.html?pagewanted=1 [Accessed 13 Jan 2010]. 
16 A. Diarra. Making a Public-Private Partnership Work - An Insider's View. B World Health Organ 2001;79: 
795-796. 
17 ACT-UP, op. cit. note 15; J.S. James. Access to Treatment Worldwide: From Talk to Action at Durban. Aids 
Treatment News 2000; #347. Available at: http://www.aegis.org/pubs/atn/2000/ATN34703.html [Accessed 21 
Feb 2010]. 
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program, which framed universal access to HIV treatment (and prevention), for those who 
needed it, as a human right. Its specific target was to gain ART for three million people by 
the year 2005. While this target was not reached, the program developed policy and 
infrastructure that greatly facilitated later scale-up. In addition to addressing barriers like 
distribution and pricing, this program devised simplified systems of ART prescription that 
required minimal health service support. This assisted in removing structural barriers to 
access.18 
 
Two other international events had major impacts on access to ART. The first was the United 
Nations General Assembly Special Session on AIDS (UNGASS 2001), which spawned the 
Global Fund for AIDS, Tuberculosis and Malaria. The second was the President’s 
Emergency Fund for AIDS Relief (PEPFAR), first announced in the United States 
President’s State of the Union address in 2003. 
 
From being considered untenable in resource-poor settings, ART was now hailed as ‘an 
appropriate, rational and cost-effective investment choice for developing countries’.19  
 
                                                            
18 WHO-UNAIDS. 2005. The 3 by 5 Initiative: Treat three million people with HIV/AIDS by 2005. Geneva, 
Switzerland: WHO. Available at: http://www.who.int/3by5/en/ [Accessed 21 Feb 2010]. 
19 J.P. Moatti et al. Antiretroviral Treatment for HIV Infection in Developing Countries: An Attainable New 
Paradigm. Nat Med 2003; 9: 1449-1452. 
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The role of community protest in the PrEP trial closures  
 
Having foreshadowed the failure of the PrEP trials due to community protest, I will now 
discuss in more detail the circumstances under which the trials were closed, the issues raised 
by protesters and how these concerns relate both to the bioethical discourse about standard of 
care and the political movement for universal treatment access. 
 
Four different clinical trials of the experimental HIV prevention strategy known as ‘PrEP’ 
had begun by 2005, with sites in Africa and Asia, and with planning underway for further 
trials in the Americas. All of the trials investigated the safety and/or efficacy of the 
antiretroviral drug tenofovir,20 in preventing HIV infection.21 The rationale for the number of 
trials was the need to explore the intervention in a variety of high risk contexts (i.e. in sexual 
activity, both gay and straight, and injecting drug use) and in different genders and body 
types.22 
 
                                                            
20 Later trials added the drug emtricitabine (FTC) combined with tenofovir in a single tablet, under the brand 
name Truvada. See for example listings on trial registries, available at: 
 http://www.controlled-trials.com/mrct/trial/438173/%27HIV+infection%27+AND+prevention [Accessed 3 
Mar 2010]. 
21 AIDS Vaccine Advocacy Coalition (AVAC). 2005. Will a Pill a Day Prevent HIV? New York, NY: AVAC. 
Available at: http://www.avac.org/ht/a/GetDocumentAction/i/3116 [Accessed 13 Jan 2010]; A. Forbes. Moving 
Towards Assured Access to Treatment in Microbicide Trials. PLoS Med 2006. 3 (7): e153: 980-983. 
22K. Page-Shafer et al. HIV Prevention Research in a Resource-Limited Setting: The Experience of Planning a 
Trial in Cambodia. Lancet 2005; 366:1499-1503. 
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Three of these trials became the focus of adverse attention: the Cambodian trial in female sex 
workers, the African trial in high-risk women with sites in Cameroon, Nigeria and Ghana, 
and the Thai trial in injecting drug users. The fourth trial, studying tenofovir in high risk 
‘men who have sex with men’ (MSM) in Malawi, was terminated without fanfare for reasons 
that remain unpublished. Allegations were made that the trials were unethical on the basis of 
not collaborating sufficiently with communities, providing selective and biased information 
about potential adverse effects, and being unwilling to provide comprehensive health 
insurance for participants.23 Each trial had a US sponsor: the Cambodian trial was sponsored 
by the United States’(US) National Institute of Allergy and Infectious Diseases (NIAID) and 
Family Health International (FHI); the African trial again by FHI and the Thai trial by the US 
Centers for Disease Control and Prevention (CDC).24 
 
US sponsorship was the root cause of unrest in the Thai trial, as it targeted injecting drug 
users. According to the Declaration of Helsinki 2000, participants in a drug trial should be 
assured of the best current prophylactic method – meaning in this instance, clean injecting 
equipment. The US, however, neither acknowledged the 2000 version of the Declaration nor 
would its government allow the provision of injecting equipment. Bleach was provided to 
                                                            
23 Mills et al. op. cit. note 2; Mills et al. op. cit. note 3. 
24 While the Cambodian study was sponsored by FHI, its funding was provided by a direct grant from the Bill 
and Melinda Gates Foundation. See Page-Shaffer et al. op. cit. note 22. 
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clean equipment, but this is sub-optimal; the US claims that its actions are in line with Thai 
policy, were disputed.25 
 
The Cambodian trial 
In Cambodia the contentious issues were: concerns about the long-term safety of tenofovir in 
HIV negative people; access to care, especially ART, post-trial; the level of HV prevention 
counselling to be provided to participants; pre- and post-test HIV counselling; and the limited 
involvement of the community in the study design.26 In particular, the issue of compensation 
was extremely problematic. Under US law research sponsors are not required to provide free 
medical care or compensation for participants injured in clinical research.27 Although 
medical care would be available for participants from the research facility for the duration of 
the trial, it was unclear whether prospective participants understood this, and at any rate there
was no provision for medical care after the trial, apart from access to ART for seroconverters 
through the then-fledgling national program. It is not clear that the preferential access to ART 
 
                                                            
25 A. Chua et al. The Tenofovir Pre-Exposure Prophylaxis Trial in Thailand: Researchers Should Show More 
Openness in Their Engagement with the Community. PLoS Med 2005; 2: 1044-1045. 
26 Page-Shafer et al. op. cit. note 22, p. 1499; A. Forbes & S. Mudaliar. 2009. Preventing Prevention Trial 
Failures: A Case Study and Lessons for Future Trials from the 2004 Tenofovir Trial in Cambodia. Washington, 
DC: Global Campaign for Microbicides; 12. Available at: http://www.global-
campaign.org/clientfiles/Cambodia.pdf [Accessed 28 Apr 2010]. 
27 R. Steinbrook. Compensation for Injured Research Subjects. N Engl J Med 2006; 354: 1871-1873. 
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for trial participants was well understood, as access to ART was cited as a key issue by 
 of attention for the prospective study participants, who were often the 
ole breadwinner for families, the survival of whom depended on the commercial sex worker 
The pro
Shafer 
in 
m payments, and the establishment of 
long-term contracts for the provision of clinical services. None of these options fits 
with the policies of our funding agencies.29 
                                                           
protesters.  
 
Adverse effects of the study drug, especially potentially serious long-term ones, became a 
very significant focus
s
being fit for work.28  
 
blem of compensation was apparent to the study investigators early on, as Page-
et al. note in their Lancet article:  
During 2003, we consulted with [other] investigators who had faced similar issues in 
other developing countries, and considered various options for the assistance of 
people with long-term health problems that could be attributed to their participation 
trials, including insurance schemes, lump-su
 
28 Tenofovir Trial in Cambodia, film, directed by Women’s Network for Unity. Cambodia: Women’s Network 
for Unity, 2008. Available at: 
http://www.drpetra.co.uk/blog/womens-network-for-unitys-account-of-the-tenofovir-trial then go to: 
http://blip.tv.file/1418090 [Accessed 3 Mar 2010]; J. Fawkes. The Cambodian PrEP Trial: The Sex Workers’ 
Perspective. Powerpoint presentation to The 2nd Symposium on Microbicides and HIV Biomedical Prevention, 
Sydney, 14 July 2008. 
29 Page-Shafer et al. op. cit. note 22. 
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 Tensions between the researchers and the sponsors are evident in the above quotation, and 
also in a later comment that in response to rising evidence of misinformation about the trial 
the community, the two universities collaborating in the study – the University New South 
Wales and the University of California – sought to place the trial p
in 
rotocol on their respective 
ebsites, but were denied permission to do so by the sponsors.30 
gators, 
ays to manage the risk of long term illness or injury 
aused by the experimental drug.33  
ants 
                                                           
w
 
Of note, it was not merely access to ART for seroconverters that the Cambodian sex workers 
sought,31 – as mentioned above, arrangements for access had been made by the investi
with ART supplied in line with the WHO guidelines for treatment in resource-limited 
settings.32 The workers also sought w
c
 
In a short documentary film, Tenofovir Trial in Cambodia,34 made from the perspective of 
the sex worker group Women’s Network for Unity, it is clear that the prospective particip
 
30 Page-Shafer et al. op. cit. note 22. 
31 Weijer and Le Blanc (2006) discuss the Cambodia trial as if this were the sole reason for the protest. Other 
sources quoted in note 25 attest that a major concern was long-term health issues resulting from a trial related 
injury – in particular, from kidney damage. See C. Weijer & G.J. LeBlanc. The Balm of Gilead: Is the Provision 
of Treatment to those Who Seroconvert in HIV Prevention Trials a matter of Moral Obligation or Moral 
Negotiation? J Law Med Ethics 2006; 34.4: 793ff.  
32 Forbes, op. cit. note 26. 
33 Ibid.  
34 Tenofovir Trial in Cambodia, op. cit. note. 28. 
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believed that the trial would expose them to significant harms, such as the possibil
requiring new kidneys due to drug toxicity. While in some respects such a fear i
disproportionate (tenofovir has an excellent safety profile compared with other 
antiretrovirals), it underscores the difficulties of communicating clearly and honestly about 
issues like risk across the vast epistemic divide between researchers and very poor women 
with minim
ity of 
s 
al access to education, whose very daily survival appears to depend upon being 
ceptical.  
 
40 years post-trial. What they were offered instead 
as US$3 per month for participation. 
 is 
ese 
NGOs - that obediently dropped work with sex worker groups so as to meet the requirement 
                                                           
s
 
The specific demand made by the Women’s Network for Unity was for health insurance to
cover any potential long-term adverse events from the trial drug (referred to in the film as 
‘life’ insurance),35 for a period of 30 to 
w
 
Tenofovir Trial in Cambodia does not distinguish between misinformation, conspiracy 
theories36 and the substantive issue of fair compensation for trial harms. Where it succeeds,
in foregrounding the profound depths of exploitation, trickery and violence to which th
women have been subjected, which makes their level of suspicion of authority all too 
understandable. Extreme poverty, gang rape, systemic discrimination and abandonment by 
 
35 Forbes & Mudaliar, op. cit.  note 26, p. 13.  
36 Conspiracy theories presented included a belief that sex workers were deemed expendable people upon whom 
dangerous drugs could be tested with impunity. 
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for getting US funding during the George W. Bush Administration – form the background for 
negotiations.37  
 
In a memorable riposte, one Cambodian sex worker in the film dismisses the charge that the 
action of the Women’s Network for Unity has denied her a chance to contribute to humanity. 
‘What has humanity ever done for me?’ she asks.38 
 
Trust – identified by the investigators as a key component in working with communities – 
would be an elusive commodity, and deservedly so.39 Indeed, the record of drug companies 
in providing reasonable access to drugs to the populations in which they (the drugs) were 
tested is not good: in Brazil, where the human papilloma virus (HPV) vaccine was tested, it is
now sold at higher price than in the U
 
S.40 
                                                           
 
On August 13, 2004 the Cambodian Prime Minister, Hun Sen, put an end to the trial (which 
had ethics approval in Cambodia, Australia and the US), stating that: ‘Cambodian people are 
not waste, and Cambodia is not a waste bin’, and researchers should take their trials 
 
37 Forbes & Mudaliar, op. cit. note 26, pp. 9-10 
38 Tenofovir Trial in Cambodia, op. cit. note. 28. 
39 B. Loff et al. Unethical Clinical Trials in Thailand: A Community Response (letter). Lancet 2005; 365: 1618-
1619. 
40 J. Beloqui. 2008. International Rectal Microbicides Advocates (listserv communication). Philadelphia, PA: 
Critical Path Project. Available at: http://critpath.org/pipermail/rectalmicro_critpath.org/2008-
November/000564.html [Accessed 13 Jan 2010] 
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elsewhere.41 Of note however, the sex workers had indicated a willingness to continue 
negotiations, so long as they were party to the decision-making processes from the earliest 
stages and their lives and wellbeing were considered appropriately in the development of the 
research design.42 
 
The African trial sites 
Six months after the termination of the Cambodian trial, the Cameroon site of the African 
PrEP trial was halted by the Minister of Public Health. Activist concerns were related to: the 
level of HIV prevention counselling provided – there were only eight counsellors for 400 
women, the lack of female condom provision (only male condoms were provided) and 
alleged inadequate preparation for ART provision. Indeed, the informed consent document 
explicitly stated that the trial would not provide ART to seroconverters, a stance that was 
informed by the notion that supplying ART in a context where it was not generally available 
would constitute undue inducement.43 Trial seroconverters would be referred to existing 
NGO sources, which the activist group ACT-UP Paris described as overburdened, with 
treatment provision for 10,000 individuals, while 40,000 people were already in need.44 
                                                            
41 Loff et al. op. cit. note 40. 
42 Ibid. 
43 E. McGrory, A. Irvin & L. Heise. 2009. Research Rashomon: Lessons from the Cameroon Pre-exposure 
Prophylaxis Trial Site. Washington, DC: Global Campaign for Microbicides - PATH: 27. Available at: 
http://www.global-campaign.org/clientfiles/Cameroon.pdf [Accessed 5 May 2010]. 
44 ACT-UP Paris. 2008. ACT-UP-Paris and Treatment Activism. Paris, France: ACT-UP Paris. Available at: 
http://www.actupparis.org/article3482.html [Accessed 12 May 2009]. 
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 In addition to these substantive concerns, Mills et al.45 cite widespread, inaccurate rumours 
that the investigators would deliberately inject participants with HIV, or that the tablets 
themselves contained HIV. These rumours appear to have their provenance in an argument 
advanced by the activist group ACT-UP Paris, who were involved in the protests, that the 
provision of inadequate HIV prevention counselling to participants was a backdoor method 
of increasing HIV infection in the cohort.  
 
Following an inquiry, the Ministry of Public Health issued a number of administrative 
requirements, including formal site accreditation and more regular reporting. The trial, 
however did not resume. A month later, the Nigerian trial site closed after it was determined 
that the site did not comply with operational and laboratory procedures. 
 
In 2006, data from the Ghanaian site alone from the African trial was reported at the 
International AIDS Conference in Toronto, Canada. Tenofovir appeared to be safe in HIV 
negative people, results showed, but the sample size was too small to show statistically 
significant efficacy.46 
 
                                                            
45 Mills et al. op. cit. note 2. 
46 L. Peterson et al. Tenofovir Disoproxil Fumerate for Prevention of HIV Infection in Women: A Phase 2, 
Double-Blind, Randomized, Placebo-Controlled Trial. PLoS Med 2007; 2: e27. 
 
 
67
The Thai trial 
Despite significant disquiet about ethical issues, the Thai PrEP trial targeting injecting drug 
users, which opened in 2005, has not stopped. The Thai Drug Users’ Network and the Thai 
AIDS Treatment Action group cite as ethical violations, the failure to provide participants 
with sterile injecting equipment, lack of meaningful community consultation, lack of 
commitment from the sponsors to promoting the safety of participants enrolled in the trial, 
assured access to tenofovir for participants for one year only post-trial and no agreement to 
work with the Thai Ministry of Public Health towards securing price reductions of tenofovir 
after the trial.  
 
The lack of consultation with communities and the failure to negotiate access to the 
experimental product, if effective, flouts both the letter and the spirit of key guidance 
documents.47 The failure to provide sterile injecting equipment, however, is most problematic 
                                                            
47 Such as Guidelines 11,12 and 13 of the Council for International Organizations of Medical Sciences (CIOMS) 
International Ethical Guidelines for Biomedical Research Involving Human Subjects 2002, available at: 
http://cioms.ch/publications/guidelines/guidelines_nov_2002_blurb.htm [Accessed 3 Mar 2010]; Articles 6,17, 
32 and 33 of the Declaration of Helsinki 2008, available at: 
http://www.wma.net/en/30publications/10policies/b3/17c.pdf [Accessed 3 Mar 2010] and Guidance points 4, 5 
13 and, depending upon the contested legality, 14 of the UNAIDS Ethical Considerations in HIV Preventive 
Vaccine Research 2000, available at: http://data.unaids.org/publications/IRC-pub01/JC072-EthicalCons_en.pdf 
[Accessed 3 Mar 2010]. It should be noted that the 2002 UNAIDS guidelines do not discuss provision of 
established HIV behavioural prevention such as condoms and clean injecting equipment under standard of care 
requirements, rather they position it as ‘risk reduction measures’ under ‘informed consent’ and only require 
provision of clean injecting equipment where it is legal to do so. The later UNAIDS guidelines, Ethical 
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because it is an established, effective intervention,48 which reliably reduces HIV acquisition 
in this population. Non-provision exponentially increases the likelihood of seroconversions 
during the trial and thus exploits participants’ vulnerability to HIV acquisition by denying 
them a proven intervention. 
 
The reason for the lack of sterile injecting equipment is contested: the CDC website claims it 
is the result of Thai government policy, but this is vigorously denied in correspondence 
appearing in The Lancet that claims there is no such Thai policy; instead it is suggested that it 
was the US government policy which precluded provision (this was changed in 2009 with the 
sweeping changes brought in by the Obama administration).49 
 
Regarding ART provision, there is a national treatment program in Thailand, but the Thai 
Drug Users’ Network claims systemic discrimination toward drug users by that service, and 
that very few of the 50,000 Thais on ART are injecting drug users.50 
                                                                                                                                                                                        
Considerations in Biomedical HIV Preventions Trials (2007) adopts a new category ‘standard of prevention’ 
(Guidance point 13) to define the control arm in HIV prevention trials. Available at: 
http://data.unaids.org/pub/Report/2007/jc1399_ethical_considerations_en.pdf [Accessed 24 Sept 2010] 
48 This is the language used in the CIOMS guidelines regarding placebo use. Guideline 11, CIOMS, op.cit. note 
44. 
49 S. Jintarkanon et al. Unethical Clinical Trials in Thailand: A Community Response (letter). Lancet, 2005; 
365: 1617-1618. 
50 K. Alcorn. 2005. Thai Tenofovir Trial Runs into Trouble after Ethics Protests from Drug Users. NAM 
Aidsmap 10 March.Available at: http://www.aidsmap.com/en/news/AF0B8B91-A54B-4632-9736-
03F66FE37CF5.asp 
 
 
69
 Given the strength of the ethical objections to the Thai trial, it seems remarkable that it has 
remained open, and continues recruiting, while the other trials closed. As to the reason why, I 
can only guess that this is concerned with the illegality of drug use in Thailand: Chua et al.51 
mention that long prison terms and even the death sentence are norms for drug-related 
offenses. Police have wide discretionary powers, and there have been an alleged 3,000 extra-
judicial executions52. These factors arguably add up to a population who will not want to 
make too much fuss or attract too much attention for fear of reprisal. 
 
The impact of the activism 
The activism surrounding the PrEP trials has generally been met with disapproval from the 
wider community of people involved in HIV research. Joep Lange, who co-chaired the 
fifteenth International AIDS Conference in Thailand, which was disrupted by PrEP trial 
protesters, claimed that the activist group ACT-UP Paris, in particular, used methods of 
‘uninformed demagogy [and] intimidation’.53 Lange’s anger at the failure of the PrEP trials is 
based on three key issues: the demonstrated need for new biomedical HIV prevention 
                                                                                                                                                                                        
[Accessed 14 Jan 2010]. 
51 Chua et al. op. cit. note 25. 
52 ibid 
53 J.M. Lange. We Must Not Let Protestors Derail Trials of Pre-Exposure Prophylaxis for HIV. PLoS Med 2005; 
2 (9): 833-834. Available at: 
http://www.plosmedicine.org/article/info:doi%2F10.1371%2Fjournal.pmed.0020248 
[Accessed 13 Jan 2010] 
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strategies, which he deems to be foiled by the trial closures; the fact that it is demonstrable 
that the researchers in the Cambodia trial did, in fact, consult with community groups (but 
arguably not the right groups, and not well enough); and thirdly, that the protests were led 
from outside, motivated by the ‘misguided ethical imperialism’ of ACT-UP Paris.54 While it 
is undeniable that there were elements of sensationalism and misinformation in the protests, 
this does not mean that there were no substantive issues involved. As the measured analysis 
written by the investigators from the Cambodia trial makes clear, the issue of compensation 
for harms was pertinent, but the trial sponsors would not negotiate.55  
 
During the controversy over the design and implementation of PrEP trials, provision of ART 
for seroconverters was treated as one of several requirements to ensure that participants got 
fair recompense for their participation. The sex workers involved in the protests were more 
interested in health care generally, particularly in the event of a catastrophic side effect like 
kidney failure, than ART alone. This demand for fair access to ongoing healthcare made by 
the PrEP protesters demonstrates a concept of equity at work, one where people – including 
trial participants – are assumed to have the same basic rights to life saving treatment 
regardless of where they live. This, of course, is a tenet of the treatment access movement: 
that universal access is a human right. 
 
                                                            
54 Ibid. 
55 Page-Shafer op. cit. note 22 
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The experience of the PrEP trials shows that even very vulnerable populations have an 
expectation that if they undertake risks, they earn an entitlement to benefits that 
comprehensively offset those risks. Further, that they should be consulted in the 
determination of the nature of those benefits. 
 
The bioethics response to the universal access movement 
  
Although access to ART in the developing world remains inadequate, the universal access 
movement has created political impetus to redress this and programmatic interventions to 
facilitate it. These changes create the context where it can be argued that obligations to 
research participants have changed due to external circumstances. This fits with the tenet that 
‘we can only morally require of people to do what they are capable of doing, or what it is 
reasonable to ask’,56 commonly expressed as ‘ought implies can’. The argument that 
treatment provision in prevention trials is too burdensome, while always contestable, is now 
clearly untenable.  
 
Ruth Macklin (2006) contends that arguments against obligatory provision of ART in 
prevention trials were based on the assumption that either the researcher or the sponsor would 
have to bear the cost. Now that treatment access programs are in place and partnerships 
between treatment and research programs are being forged, that assumption has been 
                                                            
56 R. van der Graaf & J.J.M. van Delden. What is the Best Standard for the Standard of Care in Clinical 
Research? Am J Bioethics 2009; 9(3): 35-43. 
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overturned. Within the new context of treatment access programs, she suggests an obligation 
to provide ART has arisen.57 
 
The problem for bioethics becomes how to theorise the source of the obligation. The 
obligation is not grounded in compensatory justice, argue both Slack et al.58 (2004) and 
Weijer and Le Blanc,59 as HIV acquisition is not caused by trial participation but by risk 
behaviour, against which participants are explicitly counselled. Causation is a necessary 
condition of compensatory claims. If the prevention technology itself does not cause the HIV 
infection (so the argument goes), then the infection arises from the participant’s own 
behaviour.  
 
The individualism that underpins this argument and the avoidance of addressing the structural 
determinants of HIV risk is problematic.60 An eighteen year old sex worker who has 
unprotected sex in Durban, South Africa has a much greater risk of being infected with HIV 
than her sister in Sydney Australia would have. Women and men who exchange sex for 
money, goods or favours may also have less control over the sex they have, including 
                                                            
57R. Macklin. Changing the Presumption: Providing ART to Vaccine Research Participants. Am J Bioethics 
2006; 6:W1–W5. 
58 C. Slack et al. Provision of HIV Treatment in HIV Preventive Vaccine Trials: A Developing Country 
Perspective. Soc Sci Med 2005; 60(6): 1197-1208. 
59 C. Weijer & G.J. LeBlanc. op. cit. note 31. 
60 D. Zion. HIV/AIDS Clinical Research, and the Claims of Beneficence, Justice and Integrity. Camb Q Healthc 
Ethics 2004;13: 404-413. 
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whether or not condoms are used. A trade-off between accepting more money for an 
unprotected sex act may appear a good deal to someone who is struggling to survive from 
day-to-day. The riposte to this point is that the researchers are not responsible for this 
inequity. This is true, but it is also true that they gain by it, because HIV prevention trials 
must instrumentalise the vulnerability of people who are at high risk of HIV to run successful 
trials. Weijer and Le Blanc argue that HIV prevention researchers are people ‘already 
contributing importantly to redressing injustice’.61 This contains an implicit claim that 
research is in itself a moral enterprise. Even if you take this claim to be uncontested (which it 
is not), it overlooks the fact the research is an industry – one that uses people as a raw 
material. This arguably creates an obligation on the part of researcher to provide a benefit 
that is commensurate with the risk, inconvenience and level of gratitude owed to those who 
participate in such significant research. 
 
The assertion that HIV acquisition is not causally connected to experimental biomedical 
agents is problematised by the examples of two recent – and possibly three - prevention trials 
in which the experimental technologies specifically increased, rather than diminished, 
biological susceptibility to HIV infection. Three trials in the last decade have been stopped by 
their Data Safety and Monitoring Boards due to increased susceptibility to infection in the 
active treatment group, and in two of these cases it was found that the experimental agent 
increased the likelihood of seroconversion.62 These trials are an important reminder of the 
                                                            
61 C. Weijer & G.J. LeBlanc. op. cit. note 31. 
62 Briefly, two experimental microbicides (topical agents designed to be used in the vagina to prevent infection) 
have caused an increased rate of HIV infection in women using the product in clinical trials testing their efficacy 
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risk of participating in clinical research and the possibility of unintended and unexpected 
effects when experimental products are used in the broader populations in efficacy trials. 
 
However, to argue that the basis of an obligation is risk alone, underestimates the 
responsibilities of the physician/researcher and the inescapable obscenity that the success of 
HIV prevention trials depends upon recruiting people sufficiently vulnerable to HIV 
acquisition (due largely to structural factors beyond their control), and observing the rate at 
which they acquire this life-threatening infection. 
 
Belsky and Richardson provide a moral framework for determining the care that should be 
provided to trial participants beyond that which is required for the successful conduct of a 
study.63 They argue that participants in clinical research entrust their health to researchers in 
a ‘partial and limited’ manner which creates a corresponding duty of care. Analysis of this
together with analysis of the strength of the claim, allows distinctions to be drawn.  
, 
                                                                                                                                                                                        
 
(see below); L. Van Damme et al. (on behalf of the COL-1492 study group). Effectiveness of COL-1492, a 
nonoxnol-9 Vaginal Gel, on HIV-1 Transmission in Female Sex Workers: A Randomized Controlled Trial. 
Lancet 2002; 360 (9338): 971-977; L. Van Damme et al. Lack of Effectiveness of Cellulose Sulfate Gel for the 
Prevention of Vaginal HIV Transmission. N Engl J Med 2008; 359 (5): 463-472; One vaccine trial has shown 
increased susceptibility to HIV associated with the product in certain populations; S.P. Buchbinder et al. 
Efficacy Assessment of a Cell-mediated Immunity HIV-1 Vaccine (the Step Study): A Double-blind, 
Randomised, Placebo-controlled, test-of-concept Trial. Lancet 2008; 372: 1881-1893. 
63 L. Belsky & H.  Richardson. Medical Researchers’ Ancillary Clinical Care Responsibilities. BMJ 2004; 328: 
1494–1496. 
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Although the scope of this partial entrustment will vary, it is possible to generalise. As a 
participant typically gives permission for a disease under study to be monitored, the scope of 
the entrustment typically includes caring, as needed, for that disease. Since participants’ 
permission is needed for doing tests or collecting confidential medical information, the scope 
of entrustment typically includes following up on any clinically relevant information or 
diagnoses generated.64  
 
The determination of obligation, they claim, depends upon a condition being within the scope 
of entrustment and the obligation being sufficiently strong. There are four tests of the strength 
of the claim. These are questions of the degree of the participant’s vulnerability, the depth of 
the relationship between the participant and the researcher (meaning intensity and duration - 
is the study a one-off test or of an ongoing nature), the degree of gratitude the researcher 
owes the participant and consideration of whether there are important reasons against 
providing the care. They illustrate this with the example of a woman in a trial of a vaginal 
microbicide, who is found to have vaginal thrush, and who appears to have dental problems. 
The researcher is obliged to treat the first condition, as its diagnosis is made through an assay 
used in the research, and vaginal health is a significant factor in a trial that alters the vaginal 
environment. Her dental condition, however, falls outside the scope of entrustment because 
its diagnosis does not arise from ‘exercising the permission participants grant on entering the 
study’.65 
                                                            
64 Ibid: 1495. 
65 Ibid. 
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 Applying this framework to HIV prevention trials, randomised controlled trials (RCTs) 
require seroconversions in order to get results, and HIV testing occurs as part of the trial. As 
Richardson points out in his later article, this places treatment for HIV centrally within the 
scope of entrustment, and establishes a presumptive duty of care.66 HIV prevention trials in 
developing countries involve people who are highly vulnerable, and they necessarily 
instrumentalise the socio-economic vulnerability of research subjects to HIV to produce a 
result. Trial participation requires long-term commitment with relatively frequent clinical 
contact. Participation involves risk due to the exposure to an agent that has been used in 
relatively few people and the seroconversion of a percentage of trial participants are 
foreseeable harms, necessary to the research and over-determined by circumstance. The 
participants’ agreement to volunteer for the trial provides researchers with a significant 
opportunity. The researchers, science and society all benefit from successful HIV prevention 
trials, but unless ART is provided for seroconverters and appropriate general health care to all 
participants, no commensurate benefit is provided to the participant. The degree of 
dependence upon the researcher is likely to be high given poor health infrastructure. Hence, 
all the conditions for determining that there exists a strong claim are present. 
 
                                                            
66 H. Richardson. Gradations of Researchers’ Obligation to provide Ancillary Care for HIV/AIDS in Developing 
Countries. Am J Public Health 2007: 97(11): 1958 
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Finally it needs to be considered whether there is an important reason not to provide ART. 
Prolonging the lives of otherwise healthy people who are in their most productive years 
provides a strong moral imperative for ART. The point that providing therapy for some 
members of a community but not others introduces a new level of advantage and 
disadvantage in an important one, because justice and equity are central aims of the 
enterprise.67 It is not sufficient, however, to deny research participants a justifiable claim to 
life saving treatment. Some degree of priority-setting and rationing is unavoidable in 
ratcheting up universal ART programs in resource-poor areas. Prioritising research 
participants in government or donor-funded facilities is appropriate, as research participants 
remain citizens and human beings to whom both governments and aid organizations have 
responsibilities. However such prioritisation must involve the leveraging of research funds to 
increase the overall pool available, so that research participants do not merely displace other 
eligible people.  
 
Using this model, contraception would fit into the ‘scope of entrustment’ for HIV prevention 
trials, along with testing for and treatment of sexually transmissible infections (which is 
standard practice) and compensation for illness and/or disability arising from use of the 
experimental drug (which is what the Cambodian sex workers sought). 
 
                                                            
67 B. Lo, N. Padian & M. Barnes. The Obligation to Provide Antiretroviral Treatment in HIV Prevention Trials, 
AIDS 2007; 21: 1229-1231. 
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Stobie and Slack argue that taking the principle of reciprocal justice seriously would mean 
that both infected and uninfected participants deserve equal contribution of thanks, 
suggesting that ART provision would provide an unfair benefit to those who seroconvert68. 
This account fails to recognise that while risk is theoretically borne equally by the 
participants in a randomised trial, its outcome – harm – is experienced asymmetrically. It is 
unknown who will receive the experimental agent, it is unknown whether its effects will be 
beneficial or detrimental and it is unknown who will be exposed, and at what level, to HIV 
infection while on the trial. All bear the risk, but through the confluence of a range of factors, 
only some experience the burden of actually acquiring HIV. Providing compensatory care for 
those who are ‘unlucky’ – those who experience reasonably predictable harms that affect 
some but not all individuals – is an equitable approach to off-setting the inequitable burdens. 
 
In 2008, Macklin addresses the role of changing circumstances in creating obligation. She 
argues for ART provision as an act of beneficence and an exercise in justice-as-reciprocity 
neatly reversing ‘ought implies can’ to ‘can implies ought’. 
Millum (2009) raises a problem with the claim that the obligation is there because it is now 
possible, through alliances with other parties, to provide ART with relatively little burden 
upon researchers.69 Millum points out that the putative obligation is upon researchers and 
                                                            
68M. Stobie & C.Slack. Treatment Needs In HIV Prevention Trials: Using Beneficence 
To Clarify Sponsor-Investigator Responsibilities. Dev World Bioeth, 10(3):150-7..doi: 10.1111/j.1471-
8847.2009.00272.x 
69 J. Millum. Post-trial Access to Antiretrovirals: Who owes What to Whom? Bioethics 2009. doi: 
10.1111/j.1467-8519.2009.01736.x. Available at: http://onlinelibrary.wiley.com/doi/10.1111/j.1467-
8519.2009.01736.x/full [Accessed 13 Sept 2010]. 
 
 
79
trial sponsors, not upon governments and international aid agencies, to provide ART for 
seroconverters in research trials. Governments and aid agencies, he contends, should have 
their own priorities for distribution of ART. Given that everyone who has HIV at a stage that 
requires treatment deserves it, and governments’ obligations are to the citizenship and not to 
select groups thereof, Millum argues that it is not justified to shift resources from non-
participants to participants (Recall that this was one of the issues in the Cameroon PrEP site – 
the demand for ART already outstripped supply and prioritising research participants would 
displace others.). Millum writes: 
The central problem with using either beneficence or justice to ground an obligation 
to supply ART to trial participants is that neither gives us reason to privilege trial 
participants over other equally needy people. Duties of beneficence and duties to 
rectify injustice are grounded in the unfortunate situation of the beneficiaries; they are 
not dependent on the beneficiaries participating in clinical trials. 
 
The justification for special treatment of research participants rests upon reciprocity, 
according to Millum. Their participation in research is primarily of benefit to others, and 
hence they are owed ‘an appropriate response to the benefits received’.70 Millum does not 
conclude that this obligation is necessarily that of life-long ART (recall that for the 
Cambodian sex workers, insurance against any long-term adverse effects of the trial drug was 
the key goal), but he is adamant that if ART is provided, it ought not to be at the expense of 
others. 
                                                            
70 Ibid: 7 
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 Millum’s contention that the obligation is not necessarily to provide access to ART is based 
on arguments that the strength of the obligation can vary according to individual factors 
within trials. Firstly, the researcher/participant relationship may be brief and superficial; 
secondly, the duties of reciprocation depend on the benefits generated, and that these benefits 
vary between trials.  
 
The first part of Millum’s argument pays too little attention to Belsky and Richardson’s 
‘scope of entrustment’,71 which for an HIV prevention trial clearly includes treatment for the 
condition under study. Regarding the strength of the claim, trials may vary somewhat in their 
requirements of participants, but ongoing, regular monitoring over a number of years is the 
expected obligation of participants, which is hardly an insignificant relationship. 
 
The second aspect of Millum’s argument is grounded in a notion that only some HIV 
prevention trials provide the kinds of benefits (in terms of knowledge) that would justify 
ART provision as an appropriate response. While undoubtedly some trials produce 
generalisable knowledge that could transform the prevention of HIV, it would be a very crude 
analysis that rated participation in such a trial above a trial of a failed product, or a harmful 
product. Can Millum seriously imply that participants in the male circumcision trials which 
changed the landscape of HIV prevention are owed more than, say, participants in the 
Carraguard microbicide study, which showed safety but no efficacy? Clinical research is an 
                                                            
71 Belsky & Richardson, op cit. note 62. 
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iterative process and learning progresses at each stage. Learning what does not work is as 
important as learning what does. 
 
Thirdly, Millum’s contention that the obligation to seroconverters on a research trial is borne 
by the researcher alone is flawed. The responsibility of the researcher does not nullify the 
pre-existing obligations of a government to its citizens, nor of the international humanitarian 
community to people in need. Hence a model of shared care, to which researchers contribute 
but are not solely responsible, is appropriate. This position is adopted by Lo and colleagues, 
who extend the argument to contend that ART provision should be community-wide, rather 
than limited to trial participants.72 Taking the obligation to provide ART to seroconverters as 
a given, the basis of their argument is social justice, and they advance two reasons for this 
position. Firstly, in a community where a major HIV prevention trial is being conducted it is 
possible that there will be participants from past trials in the area for whom ART was not 
provided. Secondly the research project should generally aim to reduce health disparities, not 
increase them by constructing a new level of privilege and disadvantage. 
 
In accordance with the obligation to provide ART in resource-poor setting, they argue that if 
national programs are up and running, the sponsor/researcher should contribute to these 
programs in a way that facilitates the sustainability of the programs. Donor money should be 
used in strategic ways to reduce the structural barriers to accessing treatment for communities 
                                                            
72 Lo et al. op. cit. note 66. 
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(such as distance from health facilities), not just individual participants. Providing a bus 
service, they argue, is a better intervention than simply transporting single participants to 
medical appointments. This concept fits neatly with Millum’s view that fulfilment of 
obligations to participants should maintain or increase the global provision of ART, though 
he disagrees that the researchers have any specific obligation to the wider population and that 
government and aid agencies have an obligation to research participants. It dovetails with the 
argument advanced by Shapiro and Benatar,73 that there is an obligation for researchers to 
ratchet up infrastructure and care so as to benefit the whole population, rather than limiting 
benefits to research participants. 
 
The logistical problem that arises from the argument that researchers’ obligations ought not 
to be offset to other institutions nor be fulfilled at the expense of other needy people, is 
summed up by Macklin:  
The NIH and the MRC have as their mission the conduct of research, not the 
provision of health benefits to research subjects or the developing countries from 
which they are drawn. It is in ... the[ir] interest to conduct research efficiently and 
effectively, and that can only be done by sticking to their narrow mission.74 
 
                                                            
73 K. Shapiro & S.R. Benatar. HIV Prevention Research and Global Inequality: Steps Towards Improved 
Standards of Care. J Med Ethics 2005; 31: 39–47. 
74 R. Macklin. 2004. Striving for a Single Standard. In Double Standards in Medical Research in Developing 
Countries. Cambridge, UK; Cambridge University Press: 101-102. 
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Given that true universal access remains a dream, it is timely for research funders to revisit 
their mission, and recognise that their moral obligation requires that provision of benefits to 
participants (or at least facilitation of, and contribution towards, benefits) be considered as 
legitimate an expense as the salaries of research staff, or the costs of transporting blood 
samples to laboratories. 
 
Discussion 
Why argue for the right for trial participants to access ART – and other necessary medical 
benefits, as required – when all people with HIV who require treatment have that right, 
grounded in human rights conventions?75 Does this not privilege the rights of the few over 
that of the many? It is not, in my view, a question of placing the rights of some over others, 
but of articulating the responsibilities of different agencies toward different populations and 
individuals, with a view to creating a context that facilitates the goal of universal access. 
 
The generalised right to health as articulated in human rights conventions, in particular the 
International Covenant on Economic, Social and Cultural Rights, places responsibilities 
upon governments and the international community. But other parties also bear specific 
responsibilities: for example, physicians have particular responsibilities to provide care for 
their patients, and the research community, as I have argued in the article, has a special 
                                                            
75 United Nations General Assembly. International Covenant on Economic, Social and Cultural Rights, 16 
December 1966, 993 UNTS 3 at Article 12 (entered into force 3 January 1976). Available at: 
http://www2.ohchr.org/english/law/cescr.htm [Accessed 3 Mar 2010]. Note that the US has never ratified this, 
as it appears to mandate universal access to healthcare. 
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responsibility towards research participants. Stressing both physician/patient responsibilities 
and researcher/participant responsibilities do not undermine the generalised claim for care by 
the needy, but they apportion that responsibility in specific ways. In my view, the delineation 
of responsibilities to provide care creates an enabling environment for universal access. 
 
Consider the real-world effects of short-course AZT trials, which proved that giving less of 
the drug to poor women produced a result that was less effective than best practice, but better 
than nothing. The short-course regimen was not then implemented in southern Africa. 
Proving that short-course AZT was better than nothing for vertical transmission did not create 
momentum for significant price reductions and improved access. Those results supported the 
indecent pricing of the drug, by establishing a regimen that encouraged giving less drug for 
less effect in poor populations (resulting in more HIV positive babies), rather than fuelling 
arguments for reasonable, affordable drug prices for all.76  
 
Putting the public health goals of a developing nation above the protection of the individual 
research subject, by allowing researchers to discount standards of care, places a lower value 
on the life of that subject, and this process supports, rather than challenges, global inequities. 
Access schemes created to support research projects, on the other hand, build capacity to 
scale up for broader provision of essential health services. 
                                                            
76 While there were, and are, substantial logistical problems with providing optimal treatment and prophylaxis to 
pregnant HIV positive women who present late for care, the short course AZT trials focused on giving less drug 
to poor women, rather than exploring optimal dosing within logistical constraints. The high price of the drug 
was taken as given, rather than a possible variable. 
 
 
85
 Protecting the rights of the individual research participants and requiring those who have a 
responsibility to honour them, prevents exploitation and upholds a notion of global equity. 
The alternative is the perpetuation of double standards which support an assumption that 
inequity is inevitable (and implicitly acceptable). 
 
Summary and conclusions  
 
The devastation caused by HIV/AIDS in the developing world spawns two very different 
responses: one, which I characterise as relativist, a movement to work within the contextual 
constraints to research appropriate interventions; the other, universalist in scope, is an outcry 
against exploitation, and a desire to police the obligations that the researcher has to protect 
the research participant. The basic question being asked was: do research participants 
everywhere have the same rights? The answer to this, a priori, is that they do (or should).  
 
Where the relativists and the universalists part company is on the reasoning about how to best 
protect the interests of those participants. The universalists argue that this means importing 
standards of care and post-trial care from the developed world, against which to test more 
context-appropriate interventions, as the protection of the individual research participant is 
the primary obligation of the researcher. The relativists argue that research participants are 
part of a community, and that community interests are best served by acknowledging the 
reality of local circumstance. Therefore, context-appropriate interventions should be tested 
against the baseline therapy currently available in the community, even if that is nothing.  
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 While this debate raged, in the resource-rich world, the control of HIV-related diseases using 
combination antiretroviral therapy became the good news story of the late 1990s. The 
ascendancy of ART and reframing of HIV as a manageable chronic infection catalysed a 
struggle for equity in global health: the treatment access movement. This movement sought 
to displace the assumptions of unaffordability and excessive complexity, and replace it with 
the simple demand for equity, for recognition that access to life saving treatment had to be 
seen as a necessity and a right, not a privilege reserved for the affluent.  
 
The stark disparity in access to life-saving drugs rekindled the question of what was owed to 
research participants in HIV prevention trials. The populations needed to test new prevention 
technologies were precisely those that lacked assured access to life saving treatment for those 
who seroconverted.  
 
The PrEP trials discussed in this article represent a great social failure of institutionalised 
clinical research. These trials are important, because the views of the potential participants 
are brought to the fore, and they are insistent and compelling in their demands for what they 
consider to be reciprocal justice in research.  
 
The experience of the PrEP trials, particularly in Cambodia, and the example of the treatment 
access movement, shows that people in the developing world want justice. This is to say that 
they want access to health care and treatment, and that they do not accept profit – even the 
putative future profit for humanity – being placed over their lives and well being. The 
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argument that researchers have a duty of care – indeed, a moral obligation – to ensure that 
therapy for the disease under study in prevention trials is available, is significant because it 
broadens the role of research in the developing world. Rather than functioning as a 
dislocated, disinterested machine for the production of knowledge, this obligation creates a 
new role for research as part of a capacity building project that can help to redress health 
disparities. 
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 Part 2, Chapter 1 
 
 
Survey of principal investigators of HIV biomedical prevention 
trials 
 
 
Publication status: This chapter is not intended for publication. 
 
Introduction 
HIV prevention research is usually conducted in populations at very high risk of HIV 
in order to get a timely result. Because a confluence of social, political, geographical 
and biological factors contribute to HIV risk, people from high risk populations are 
also likely to be vulnerable to exploitation (UNAIDS 2012, 10). People from these 
populations may also derive great benefit from getting access to effective HIV 
prevention technologies. Accordingly, it is well recognised that those conducting HIV 
prevention research are obliged to promote the rights and welfare of participants, and 
specifically to provide them with HIV prevention options that lower their risk rather 
than exploit their vulnerability to HIV acquisition (e.g. UNAIDS 2012, Rennie and 
Sugarman 2010, UNAIDS 2000). 
 
Therefore, a complex package of prevention and care is negotiated for participants in 
HIV prevention trials. This can include effective HIV prevention interventions, sexual 
and reproductive health care, other medical care whether or not it is directly related to 
trial participation, access to antiretroviral therapy (ARV) for those who acquire HIV, 
and development of capacity and infrastructure within trial communities. These 
measures collectively constitute the standard of care for trial participants.  
 
While standards of care in different trials contain common elements, implementation 
can vary significantly (Heise, Shapiro and West Slevin 2008). In addition, 
technological advances in HIV treatment and lessons learned from initial HIV 
prevention trials have led to expectations evolving over time different levels of care, 
and an increased emphasis upon community negotiation and collaboration (e.g. Page 
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Shafer et al. 2005; Feldblum et al. 2008, 7; Ramjee, Kamali& McCormack 2010, 
UNAIDS 2011). 
 
This raises the question of what the standard of care should be for trials, whether there 
should be a minimum standard, and how the affected communities can have a say in 
the matter. This survey seeks to determine how principal investigators of HIV 
biomedical prevention trials approach determinations of standard of care. 
 
Aims 
This study sought to survey principal investigators who had conducted HIV 
biomedical prevention research between 2000 and 2011, a period in which there was 
significant change in terms of access to antiretrovirals in low- and middle-income 
countries. The aim was to assess the self-reported factors that principal investigators 
took into account when making decisions about standards of care for participants in 
HIV prevention research, as background to further in-depth interviews with a subset 
of participants. Specifically the survey aimed: 
 To establish what forms of ethical guidance, if any, that the principal 
investigators based their deliberations upon; 
 To determine whether principal investigators were committed to 
particular standards of care (including ancillary care and treatment for 
seroconverters); 
 To see if either standards changed over time, and/or if reliance on 
particular forms of ethical guidance changed over time; 
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 To establish whether/how principal investigators facilitated  capacity 
building in the form of community collaboration and/or development 
of health infrastructure; and 
 To ask whether principal investigators were satisfied with the final 
outcome. 
 
Methods 
Eligibility 
People were considered eligible for the study if, between 2000 and 2011, they had 
conducted a phase IIb or phase III trial of a biomedical intervention that was designed 
to prevent sexual transmission of HIV.  
 
To identify the study population, I searched the Current Controlled Trials and clinical 
trials.gov databases for trials between 2000 and 2011 using the term ‘HIV prevention’ 
I then sorted through results to find efficacy trials of biomedical HIV prevention 
interventions for sexual transmission that were either phase III or IIb. Twenty-eight 
trials met these criteria. Principal investigators (PIs) and first authors of key 
publications from these trials were contacted by email and invited to participate in the 
study by responding to a survey. 
 
Recruitment 
Eligible PIs were contacted by email and sent information forms and a link to the 
questionnaire. Potential participants were also followed up in person at international 
conferences (Microbicides 2010 in Pittsburgh, International AIDS Society in Rome 
and Microbicides 2012 in Sydney) and through mediated email introductions and 
 83
recommendations provided by colleagues. Each eligible PI was sent at least one 
reminder email. Four ineligible responses were received and deleted. The recruitment 
aimed at achieving a purposive sample of PIs in which all of the prevention trial 
modalities were represented and key opinion leaders who had conducted more than 
one HIV prevention trial were included. 
 
Study design 
 The questionnaire was designed using SurveyMonkey Select software.  The 
conceptual framework was based on categories established in a seminal ‘standards of 
care’ mapping study (Heise, Shapiro and West Slevin 2008).  The questionnaire was 
piloted online with two staff members and three students at the Centre for Values 
Ethics and the Law in Medicine (VELiM). The survey went live in May 2010.  
 
Initial responses from eligible PIs highlighted some further difficulties with the 
questionnaire design, particularly the requirement that people repeat the questionnaire 
several times depending on the number of trial they had conducted. Accordingly, the 
study was re-designed and piloted again with two members of the ethics committee of 
ACON (formerly known as the AIDS Council of NSW) and two staff members from 
the Kirby Institute. Following feedback, further alterations were made to the format 
wording and the sequence of questions, and provision was made within the 
questionnaire to report on more than one study. Due to the difficulty of recruiting PIs, 
those who had responded to the initial questionnaire were not asked to complete the 
revised one.  
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The questionnaire had a multiple choice format, with specific questions allowing 
more than one response, and others limited to one only. In many cases, a free text 
field was also provided for respondents to add additional information (see Appendix 
D for full questionnaire and summary of responses). Respondents were asked about 
the first HIV prevention trial they had reviewed and then about the most recent. 
Descriptive statistics in the form of simple frequencies were calculated for responses 
to closed-ended questions, and summaries were compiled for free-text responses 
where they were provided. 
 
Data collected from both the initial survey are reported alongside data collected from 
the revised survey. Where the questions differed slightly, this has been noted. If the 
difference is such that the two sets of results are not commensurate, the initial survey 
results are reported separately. 
 
Data were collected from all respondents on the inclusion of male circumcision in 
standards of prevention. However it was not clear from these data which trials took 
place after the release of circumcision efficacy results in 2007. In trials that took place 
before 2007, there would be no expectation of including circumcision in the standard 
of care, but for those that took place afterward and had male uncircumcised HIV 
negative participants, it is an important question. Accordingly, the relevant PIs were 
contacted by email to provide clarification. This information is presented along with 
survey results.  
 
These surveys were approved by the Human Research Ethics Committee of the 
University of Sydney. 
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Results 
Final survey 
Seventeen eligible respondents began the survey and 16 completed it. Five 
respondents had completed one trial and 12 more than one. All HIV prevention 
modalities except for HIV treatment-as-prevention were represented in the final 
survey.  
Respondents were asked about their first and their most recent trial, and to provide 
dates where possible. Six of the dates listed for the first trial however fall outside the 
eligibility criteria set for this study. Entry into the survey was by invitation only, and 
invitations were only sent to eligible individuals.  Therefore principal investigators 
who were eligible based on their more recent work had also worked on much earlier 
trials, which I had not anticipated. Rather than deleting these responses I have kept 
then in the analysis, which therefore gives a picture of a slightly wider time period 
than was originally intended (from 1994 -2011 rather than 2000-2011). 
 
Initial survey 
Ten eligible participants completed the survey. HIV prevention modalities represented 
were PrEP, HIV vaccines, microbicides, HIV treatment-as-prevention and the 
diaphragm. 
 
HIV prevention modalities represented 
When the initial survey and the final survey are combined, PIs from all of the HIV 
prevention modalities researched between 200 and 2012 are represented in the 
purposive sample. 
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Table 1 HIV prevention modalities represented 
Survey question: Which HIV prevention modality did your prevention trial/s study?  
  INITIAL SURVEY 
(n=10) 
REVISED SURVEY (n=17) 
    One trial only  
(n=5) 
FIRST HIV 
prevention trial  
(n=10) 
MOST RECENT 
HIV prevention 
trial (n=12) 
PrEP 
 
4 (40%)  1 (20%)  2 (20%)  6 (50%) 
HIV vaccine 2 (20%)  0  1 (10%)  2 (17%) 
 
Male circumcision 
 
0 
 
2 (40%) 
 
0 
 
2 (17%) 
 
Microbicide  
 
 
8 (80%) 
 
2 (40%) 
 
3 (30%) 
 
1 (8%) 
PrEP/microbicide 
(single trial) 
 
0  0  0  1 (8%) 
HIV Treatment-as-
prevention 
 
1 (10%)  0  0  0 
STI Treatment-as-
prevention 
 
0  0  2 (20%)  0 
Diaphragm 
 
1 (10%)  0  2 (20%)  0 
 
Dates of first trial 
 June 2008 
 February 2005 
 1994 
 2004 
 1999 
 1994 
 1996 
 None of the above: I was involved in trial of AZT to prevent MTCT in 
1995-6 
 1995 
 
Dates of most recent trial 
 2005 
 2007 
 2010 
 August 2009 
 2007 
 February, 2002 
 2008 
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Initial survey 
In the initial survey respondents reported names of trials rather than dates, which will 
not be reported for reasons of confidentiality. 
Guidance questions 
Each PI cited several sources of ethical guidance. The Declaration of Helsinki was the 
most commonly consulted document overall, with 28 respondents citing it. Both the 
national guidelines of the host country and the researchers’ institutional guidelines 
increase from the first to the most recent trial, as does ICH-GCP. 
Table 2. Ethical guidelines consulted by principal investigators 
Survey question: ‘Did you consult any ethical guidelines in designing your trial? If so, 
which guidelines did you consult?’ 
  INITIAL SURVEY 
(n=10) 
REVISED SURVEY (n=17) 
    One trial only  
(n=5) 
FIRST HIV 
prevention trial  
(n=11) 
MOST RECENT 
HIV prevention 
trial  (n=11) 
Declaration of 
Helsinki 
 
8 (80%)  5 (100%)  7 (63%)  8 (72%) 
ICH-GCP 
 
0  4 (80%)  6 (54%)  9 (82%) 
Host country 
national guidelines 
 
3 (30%)  1 (20%)  6 (54%)  9 (82%) 
Sponsoring country 
national guidelines 
 
0  2 (40%) 
 
6 (54%)  0 
Researcher’s 
institution national 
guidelines 
 
0  2 (40%)  6 (54%)  9 (82%) 
US federal 
regulations (the 
Common Rule) 
1 (10%)  2 (40%)  6 (54%)  8 (72%) 
 
CIOMS 
 
3 (30%) 
 
1 (20%) 
 
3 (27%) 
 
3 (27%) 
 
UNAIDS 
 
3 (30%0 
 
1 (20%) 
 
4 (36%) 
 
7 (64%) 
 
Nuffield Council on 
Bioethics 
 
1 (10%) 
 
0 
 
1 (9%) 
 
0 
 
HPTN 
 
1 (10%) 
 
0 
 
3 (27%) 
 
5 (45%) 
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Additional guidance cited: 
 MRC Guidance on Provision of ART in developing countries May 2003 (I trial 
only) 
 Read numerous issues of the Hastings Institute's "IRB: Ethics and Human 
Research" (I trial only) 
 Regularly read Hastings Institute "IRB: Ethics and Human Research." (most 
recent trial) 
 Collaborative Institutional Training Initiative (CITI) (initial survey) 
 
Where was ethics approval obtained? 
Ethics approval was obtained from multiple sources by all PIs. All PIs in the initial 
survey, and those who had conducted one trial only, reported obtaining ethical review 
in the trial’s host country. Most, but not all PIs who conducted multiple trials also 
reported this (10/12 for the first trial, 11/12 for the most recent). 
 
Table 3. Where was ethics approval obtained? 
Survey question: ‘Where did you obtain ethical review?’ 
  INITIAL SURVEY 
(n=10) 
REVISED SURVEY (n=17) 
    One trial only 
(n=5) 
FIRST HIV 
prevention 
trial (n=12) 
MOST RECENT 
HIV 
prevention 
trial (n=12)  
Host country 10 (100%)  5 (100%)  10 (83%) 
 
11 (92%) 
Sponsoring 
country 
 
9 (90%)  4 (80%)  7 (58%) 
 
8 (67%) 
Country of 
researcher’s 
academic 
institution 
 
0  2 (40%)  11 (92%)  10 (83%) 
 
 89
Most recent trial 
Respondents from both the final and the initial surveys supplied a list of ethics 
committees who reviewed the HIV prevention trials. Forty-one distinct ethics 
committee were named. Six respondents provided only general information, such 
as ‘plus each group with whom we collaborated for trial implementation’ 
‘multiple African IRBs’, ‘plus two UK ethics committees; and ‘too many to list’.  
(For further information on how this list was used, see Pt 2 Chapter 2.) 
 
Standard of Prevention/risk reduction package (including 
contraception) 
 
Respondents were asked which particular components in the HIV risk reduction 
package offered to all participants (‘standard of prevention’).  
All respondents in both the final and the initial survey reported that male condoms 
were supplied, and all final survey respondents also provided counselling 
(respondents in the initial survey were not asked about counselling). There was 
less unanimity with other prevention options. Treatment for sexually transmissible 
infections (STI) was offered by all but one respondent (most recent trial), and 
testing for STI was offered in all but two instances (most recent trial and first trial 
– same respondent – STI treatment was available on the basis of symptoms, 
known as ‘syndromic management’). As Table 4 shows, there was considerable 
variation regarding provision of contraceptive options, cervical screening and 
treatment, male circumcision and other preventive medical services. Of note, 
some trials enrolled men only and some women only, so all options were not 
applicable to all respondents. 
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Table 4. Health/prevention services offer to trial participants 
Survey question: ‘Which health/prevention services did the trial offer participants?’ 
  INITIAL SURVEY 
(n=10) 
REVISED SURVEY (n=17) 
    One trial only 
(n=5) 
First trial (n=12)  Most recent trial 
(n=12) 
Counselling  n/a  5 (100%)  12 (100%)  12 (100%) 
Male condoms 10* (100%)  5 (100%)  12 (100%)  12 (100%) 
STI treatment 10† (100%)  5 (100%)  12 (100%)  11 (92%) 
STI testing 10† (100%)  4 (80%)  10 (83%)  11 (92%) 
Oral contraceptive pill 4‡ (40%)  2 (40%)  6 (50%)  7 (58%) 
Injectable 
contraception 
4‡ (40%)  2 (40%)  4 (33%)  7 (58%) 
Male circumcision for 
partners/participants 
0  2 (40%)  1  4 (33%) 
Female condoms 5* (50%)  1 (20%)  5 (41%)  8 (66%) 
Contraceptive 
implants 
3‡ (30%)  1 (20%)  0  0 
Cervical screening 7 (70%)  1 (20%)  6 (50%)  7 (58%) 
Treatment of cervical 
dysplasia 
3 (30%)  0  0  2 (17%) 
Hepatitis B 
vaccination 
1 (10%)  1 (20%)  2 (17%)  5 (41%) 
Referral to local 
services for non-trial 
related conditions 
8 (80%)  0  10 (83%)  12 (100%) 
 
 
Notes on differences between the initial survey and main survey: 
Respondents were not asked about counselling. 
*Male condoms supply was divided into ‘free and unlimited access’ (9) and ‘limited 
number’ (1).  Female condoms use was also divided into ‘free and unlimited access’ 
(4) and ‘limited number’ (1). 
† STI testing and treatment were treated as a single question. 
‡Hormonal contraceptives were categorised as ‘limited options’ (1) and 
‘comprehensive options’ (3). 
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Comments 
 Female condoms not offered only because the trial was a diaphragm 
trial and their use together was contraindicated 
 Female condoms were hardly available; MC was not proven to be 
effective yet; cervical screening was done where feasible with referral for 
care 
 We talk about male circumcision but since we work with women only, 
do not offer it for their partners. We refer for cervical dysplasia 
 The number of condoms was locally determined; referral for treatment 
of cervical dysplasia if locally available, cervical screening was only done 
if local referral was possible. 
 This arrangement is made through PEPFAR programs in the country 
 Research clinics in primary health care location and therefore all 
primary health care services provided to participants by research staff, 
with reporting via local clinic 
 [Contraceptive] implants were not universally available, and cervical 
screening was only available in South Africa where there is a national 
programme 
 There were no women enrolled in the study 
Addition information about male circumcision as ‘standard of 
prevention’* 
Four trials in this sample enrolled HIV negative heterosexual men after the release of 
efficacy data on circumcision. Phambili (HIV vaccine trial) provided proactive access 
(before national or international guidelines were released). TDF-2 (PrEP trial) 
provided information once the official recommendations from the government were 
released. HPTN052 (Treatment-as-prevention) did not inform participants in a formal and 
systematic way regarding the results of the circumcision studies because this was not a 
procedure that was being offered at most of the local settings in which study sites were 
located. Partners PrEP sites informed relevant participants (HIV- uncircumcised men) and 
provided active referral (checking in on whether successfully taken up, etc.) for interested 
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men.  Additional scope of activities in Partners PrEP sites varied by site – some sites had 
circumcision programs as part of their other funded activities. 
*Specific information obtained by emailing respective PIs or senior staff. 
Other ancillary care 
Respondents were asked whether their committees required particular elements to be 
available as ancillary care for trial participants, and most offered some level of care, 
limited either by site capacity alone or to conditions that might impact on trial 
findings.  Only two respondents overall reported no ancillary care was available (from 
the initial survey).  
 
Table 5. Ancillary care 
Survey question: ‘Did your trial proposals offer other medical or prevention services 
to participants (such as treatment for common illnesses)?’ 
  INITIAL SURVEY 
(n=10) 
REVISED SURVEY (n=17) 
    One trial only (n=5)  FIRST HIV 
prevention trial 
(n=11) 
MOST RECENT 
HIV 
prevention 
trial? (n=12) 
Yes limited to 
conditions that might 
impact the research 
findings 
3* (30%)  2 (40%)  6 (54%)  5 (42%) 
Unlimited, except by 
site capacity 
 
4† (40%)  3 (60%)  4 (36%)  5 (42%) 
No 2 (20%)  0  0  0 
 
Yes, to treat 
conditions associated 
with HIV (such as 
TB, cervical cancer) 
 
 
1‡ (10%) 
 
 
0 
 
 
1 (9%) 
 
 
2 (17%) 
 
Phrasing of questions for initial survey was slightly different: 
* Sufficient to ensure the smooth running of the research 
†To treat conditions uncovered by the research process 
‡To the degree possible on the basis on need. 
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Comments: 
 In practice, care was unlimited for participants that presented to the 
research clinics with problems, although none of the centres could admit 
to hospital 
 This question cannot be accurately answered as it is worded. As I 
indicated, we offered a full range of HIV prevention services which had 
been proven to work at that time, and we offered mass STI treatment in the 
intervention arm. For ethical reasons, we referred symptomatic control 
arm persons to government clinics. 
 Physical and medical examination and as well as providing all the known 
bio-medical prevention tools available on the site eg condoms, risk 
reduction counselling, STI treatment etc. 
 Regarding the previous question, the trial enrolled only young HIV-
negative men, so many of the services asked about were not applicable. 
 
Benefits for families/partners 
Most respondents reported that trial related benefits were not available to partners or 
families of participants, though services to partners and families increased for the 
most recent trial. The main partner/family services detailed were STI treatment, HIV 
testing and counselling and condoms. 
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Table 6 Benefits for families/partners 
Survey question: ‘Did your committee require benefits to be provided to partners of 
families of participants?’ 
  INITIAL SURVEY 
(n=10) 
REVISED SURVEY (n=17) 
    One trial (n=5)  FIRST HIV 
prevention trial 
(n=12) 
Most recent HIV 
prevention (n=12) 
No 5 (50%)  3 (60%)  7 (59%)  5 (41%) 
 
Yes 
 
3 (30%) 
 
2 (40%) 
 
5 (41%) 
 
7 (59%) 
 
 
Comments (1 trial only) 
 This varied between centres, but in one centre the trial was enrolling 
serodiscordant couples, and in another running a VCT service for the 
community 
 Limited to treatment of STIs 
First trial 
 Not formally (not allowed by NIH rules) but informal care was provided by 
many Centers 
 Partners could get counselling, VCT and condoms 
Most recent trial 
 As above informal care was offered on a site by site basis 
Initial survey  
 HIV VCT and treatment for curable STIs 
 Partners were able to come to the clinics for HIV testing and counseling and 
for STI - also locally dependent. 
 This research specifically works with discordant couples so the partner 
benefits from health education and access to services provided by other donor 
funded activities 
 Services available to partners and children 
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Access to ARV for seroconverters 
Of the ten respondents in the initial survey, two reported that ARV access was not 
available to seroconverters and eight reported that it was (though different means, as 
detailed in the table below). In the final survey, six reported that ARV access was not 
supplied, in the first trial and two reported they were not sure in the first trial. For the 
most recent trial, however, all respondent reported ARV access with the most 
common provider being government programs (8), an equal number provided directly 
through research programs and non-government organisations respectively (4), and 
three reporting access through international donors. Many respondents also provided 
more detailed comments about implementation of ARV access, listed below in Table 
7. 
Table 7. ARV access for seroconverters 
Survey question: Was antiretroviral therapy (ARV) provided to participants who 
seroconverted during the trial? 
  INITIAL SURVEY 
(n=10) 
REVISED SURVEY (n=17) 
    One trial only 
(n=5) 
FIRST HIV 
prevention trial 
(n=12) 
MOST RECENT HIV 
prevention trial 
(n=12) 
Yes, through 
government 
programs. 
 
4 (40%) 
 
2 (40%) 
 
5 (42%) 
 
8 (66%) 
 
Yes, through NGO 
programs 
 
 
0 
 
1 (20%) 
 
1 (8%) 
 
4 (33%) 
Yes, through 
international donor 
programs 
 
 
1 (10%) 
 
2 (40%) 
 
1 (8%) 
 
3 (25%) 
Yes, directly linked 
to the research 
program 
 
 
1 (10%) 
 
0 
 
1 (8%) 
 
4 (33%) 
Not sure 
 
0  0  2 (17%)  0 
No 2 (20%)  0  6 (50%)  0 
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Comments (I trial) 
 3 centres referring into trial that provided immediate ART for 2 
randomisation groups 
 Seroconvertors were initially accompanied to ART services at the host 
institutions. 
First trial 
 Encouraged the participants to join other studies [such as] the START trial, 
depending on their CD4 count results. 
 Participants were referred to local HIV treatment centers and managed 
according to local standards of practice. Who paid for the drugs would vary 
by country and site. 
 We are part of the local health department and were able to provide linkage 
to clinics that provide ARVs. 
 Combination ART was not even proven to work until the trial was almost 
finished, and as noted in my prior answer, our donors (NIH, Gates,) 
specifically prohibit us from buying ART with their money, and until PEPFAR 
came to Uganda in 2004, we had NO access to ART. Again, this was not a 
decision made by the research team. 
 Antiretrovirals were not available when we did our first microbicide efficacy 
trial in the 1990s 
 The intervention itself was AZT, which is an antiretroviral. However, the trial 
occurred before ARVs were widely available. After the trial was over, the 
participants had priority to obtain ARVs. 
Most recent trial 
 All sites participating in our most recent study have to have a pathway for 
referring all participants who seroconvert. Depending on the stage of 
infection (usually early) they may or may not need immediate treatment. If 
they need treatment it might be provided through local resources or through 
agencies / programs such as PEPFAR. 
 We provide ARVs to trial participants and their communities through a 
PEPFAR program 
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 We created a post-test support group, provided free care for opportunistic 
infections, and linked positives to care and treatment facilities 
 Initial survey  
 At the start of the MIRA study in 2003, nothing was really in place. By the end 
of the study each site had a plan to link seroconverters to care. In Durban and 
Harare, participants were linked to government programs. In Jo’burg, the 
same, although I think the ARV clinic was a direct PEPFAR clinic, if that is 
what you mean by "international donors". The study assisted the participants 
in enrolling into national programs by providing transport, CD4 results, etc. 
and in some cases escorting people to the ARV clinics to assist them in 
navigating the process 
 At the time of COL-1492, ARV was not widely available yet. 
 We refer participants to existing facilities and that can be government or 
international. You should allow these two options to be checked. 
 Last three options - most women were referred, funds were made available to 
help with the care of seroconverters. 
 ARV access to volunteers who test positive. Seroconverters are referred to an 
acute infection study initially and transition to the treatment program when 
eligible based on local treatment guidelines 
 Available through PEPFAR funding to the host research institution and 
implemented in partnership with the government program who provide all 
drugs. Very integrated to the research process and available in clinics next 
door to the study clinics. 
 
 
Access to ARV for the screened out 
Incomplete data only are available on respondents’ reports of ARV access for people 
who volunteered to participate, but were ineligible due to pre-existing, hitherto 
unknown, HIV infection. Due to an error in the survey, this question was not asked 
for the most recent trial. Eleven of the total number of participants asked this question 
reported that access was not available to this group (50%). Only two respondents said 
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this access was directly linked to the research program, the rest were through other 
government, donor or non-government sources. 
 
Table 8. ARV access for the screened-out* 
Survey question: ‘Was ARV provided to volunteers found HIV positive at screening 
and therefore ineligible?’ 
  INITIAL SURVEY 
(n=10) 
REVISED SURVEY (n=17) 
    One trial only 
(n=5) 
FIRST HIV 
prevention trial 
(n=12) 
Yes, through 
government 
programs. 
 
3 (30%) 
 
2 (40%) 
 
4 (33%) 
 
Yes, through NGO 
programs 
 
0 
 
1 (20%) 
 
1 (8%) 
 
Yes, through 
international donor 
programs 
 
 
 
2 (20%) 
 
 
2 (40%) 
 
 
1 (8%) 
Yes, directly linked 
to the research 
program 
 
 
1 (10%) 
 
0 
 
1 (8%) 
Not sure 0 
 
0  0 
No 3 (30%)  0  8 (66%) 
 
 
Comments 
 The uptake of referral to care providers that could provide access to ART was 
disappointingly low, particularly for those that were screened out because of 
being HIV positive 
 I think there were studies going on in some centres that those positive at 
screening were referred to. 
 Women were referred to existing programs 
 CD4 equal to or less than 200 or clinical AIDS 
 During the pilot study in 2005 the ART program was initiated. In discussion 
with the program there was concern that the study would identify high 
 99
numbers of women in need of treatment (in feasibility study 50% of volunteers 
had been positive at screening). Consequently hospital asked the research 
team to provide CD4 tests and refer in priority order so as not to overwhelm 
the new service - this was funded by our sponsor and maintained throughout 
the trial 
 Due to a programming error, data are not available for the screened-out on 
most recent trials. 
 
Community consultation/collaboration 
 
Community consultation throughout the research project was reported by two 
respondents who had conducted a single HIV prevention trial. Consultation in the 
planning stages only was reported by six respondents in the first trial and four in their 
most recent. Consultation during both planning and recruitment phases was the most 
popular response for the most recent trial, with nine reporting this. Five respondents 
reported no consultation; of these, three had conducted a single trial, one report was 
for a first trial and one was from the initial survey, where the timing of the trial is not 
clear from the data and the question was somewhat different, as is detailed below in  
Table 9. 
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Table 9. Community consultation 
Survey question: ‘Did you consult with communities affected by the trial about the 
care/prevention services that would be provided within the trial?’ 
  INITIAL SURVEY 
(n=10) 
REVISED SURVEY (n=17) 
    One trial (n=5)  First trial (n=11) 
 
Most recent 
(n=11) 
Yes, throughout the 
research project 
0  2 (40%)  0  0 
 
Yes, in planning 
stages 
 
 
2 (40%) 
 
0 
 
6 (54%) 
 
4 (36%) 
No 
 
1 (20%)  3 (60%)  1 (9%)  0 
Yes, in recruitment 
stages 
 
 
2 (40%) 
 
0 
 
2 (18%) 
 
3 (27%) 
Yes, in planning and 
recruitment stages 
 
 
5 (100%) 
 
0 
 
4 (36%) 
 
9 (81%) 
During the trial 
 
0  0  0  10 (91%) 
 
Initial survey (n=10) * question was worded differently: Did you discuss the 
distribution of research benefits with local communities? 
Comments from initial survey 
 This was also an ongoing dialogue with trial participants during 
interviews and focus group discussions, as well as with community 
advisory groups. 
 
Comments from final survey 
 One trial 
 The negotiation was undertaken by the PIs of each clinical research centre, so 
not by me. 
First trial 
 "Care" is a rather vague term 
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 I came on board the study after the initial planning so I'm not entirely sure 
about this question. 
 We provided everything that was proven at that time: health ed, condoms, HIV 
testing and counseling, phased in p-MTCT as the data accrued on how to do it in 
rural areas. The RCTs on combination ART were not completed until towards the 
end of our study, so they were not yet standard of care; in any case, our donors 
do not allow us to buy ARTs with our grants. We informed community leaders of 
what we could offer, but there was not much we could negotiate! It is often 
assumed that the researchers make the decisions as to what to offer, but in many 
cases, our hands are tied. 
 
Infrastructure 
Most respondents reported that their research contributed to in-country infrastructure. 
Table 10 Contribution to infrastructure 
Survey question: Did your prevention trial contribute infrastructure to the host 
country, e.g. the training of health care workers, establishment of clinical facilities? 
  INITIAL SURVEY 
(n=9) 
REVISED SURVEY (n=17) 
    One trial only 
(n=5) 
FIRST HIV 
prevention trial 
(n=12) 
MOST RECENT HIV 
prevention trial 
(n=12) 
Yes 
 
7  5 (100%)  10 (83%)  10 (83%) 
No 2  0  2 (17%)  2 (17%) 
 
Details of infrastructure 
One trial only 
 This was not the case in all centres 
 A fully equipped clinic and laboratory, renovation of an additional clinic 
and provision of some equipment. 
 Training; data management infrastructure; laboratory equipment; 
laboratory renovation 
 Establishment/maintenance of clinical facilities and training of research 
staff 
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 Male circumcision center 
 
First trial 
 In addition to training project staff, there was considerable building of 
clinic and research facilities and local clinics were given assistance with 
medical supplies. 
 Training of staff as required by protocol. research centre 
development(infrastructure) 
 Training, renovations, new clinical and laboratory resources, and much 
more. 
 Enhanced facilities' human and physical resources 
 
Most recent trial 
 MSM Training manual was produced by the site and is in the proposal 
stage of being involved in the health professionals’ curriculum. 
 Training of health care workers 
 training of health workers, establishment of clinical and laboratory 
facilities, community education and training of community health workers 
 Training of staff, clinical and lab buildings. 
 Training, infrastructure development 
 Training of surgical teams, counselors, establishment of surgical 
facilities, improved lab infrastructure 
 
Initial survey 
 Built a clinic in Cotonou. 
 Lab and clinical infrastructure 
 Laboratory equipment, vehicle, motorcycles, office equipment and 
furniture. 
 We renovated clinics and labs. 
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 The CAPRISA Vulindlela Clinical Research and Ethekwini sites work 
closely with the local primary care clinics and in addition to physical 
infrastructure in close proximity they provide services that are not 
available at the PHC clinic such as ARV treatment services; patients can 
access other care and services not otherwise available at the PHC clinic. 
Staff training and support, new information sharing and technical 
assistance is provided to staff at the PHC clinics. 
 lab equipments colposcopy and clinic setup 
 Porta cabins purchased for the study mostly transferred to HIV program. 
Plus assisted primary health care clinics over the years with building 
repairs and changes to their infrastructure 
 
Respondents to the initial survey were asked an extra question regarding 
infrastructure: will this infrastructure contribute to meeting health needs or 
research capacity of the community post-trial?: yes (seven);  no (two). 
Comments: 
 if the local people pick it up 
 if the local people choose so 
 Laboratory equipment are useful for research 
 if the local people continue 
 Infrastructure and services are in place permanently and not linked 
specifically to this/a trial 
 lab equipments can continue to be functional 
 
Sponsor policies: did the sponsor have policies that impacted on 
the health and prevention services offered to participants? 
Most respondent reported that trial sponsors had policies that affected provision of 
health and prevention services to participants (two for one trial only, ninefor the first 
trial and ten for the most recent). 
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Table 11 Sponsor policies 
Survey question: ‘Did the trial sponsor have policies regarding health/prevention 
services that were made available to participants’ 
  REVISED SURVEY (n=17) 
  One trial (n=4)  FIRST HIV 
prevention trial 
(n=11) 
MOST RECENT HIV 
(n=12) 
Yes 
 
2 (50%)  9 (82%)  10 (83%) 
No 2 (50%)  2 (18%)  2 (17%) 
 
 
The initial survey asked a different question: did the sponsor limit benefits that are 
made available to participants? Four respondents said yes to this, three said no, with 
the following comments: 
 
 As long as benefits are not coercion 
 PIs [in this study] are not foreigners and infrastructure and services are 
in place through diverse funding sources and not just through the specific 
trial being discussed in this survey. 
 Sponsor responded positively to all requests made by community 
stakeholders - including funding for CD4 tests and cervical cancer 
screening. 
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How did sponsor policies impact on care? 
 
Only one respondent indicated that sponsor policies had had a negative impact on 
care, while nine reported a positive impact for both the first and most recent trial. 
Three respondents reported that their sponsors did not have policies – one who had 
completed a single trial, one for the first trial and one for the most recent trial. 
Table 12. Sponsor policies 
Survey question: ‘How did sponsor policies affect the care/prevention services offered 
to participants?’ 
  REVISED SURVEY 
  One trial (n=4)  FIRST HIV 
prevention trial 
(n=10) 
MOST RECENT HIV 
(n=10) 
Positively 
 
2 (50%)  9 (90%)  9 (90%) 
Negatively 
 
1 (25%)  0  0 
Sponsors did not 
have policies 
1 (25%)  1 (10%)  1 (10%) 
 
 
Comments 
One trial 
 MRC policy for provision of ART was very helpful as it allowed flexibility 
which meant that PIs were able to provide as much as feasible within their 
setting. A strict uniform policy would probably have reduced the care to the 
minimum feasible 
First trial 
 Neither increase nor decrease 
 The whole field moved several quantums (sic) in the provision of trial 
services/follow up... 
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Satisfaction 
Only one trial: 5/5 
 Slightly concerned (as was our Trial Steering Committee) that the benefits 
and services provided to participants were too out of sync with what was 
available in reality 
 First trial: 7 yes, 5 partially 
 I do not know how provision of services was monitored nor what standard 
was truly required by the sites. 
 in those days, care for AIDS patients were very limited in and outside of 
the trial 
 In retrospect, more services could have been provided, but for that time 
(mid-1990's) the services were much more than was standard at the time. 
 At the time, the trial was ahead of the ethical bell-shaped curve; in 
retrospect, it was behind as standards evolved 
Initial survey satisfaction: Six respondents said yes they were satisfied, while 
two said they were partially so. 
Comments: 
 However[respondent had  indicated full satisfaction], I  feel we still could 
have done more to attract male partners to the clinics as although 
services were available for them the uptake was very low 
Discussion 
The results of this questionnaire illustrate the move toward increased ARV access for 
participant seroconverters, with the progression from half the surveyed PIs making no 
provision for ARV access for their first trial to all making provision in their most 
recent.  This demonstrates how ARV access for seroconverters has become a norm 
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over time. The finding is not surprising, however, as the phenomenon of increased 
access to ARV in low- and middle-income countries is well-documented (Macklin 
2006), and this removed barriers that PIs would formerly have faced to securing 
access. 
 
Several of the comments however indicated that while policies were in place, there 
was a degree of concern or at least nervousness as to how effective implementation of 
ARV access was in practice, with people referred for ARV access not necessarily 
getting it. Monitoring of implementation of ARV access was also a concern, as was 
‘overwhelming’ ARV service providers with newly diagnosed HIV infections as a 
result of screening volunteers for prevention studies Researchers who were based 
permanently in the countries in which their research took place did not report these 
concerns, probably because they were already integrated into service networks or had 
the capacity to provide ARV within their research sites. 
 
A more surprising finding is the majority perception that sponsor policies affected 
provision of prevention and or care services positively rather than negatively. 
Previous work of standards of care in HIV prevention research showed how policies 
such as those of the United States’ National Institutes of Health (NIH) vetoed 
spending grant money from this source both non-trial related care and the building of 
permanent infrastructure, such as clinics or even significant renovation of existing 
facilities without specific permission. With the majority of studies (though not all) 
having significant funding from the NIH, it is surprising to see that a positive impact 
is reported by respondents. This may be due to some level of diversification of 
funding sources, with funders other than the NIH providing sponsorship for certain 
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aspects of the trial. It is possible that some respondents interpreted the question as 
being specifically about standard of prevention, in which case there is no barrier to the 
provision of condoms and STI-based HIV prevention services in NIH policy. One 
respondent did however provide the anticipated response, which emphasised that the 
donor requirement did not sit well with this particular research team:  
Our donors (NIH, Gates,) specifically prohibit us from buying ART with their 
money, and until PEPFAR came to Uganda in 2004, we had NO access to 
ART. Again, this was not a decision made by the research team. 
 
Community consultation 
 The length and depth of community consultation appeared to increase over time, with 
more investigators reporting consultation during design, recruitment and throughout 
the trial for their most recent research compared with the first trial.  
 
There are a number of factors that probably contributed firstly to low rates of 
community involvement prior to trial recruitment, and to the increased attention to 
community involvement in later trials. Firstly, at grant-writing stage, researchers 
frequently plan their research for a high risk population generally, but the specific 
population is determined later in the process (McCormack 2012), which can impede 
early community participation work. Whether or not community involvement is 
adequately funded is also an issue. Following the closure of the PrEP trials in the 
early 2000s, however, there was increasing international emphasis on community 
preparedness work, including the development of UNAIDS/AVAC Good 
Participatory Guidelines for biomedical HIV prevention trials, first published in 2007. 
The publicity surrounding the development and publication of this document 
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foregrounded the need for adequately funded community involvement, so it would be 
reasonable to expect an increase in earlier community involvement  from this time 
onwards. This is not surprising, given the emphasis of community consultation in the 
Good Participatory Practice Guidelines (UNAIDS 2011) and also the HPTN guidance 
(Rennie and Sugarman 2009).    
 
Ethical guidance 
Investigators reported seeking ethical guidance from a range of sources, and each 
cited more than one.  The choice of guidelines is likely to reflect compliance 
requirements of the various institutions involved, which shifted somewhat over time. 
The low rate of citation of the UNAIDS guidance is likely to be because this was not 
a national or institutional requirement. The guidelines of the host country, the 
researcher’s institution, the US Common Rule and ICH-GCP became increasingly 
popular, but overall the Declaration of Helsinki was the most cited form of guidance. 
Investigators reported seeking ethics approval from multiple sources, nearly always 
including the host country and then at least one of the investigators’ institution and/or 
another committee from the sponsoring country. 
 
The normative question of whether investigators should aim for best practice, local 
standards or something in between, is touched on in several responses. One 
investigator reports providing ‘everything proven at the time’ while another has a 
concern that the benefits and services provided to participants were too out of sync 
with what was available in reality. ‘Reality’ in this quote presumably refers to the 
local standard in the absence of a major research project. This concern echoes an issue 
raised in a Lancet review article, that suggested that high standards of prevention in 
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HIV prevention research were potentially masking the efficacy of modestly effective 
experimental products (Padian 2008). Another quote concerning ancillary care refers 
to flexibility within institutional guidelines that allow as much as feasible within their 
setting. A strict uniform policy would probably have reduced the care to the minimum 
feasible. This comment speaks to the importance of context even within a paradigm 
that strives for best practice, implicitly arguing that variations between trial sites can 
be acceptable if that maximises care provision. 
 
The uneven introduction of voluntary medical male circumcision in trials 
commencing after 2007 that enrolled eligible participants1 is noteworthy. The use of 
national guidelines to determine eligibility means that in countries that were slow to 
include circumcision in national guidelines, eligible participants were not offered a 
proven beneficial intervention.   
 
Limitations 
This research has several limitations. Most obviously it comprises two surveys that 
are not identical, and there are some inconsistencies in language within surveys. The 
initial survey does not capture differences over time, while the final survey does so 
only crudely, as one respondent’s ‘most recent’; trial may be contemporaneous with 
another’s first trial. In addition, as noted earlier, many of the first trials fall outside of 
the eligibility criteria, so may not be precisely comparable with the most recent trials. 
 
                                                 
1 HIV negative uncircumcised heterosexual men living in countries with generalised epidemics 
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The survey was designed and went ‘live’ prior to the positive efficacy findings of new 
HIV biomedical prevention from July 2010, so it does not address issues of how 
standards might evolve in the light of new evidence. 
 
Conclusion 
Not withstanding the limitations of this section, the results of this survey suggest that 
there is significant variation in the ways that standards of prevention and care are 
conceived, designed and implemented, despite considerable attention given to 
normative ethics guidance. It also suggests that the ARV access movement has had a 
decisive impact on the care made available to both seroconverters from trials and, to a 
lesser extent, volunteers screened out due to pre-existing HIV infection.  
 
The failure to introduce voluntary medical male circumcision in some sites due to 
slow uptake in national guidelines shows how the use of host country standards (as 
distinct for best practice standards) can deny participants access to a proven effective 
intervention in particular settings, introducing  a specific difference between trial 
participants in the same trial who come from different countries. 
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Abstract 
In clinical research there is a tension between the role of a doctor, who must serve the 
ant. 
me 
ants 
 at times 
 
d 
 
 
best interests of the patient, and the role of the researcher, who must produce 
knowledge that may not have any immediate benefits for the research particip
This tension is exacerbated in HIV research in low and middle income countries, 
which frequently uncovers co-morbidities other than the condition under study. So
bioethicists argue that as the goals of medicine and those of research are distinct, it is 
a mistake for researchers to assume therapeutic responsibilities while engaging in 
research. Others propose that there is a duty of care, but disagree as to how this is 
limited and specified. In this qualitative study, principal investigators from HIV 
prevention trials discuss their experience of providing medical benefits to particip
within the context of conducting research into HIV biomedical prevention 
technologies. They describe the limitations imposed at times by funders and
by infrastructure constraints, and canvass the importance of ancillary care provision 
and capacity building in trial communities. The views of the principal investigators 
are compatible with the perspective that there is a duty of care, limited by the nature 
of the research, the depth of the relationship between research and participant, and the
capacity of the research site. The therapeutic orientation in HIV prevention trials 
appears to be indivisible from competent research practice by making concrete an
appropriate benefits available to trial participants and their communities that support
rather than compete with local infrastructure. 
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 Introduction 
In clinical research there is a tension between the role of a doctor, who must serve the 
best interests of the patient, and the role of the researcher, who must produce 
knowledge that may not have any immediate benefits for the research participant. [1, 
2] This tension is exacerbated in HIV research in low and middle income countries, 
which frequently uncovers co-morbidities other than the condition under study. Local 
healthcare resources may be unable to meet these needs, so researchers have to 
determine the extent to which the research site should provide ancillary care (care not 
directly related to trial participation) to trial participants.[3]  
 
This article explores the doctor/researcher role in the context of HIV biomedical 
prevention efficacy trials. It examines researchers’ perceptions of their obligations to 
trial participants and their reflections on their experience of the doctor/researcher 
conflict, which may exist regardless of whether the researcher is actually medically 
trained. It considers these perceptions and experiences in the light of normative 
theoretical models that aim to define and determine the scope of the 
doctor/researcher’s responsibility to participants, with a focus on the provision of 
ancillary care.  
 
Theoretical positions of ancillary care span the gamut of positions on researcher 
responsibility, from the fiduciary view which considers the well being of the 
participant to be the primary responsibility of the researcher [4] to the non-
exploitation approach, which limits researcher responsibility to implementing the 
protocol.[5]  
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 Within this range two nuanced models recognise that a responsibility exists, but that it 
needs both to be limited and specified. The partial entrustment model delineates the 
scope of responsibility according to the connection between the condition under study 
and the co-morbidity, together with the strength of the claim, assessed largely by 
participant vulnerability and the potential impact of non-treatment.[3] The capacity-
based model considers the urgency of the need, the strength of local healthcare 
infrastructure and the scope of the research infrastructure.[6] I will argue that the 
partial entrustment and the capacity-based models can be combined to provide a 
useful account of how to address relevant medical needs within the capabilities of the 
research project. 
 
Background 
The doctor/researcher role has an interesting history in HIV research. In the early days 
of the epidemic when HIV infection was synonymous with illness and death, activists 
argued that “a drug trial is health care too”, [7] and transformed regulatory systems to 
get better access to experimental treatment .[8, 9] With the advent of effective 
antiretroviral treatment in 1996, attention turned to HIV prevention research, which is 
qualitatively different to treatment research, insofar as participants in prevention trials 
are not ‘patients’, but are people at high risk of acquiring HIV. 
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Prevention research did not produce effective products for more than a decade, and 
various strategies were explored including, treatment-as-prevention, pre-exposure 
prophylaxis (PrEP), circumcision, vaccines, the diaphragm and microbicides.i[10]  
 
Microbicides are topical agents designed to prevent HIV infection through vaginal 
exposure.ii The first of these, nonoxynol-9, paradoxically increased participants’ risk 
of HIV acquisition.[11] Nonoxynol-9 was followed by five subsequent microbicide 
products that all failed to protect against HIV, two of which arguably increased HIV 
risk, albeit at non-statistically significant levels.[12, 13] To date, the sole partially 
effective microbicide product is tenofovir gel, found to reduce HIV acquisition by 39 
percent in 2010, a result awaiting confirmation.[14] 
Another female-controlled approach, the diaphragm showed no protective benefit.[15] 
 
Of four vaccine trials conducted, only one produced a marginally positive effect and 
another appeared to increase risk in a sub-population.[10,16] 
 
Circumcisioniii was the first biomedical prevention breakthrough, with three trials 
showing it reduces HIV acquisition in heterosexual men in HIV endemic areas by 
about 50 percent.[17, 18, 19] 
 
                                                 
i This research does not include biomedical prevention of vertical (parent-to-child) HIV transmission as 
the issues are significantly different, given that incidence of vertical transmission is predominantly 
about the failure to implement universally accessible programs successfully in high incidence regions. 
ii Rectal microbicides are also being developed to protect women and men who have receptive anal sex. 
iii I am not adopting the term ‘medical male circumcision’ because of activist critiques that claim this 
terminology implicitly legitimises the notion of a ‘female’ circumcision. 
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Daily use of antiretroviral drugs for HIV prevention (pre-exposure prophylaxis or 
PrEP), reduced HIV acquisition by 44 percent in iPrEx,[20] with two subsequent trial 
results showing higher risk reduction of 62 percent[21] and 75 percent [22] 
respectively.  Prior to iPrEX, however, three of four trials testing PrEP had been shut 
down prematurely due to community concerns.[23]  
 
Treatment-as prevention strategies were initially focused on treating sexually 
transmissible infections (STIs) understood to facilitate HIV infection, with mixed 
results.[16] In 2011, however, early treatment of HIV with  antiretroviral drugs 
(ARV) reduced the acquisition of HIV by sexual partners by 96 percent, a ground 
breaking result.[24] 
 
Many of the same HIV prevention researchers were involved in successive trials of 
products that were unsuccessful. How this experience affected subsequent decisions 
regarding the negotiation of participant benefits in HIV prevention trials is important 
for understanding the researchers’ self-perception and the doctor/researcher role. In 
addition, rapid scale up of HIV treatment services occurred in countries that hosted 
HIV prevention trials during the period spanned by this research, which had 
considerable impact on the levels of care that were considered feasible and coloured 
perceptions of what care ought to be available.iv 
 
Methods 
Twenty-eight efficacy trials of biomedical HIV prevention (either phase III or IIb) 
were identified between 2000 and 2011 through the Current Controlled Trials and 
                                                 
iv Thanks to an anonymous reviewer for pointing out the importance of this contextual element 
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clinical trials.gov databases. Principal investigators and first authors of key 
publications were contacted by email and invited to participate in the study by 
participating in a semi-structured interview.  
 
A purposive sample of 14 principal investigators from the 28 trials identified were 
interviewed, who between them had worked on more than 20 HIV prevention trialsv.  
Both men and women were included in the sample. Of the principal investigators 
interviewed, two were ‘in-country’ investigators, meaning that they headed the study 
at a particular trial site, but did not have oversight of the trial as a whole. The 
remaining 12 informants oversaw whole trials and in some cases networks of HIV 
prevention trials. Most of these informants had been a principal investigator or a 
senior member of the research team on more than one study.  Eight of the informants 
were doctor/researchers (informant numbers 1-8) and six were public health experts 
(informant numbers 9-14). 
 
All of the interviews were conducted by the author. Nine interviews were conducted 
by telephone and five were face-to-face. The study was reviewed and approved by the 
ethics committee of the University of Sydney. Informants were asked ‘Have you, or 
others in your research team, experienced tensions or conflict in the role as a doctor 
and role as a researcher in HIV biomedical prevention trials in developing country 
                                                 
v None of the interviewees had led a circumcision trial, but all other horizontal biomedical prevention 
modalities were represented in the sample. 
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settings?(Prompts: details of incidents, broad tensions?)’vi Data was coded using N-
Vivo 9 software and analysed thematically. 
Data were analysed from a symbolic interactionist perspective, in which interviews 
are understood not as mirror images of an objective reality (the positivist view), but as 
accounts of experience through which participants in the interview purvey their 
understandings of the social world under scrutiny (the ‘world’ of the HIV prevention 
trial). [25] 
 
Results 
 
Role perception  
Informants readily articulated the potential conflicts between acting as a researcher 
and acting as a doctor, but for those who were medically trained the doctor role was 
an important aspect of self-perception.  
In the prevention field we do have a conflict between the social roles, between 
researchers and participants and doctors and patients…there’s a prevailing 
concept that investigator/participant relationships are essentially a version of the 
doctor/patient relationship. In the prevention settings, it’s not really a good fit – 
in the prevention setting there are no patients, no one has the disease, and the 
investigators, even though they may be physicians, they’re not really acting 
exactly like a physician. I1 
                                                 
vi This was question eight in a series of ten broad questions regarding the negotiation of benefits for 
participants in HIV prevention trials. Informants also made references to the doctor role in answer to 
other questions regarding participant benefits in trial, which are also included in this analysis. 
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Identity as a doctor (or clinician or physician) was frequently invoked by informants 
to emphasis particular lines of moral reasoning or intuition. 
 But me personally I think that everything I was doing made complete sense as a 
physician as well as a community advocate, as well as an investigator. I1 
Imposed limitations on care 
Being a doctor was cited as a rationale for a participant-centred thinking by several 
participants, for example, when limitations were imposed by funders on non-trial 
related care that may be provided during a trial: 
As a medical doctor myself, I think [the limitations are] a bit too strict, but at 
the same time I can understand the money available for the research is 
limited. I2 
The perception of having a doctor-like responsibility was not limited to researchers 
who were medically trained – those whose background was public health also 
described a strong sense of responsibility toward trial participants and concern at 
resource-imposed limitations on care. 
So in terms of the ethical obligations of the trial site, we feel sometimes very, 
very compromised as to where our role is, is it as a healthcare provider, or is 
it as a researcher only.  And because you grow those relationships with 
participants, you feel almost obligated to make sure that she gets the treatment 
and the care that she should be getting. – I10 
 
Negotiating provision for trial-related injury or illness with the funding body was 
particularly frustrating for this public health trained PI: 
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We were certainly conscious of the need to provide for [medical] complications 
[that arise due to the trial product], but the primary funding agency was the NIH, 
and the NIH made it quite clear that their funding policies didn’t allow for that, 
and they didn’t allow you to purchase insurance, they didn’t allow you to pay for 
healthcare for trial related complications.  There were a lot of things that were 
precluded by their policies, and we found that very problematic.  I11 
Varying ancillary care standards between sites 
Pap smears were a particular point of contention, as cervical cancer is a major cause 
of death in countries where prevention trials are held, but not all countries provide 
treatment. A compromise was to conduct cervical screening in sites where there was 
linkage to treatment, but not otherwise. 
 
We didn’t do cervical screening in all of the sites because we couldn’t link to 
treatment in a sustained way .I4 
While the rationale for limitations upon care provision were both accepted and 
deemed acceptable, informants spoke of discomfort: 
We made the decision a while ago, after ethical review and consideration and 
discussion, it was probably inappropriate to offer a [cervical] screening service 
[i.e. pap smears] if the treatment for that condition couldn’t be provided within 
country…It does make me uncomfortable, but I think it’s more reflective of the 
inequities of healthcare delivery in the developing world, rather than we can’t do 
everything for everyone. –I3 
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ARV access for seroconverters 
The history of the nonoxynol-9 study, which found that the study product increased 
rather than decreased HIV acquisition, was identified as a catalyst for the 
development of more extensive benefits packages for participants, including access to 
antiretroviral drugs (ARV) for those who become HIV positive during a trial. As one 
informant explained: 
The nonoxynol-9 experience was still very very fresh in my mind…I felt very 
strongly we as sponsors have a responsibility to make sure that women who do 
seroconvert in the trial can get access to really good care… for me it was not 
a point of discussion even, you needed to provide it as sponsors. I2 
 
International pressure to supply ARV globally made provision within trials less 
onerous. 
At the end of the 90s antiretrovirals had a big breakthrough, for the first time 
treating infection in developing countries… plus the n-9 results became 
available which increased the risk of infection. I think those two gave a big 
push to the discussion of what should be the standard of care with regard to 
HIV. I2 
 
ARV access for the screened-out 
Investigators identified a second group of people who required HIV therapy: those 
who were screened out of prevention trials for which they had volunteered, on 
account of being already HIV-infected.  
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Our main burden of care if you like, our main obligation, the moral and ethical 
imperative that we felt was more to the women that were coming forward being 
screened [out], they weren’t actually becoming participants of the study, but they 
were women that had volunteered to join the study, and if they then found that 
they were HIV positive, we felt …we really have a burden of care to these women, 
and they’re the ones that are far more likely to require antiretrovirals at the point 
of diagnosis, because they could have been living with the virus unknown for 
many years.  I6 
Trial communities fed back to researchers that ensuring people screened-out were 
referred for care was an important part of building trust. 
When we did our first participant event we asked a group of participants to do a 
play on their experiences in the study, and I was amazed that they spent 20 
minutes going on about a woman who had been screened out because she was 
ineligible because she was HIV positive … and then we took her and put her on 
antiretrovirals… that showed the level of priority that [study participants] placed 
on the services that other women who didn’t get into the study got. I13 
Partnership approaches to providing care 
Ancillary care was not always provided directly, but could include referrals through 
established partnerships. 
As I learnt more and more about the needs of participants and the general health 
profile of the public, I felt that it was my ethical imperative, that I should put 
something in place to ensure that my responsibility to the trial participant, in full, 
in the sense that I must ensure that we provide complete healthcare, not 
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necessarily at the research site, but through partnerships.  And I personally 
believe that that is the ethical thing to do. I10 
Building effective partnerships that complemented local service infrastructure 
consolidated public favourable opinion for the researchers. 
The primary healthcare clinics had a large burden of work around family 
planning services, so we knew that it would be advantageous if we could offer 
family planning services, so we agreed with them that we would provide study 
participants with their family planning, and we would complete our own study 
documentation, but also their district healthcare documentation, so as we are 
reporting it back through their system as well.  So we got all of those services for 
free, but by our nurses providing it, it supports their service…At the last 
participant event, the women got up on the stage and they said ‘we’re 
disappointed [that the product did not prevent HIV], but we got really good 
reproductive healthcare, we got pap smears, we got all of these services, these 
people looked after us and they were good to us’.  And that is not necessarily 
something that people would say about the nurses in the [local] health clinic.  I13 
Building goodwill through care provision 
When care provided within a trial uncovered other readily treatable conditions in a 
population, this was celebrated. 
 
That’s where it is good, when people don’t get any care, studies like this can be a 
win/win to an extent, because you diagnose things that are wrong, and serious, 
and could be life threatening, had they not come to you. – I5 
With the emphasis on delivery of ancillary care, researchers generally described their 
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focus broadly in terms of having a beneficial impact on individuals and communities, 
rather than a narrow focus on simply answering a research questions. 
[Ancillary care is] a good example of how HIV prevention trials can actually 
impact on the health of the community in a way even go over and above the HIV 
prevention study, in another disease category.I5 
 
Discussion 
Informants saw provision of medical care as necessary (both ethically and practically) 
but this created ethical conflict around what people should offer and what they simply 
could not provide due to constraints of either funding or local infrastructure. 
There are several different theories regarding the responsibility of the 
doctor/researcher to research participants. Chief among these are the fiduciary 
view,[4] the non-exploitation approach,[5] the partial entrustment model [3] and the 
capacity-based model.[6] 
The fiduciary view posits the health of the participants as the highest priority, [4] and 
requires that the doctor/researcher uses “reasonable diligence, care and skill” in 
making judgements that affect the interests of the participant. It does not however 
specify the parameters of this responsibility in a resource-constrained environment 
where local care capacity may be below what is recognised as ‘competent medical 
care’ elsewhere. 
In contrast, the non-exploitation approach limits the researchers’ role to the 
implementing the research protocol,[5] and requires a favourable risk/benefit any 
provision of ancillary care. This rests on the premise, articulated elsewhere,[26, 27] 
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that the tension between the therapeutic obligations of the doctor and the scientific 
obligations of the researcher arise from the adoption of a ‘mistaken therapeutic 
orientation’ in clinical research.  
Informants’ responses in this study were incompatible with this approach. They attest 
that the tension exists, but do not support the conclusion that the ‘therapeutic 
orientation’ is mistaken as the health-related benefits were an important aspect of 
making research acceptable in trial communities. 
A vivid case example is provided in the literature by Vallely et al from the MDP 301 
microbicide trial.[28]  Despite having adopted a standard of care based on locally 
available best practice within trial sites, a participant with an emergency life-
threatening condition unrelated to the study was transported to hospital, admitted and 
had medicines procured through the private sector for her immediate and on-going 
inpatient treatment all at the expense of the research site. This exceptional care was 
provided because the researchers on site felt ”a clear duty of care to the participant 
and that it was appropriate to use whatever project resources were required to avert a 
life threatening situation” [p 7], an intuition that echoes Jonsen’s ‘rule of rescue’ – the 
“moral response to the imminence of death [that] demands we rescue the 
doomed”[29]. 
 
Even so, the best medical interests of individual participants were generally not the 
key priority for the informants, but one factor to be balanced with several others. The 
competing factors included the scientific integrity of the trial, limitations imposed by 
funders, and the constraints of local infrastructure.  
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The ‘partial entrustment’ model is compatible with the fiduciary view in that it 
upholds the concept of a duty of care,[3] but it defines the limits of researcher 
responsibility by analysis of what they call the ‘scope of partial entrustment’. 
Defining scope, they argue that a trial participant gives permission for the disease 
under study to be monitored, which involves tests and collection of other confidential 
material. The responsibility is then mediated (weakened or strengthened) by four 
factors: participants’ vulnerability, uncompensated risks or burdens, depth (intensity 
and duration) of the researcher participant relationship, and participants’ dependence 
on the researchers. [p 1495].  
 
This model can be applied to scenarios described by informants, and is particularly 
apt regarding the issue of cervical screening (pap smears) in microbicide trials. 
Cervical screening arguably fits within the scope of entrustment in microbicide trials 
in that the screening test fits within the range of tests that are done within the trial and 
it is related to a sexually transmissible infection – HIV prevention trial treat STIs as 
part of their core function – and HIV prevention trial infrastructure includes 
laboratory capacity which could readily diagnose abnormal results. With regard to the 
strength of the claim, microbicide trial participants are typically vulnerable, the risk of 
the research has been amply demonstrated in the early trials that increased HIV 
acquisition, and both the duration of the participant-researcher relationship and the 
level of dependence is generally strong.  
 
The extra factor that needs to be taken into account, however, is the capacity to 
provide treatment for cervical dysplasia, which goes beyond the normal capacity of a 
trial site and thus relies on referral to national programs, which did not exist in all 
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sites. The burden that a particular treatment may place on a research facility was 
acknowledged in an article further detailing the ‘partial entrustment’ model by 
Richardson,[30] adding this as a fifth factor with which to assess the strength of a 
claim.  
 
Assessing a research site’s capacity to respond to such a burden is the focus of the 
capacity model.[6] The capacity model bases decision making on the urgency of the 
need, local capacity and internal research capacity. It can be used to better specify 
both the ‘vulnerability’ aspect and the ‘burden’ element in the partial entrustment 
model, and can provide an approach for dealing with life-threatening episodes such as 
that described by Vallely et al,[28] thus allowing for the grand (expensive) gesture of 
life-saving within an otherwise rational model 
 
Returning to the question of treatment for cervical dysplasia, as provision of treatment 
at trial sites would put a major burden on researchers for a condition not directly 
related to the trial, the strength of the obligation to provide was weak. The decision to 
screen only where treatment facilities existed also fits within the framework of 
screening programs – only screen if there is both a useful test and an available 
effective treatment. 
 
The emphasis on access to ARVvii to trial participants who acquire HIV during a trial 
(seroconverters) following the nonoxynol-9 trial also fits within the ‘partial 
entrustment’ model.[3] The reasoning behind the perceived obligation was two fold: 
                                                 
vii ‘Access’ including referral to treatment programs funded from outside the trial, such as through 
PEPFAR, the Global Fund, and local governments. 
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an increased perception of the risk that trial participation entails, and improved access 
to effective treatment. 
 
Provision of care to those screened-out ranks as a weaker obligation in the ‘partial 
entrustment’ model, given the brevity and lack of depth of the relationship. The moral 
imperative to provide for the screened-out that some participants expressed rests 
predominantly on a sense of this group’s vulnerability – their acute need for 
treatment, given a presumed longer duration of HIV infection. Arguably this is an 
example of doctor-like reasoning, placing the interest of a patient – defined as 
someone needing care – above those of a person who may at some point in the future 
need careviii.[31] 
 
 
Conclusions 
The researchers in this study frequently described their ethical deliberations in terms 
of a doctor-like responsibility. This was not limited to the doctor/researchers in the 
study – the public health-trained researchers also demonstrated this kind of ‘doctorly’ 
reflection. The identification of the ‘screened out’ is a significant case in point, as the 
perceived obligation to this group is built on  doctor-like moral premise that care is 
owed to those who most need it, rather than stratifying obligations by the depth of the 
researcher/participant relationship, which is how it would be framed from a research 
ethics perspective. 
 
                                                 
viii As Carrese and Sugarman point out, doctors’ responsibilities for the sick are emphasised in 
documents ranging from the Hippocratic Oath to professional codes of ethics. 
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While participants in HIV prevention trials are not ‘patients’ – they are healthy people 
at high risk of HIV acquisition – their vulnerability to infection  combined with the 
uncertainties surrounding life-long ARV treatment in resource-poor countries compels 
attention to their health care needs. Provision of routine primary care in resource-
limited settings can ultimately save lives, in addition to the instrumental value of 
earning the trust that is essential to run such trials. 
 
The nonoxynol-9 experience demonstrated that research participation is inherently 
risky and that unexpected adverse events can occur with devastating effect. This 
history pervades ethical deliberation about HIV prevention trials and arguably has 
predisposed researchers to consider very carefully the benefits that can be weighed 
against any risks for these populations. 
 
The conduct of HIV prevention trials challenges the notion that a large-scale trial is 
simply a construct for answering a question. The complexity of how these trials 
operate within communities, how they sit with regard to national health infrastructure 
and ultimately how they work with each person who volunteers to participate, impacts 
on the health status of the communities involved and on the surrounding health 
infrastructure. 
 
The ‘therapeutic orientation’ in HIV prevention trials appears in this study population 
to be indivisible from competent research practice. By making concrete and 
appropriate benefits available to trial participants, the research supports local 
infrastructure making it acceptable to host communities. 
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 Abstract  
Background 
 UNAIDS Guidelines require that participants in HIV prevention trials are provided 
with ‘state of the art’ risk reduction measures. Published data showing that new HIV 
prevention strategies are highly, but not completely, effective problematize ‘standard 
of prevention’ packages that provide access to condoms and counselling only. This 
qualitative study asks how principal investigators on HIV prevention studies 
determine appropriate standards of prevention. It builds on previous work mapping 
standards of care in HIV prevention trials by investigating how decisions were arrived 
at, in addition to reporting what was decided. 
 
Methods  
Semi-structured interviews were conducted with fourteen principal investigators of 
biomedical HIV prevention trials. Interviews were transcribed, coded, and analysed 
thematically using pre-determined categories derived from the ethics literature and 
spontaneous coding. 
Results  
A spectrum of views was given by informants as to how standard of prevention 
should be determined, ranging from an ethical requirement to include newly validated 
technologies as soon as feasible to a perceived need to reduce the prevention package 
to make it more like real life, thus enhancing conditions for subsequent trials. Each 
informant argued her position with reference to the feasibility of ongoing studies, the 
need for conclusive data on the effectiveness of preventive interventions, perceived 
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duties to trial participants and regulatory requirements. Some saw re-consent as the 
critical issue in ongoing trials when relevant data from other studies was released. 
 
Conclusions 
There was no ethical consensus about the standard of prevention among principal 
investigators. Rational arguments were made to support disparate positions. This 
suggests a need to examine and articulate the ways that the narrow aims and 
obligations of a research study sit within the broader context of disease burden and 
inequitable access to health care in the resource-poor world, to address how research 
should proceed to ensure justice and feasibility. 
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Introduction 
Whether participants in HIV prevention studies should receive the best possible 
standard of care or a ‘good enough’ package is a normative issue in bioethics that is 
so contentious that even the key guidance documents take different positions.  Best 
possible, or ‘state-of-the-art’ packages are called for in the UNAIDS 2007 guidelines, 
while the HPTN guidelines stipulate that a basic prevention package is acceptable – if 
it is effective, achievable and accessible (Rennie, Sugarman et al. 2009).   
‘Standard of care’ is a broad term that encompasses the HIV prevention 
package offered to all trial participants (now called ‘standard of prevention’), care for 
non-trial related conditions (ancillary care) and access to antiretroviral therapy for 
those who acquire HIV during a trial. 
‘Standard of prevention’ is particularly important now in the light of a 
growing body of evidence on the efficacy of HIV biomedical prevention. 
Antiretroviral drugs have shown efficacy as preventive agents in five studies using 
treatment-as prevention or pre-exposure prophylaxis strategies1 (Abdool Karim et al. 
2012, Grant et al. 2010, Cohen et al. 2011, Baeten et al. 2012, Thigpen et al. 2012), 
while circumcision2 has shown efficacy in three studies (Auvert et al. 2005, Bailey et 
al. 2007, Gray et al. 2007 ). Both circumcision3 and treatment-as-prevention have 
been recommended by UNAIDS/WHO for HIV prevention (UNAIDS WHO 2007; 
UNAIDS WHO 2012). Oral pre-exposure prophylaxis (tenofovir/emtricitabine as a 
                                                 
1 ‘Pre-exposure prophylaxis’ includes both topical (tenofovir gel as a vaginal microbicide) and 
systemic use (tenofovir/emtricitabine in combined oral form). 
2 We adopt the term ‘circumcision’ rather than ‘medical male circumcision’ because the latter suggests 
that there is a corresponding ‘female’ form of circumcision. 
3 The caveat regarding circumcision in HIV prevention is that it is only recommended in generalised, 
high burden epidemics. 
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combined tablet) – henceforth referred to as ‘PrEP’ – was approved for prevention of 
HIV in women and men at risk of HIV in the United States on July 16, 2012. The US 
Food and Drug Administration’s approval of PrEP and the UNAIDS/WHO 
recommendation regarding circumcision and treatment-as-prevention raise the issue 
of whether any or all of these interventions should be included ‘standard of 
prevention’ in HIV trials (Food and Drug Administration 2012).   
This article reports findings from a qualitative study concerning the 
negotiation of benefits for participants in HIV prevention trials.  The study is based on 
interviews with principal investigators of prevention trials held between 2000 and 
2011, the period in which a wide range of HIV prevention efficacy trials testing a 
range of strategies were conducted. The FDA approval of PrEP had not occurred at 
the time that the interviews were conducted, but the issues associated were discussed 
hypothetically. 
The study documents how principal investigators’ recollect and represent their 
practice with respect to negotiating participant benefits within the ethically and 
logistically fraught context of managing research programs that recruit people 
vulnerable to HIV acquisition in resource-limited settings. Critical analysis of this 
data raises important normative questions such as problems with evidentiary 
standards, equipoise and the structural and inter-sectoral factors that affect access to 
medicines (whether approved or not approved) in situations of scarcity, poor 
healthcare access and HIV stigma. 
Background 
Controversy over standards of care erupted in 1997 over mother-to-child prevention 
trials in the developing world that tested experimental regimens against placebo 
controls (Lurie and Wolf 1997; Angell 1997). The use of a placebo control was 
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controversial because several years earlier the seminal PACTG076 study had shown 
an intervention to be effective (Connor et al. 1994). Critics of the placebo-based trials 
argued that they constituted a double standard in research between rich and poor 
countries. Defenders of the trials argued that the PACTG076 regimen was not feasible 
in the developing world and that the critical research question was whether the 
experimental regimens were better than nothing (e.g. Varmus and Satcher 1997). 
In the late 1990s, the new-found efficacy of combination ARV therapy in 
treating HIV disease catalysed a surge of research interest in biomedical prevention. 
The issues raised by the mother-to-child prevention trial led to heightened ethical 
scrutiny of other HIV prevention trial design. Two key questions were raised. One 
was whether researchers had an obligation to decrease the likelihood of HIV 
acquisition in prevention trials by facilitating access to condoms, safe sex counselling 
and treatment for sexually transmissible infections (STIs). The other question was 
whether those who acquired HIV during a trial should be provided with access to life 
saving ARV therapy. Provision of ARV was the more contentious question, 
particularly because it had massive resource implications at a time when donor 
programs had not been established and national health systems were not supplying 
ARV (Slack et al. 2005). 
The UNAIDS ethical guidelines of 2000 (reprinted 2004) stipulated that 
condoms, counselling and STI treatment should be made available to trial 
participants. Access to ARV was seen as subject to negotiations that turn on three key 
factors: the level of care available in the sponsoring country, the highest level of 
treatment and care available in the host country, and sustainability of treatment 
(UNAIDS 2000).  
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Notably, neither the VAXGen phase III vaccine study published in 2005 nor 
the COL 1492 phase III microbicide study that ended in 2000 facilitated access to 
ARVs (rgp120 Vaccine Study Group 2005; Van Damme et al. 2002)4. Indeed, COL 
1492 investigators sought guidance from an ethicist on this question, and were told 
that to do so would constitute ‘undue inducement’ as it was a benefit that trial 
participants could not access except through the trial (Van Damme 2010)  
Community opinion, however, was that antiretroviral access should be 
provided. By the early-to mid 2000s three separate trials of a new HIV prevention 
strategy, pre-exposure prophylaxis or ‘PrEP’5, were stopped due to community 
protest. While the reasons for the trial closures were complex and multi-factorial, the 
issue of access to antiretrovirals was cited as a key concern in each6 (Page-Shafer et 
al. 2005, Forbes and Mudaliar 2009, McGrory, Irvin and Heise 2009, Haire 2011).  
Increased global availability of antiretroviral (ARV) therapy through the 
WHO initiative aimed at treating three million people by 2005 (WHO 2012), and 
donor programs including the Global Fund and PEPFAR, allowed a consensus 
position to emerge regarding standard of care. Participants in prevention trials were 
provided with access to condoms and safe sex counselling, and people who acquired 
HIV during the trial (seroconverters) were linked with care programs as needed for 
ARV access (Macklin 2006, Heise et al. 2008). The provision of these services varied: 
                                                 
4 The study product in the COL 1492 study, nonoxynol-9, was subsequently found to increase risk of 
HIV acquisition. 
5 Pre-exposure prophylaxis is a strategy that uses antiretroviral drugs in HIV negative people to prevent 
infection. The ARVs tested as PrEP are tenofovir alone, and tenofovir with emtricitabine combined in a 
single tablet. 
6 This concern was a perception rather than a reality in the case of the Cambodia trial, where access to 
ARV for seroconverters was secured for a limited time post-trial. 
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some trials consolidated links to care more thoroughly and proactively than others, 
and quantity and quality of prevention services also varied (Heise et al. 2008). 
Nevertheless, there was broad acceptance that these services should be provided, even 
though concerns were occasionally expressed about their possible negative impact on 
results such as prevention services reducing HIV incidence in the trial population to a 
degree hard to predict and thus factor into sample size calculation (e.g. Padian et al. 
2008).  
Accordingly, the debate about the standard of prevention (the package of 
preventive interventions offered) slumbered while there was a lack of evidence 
supporting new HIV prevention methods.  It has been reignited, however, by the 
recent publication of evidence that a range of new prevention measures are partially 
effective. These include tenofovir gel (Abdool Karim et al. 2010), pre-exposure 
prophylaxis (Grant et al. 2010, Baeten 2012), ‘treatment-as-prevention’ (Cohen et al. 
2011) and circumcision (Auvert et al. 2007, Bailey et al. 2007, Gray et al. 2007). 
This study explores the negotiation of the standards of care for research 
participants from the perspective of principal investigators of HIV biomedical 
prevention trials. Drawing on a series of interviews with principal investigators, it 
documents the structural factors they identified as affecting the benefits that are 
available to participants, and their views on how partially effective biomedical 
technologies may introduce a tension between research ethics and the ongoing 
feasibility of HIV prevention research. This article focuses on standard of prevention 
rather than the other aspects of standard of care. 
Methods 
Twenty-eight efficacy trials of biomedical HIV prevention (either phase III or IIb) 
were identified between 2000 and 2011 through the Current Controlled Trials and 
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clinical trials.gov databases. The search term ‘HIV prevention’ was used, and efficacy 
trials (phases III or IIb) were selected from the results. Principal investigators and first 
authors of key publications were considered eligible for the study and were contacted 
by email and invited to participate in a semi-structured interview. The sample is 
purposive, as some eligible individuals did not respond to repeated invitations to 
participate, and some declined. 
All of the interviews were conducted by the first author. Nine interviews were 
conducted by telephone and five were conducted face-to-face. In the interview, 
informants were asked to describe how they negotiated benefits for research 
participants in particular trials. They were also invited to speak to the following 
specific issues:  
 How they formed their views about obligations to participants  
 The role of guidelines and ethics literature in informing their 
views 
 Structural factors that affected the provision of standards of 
care 
 How the accumulation of efficacy data affected standard of 
prevention in ongoing and future trials 
 Whether they were satisfied with how negotiations had been 
conducted 
 Whether they felt that planned standards of care were achieved. 
Interviews were conducted between May 2010 and May 2012. During this 
period, positive efficacy data from five trials was published (see figure 1, timeline). 
This was punctuated by surprise futility findings from two other trials (FemPrEP and 
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two of the three active arms of VOICE). The interview schedule was adapted to 
capture key issues raised by these new developments in the field. 
Interviews were audio taped, transcribed, checked for accuracy, and coded 
with N-Vivo-9 software, using a combination of inductive and pre-determined codes, 
which were then analysed thematically. Predetermined codes were derived from the 
ethics literature on standard of care/prevention, and included equipoise, evidentiary 
standards and participatory practice. Inductive coding was a sentence by sentence 
process that categorised concepts as they were framed by the participants, such as 
‘real world’, ‘attention to form not substance’ and ‘too-good care as inequitable’. All 
coding was done by the first author. 
Data were analysed from a symbolic interactionist perspective, which treats 
interview data as accounts of experience through which the interviewees 
communicate their understandings of the social world (the world of the HIV 
prevention trial), as distinct from a positivist perspective, which would view interview 
data as a mirror image of an objective reality. This perspective recognises that 
interview is a particular interaction that inflects the responses given, while 
nevertheless allowing that the participants are discussing a reality that exists outside 
the interview (Miller and Glasner 2004). 
Quotes from interviews have been anonymised, and all informants are referred 
to as ‘she’. The study was reviewed and approved by the ethics committee of the 
[name of institution] 
Results  
This analysis is based on interviews of 14 male and female principal investigators 
who between them had worked on more than 20 HIV prevention trials. Of the 
principal investigators interviewed, two were ‘in-country’ investigators, meaning that 
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they headed the study at a particular trial site, but did not have oversight of the trial as 
a whole. The remaining 12 informants oversaw whole trials and in some cases 
networks of HIV prevention trials. Most of these interviewees had been a principal 
investigator or a senior member of the research team on more than one study 
Informants had a spectrum of opinion about how best to approach standard of 
prevention in future trials. They expressed a range of different views about the role of 
research in the HIV prevention endeavour, and about optimal processes for achieving 
common goals, such as access to ancillary care and/or antiretrovirals.  
At one end of the spectrum was the view that the prevention package offered 
in clinical trials actually distorts clinical trials for new prevention modalities by 
reducing HIV incidence in the trial population to an extent that would not occur 
outside the trial context: 
 
We need to concentrate on the thing we want to measure and peel back 
from offering everything. – P1 
 
The practice of optimising HIV prevention7 for participants was criticised by 
some respondents on the grounds that it creates a set of conditions that differ from 
those in the ‘real world’ outside the trial for which new HIV prevention technologies 
are intended: 
                                                 
7 Comprehensive HIV prevention comprises condoms (ideally male and female versions), STI 
treatment, and behavioural strategies such as partner reduction, ‘negotiated safety’ (agreements about 
condom use outside of a primary relationship), withdrawal before ejaculation and ‘strategic 
positioning’, where an HIV negative man opts to penetrate rather than be penetrated by a male partner 
of positive or unknown serostatus. 
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What we have created is a massive gap between the real world and 
clinical trials. – I1 
This view is elaborated further by a second informant: 
The more you provide to the control arm, the more difficult it becomes 
scientifically then, to come up with a reliable result in terms of the impact of 
the intervention itself…And that means that ironically, the better you are at 
doing that, the more you’re undermining the value of the trial itself, because 
you may then be unable to show that the intervention is effective, and that 
might then deny the intervention to very large numbers of people and 
communities in the future.  I  –I2 
In other words, comprehensive standard of prevention packages make it 
difficult to demonstrate efficacy of a preventive measure.  
A third position articulated by Informant 14 is that so long as placebo controls 
best meet the requirements of regulatory bodies, their use is ethically justified by the 
public health need for a new effective and acceptable HIV prevention method: 
[T]he FDA has standards no matter where the trial’s conducted, about 
physical standards in controlled trials.  And that’s how you test two medicines.  
So first you have to see if it works at all, you have to test against the placebo, and 
then you want to test it to see if it’s better than something else before 
[licensure]… I can’t envision a time when there’s never going to be a need for 
any placebo controlled trial. –I 14 
At the other end of the spectrum was the view that in order to be sure that an 
experimental intervention made a real difference, it needed to be compared to best 
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practice prevention. Thus, an optimised prevention package can be viewed as a sound 
epistemological decision as well as an ethical one: 
We wanted to be able to show that our intervention for HIV prevention 
added to the benefit of existing care… above and beyond everything else that 
we know how to do. – I3 
Informant 3’s position contrasts with that of Informants1 and 2, who argue 
that experimental interventions should be compared to prevention packages that are 
closer to standard practice in the host country, rather than ‘best practice’, for 
implementation purposes.  
The rationale for the argument provided by Informant 1 is that prevention 
services within trials should approximate locally available prevention. Informant 11 
introduces the notion that any improvements to local practice should be sustainable in 
the community when the trial concludes: 
I think you have to be careful about getting ahead of the curve, 
because if you do start providing services that cannot be sustained after 
participants exit the study, you create another ethical dilemma. –I11 
As Informant 4 states, 
It’s a very fine balance between the elevation of the standards just for 
the duration of the study, versus elevation and advocacy for standards that are 
higher than when you got there.  So, to me, whatever you do, you have to leave 
your participants in communities better off. – I4 
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This notion of sustainability introduces the idea that a prevention trial can 
operate to some extent at least as a capacity- building development project, rather than 
simply as an experiment.  
Informant 3 argues explicitly for the trial as an exemplar of best practice 
prevention: 
We’re better off being advocates for providing the best possible 
prevention care, and at the very least improving it in every environment.  If 
something is not practical, or not feasible for a given population, then no I 
don’t think you have to provide something that is not feasible.  But I think that 
most things that we are talking about are feasible…it’s just a matter of 
lowering the price and raising the funds to make these things available.– I3  
Informant 9 argued that high standards of evidence were needed to ensure that 
scientific questions were answered decisively, and that accepting preliminary or non-
definitive evidence as disturbing equipoise jeopardised the production of knowledge: 
In every trial, the herd is going to make the decision [to change 
standards] during the course of the trial, where the very question is being 
addressed.  This is the danger and the tension of equipoise. I 9 
The tension between the scientific imperative to answer a research question 
and the ethical imperative to maximise benefits for their participants was articulated 
by another informant as balancing between shades of grey. 
I think it’s a fine line between the importance and the impetus and the 
imperative for your research question, versus all the other things that we can 
potentially help to improve [conditions for participants and their 
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communities], how much of that is directly related [to the trial], how much of 
that is indirectly related, how much of that is essential, how much of that is 
aspirational.  And I think that’s where things get varied between lighter and 
darker shades of grey, for some people, and for some people it becomes black 
and white issues. I4  
Informants frequently referred to ambiguity and ethical ‘grey areas’, 
particularly those interviewed after the FemPrEP trial. FemPrEP, which tested pre-
exposure prophylaxis (the combination of tenofovir and emtricitabine) in African 
women, was stopped due to futility in April 2011 (Celum and Baeten 2012), despite 
evidence from three randomised controlled trials in different populations showing 
efficacy (Grant et al. 2010, Roehr 2011).   
After the Fem-PrEP result, rather than talking about whether ‘state-of-the-art’ 
interventions should be offered as standard of prevention, the participants focussed on 
how ‘state-of-the-art’ might be determined for new prevention interventions.  
 
It’s a genuinely difficult issue, as to what stage placebo controlled 
trials become inappropriate or unethical or both ….  And indeed even when 
we do have sufficient evidence, is it only when the product is licensed and 
available that a placebo controlled trial would become unethical, or is the 
mere fact that the evidence is there, sufficient to make further trials 
inappropriate?  I5 
There are two aspects to the problem posed by Informant 5’s question: the 
strength of the evidence and the difficulty of pinpointing exactly when equipoise 
evaporates. 
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One investigator summed up the new tension from conflicting sources of 
authority thus: 
Your ethics committee says you can’t have a placebo controlled study, 
and your regulator says that’s the only study we will licence the products on.  
So what do you do? I8 
In the field of HIV prevention trials, research ethics faces a tricky 
epistemological question: Can equipoise persist in light of positive efficacy results 
from a well-conducted randomised controlled trial?   
Researchers enrolling heterosexual men in their prevention trials were the first 
to grapple how the loss of equipoise should affect clinical trial design, as medical 
male circumcision was the first intervention that warranted consideration for inclusion 
as part of a prevention package in other trials. The issue remained contentious, 
however, even after evidence from three randomised controlled became available: 
We introduced circumcision before WHO and we were criticised 
because we went before anyone, because we thought the nature of the data 
was overwhelming. I8 
In Informant 11’s trial, circumcision was provided through referrals and in line 
with national guidelines rather than proactively, which meant that it was not 
uniformly available at all trial sites at the same time: 
With male circumcision, it took Uganda longer than Kenya for 
example, to adopt the national policy.  Until they really did adopt the policy … 
we were limited in our ability to actually make it available. I11 
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Informant 10’s study offered medical circumcision to male participants using 
an objective evidentiary standard, while Informant 11’s study used referral to national 
infrastructure. This meant relying on a local standard, and participants’ access to the 
procedure was therefore determined by where they lived.  
The circumcision example illustrates the kinds of inequities that can result 
from depending on local infrastructure to define and implement a standard, but the 
issues confronting the field now with PrEP are different. Firstly, only the US has 
approved PrEP; and secondly – despite successful trials conducted in low- and 
middle-income countries (Kenya, Uganda, Botswana, Brazil, Ecuador, Peru, South 
Africa and Thailand) the question arises as to whether PrEP would, could, or should 
be provided as a standard in resource-poor countries. 
As Informant 5 says, 
I think where we get into ambiguity is … let’s say a new intervention 
has shown some level of effectiveness, but clearly isn’t imminently available in 
the communities where we’re doing our studies, and may never be – to what 
extent should that then become part of your prevention package?  I5 
Both Informant 5 and Informant 10 articulated the need to rationalise concepts 
of ‘efficacy’ as demonstrated in statistical terms, with an assessment of whether or not 
a result is clinically important. For Informant 10, this meant the magnitude of the 
effect of the intervention (efficacy of at least 50%), while for Informant 5, it was a 
balance between improvement the new product offered over existing prevention 
combined with a real ability to make the product available in the community for 
which it is intended.  
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Cost-effectiveness was also an issue.  As Informant 8 states: 
It would be horrible if we asked the government to register Tenofovir gel 
at seven rand or one dollar a pop, and then you find out later that it was only 6% 
effective [the lower end of the CAPRISA 004 confidence interval].  
Discussion 
The key issues relating to standards of prevention identified by the informants in this 
study were the perceived conflict between ensuring sustainability of interventions and 
improving local standards, the generalisability of findings, equipoise and the necessity 
to obtain a clear scientific result .  The shifting evidentiary landscape, with new trial 
data being released during the time period, and the normative ambiguities created by 
the differences between ethical guidelines and the flexibility within the guidelines 
regarding when or if new standards must be adopted, created a context in which there 
was no undisputed approach as to how new trials should be designed (Philpott et al. 
2011).  
Real worlds: sustainability, or improvement of standards? 
 
The concept of the ‘real world’ was frequently invoked by participants. 
Sometimes it was used to make a point about an unbridgeable gulf between standards 
of health care in resource-rich and resource-poor settings/countries. Sometimes it was 
used to make the point that one ‘reality’ is codified in the written health care 
standards of host countries, while a different ‘reality’ is observed in clinics where 
these written standards are not always met. Thus if a study opted to ensure 
implementation of the codified healthcare standards – such as hepatitis B 
vaccinations, or regular pap smears – they were in some cases “rachetting up” the 
actual care delivered in the community (Benatar and Singer 2000). 
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The gulf between actual health care delivery in a community and the formal 
standard documented for that country could also play out in a different way. In one 
study, the formal standard for access to ARV changed (i.e. the revised standard 
stipulated that ARV should be provided at a higher CD4 count than before). The 
principal investigator responding by ‘re-consenting’ the participants – that is, she 
informed them of the revised standard, reminded them that they were free to leave the 
study in order to benefit from it, and formally obtained their renewed consent to 
remain in the trial in the light of the new information. The ‘new standard’ was not in 
any practical sense available, however, as the countries in question did not have a new 
influx of drugs to respond to increased demand (though the trial site did offer to assist 
with identifying access points, and four participants took up this offer). In this case, 
the notional autonomy of the participants to remain in the study or to leave to pursue a 
(largely unattainable) standard was invoked, but unsurprisingly, participants 
overwhelmingly opted to stay in the study (Cohen, McCauley and Sugarman 2012). 
 
Generalisability: the adherence issue 
 
Randomised controlled trials (RCT) are designed to produce results that are 
generalisable to comparable populations (Little 2003, 7). Phase III trials (and to a 
lesser degree, IIb trials), aim to establish the efficacy of an intervention. Evidence of 
‘efficacy’ means evidence that the intervention being evaluated produces a desired 
outcome under optimal conditions where confounding variables are controlled for by 
the experimental design (Compher 2010). Recent evidence about the lack of 
adherence to preventive measures in HIV trials – including successful ones such as 
iPrEx that that produced evidence of efficacy results despite, rather than because of, 
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adherence issues – suggest that, despite intensive efforts, the trial context may not 
facilitate adherence. Participants are constantly reminded that it is not known whether 
the intervention works, and that they might be receiving a placebo rather than the 
experimental intervention. As Kippax and Stephens point out (2011, 394), biomedical 
prevention that relies on sustained use has major behavioural and structural 
components because effectiveness depends on access to, acceptance of and adoption 
of the intervention.  
PrEP showed efficacy in heterosexual women in the Partners PrEP and TNF 2 
studies but not in FemPrEP and VOICE8, and tenofovir gel showed efficacy in 
CAPRISA 004 but not in VOICE. (VOICE used the same product as CAPRISA 004 
but a different dosing schedule). Arguably these disparate trial results reflect different 
acceptance and uptake of the study product in their respective populations, and 
different perceptions of risk affecting the motivation of participants to take a pill or 
use a gel. Adherence to the study product is critical for trials, but there is 
accumulating evidence that trial participants do not accurately report adherence or 
lack thereof (Van Damme et al.  2012, Grant et al. 2010). Arguably then these trial 
results reflect the products’ effectiveness in particular populations rather than 
providing a measure of efficacy that can be generalised (Donnell 2012). 
When trials produce different findings as to the efficacy of a preventive 
measure, they augment rather than reduce uncertainty. These vastly different trial 
results for the same interventions, if understood as ‘efficacy’ results, add up to a state 
                                                 
8 Tenofovir PrEP was efficacious in TNF 2 but not in VOICE, and while tenofovir/emtricitabine PrEP 
was futile in FemPrEP, it was efficacious in TNF2 and Partners PrEP. The efficacy 
tenofovir/emtricitabine PrEP in VOICE is not yet known. 
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of uncertainty about the efficaciousness of the interventions. If understood as 
‘effectiveness’ studies, however, the picture is somewhat different: that the efficacy of 
the intervention is impacted negatively by the particular context of the less successful 
trials – as the FDA has recently noted in its review of tenofovir/emtricitabine for HIV 
prevention: 
In sum, individuals may have any number of reasons or influences that 
increase or decrease adherence to medications. Some believe that PrEP clinical 
trials represent ideal circumstances that cannot be replicated in a real world 
setting. At this time, however, it is not known if PrEP adherence is better or worse 
outside the clinical trial setting (The Review Team for NDA 21-752/S-30 2012). 
Equipoise 
 
Equipoise has traditionally been defined as a state of uncertainty that arises when 
there is no reason or evidence to prefer one intervention to another (e.g. Fried 1974, 
Freedman 1987). It is a contested concept. Some see it as the premise that justifies 
clinical research: the clinician/researcher can randomise patients because there is 
genuine uncertainty as to what is the best course of action. On the other hand, some 
bioethicists see it as unnecessary to ethical research as the public good of health 
research requires no justification (Miller and Joffe 2011). But assuming that we 
accept equipoise as a valid concern in research (and none of the PIs in this research 
questioned this), the big questions about equipoise are who is meant to have it, and 
how do you know when it is gone? 
Equipoise is increasingly understood less as an individual disposition than as a 
consensus view held by a community of experts (or ‘the herd’, Informant 9 describes 
it). This notion of equipoise is somewhat vague in that the community is not clearly 
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defined, and nor is the process by which consensus is achieved.  One response to this 
problem in discussions about standards of prevention is to “hitch” equipoise to a 
standardised measure, such as a regulatory standard, or ethical guidelines.  
Guidance point 13 of the UNAIDS/WHO Ethical Considerations in 
HIV Biomedical Prevention trials (2007)  states that there is an obligation to 
provide “access to all state of the art HIV risk reduction methods … to 
participants throughout the duration of the biomedical HIV prevention trial” 
and goes on the state that, “new HIV-risk-reduction methods should be added, 
based on consultation among all research stakeholders including the 
community, as they are scientifically validated or as they are approved by 
relevant authorities”. There are several points of flexibility here: firstly the 
addition of new risk-reduction methods is subject to consultation, and second, 
there are two separate conditions that are to be taken into consideration: 
scientific validation, or approval by relevant authorities. Does scientific 
validation mean data from one trial, or two, or more? Does ‘relevant 
authorities’ mean approval by any regulatory or normative boy, or does it 
mean approval by the national regulatory authority of the country or countries 
in which the trial takes place – and what if several countries are involved, and 
some regulatory bodies have approved and intervention while others haven’t?  
These questions are particularly pertinent now that the FDA has 
approved TDF/FTC as PrEP, while other regulatory bodies have not. While it 
stretches credulity to argue that equipoise persists once an intervention has 
been approved by a body such as the FDA, the framing of Guidance point 13 
arguably provides a source of moral authority for delaying the introduction of 
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a ‘state-of-the-art’ intervention until such time as it is listed in national 
guidelines. 
 
Generalisability: should prevention standards be optimised? 
 
The extent to which findings can be generalised to the ‘real world’ outside the trial is 
one of the classic epistemological problems with experimentation (Ashcroft 2004). 
Informants in this study had different perspectives as to whether standards of 
prevention should be optimised or kept closer to pre-existing local standards.  Recent 
efficacy trials of HIV prevention have reduced HIV incidence in trial populations, 
regardless of whether the experimental intervention is effective, due to the increased 
emphasis on providing and promoting existing prevention methods such as condoms 
and STI treatment (e.g. Peterson et al. 2007, Feldblum et al. 2008). An 
epistemological problem particular to HIV prevention trials is that it is not possible to 
discern (a) which sex acts actually involved risk of HIV acquisition for a participant 
(i.e. when s/he had sex with a person with an HIV viral load high enough to cause 
infection); or (b) whether the experimental intervention/placebo was used, or a 
condom, or both experimental intervention/placebo plus condom, during the actual 
risk event/s. This raises complex issues for the interpretation of trial results 
particularly as participant self-report regarding use of prevention interventions may be 
unreliable (Van Damme et al. 2012, Grant et al. 2010), and HIV exposure does not 
necessarily cause infection (Boily 2009).  
Randomisation, together with sufficient sample sizes, are the tools that are 
intended to isolate the efficacy of an experimental intervention regardless of the 
standard of prevention available to participants in intervention and control arms.  If 
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however standards of prevention are adopted differently in control and intervention 
arms, this might confound trial findings. Further, if the intervention itself is of very 
marginal benefit, this might be masked by enthusiastic uptake of a standard of 
prevention in a trial community. Weeding out marginally effective products is a 
problem if a biomedical intervention is deemed inherently better (i.e. cheaper and 
more sustainable) that a barrier-and-behavioural intervention.  
The argument against optimised prevention as made by Informants 1 and 2 
echoes that made in a Lancet review article by Padian and colleagues (2008, 593).  
To comply with ethical guidelines, we have reduced our ability to 
assess new prevention methods by comparing them to the best available 
prevention standards of care (e.g., limitless sexually transmitted infection 
treatment; frequent, individualised, and expensive condom counselling). Such 
strategies are not representative of the standard of typical prevention services 
in the community and are not sustainable after completion of the trial. The 
complexity of the design is increased by addition of these packages to the 
intervention, so at best we can measure the marginal benefit of the new 
intervention compared with the effect of the ideal prevention package. Thus, 
the ability to detect any effect of interventions postulated to be moderately 
effective (e.g., <50%) is reduced. (Padian, Buvé, Balkus et al. 2008, 593) 
First author of the article quoted above was the principal investigator of the 
MIRA trial which tested the diaphragm as an HIV prevention method and found that 
it was no more effective than placebo (Padian et al. 2007). Sub-analysis showed that 
women in the control arm of the trial used condoms more consistently than those in 
the intervention arm of the trial. There has been speculation that greater condom use 
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in the control arm combined with lower than expected adherence to the study product 
in the active arm, may have produced a flat trial result even if the diaphragm had 
modest efficacy. This shows that the randomisation process may not smooth out 
differences between experimental and control groups, particularly when a study is not 
blinded, as was the case with MIRA.  
Arguing along similar lines to Padian, Informants1 and 2 privilege a research 
outcome – optimising the chances of getting a positive efficacy result in a trial – over 
the researchers’ putative obligation to minimise HIV acquisition in order to hasten 
access to a (presumed) partially effective product. 
 Taking the opposite view, Informant 3 argues for optimisation of the standard 
of prevention on the basis that an optimised standard could show that the 
experimental intervention had an effect over and above ‘everything else that we know 
how to do’. In other words, if a standard of prevention does not include an element 
known to reduce HIV acquisition – say STI treatment, or post-exposure prophylaxis – 
and was shown to be effective against that prevention background, it would remain 
unknown whether adding in the missing element/s would be as good as, or better than, 
the experimental intervention.   
Informant 3, in advocating the ‘best possible prevention care’ within a trial 
privileges the improvement of local standards by adopting best practice for the trial 
duration at least, again in contrast to informants 1 and 2 who privilege getting a 
research outcome. Both positions are ethically defensible, but each defines its key 
responsibility slightly differently. In one case, production of knowledge takes 
precedence; in the other, maximisation of benefits to participants takes precedence. 
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In theory, if a trial relied on prevention programs that were already operating 
in the host community rather than optimised programs, it would be more likely to 
detect the efficacy of a marginally effective product. Efficacy studies of HIV 
prevention take place in communities that have a high HIV incidence, so it is highly 
likely that background HIV prevention programs in these communities are ineffective, 
particularly for the population(s) identified as being at high enough risk to participate 
in a prevention trial. A biomedical product that is proven efficacious against a 
background of suboptimal behavioural prevention programming could eventually 
have a population health benefit in that particular population if the intervention was 
low-tech, readily available, user-friendly and affordable.  But as well as failing to 
optimally protect research participants, such an approach would create a new problem 
for generalisability of findings. There is no single ‘real world’ HIV epidemic. 
Epidemics have social, cultural and political dimensions (Kippax and Stephenson 
2012), and the relative successes of prevention programs depend on these factors as 
well as on the underlying incidence of infection.  Therefore, not optimising the 
prevention package (whatever that entails in a particular community) arguably makes 
it harder to extrapolate a result outside the trial community. 
‘Getting ahead of the curve’ is an ethical dilemma that Informant 11 identifies, 
arguing that setting up enhanced prevention services for which there is no assured 
funding post-trial potentially leaves a community worse off at the trial’s conclusion 
due to withdrawal of some services. From a utilitarian perspective what ethically 
important here however is that the community is not worse off than it would have 
been had the trial not taken place. Whether the trial has brought benefits and services 
which can be sustained after its completion is a different issue.  If a trial enhances 
HIV prevention services for its duration, the outcome is reduced HIV acquisition. 
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Reduced HIV acquisition for the time period of a clinical trial is a real benefit that 
affects not only those who did not acquire HIV during the trial, but their sexual 
partners who may have been at risk post-trial. Thus it impacts on HIV incidence in an 
ongoing beneficial way, even if there is a perception of services being withdrawn at 
the closure of the trial. Reducing HIV incidence is a real and tangible benefit.  
 The argument to limit available services during a trial so as to ensure 
sustainability post-trial contrasts with the view that the prevention trial is in itself 
a catalyst for change that can (and arguably should) improve health care 
standards.  
Notably, most though not all of the informants who framed prevention 
trials as an opportunity to improve services in host communities lived and worked 
in countries that hosted HIV prevention trials. ‘Insider’ status in a host community 
appeared to be linked to a greater sense of agency with regard to capacity 
building, possibly because these investigators would themselves be there post-trial 
to continue to implement services 
Conclusion  
International ethical guidelines enshrine the principle that research participants are 
entitled to the best current treatment or prevention standard regardless of where they 
live (World Medical Association 2008,  UNAIDS 2007). Nevertheless, there is 
ongoing dispute whether this is a binding ethical norm or an aspiration (e.g. Rennie 
and Sugarman 2009). Operationalising ‘state of the art’ prevention in the context of 
HIV biomedical prevention trials is fraught, and requires a series of judgements on 
controversial issues. 
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The informants in this study negotiated complex systems that structured what 
was and was not possible in their particular studies, including funding constraints, 
regulatory systems, host-country health systems, guidance documents and ethical 
review processes, in a context where the realm of HIV biomedical prevention was in 
flux, with new and sometimes apparently conflicting data being released from other 
studies.  
This study shows that there is still division at the level of principle as to 
whether standards in research should be universal, local or somewhere in-between. 
More importantly, it shows that ‘best current’ or ‘state of the art’ are not clear-cut 
judgements. The issue of how a ‘validated’ or ‘proven’ intervention is defined is 
critical to how decisions are made regarding standards of prevention, and the current 
lack of clarity on evidentiary standards means that regulators are the default deciders. 
Other factors can also impact on standards of prevention. It matters, for 
example, whether a research project is based at a comprehensive health facility in the 
host country. This was evident in trials that have sought to provide male circumcision, 
and were delayed by the slow introduction of a host country program. 
There are different conceptions of what a research study can or should 
achieve. Does the importance of answering a scientific question justify the ongoing 
use of placebo controls in circumstances where access to new technologies is not 
meaningfully available in the community? Or does securing access to new 
technologies become part of the increasingly complex process of managing HIV 
prevention trials?  
The FDA approval of PrEP for HIV prevention brings these issues into sharp 
focus. The provision of PrEP in populations with endemic HIV has the potential to 
prevent hundreds of thousands of HIV infections. This is highly unlikely to occur 
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through African health systems and established donor ARV programs in the 
immediate future, however, given current problems with sustaining ARV access for 
people who need these drugs to survive. If PrEP became ‘standard of prevention’ in 
trials, then HIV trial populations might become low incidence rather than high 
incidence populations, and this would add new levels of complexity to testing other 
prevention interventions. PrEP is hardly a “magic bullet”: it is a high-cost, high-
maintenance strategy, requiring ongoing supplies of an expensive drug combination 
and daily adherence. 
Could, or should, HIV prevention studies deliver costly prevention 
technologies like PrEP as ‘standard of prevention’? If so, the distinction between a 
research study and a prevention program or intervention becomes blurred, and the size 
and cost of trials would have to increase exponentially in order to be able to discern 
the benefit of any new intervention of top of the package. If not, then the question 
needs to be asked, for whom was PrEP developed, if not for populations at the 
greatest risk of HIV acquisition? 
It is seductively easy to conclude that PrEP should be added to standard of 
prevention immediately. To do so however would be to ignore the role of host country 
regulators who have a valid stake in determining which interventions are prioritised in 
their countries, and at what cost. If PrEP is deemed too expensive by host country 
regulators, then the need for an affordable intervention, such as a vaccine or other 
long-acting technology, remains. 
Finally, there are clear grounds to explore alternative trial models, such as 
innovative comparator studies that avoid placebos, in order to answer ‘real world’ 
questions, such as how PrEP measures up against other experimental prevention 
methods, whether that be new compounds or novel delivery systems of drugs already 
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in use. Ultimately, people at high risk of HIV acquisition need access to prevention 
interventions that are under their control, and low- and middle-income countries need 
data about which technologies perform best. 
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Figure 1: Positive results of HIV prevention trials* 
 
 
 
 
*The sexually transmitted diseases trial is not discussed in this article. 
 
Source: S. McGregor, G. Tachedjian, B.Haire, J. Kaldor. The Seventh and Last 
International Microbicides Conference: From discovery to delivery. Sexual Health 
Inpress. 
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Abstract 
The principle of providing post-trial access for research participants to successful 
products of that research is widely accepted and has been enshrined in various 
declarations and guidelines. While recent ethical guidelines recognise that the 
responsibility to provide post-trial access extends to sponsors, regulators and 
government bodies as well as to researchers, it is the researchers who have the direct 
duty of care to participants. Researchers may thus need to act as advocates for trial 
participants, especially where government bodies, sponsors, and regulatory bodies 
have complex interests vested in decisions about whether or not new interventions are 
made available, how, and to whom. This paper provides an empirical account of post-
trial access in the context of HIV prevention research. It describes both access to the 
successful products of research and the provision antiretroviral drugs for trial 
participants who acquire HIV. First, we provide evidence that, in the current system, 
there is considerable variation in the duration and timeliness of access. We then argue 
that by analysing the difficulties faced by researchers to this point, and their efforts to 
meet this obligation, much can be learned about how to secure post-trial access in 
HIV biomedical preventions trials.  While researchers alone have a limited obligation, 
their advocacy on behalf of trial participants may be necessary to call the other parties 
to account. 
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 Introduction 
Providing research participants with post-trial access to successful interventions is 
required by key international ethical guidelines.1  It is intended to protect research 
participants from exploitation, and to give trial populations an opportunity to benefit 
directly from research to which they contributed, where the research resulted in a 
successful product or intervention.2  Post-trial obligations are particularly important 
for participants from lower income countries, where the obligations are linked to the 
principle that research conducted in lower income countries should be responsive to 
the health priorities of the country in which it is tested. Without these provisions, 
participants from lower income countries run the risk of being used to test 
                                                 
1 World Medical Association (WMA). 1964, amended 2008. Declaration of Helsinki Ethical Principles 
for Medical Research Involving Human Subjects; 
Council for International Organizations of Medical Sciences (CIOMS). International Ethical Guidelines 
for Biomedical Research Involving Human Subjects. 2002; Joint United Nations Programme on HIV ⁄ 
AIDS (UNAIDS), World Health Organization (WHO). 2012 (English  original 2007, additional 
guidance point added 2012).UNAIDS ⁄ 07.28E ⁄ JC1349E Ethical Considerations in Biomedical HIV 
Prevention Trials. UNAIDS ⁄ WHO Guidance Document. Geneva: UNAIDS and World Health 
Organization. Available at: 
http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2012/jc1399_ethic
al_considerations_en.pdf [Accessed 18 Feb 2013]. 
2 D. Schroeder & E. Gefenas. Realising benefit sharing – The case of post-study obligations. Bioethics 
2011; 26: 305-314. 
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interventions intended chiefly or solely for the benefit of populations in high income 
countries, because research in low incomes countries tends to be cheaper.3 
The requirement to ensure post-trial access is complex, however. While investigators 
and research sponsors can provide access to interventions that are approved by 
regulatory bodies, they cannot supply unapproved medicines or interventions. Indeed, 
the term ‘post trial’ is in some respects misleading, as the key investigator-controlled 
method of supplying drugs for unapproved indications involves cross-over from 
placebo to active drug within trials, or clinical trial ‘extension’ mechanisms, and both 
mechanisms require regulatory and ethics approval. Investigators may thus undertake 
in good faith to supply any successful intervention to trial participants, but be stymied 
by regulatory authorities that deny or delay approval for extension-trial access. This 
raises two questions. First, how can trial investigators be required to deliver access to 
a product over which they have limited control? Second, what role should regulatory 
bodies and governments play? 
The responsibility to facilitate post-trial access cannot rest on the investigator alone, 
as both CIOMS (2002) and the UNAIDS Ethical considerations in biomedical HIV 
prevention trials (2012) recognise.4 The obligation is shared with sponsors, regulatory 
authorities, and other government bodies. This is logical, in that these bodies are 
essential to ensure timely access to newly validated interventions.  It is also 
problematic, however, in that that government bodies and regulatory authorities have 
complex responsibilities when it comes to approving new medicine and interventions, 
                                                 
3 R. Macklin. 2004. Double standards in medical research in developing countries. Cambridge, UK ; 
New York: Cambridge University Press. 
4 Op. Cit Note 1. 
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and they do not have the same direct duty of care to the research participant as a trial 
investigator. 
Post-trial obligations also include arrangements to compensate participants for 
injuries or illness resulting from trial participation, and access to antiretrovirals 
(ARV) for participants in HIV prevention trials who acquire HIV during the trial 
(seroconverters). The basis for the obligation to supply ARV for seroconverters has 
been debated extensively.5 Concerns about providing ARV access within trials were 
initially raised on the grounds that, if the trial were the only source of access, this 
could be seen to constitute an undue inducement,6 and that it placed too great a 
burden upon research infrastructure.7  Since ARV access programs have grown 
                                                 
5 C. Slack, M. Stobie, C. Milford, G. Lindegger, D. Wassenaar, A. Strode & C. Ijsselmuiden. Provision 
of HIV treatment in HIV preventive vaccine trials: a developing country perspective. Socl Sci Med 
2005; 60: 1197-1208; M.Merritt &C. Grady Reciprocity and post-trial access for participants in 
antiretroviral therapy trials. AIDS 2006; 20: 1791–1794; R. Macklin. Changing the Presumption: 
Providing ART to Vaccine Research Participants. The American Journal of Bioethics 2006; 6: 1 – 5; B. 
Lo, N. Padian & M. Barnes. The obligation to provide antiretroviral treatment in HIV prevention trials. 
AIDS 2007; 21: 1229-1231 10.1097/QAD.0b013e3281338371; J. Millum. Post-trial access to 
antiretrovirals: Who owes what to whom? Bioethics 2011; 25: 145-154; Op Cit note 2. 
6 I. de Zoysa., Elias, C. J., & Bentley, M. E. Ethical challenges in efficacy trials of vaginal microbicides 
for HIV prevention. American Journal of Public Health 1998; 88(4): 571-5; Kilmarx, P. H., Ramjee, 
G., Kitayaporn, D., & Kunasol, P.. Protection of human subjects’ rights in HIV preventive clinical 
trials in Africa and Asia: Experiences and recommendations. AIDS, 2001; 15(supplement 4), S1–S7. 
7 D. Fitzgerald, , Pape, J. W., Wasserheit, J., Counts, G., & Corey, L. .Provision of treatment in HIV-1 
vaccine trials in developing countries. Lancet, 2003; 362, 993–994. 
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exponentially, however, the debate now concerns the best mechanisms for deliver
rather than whether or not delivery is appropriate and/or
y, 
 feasible.8  
                                                
The aim of this paper is to provide a comprehensive empirical account of post-trial 
access to successful interventions and ARV for seroconverters in the context of HIV 
prevention trials. We will analyse the efforts investigators say they make to vouchsafe 
post-trial access and the various outcomes achieved. We will also consider the 
procedural problems encountered in particular trials and the lessons that can be 
learned for planning future post-trial access provisions in order to inform future 
efforts for what is an ethically important endeavour. 
Background – the HIV prevention context 
In the last seven years, five different HIV prevention modalities have had positive 
results in nine clinical trials (Figure 1, Positive results of HIV prevention trials). The 
levels of relative risk reduction varied from a modest and contested 31% for a 
candidate vaccine9 to an overwhelming and celebrated 96% for treatment-as 
prevention. 10 The evidence of efficacy for the various modalities is complex, with 
different trial populations showing varying levels of efficacy, and adherence emerging 
as a major problem in some of these populations.11 Nevertheless, post-trial access 
 
8 Macklin Op. Cit note 5. 
9 S. Rerks-Ngarm, P. Pitisuttithum, S. Nitayaphan, et al. Vaccination with ALVAC and AIDSVAX to 
Prevent HIV-1 Infection in Thailand. N Engl J Med 2009; 361: 2209-2220. This figure is from the 
modified intent-to-treat analysis – the figure from the intent –to-treat analysis is 26%. 
10 M.S. Cohen, Y.Q. Chen, M. McCauley, et al. Prevention of HIV-1 Infection with Early 
Antiretroviral Therapy. New Engl J Med 2011; 365: 493-505. 
11 L. Van Damme, A. Corneli, K. Ahmed, et al. Preexposure Prophylaxis for HIV Infection among 
African Women. New Engl J Med 2012; 367: 411-422; J.M. Baeten, D. Donnell, P. Ndase, et al. 
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provisions for participants in HIV prevention trials need to be examined in light of 
these results. It is also important to discuss how, in the case of each different product, 
post-trial access conditions have been met, and identify the barriers to access. 
Prior to the prevention trials described above, biomedical HIV prevention 
interventions designed to prevent sexual transmission of HIV (as opposed to mother-
to-child, or ‘vertical’ transmission) had been unsuccessful. Indeed, the vaginal 
microbicide nonoxynol-9 was found to increase the risk of HIV acquisition.12 A 
subsequent product, cellulose sulphate also showed a trend toward enhancing 
transmission, though it did not reach statistical significance.13 Other investigational 
microbicide products also showed trends towards increasing risk.14 Further, an 
investigational HIV vaccine trial in 2007 was also prematurely halted, again because 
                                                                                                                                            
Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women. New England 
Journal of Medicine 2012; 367: 399-410. 
12 L. Van Damme, G. Ramjee, M. Alary, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, 
on HIV-1 transmission in female sex workers: a randomised controlled trial. The Lancet 2002; 360: 
971-977. 
13 L. Van Damme, R. Govinden, F.M. Mirembe, et al. Lack of Effectiveness of Cellulose Sulfate Gel 
for the Prevention of Vaginal HIV Transmission. N Engl J Med 2008; 359: 463-472. 
14 P.J. Feldblum, A. Adeiga, R. Bakare, et al. SAVVY Vaginal Gel (C31G) for Prevention of HIV 
Infection: A Randomized Controlled Trial in Nigeria. PLoS ONE 2008; 3: e1474; A. Nunn, S. 
McCormack, A. Crook, R. Pool, C. Rutterford & R. Hayes. Microbicides Development Programme: 
design of a phase III trial to measure the efficacy of the vaginal microbicide PRO 2000/5 for HIV 
prevention. Trials 2009; 10: 99. In this latter study, the 2% Pro 2000study arm was discontinued but 
the 0.5 % arm continued. 
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it enhanced transmission, in this instance in the sub-population of uncircumcised 
men.15 
During this period of HIV prevention research, which began with the oral reporting of 
the nonoxynol-9 results at the Durban International AIDS Conference in 2000, ‘post-
trial access’ debates focussed on access to antiretrovirals (ARV) for trial participants 
who became HIV positive (seroconverted) during prevention trials, and ongoing 
provision of medical care for trial-related medical conditions. Accordingly, we will 
adopt a broad definition of post-trial access to include ARV access for seroconverters 
and access to successful products from clinical trials. 
The treatment access movement 
 
The efficacy of antiretroviral drugs in the treatment of HIV was established in 1996, 
but initial access was predominantly limited to high-income countries and elites 
within lower income countries. Consequently, countries that were suitable sites for 
HIV prevention trials because of their high HIV incidence frequently lacked both the 
health budget and the infrastructure to provide ARV. Access to ARV for people who 
seroconverted during trials in countries where there were no general ARV 
programmes was thus a fraught issue both logistically and ethically. 
The treatment access movement, spearheaded by Treatment Access Campaign in 
South Africa and various ACT-UP chapters elsewhere, gained significant momentum 
                                                 
15 S.P. Buchbinder, D.V. Mehrotra, A. Duerr, et al. Efficacy assessment of a cell-mediated immunity 
HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. 
Lancet 2008; 372: 1881-1893. G.Gray, S Buchbinder and Ann Duerr. Overview of STEP and Phambili 
trial results: two phase IIb test of concept studies investigating the efficacy of MRK ad5 gag/pol/nef 
sub-type B HIV vaccine. Curr OpinHIV AIDS 2010; 5: 357-361. 
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in early 2000.16  Drug discounting, the rise of generic ARV, and the UNAIDS/WHO 
initiative ‘3 by 5’ (an action plan to supply ARV to three million people living with 
HIV by 2005) were major drivers of this momentum. Importantly, the ‘3 by 5’ 
initiative took a public health approach, simplifying and standardising ARV 
regimens17 with a focus on minimising infrastructural requirements to improve the 
feasibility of ARV in resource-limited environments. 
The other great enabler of ARV access in lower income countries was the 
establishment of the Global Fund to Fight AIDS, Tuberculosis and Malaria in 2002, 
and the President’s Emergency Fund for AIDS Relief (PEPFAR) in 2003. Of the eight 
million people worldwide on ARV in 2011, the vast majority were funded through the 
Global fund or PEPFAR.18  
Prevention of vertical (mother-to-child) transmission 
 
Programs to prevent vertical transmission in lower income countries have evolved 
considerably in the last decade. Key changes in recommendations from the World 
Health Organization in 2010 included earlier access to ARV in pregnancy, longer 
                                                 
16 M. Heywood. South Africa’s Treatment Action Campaign: Combining Law and Social Mobilization 
to Realize the Right to Health. Journal of Human Rights Practice 2009; 1: 14-36. 
17 There are some down-sides to this, such as the ongoing use of the now-supplanted drug, d4T or 
stavudine, in many low-income countries. This drug while effective has a very problematic side effect 
profile. 
18 In point of fact, the estimates provided on the PEPFAR and Global Fund websites exceed the total 
number of people worldwide estimated by UNAIDS to be accessing ARV. Available at: 
http://www.theglobalfund.org/en/about/whoweare/ http://www.pepfar.gov/funding/results/index.htm 
[Accessed 7 March 2013] 
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provision of ARV to women with relatively healthy immune systems19, and provision 
of ARV to the mother or child during breastfeeding (WHO 2010).20  Treatment 
regimens also changed. Single dose nevirapine, an antiretroviral drug which reduced 
transmission but caused option-limiting maternal drug resistance, was no longer 
recommended as a stand-alone prophylaxis, but was recommended in combination 
with other drugs to further suppress viral replication and prevent drug resistance 
(Option A).21 Fully suppressive triple combination therapy throughout pregnancy and 
breastfeeding (Option B) was recommended where feasible. These interventions are 
intended to reduce HIV transmission to less than 5 percent in breastfeeding 
populations, and less than 2 percent in non-breastfeeding populations. 
In April 2012, a further update on pregnancy guidelines was introduced with an 
‘Option B+’, which differed from Option B in that the maternal treatment would be a 
life-long a universal triple combination ARV regimen, as distinct from one that ends 
                                                 
19 ‘Relatively healthy immune systems’ in this context means women with CD4 cell counts of over 350. 
In 2010, people with CD4 cell counts above this level were assessed to not need ARV for their own 
health (but might require ARV as prophylaxis in pregnancy). Subsequent trial data, while not 
definitive, now suggests health benefits of earlier treatment. (Cohen et al. 2011; The SPARTAC Trial 
Investigators 2013, Le et al.. 2013) 
20 World Health Organisation. 2010. New guidance on prevention of mother-to-child transmission of 
HIV and infant feeding in the context of HIV. Available at: 
http://www.who.int/hiv/pub/mtct/PMTCTfactsheet/en/index.html 
21 The regimen known as WHO  ‘Option A’ is maternal AZT from 14 weeks if possible, single dose 
nevirapine plus AZT/3TC during birth, then AZT/3CT for seven days post partum, with breastfeeding 
infants taking nevirapine until seven days after weaning. Prophylaxis for non-breastfeeding infants is 
nevirpine or single dose nevirapine plus AZT for 4-6 weeks for Option A.  WHO ‘Option B’ is an 
effective triple combination therapy  with infant post-exposure prophylaxis of nevirapine or AZT for 4-
6 weeks.  
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at weaning. The purpose of the B+ option is to optimise care for HIV positive women 
in the light of evidence that stopping and restarting therapy may be detrimental, better 
treatment outcomes may proceed from earlier ARV initiation, and ARV treatment has 
a preventative aspect for sexual partners. 22 
Importantly, WHO guidelines recommend that national HIV programs in southern 
Africa implement within different timeframes, according both to resourcing issues 
and political will. For instance, Malawi is the only low income country to date to 
introduce Option B+ as policy.23 In southern African countries that hosted the HIV 
prevention trials discussed above (Figure 1), there were different national standards of 
care for ARV access, and they sometimes changed during those trials.24 In addition, 
WHO guidance and even national guidelines can be ‘aspirational’ rather than actually 
implemented in some countries.25 Thus the standard of care implemented at a local 
level may differ from national guidelines,26 and rigorous implementation of national 
guidelines in such a setting would therefore improve the standard of care available. 
                                                 
22 World Health Organization. 2012. Use of Antiretroviral Drugs for Treating Pregnant Women and 
Preventing HIV Infection in Infants. Available at: http://www.who.int/hiv/PMTCT_update.pdf 
[Accessed 6 March 2013] 
23 Schouten E.J., A. Jahn, D. Midiani, et al. Prevention of mother-to-child transmission of HIV and the 
health-related Millennium Development Goals: time for a public health approach. Lancet 2011; 378: 
282–84. 
24 M.S. Cohen, M. McCauley & J. Sugarman. Establishing HIV treatment as prevention in the HIV 
Prevention Trials Network 052 randomized trial: an ethical odyssey. Clinical Trials 2012; 9: 340-347. 
25 ibid 
26 A.J. London. The Ambiguity and the Exigency: Clarifying ‘Standard of Care’ Arguments in 
International Research. J Med Philos 2000; 25: 379-397 
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 We will focus on the investigator role in post-trial access, and provide an empirical 
account of how the issue has played out in HIV prevention trials with successful 
interventions, along with accounts of ARV treatment access for seroconverters 
(including those who were pregnant). We will describe the variations in both the 
timelines and duration of access to successful interventions and discuss how 
regulatory authorities and other government bodies can face multiple conflicts of 
interests when it comes to ensuring access to particular interventions. 
 
Methods 
Empirical data are drawn from HIV prevention trial websites, published literature, 
email exchanges with principal investigators of HIV prevention trials and semi-
structured interviews with principal investigators who conducted biomedical HIV 
prevention trials for sexual exposure between 2000 and 2011 that had positive 
findings. This is part of a larger qualitative study on standards of care in HIV 
prevention trials. 
Twenty-eight efficacy trials of biomedical HIV prevention (either phase III or IIb) 
were identified between 2000 and 2011 through the Current Controlled Trials and 
clinical trials.gov databases. Of these, nine had positive findings. Principal 
investigators (PIs) and first authors of key publications were contacted by email and 
invited to participate in the study by participating in a semi-structured interview. Each 
was sent at least one follow-up interview request email. 
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The interviews were conducted from May 2010 to March 2012, a period during which 
five of the nine successful HIV biomedical prevention trials had positive findings 
(CAPRISA 004, iPrEX, HPTN 052, Partners PrEP and TDF-2). In several cases, the 
positive trial results were known by the informant but not by the interviewer.  
All of the interviews were conducted by the first author. Three interviews were 
conducted by telephone and one was face-to-face. The study was reviewed and 
approved by the ethics committee of the University of Sydney.  Data was coded using 
N-Vivo 9 software and analysed thematically.  
Where interview data were factual (as distinct an expression of an opinion), facts were 
verified against other sources, such as trial protocols. Principal investigators (PI) of 
HIV prevention trials with positive findings were contacted by emails for fact-
checking and to supply additional information.  This group included PIs who had not 
been interviewed. In instances where PIs had been interviewed, specific permission 
was requested and granted to use some quotes from interviews in a manner that might 
allow identification. In one instance the PI referred the authors to another senior 
member of the research team to supply further details. 
PIs who were not interviewed were engaged in email exchanges on post-trial access 
issues. Of the nine positive trials, two PIs did not respond either to requests for an 
interview or to provide email comments. In these case (the RV144 vaccine trial and 
the Orange Farm circumcision trial), information about post-trial access plans was 
sourced from publications, pre-trial documents and post-trial access meeting minutes 
provided by AVAC (AIDS Vaccine Advocacy Coalition) and by an RV144 trial-
related public relations officer. 
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Personal communications were re-checked for accuracy with the PIs who made the 
comments. 
 
Results 
 
Four of the nine PIs responded to requests for interviews. Of the remaining 5 PIs, 
three engaged in email exchanges explaining and clarifying aspects of the post-trial 
access. The PIs interviewed also provided clarifications and further information 
through email exchanges. Two did not respond. 
Access to successful products in the positive trials 
 
In trials of the five biomedical HIV prevention modalities that were shown to 
significantly reduce the risk of infection, there was an arrangement in place to ensure 
access to successful interventions for trial participants. Eight of the nine trials were 
obliged to provide access to a product for participants, as one of the pre-trial 
agreements specified an efficacy threshold that was not reached.  
Following is an account of the post-trial access provided by each trial. 
HPTN 052 
 
The landmark HPTN052 study tested the proposition that treating people with HIV 
could have a preventive benefit for their partners. It was conducted in 1763 
serodiscordant couples, with the HIV positive (or ‘index’ partner) randomised either 
to receive immediate ARV, or to delay treatment until such time as his or her CD4 
cell counts fell to 350 or below. The study was projected to run for five years, with an 
agreement in place for people on the delayed treatment arm to be switched to 
immediate treatment once if immediate treatment showed an HIV prevention benefit 
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(an ‘intra-trial’ access provision rather than a post-trial access). The trial released 
results when it had be running for less than two years, upon advice from the Data 
Safety Monitoring Board. All participants on the delayed arm were offered immediate 
treatment, though the study would continue until May 2014.27 
Most, though not all, participants on the delayed therapy arm took advantage of the 
offer to switch to immediate therapy, and many of those who did not do so initially in 
2011 are now doing so.28 Post-trial access proper will commence at the end of the 
study in 2015. Each trial site has an access plan, which is about transitioning 
participants from trial-supplied ARV to locally provided ARV.29 
CAPRISA 004 
 
The CAPRISA 004 IIb study tested a 1% tenofovir gel as a vaginal microbicide, using 
a very specific dosing regimen with doses before and after sex, with no more than two 
doses in a 24 hour period. While the CAPRISA 004 trial produced a positive result 
with a relative risk reduction of 39%,30 the statistical power of the study was deemed 
insufficient for licensure.31 Despite the 004 investigators having secured access to the 
                                                 
27 M.S. Cohen,Y.Q. Chen, M. McCauley, et al. Prevention of HIV-1 Infection with Early Antiretroviral 
Therapy. New Engl J Med 2011; 365: 493-505. 
28 Marybeth McCauley, senior member of the HPTN research team, personal email communication 
29 ibid 
30 Q. Abdool Karim, , S. S. Abdool Karim, J. A. Frohlich, et al. Effectiveness and Safety of Tenofovir 
Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women. Science 2010; 329: 
1168-1174. 
31 UNAIDS. 2010. Road-map agreed for confirmatory trials of promising microbicide. Geneva. 
Available at: 
http://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2010/september/2010
0903prcaprisa [Accessed 5 March, 2013] 
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patent for the product in Southern Africa where the trial took place, 32participants of 
CAPRISA 004 faced a 24-month delay between the end of the initial study and the 
commencement of a roll-over study, CAPRISA 008. At the time of writing, past 
CAPRISA 004 participants can enrol in this open label study, which compares 
accessing tenofovir gel through trial site mechanisms to accessing it through family 
planning providers. The study investigators intended that participants from other HIV 
prevention studies and volunteers from the communities where the trial took place (as 
per UNAIDS Guidance point 19) should be able to join the 008 study, but regulatory 
approval for this was not secured at the time of writing.33 
PrEP trials: iPrEX, Partners PrEP and TDF-2 
 
The three positive PrEP trials provided access to PrEP products (TDF/FTC, or TDF 
alone) to participants through extension studies, which operated slightly differently to 
each other. 
 Partners PrEP tested two different PrEP regimens, tenofovir alone and 
tenofovir/emtricitabine combined as a single tablet (TDF/FTC) in a population of 
4758 serodiscordant heterosexual couples in Kenya and Uganda. The HIV positive 
partner in each of the couple was not yet eligible for ARV under national guidelines. 
                                                 
32 Press release. Terms of deal to make gel affordable and accessible in Africa following regulatory 
approval. Eureka Alert 2010. Available at: http://www.hst.org.za/news/next-steps-tenofovir-gel-
conrad-and-tia-sign-license-agreement [Accessed 5 March, 2013] 
33 Centre for the AIDS Programme of Research in South Africa (CAPRISA). CAPRISA 008 MCC 
Correspondence: Sequence of Events; Q. Abdool Karim, S.S Abdool Karim & L. Mansoor. Letter to 
Dr Portia Nkambule, Medicines Control Council. 22 March 2012. 
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The trial found that tenofovir PrEP showed a relative reduction in HIV acquisition of 
67%, while for TDF/FTC it was 75%.34 
Once these results were released, access to active PrEP for participants on placebo 
was achieved through an amendment of the existing protocol to randomise 
participants from the placebo arm to 12 months of PrEP (either TDF/FTC or TDF 
alone) through an extension within the study protocol.35 Participants already 
randomised to either TDF or TDF/FTC continued to receive their assigned treatment 
for that additional 12 month period.36 
The ethical justification for continuing to randomize to the two different PrEP arms 
was that the difference in efficacy between the two active arms, TDF alone (67%) and 
TDF/FTC (75%) was not statistically significant. TDF alone is a cheaper option, so 
extra data on the comparison between the two was of significant public health 
importance.37 
TDF-2 tested combined TDF/FTC in a population of 1219 heterosexual men and 
women in Botswana. It found that TDF/FTC reduced the relative risk of HIV 
acquisition by 62%. Once the results were released, TDF/FTC was supplied to all 
participants who wanted it post-trial through a 12-month open-label extension study.38 
                                                 
34 J. M. Baeten., D. Donnell, P. Ndase, et al. Antiretroviral Prophylaxis for HIV Prevention in 
Heterosexual Men and Women. New Engl J Med 2012; 367: 399-410. 
35 Protocol Addendum #8, 28 July 2011. Parallel Comparison of Tenofovir and Emtricitabine/tenofovir 
Pre-Exposure Prophylaxis to Prevent HIV -1 Acquisition within HIV-1 Discordant Couples.  Version 
3.0, 12 October 2007 p 2. 
36 ibid 
37 Ibid; J. Beaten, personal email communication, 14 January 2013. 
38 M. Thigpen, personal email communication, 25 January 2013. 
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There was however a gap of 12 months from the time that the study results were 
released to the time that the extension study began.39 
iPrEx tested combined TDF/FTC in a population of 2499 men and transgendered 
women who have sex with men in Peru, Ecuador, Brazil, the US, Thailand and South 
Africa. It found that TDF/FTC reduced the relative risk of HIV acquisition by 44%.40 
Subsequent data analysis has shown higher levels of efficacy related to better 
adherence to the drug (Anderson et al. 2012).41  Post-trial access for iPrEX 
participants (both placebo and active drug arm participants) was through a 72-week 
open label extension study, which began three months after iPrEx stopped.42 
                                                 
39 AVAC.  ARV-Based Prevention Options Timeline Available at: 
http://www.avac.org/ht/a/GetDocumentAction/i/46212 Accessed 5 March 2013. 
40 R.M. Grant, J.R. Lama, P.L. Anderson, et al. Preexposure Chemoprophylaxis for HIV Prevention in 
Men Who Have Sex with Men. New Engl J Med. 2010; 363: 2587-2599. 
41 P. L. Anderson, D.V. Glidden,  A. Liu, et al. Emtricitabine-Tenofovir Concentrations and Pre-
Exposure Prophylaxis Efficacy in Men Who Have Sex with Men. Science Translational Medicine 
2012; 4; Anderson P, Liu A, Buchbinder S, et al.; the iPrEx Study Team. Intracellular 
tenofovir-DP concentrations associated with PrEP efficacy in MSM from iPrEx. 
Presented at: 19th Conference on Retroviruses and Opportunistic Infections; March 
2012; Seattle, Washington. 
 
42 AVAC. Op. Cit. Note 33. 
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Circumcision trials 
 
In the three randomized controlled trial of circumcision, participants in the control 
arm were able to access circumcision through trial mechanisms at the end of the 
follow-up period (i.e. once the trials were stopped by their respective Data Safety 
Monitoring Boards due to evidence of efficacy). In the Orange Farm (South Africa) 
trial, circumcisions were performed by contracted local practitioners, while in the 
Kenya trial, they were performed by trial doctors. In Rakai, Kenya, the circumcisions 
were performed by trial trained and certified physicians in well-equipped operating 
theatres’. 
The Orange Farm trial was followed by an implementation trial, The ANRS 12126 
“Bophelo Pele” project (Lissouba et al. 2010),43 which was intended demonstrate the 
feasibility of MMC in ‘real life’ settings. 
 
Vaccine trial RV 144  
 
The Thai ALVAC/AIDSVAX vaccine tested two vaccines in a prime and boost 
regimen (six vaccinations in all), in a population of 16,402 Thai people (participants 
were not at increased risk of HIV). The trial reported a modest positive result (31.2%) 
in September 2009. This result reached statistical significance on only one of three 
key statistical analyses (the reported result was the  modified intent-to-treat analysis, 
while both the intent-to-treat and per-protocol analyses did not reach statistical 
                                                 
43 P. Lissouba, D. Taljaard, D. Rech, et al. A Model for the Roll-Out of Comprehensive Adult Male 
Circumcision Services in African Low-Income Settings of High HIV Incidence: The ANRS 12126 
Bophelo Pele Project. PLoS Med 2010; 7: e1000309. 
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significance and showed a lower relative risk reduction of around 26%). Thus there 
remains a higher possibility that the reduction in HIV acquisition was due to chance 
than in the other positive prevention studies. In addition, the vaccines’ efficacy 
appeared to wane over time, and was more effective in people at lower risk of HIV 
rather than those at higher risk.44  
It was predetermined that placebo recipients in the trial would be offered the active 
vaccine if it were 50% or more effective (RV 144 meeting report March 16-18),45 
which is also the threshold for licensure in Thailand. There is however no evidence 
that the affected communities were involved in setting this threshold.46 This decision 
regarding placebo recipients was re-examined at a meeting of international experts in 
March 2010. Reasons cited against provision of the vaccines for placebo recipients 
were: 
 The low level of efficacy and wide confidence intervals (ranging from 1% to 
52%); 
 The vaccine regimen did not reduce viral burden in the volunteers who 
became infected with HIV following vaccination; 
 The possibility of behavioural disinhibition (increased risk-taking) 
counteracting any biological efficacy; and 
                                                 
44 S. Rerks-Ngarm, P. Pitisuttithum, S. Nitayaphan, et al. Vaccination with ALVAC and AIDSVAX to 
Prevent HIV-1 Infection in Thailand. N Engl J Med 2009; 361: 2209-2220. 
45C. Hankins, R Macklin, N Michael, D. Stablein and participants. Meeting Report. Recommendations 
for the Future Utility of the RV144 Vaccines to the Thai Ministry of Health. March 16-18, 2010. 
46 Ibid. 
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 Provision of active vaccine to placebo recipients could compromise their 
participation in subsequent vaccine studies.   
Thus the group recommended that there was no obligation at this point in time to offer 
the RV144 vaccine regimen to the placebo group in the trial.47 
In a similar vein, the meeting decided that the use of placebos in further vaccine trials 
remains appropriate, and that RV 144 vaccines should not be added to the standard of 
prevention in other trials. On the other hand the group also decided that volunteers 
who were in the placebo group for the RV144 trial should be given priority in the 
future for access to the RV144 vaccine regimen, or new iterations of the RV144 
vaccine regimen.48 
Participants who acquired HIV on the trial (from both active vaccines and placebo 
arms) were eligible for the RV 152 follow-on study, looking at viral dynamics. A 
small number of participants who had received active vaccine and remained HIV 
negative were eligible for a follow-on study that re-boosted vaccine levels (RV 
306).49 
One PI, for whom access to successful products was very important, summed the 
issue up thus: 
                                                 
47 Ibid 
48 Ibid 
49 IAVI. Understanding Vaccine Licensure  What factors do regulatory bodies consider before 
licensing a vaccine for public use? Vax 2009; 7 (12).  
Available at: http://www.vaxreport.org/Back-Issues/Pages/UnderstandingVaccineLicensure.aspx 
[Accessed 7 March 2013]. 
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I think that whenever we asked people or communities to support a clinical trial or 
new intervention, we are asking them to believe that at some point in the future, if 
the trial shows that it’s safe and effective, that intervention will become available.  
And I don’t think that anyone necessarily expects the trial itself to guarantee future 
access to therapies that are found to be effective in the trials.  But there has to be the 
belief that they will become available through the concerted efforts of the scientists 
and the public health community and government leaders and community 
stakeholders – there has to be a faith that what we learn from these studies will 
actually become available.  And if you’re working in an environment where 
therapies that are known to be beneficial are not yet available, it strains credibility.  
(PI interview, August 2011)  
Provision of ARV in the positive trials 
 
In all of the trials with positive results, ARV access was available to seroconverters, 
with some variations as to how this was achieved:  
 CAPRISA 004 sites had ARV treatment programs and were not reliant on 
referrals to other facilities, with ARV available according to national 
guidelines50; 
 HPTN 052: HIV negative partners who seroconverted were released from the 
study and referred to a prearranged local clinic for care according to national 
guidelines. Any woman who was pregnant at enrolment or became pregnant 
was provided antiretroviral therapy appropriate for use during pregnancy at the 
start of the second trimester. On the basis of the judgment of the site 
                                                 
50 Principal Investigator interview, June 2010. 
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investigator, women in the delayed-therapy group discontinued antiretroviral 
therapy after delivery or when breast-feeding ended.51 (Cohen et al. 2011) 
 HIV positive participants52 from the Orange Farm (South Africa) circumcision 
trial accessed ARV through a specific program at the Voluntary Testing and 
Counselling centre, which was to remain in place until the public sector 
programme became operational in the area;53 
 Seroconverters from the Kisumu (Kenya) circumcision trial were referred to 
the project’s post-test counselling and support group and provided access to 
free HIV treatment and care;54 
 Seroconverters in the Rakai (Uganda) trial were referred to a PEPFAR-funded 
HIV treatment programme. Those who were eligible for antiretroviral therapy 
(CD4 cell count less than 250 or WHO advanced stage III or stage IV disease) 
and who agreed to receive care were provided with antiretrovirals;55 
                                                 
51 Cohen et al. op cit. Note 21 
52 This trial enrolled both HIV positive and HIV negative men. Men who were HIV positive at baseline 
were excluded from the statistical analysis. B. Auvert,, D. Taljaard, E. Lagarde, et al. Randomized, 
Controlled Intervention Trial of Male Circumcision for Reduction of HIV Infection Risk: The ANRS 
1265 Trial. PLoS Med 2005; 2: e298. 
53 ibid. 
54 R. Bailey, S. Moses, C. Parker, et al. Male circumcision for HIV prevention in young men in 
Kisumu, Kenya: a randomised controlled trial. Lancet 2007; 369: 643 - 656. 
55 R. Gray, G. Kigozi, D. Serwadda, et al. Male circumcision for HIV prevention in men in Rakai, 
Uganda: a randomised trial. Lancet 2007; 369: 657 - 666. 
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 Partners who had HIV in PP: Those who became eligible for the initiation of 
antiretroviral therapy according to national guidelines were actively 
counselled to initiate treatment and referred to local clinics;56  
 Vaccine trial RV 144: Volunteers who acquired HIV infection during the trial 
were given free access to HIV care and treatment, including highly active 
antiretroviral therapy (HAART), according to the guidelines of the Thai 
Ministry of Public Health. Seroconverters were also offered extended 
follow‐up in a separate study (RV152).57  
Discussion 
 
Each of the nine positive HIV prevention trials had done some kind of access 
planning in the event that their trial produced an effective intervention, and each had 
provisions for access to ARV for seroconverters. This suggests that post-trial access is 
considered normative. Differences were evident however in the mechanisms for 
providing access, the timeframes in which this was achieved, and the length of time 
for which it was sustained.  
Product-dependent feasibility  
The nature of the prevention modality affects the ease with which access can be 
provided. Access to male circumcision, for example, is achievable at a practical level 
because it requires a single intervention (plus healing time and follow-up as 
                                                 
56 Baeten et al. Op cit note 28 
57 US Military HIV Research program. RV152: A Follow-up Study for RV144. Available at: 
http://www.hivresearch.org/media/pnc/9/media.549.pdf [Accessed 6 March 2013]. 
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required).58 Vaccines too have this advantage, and even though the Thai 
ALVAC/AIDSVax required an unusually high number of vaccinations – six – this a 
finite number rather than an ongoing program (of note the number of vaccinations ma 
be increased in subsequent trials – website)59.   
Interventions that require ongoing use are far more complex to supply, as is the case 
with tenofovir gel, PrEP (either tenofovir alone or TDF/FTC) and treatment-as-
prevention. While PrEP has US FDA approval, it has not been approved in the other 
eight countries in which it was trialled (South Africa, Kenya, Uganda, Ecuador, 
Brazil, Peru, Thailand, Botswana). Demonstration sites (access programs that also 
collect further data) are being organised in the US and several cities in Brazil (Brazil 
requires post-trial access by law).60 
Provider-dependant safety/efficacy 
 
Of note in the three circumcision studies, there was a lower incidence of adverse 
effects in the Kisumu trials compared with Orange Farm (1.5% compared with 
3.6%).61 This was attributed to the use of trial doctors rather than contracting local 
practitioners, as occurred in Orange Farm. In the Rakai trial physicians were trained 
                                                 
58 Campaigns against circumcision, such as that waged by the Ugandan president, obviously have a 
negative impact on its achievability. 
59 RV144 Follow-up Study RV305 Begins in Thailand. November 4 2012. Available at: 
http://www.hivresearch.org/news.php?NewsID=238 [Accessed 6 March 2013]. 
 
60 Track C Session summary TUWS02, Implementing Pre-exposure Prophylaxis: Current Progress and 
Future Challenges. AIDS 2012. Available at: 
http://rapporteurs.aids2012.org/SummaryView.aspx?summary_id=187 Accessed 6 March 2013. 
61 Bailey et al. op. cit note p 653 
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to perform the circumcisions, but subsequently the investigators showed that clinical 
officers (roughly equivalent to physicians’ assistants) could perform the surgery 
safely.62 
The gaps 
Despite the considerable commitment to post-trial access displayed by the CAPRISA 
004 investigators in securing the patent to tenofovir gel for southern Africa, 
participants waited more than two years between the end of that trial and the 
beginning of CAPRISA 008, which would provide open label access to tenofovir 
gel.63 The delay was due to regulatory processes. The first iteration of the CAPRISA 
008 trial was submitted in November 2010, within four months of the trial results 
being released. The trial did not begin enrolment until November 2012, however, due 
to protracted negotiations over the protocol and a series of newly imposed 
requirements from the regulator.64 
As the CAPRISA 004 participants on the placebo arm had an HIV incidence of 9% 
during that trial, 65 an estimated 134 of the 745 women eligible for the 008 trial might 
be expected to seroconvert within the two years that elapsed between the end of 004 
and the beginning of 008 (prior to 004 the HIV incidence in the CAPRISA 004 
population was 15.6 % in the urban site and 11.2% in the rural). 
The TDF 2 trial had a gap of 12 months before the end of the trial proper and the 
commencement of the open label extension trial, attributed to delays in the ethics 
                                                 
62 R. Gray, personal email communication, 8 January 2013. 
63 CAPRISA 008 is an open-label study, with participants randomised to receive the gel either through 
trial-type settings or through family planning clinics. 
64 Q. Abdool Karim, SS Abdool Karim, L. Mansoor. op cit note 27 
65 Abdool Karim et al. op cit note 24 
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approval process, and concerns from the Ministry of Health that the extension study 
could be confused with government policy.66 The iPrEx trial had a gap of three 
months. The Partners PrEP study however had virtually no gap,67 which the principal 
investigator attributed to the access mechanism being an addendum to the trial rather 
than a separate access study.68 
 
ARV access 
Elevating the standard: pregnancy 
 
Both HPTN 052 and Partners PrEP provided pregnant women with HIV with a higher 
standard of care than the national guidelines (whether the women seroconverted on 
the study, or in the case of HPTN, women who already had HIV but were on the 
delayed treatment arm). Pregnant HIV positive women – and breast feeding women 
who seronverted in Partners PrEP –  were initiated on triple  combination ARV 
therapy to minimise the risk of infant infection. WHO guidelines have now moved 
toward recommending this level of treatment for women in lower income countries 
more generally and continuing it indefinitely rather than stopping treatment after 
weaning (the B+ option), but at the time of these trials, lower standards such as single 
or dual therapies were in place.69 
                                                 
66 Michael Thigpen, personal email communication, 13 January 2013. 
67 AVAC. Op cit note 33. 
68 Baeten. Op cit note 31 
69 World Health Organisation. Summary of new recommendations: When to start ART in people with 
HIV. Available at: 
 210
This is an example of researchers taking an opportunity to maximise a benefit to 
particular participants at a time when the stakes are high (the infant is at risk) and the 
participant is vulnerable (having just acquired HIV). Triple combination therapy 
reduces HIV acquisition to below 2%,70 and does not carry the same risk of 
subsequent drug resistance as single or dual therapy for the mother once therapy is 
ceased. Provision of triple therapy in pregnancy/breastfeeding is unlikely to be too 
burdensome, in that it is time limited, and only a small number of women within a 
trial would both become pregnant and acquire HIV, but the intervention is grounded 
in sound evidence, feasible within the trial context, and of incalculable value to the 
women who were thus able to provide additional protection for their infants. 
Of note in HPTN 052, participants who seroconverted during the trial and did not 
become pregnant accessed ARV through local programs operating within national 
guidelines. As seroconversion signalled an end to trial participation, these 
seroconverters were not able to avail themselves of the early treatment option when 
the results were released and early treatment supplied to those initially allocated to the 
delayed treatment arm. So while all HPTN 052 participants had treatment options at 
least equal to the national standard, those who seroconverted during the study did not 
have the same options as those who were HIV positive at entry, or those who became 
pregnant. 
 
                                                                                                                                            
http://www.who.int/hiv/pub/guidelines/arv2013/intro/summarynewrecommendations.pdf [Accessed 27 
August 2013]. 
70 E.R.Cooper, M. Charurat, L. Mofenson, et al. Combination Antiretroviral Strategies for the 
Treatment of Pregnant HIV-1-Infected Women and Prevention of Perinatal HIV-1 Transmission. 
JAIDS 2002; 29: 484-494. 
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How good is good enough? 
 
Both the CAPRISA 004 result and the Thai RV 144 vaccine warrant discussion of the 
levels of efficacy required before access to participants is required. 
The predetermined threshold of 50% relative risk reduction before access in RV 144 
is a high one, and one that was apparently set by researchers and sponsors without 
community input. 71At an international meeting of experts in 2009, views about the 
level of efficacy required for an intervention to be considered a valuable public health 
tool ranged between 20-80 percent, with most views falling between 30-50% .72 
Mathematical models have shown public health benefits of prevention interventions 
with only 30% relative risk reduction.73 However, the fact that the relative risk 
reduction appeared to decrease over time and that people at higher risk seemed less 
protected than those at lower risk, mitigate against arguments for access either for 
participants or more broadly. While there appears to be some scientific basis for 
believing that the vaccines did indeed induce an immune response that had marginal 
efficacy in some participants,74 the question of whether or not these participants were 
truly exposed to HIV at infectious levels remains unanswerable. Together with the 
                                                 
71 Hankins et al. op cit note 39. 
72 R. Macklin. Ethical challenges in HIV microbicide research: What protections do women need? 
International Journal of Feminist Approaches to Bioethics 2011; 4: 124-142, 128.  
73 J.M. Kaldor, & D.P. Wilson. How low can you go: the impact of a modestly effective HIV vaccine 
compared with male circumcision. AIDS 2010; 24: 2573-2578 10.1097/QAD.0b013e32833ead96. 
74  G. Pantaleo, M. Esteban, B. Jacobs & J. Tartaglia. Poxvirus vector-based HIV vaccines. Current 
Opinion in HIV and AIDS 2010; 5: 391-396 10.1097/COH.0b013e32833d1e87. 
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issues of statistical significance,75 this adds up to the reasonable conclusion that the 
RV 144 vaccines are a poor prospect for public health right now, though a rich source 
of hypotheses for further vaccine trials. 
CAPRISA 004 is rather different. Tenofovir gel is a user-dependent technology, 
unlike a vaccine. A vaccine trial gives a fairly straightforward account of biological 
efficacy, but with a user dependent technology the question ‘was it used?’ is integral 
to working out whether it worked. Quantifying adherence is essential to sorting out 
efficacy, and the high adherers – those who adhered to the gel dosing schedule 80% or 
more of the time – had a relative risk reduction of 54%, while the incidence reduction 
in low adherers (less than 50% adherence) was 28%.76 The adherence issue with a 
user-dependent technologies means that modest results in trials may be an indication 
of failure to use the product rather than the product itself being only modestly 
effective.77 
                                                 
75 P.B.Gilbert, J.O. Berger, D. Stablein, et al. Statistical Interpretation of the RV144 HIV Vaccine 
Efficacy Trial in Thailand: A Case Study for Statistical Issues in Efficacy Trials. Journal of Infectious 
Diseases 2011; 203: 969-975. 
76 Abdool Karim et al. op cit note 24 
77 The VOICE results, released on March 4 2013, are an excellent case-in-point. Despite the biological 
efficacy of interventions such as tenofovir/emtricitabine PrEP, this intervention had no effect on HIV 
transmission in a  non-adherent population. J. Marrazzo., G Ramjee, G Nair, et al. Pre-exposure 
prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine or vaginal tenofovir 
gel in the VOICE study (MTN 003). 20th Conference on Retroviruses and Opportunistic Infections, 
Atlanta, abstract 26LB, 2013. 
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Despite relative risk reduction of more than 50% in high adherers and an overall 
reduction of 39%, the CAPRISA 004 trial was a relatively small trial (889 
participants) had wide confidence intervals of 6-60%, meaning in the worse case 
scenario it is possible that the relative risk reduction gel produced was as low as 6 %. 
Accordingly, both South Africa’s Medicines Control Council (MCC) and the USA’s 
Food and Drug Administration (FDA) ruled that a confirmatory trial or trials would 
be required for licensure. 
The VOICE trial (MTN003) tested three difference active arms – tenofovir gel, 
tenofovir oral PrEP and TDF/FTC combined oral PrEP – against matched placebos. 
Although VOICE had already begun, the FDA decided that data from the tenofovir 
gel arm of this trial, when available, could be used to confirm CAPRISA 004.78 The 
trial was statistically powered to detect a relative risk reduction of 25% or more.79  
Moves toward licensing tenofovir gel faced a serious setback in November 2011, 
however, when the tenofovir gel arm was closed for futility after an interim 
                                                 
78 CONRAD. FDA and CONRAD Chart U.S. Regulatory Path for 1% Tenofovir Gel for HIV 
Prevention: Collaborative meeting held with key stakeholders. 2010. Available at: 
http://www.conrad.org/media/news/88_CONRAD%20FDA%20Meeting%20Release%2020%20Final.
doc. [Accessed 6 March 2013]. 
79 Protocol. Microbicides Trial Network. MTN-003 Phase 2B Safety and Effectiveness Study of 
Tenofovir 1% Gel, Tenofovir Disoproxil Fumarate Tablet and Emtricitabine/Tenofovir Disoproxil 
Fumarate Tablet for the Prevention of HIV Infection in Women (VOICE). Version 2. Available at: 
http://www.mtnstopshiv.org/sites/default/files/attachments/MTN-
003_FINAL_Version_2.0_31DEC2010.pdf Accessed 5 March 2013 
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analysis.80 The analysis showed that HIV incidence was 6.1 percent in the placebo gel 
group and 6 percent in the tenofovir gel. Given that the trial had reached 75% of its 
endpoints, it was not possible that in the remaining time for a statistically significant 
result to be reached.  Thus, rather than confirming CAPRISA 004, VOICE cast doub
on the 004 findings. Significantly, VOICE used a different dosing schedule to 
CAPRISA 004 – daily gel use, rather than the coitally dependant regimen. It had been
hypothesised that this might enhance adherence, but the futility result suggests the 
opposite. 
t 
 
% 
l). 
                                                
Subsequently the other two active arms in VOICE: oral tenofovir as PrEP and 
combined oral tenofovir/emtricitabine as PrEP, were also found to be ineffective in 
that trial.81Adherence to all interventions in VOICE was found to be very low, with 
on average less than 30% of women randomised to each of the interventions arms 
having detectable blood levels of the respective drugs (28% for oral tenofovir, 29
for tenofovir/emtricitabine and 22% for tenofovir ge
The VOICE study does not show that the interventions are ineffective. The evidence 
shows that they were not effective in the study population for that trial due to 
adherence problems. VOICE provides a counterpoint to the CAPRISA 004 result that 
arguably justifies a further placebo-based trial, given the importance of having a more 
 
80 Microbicides Trials Network (MTN). MTN Statement on Decision to Discontinue Use of Tenofovir 
Gel in VOICE, a Major HIV Prevention Study in Women. November 25, 2011. Available at: 
http://www.mtnstopshiv.org/node/3909  [Accessed 6 March 2013]. 
 
81 J. Marrazzo, G Ramjee  G Nair, , et al. Pre-exposure prophylaxis for HIV in women: daily oral 
tenofovir, oral tenofovir/emtricitabine or vaginal tenofovir gel in the VOICE study (MTN 003). 20th 
Conference on Retroviruses and Opportunistic Infections, Atlanta, abstract 26LB, 2013. 
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robust estimate of biological efficacy.82  The importance of such a study being 
carefully designed to take into account the problem of poor adherence potentially 
confounding efficacy cannot be overestimated. 
As tenofovir gel was effective in the CAPRISA 004 cohort, the reluctance of the 
regulatory agency to make the product available in a timely manner through an 
extension study is questionable, however. Firstly, women participating in this study 
were drawn from populations with very high HIV incidence. In addition, given the 
history of microbicide trials causing harms that only became apparent in efficacy 
studies, the women in CAPRISA were undertaking a significant risk, however well-
minimised this was by the practices of the investigators. Sharing the benefits as well 
as the burdens of research is a fundamental tenet of research ethics and, given that 
adherence appears to have been a major factor in reducing the overall efficacy, open 
label access in which participants understand that they are taking a product that has 
offers partial efficacy is highly likely to have a positive impact of adherence 
behaviours.  Further, the biological efficacy of tenofovir gel is supported by the step-
wise relationship between better adherence and lower risk of HIV acquisition. 
Had the CAPRISA extended access study, CARPRISA 008, commenced in 2010 
rather than 2012, further information about the product efficacy in the cohort would 
have been available by the time that the VOICE interim analysis occurred. The 
prolonged gap before CAPRISA 008 began, and the limitations placed on the study 
population (the population who would thus obtain open-label access to tenofovir gel), 
shows how a conservative ‘take’ on efficacy data at a regulatory level can stymie 
investigator intentions to provide the kind of post-trial access recommended by the 
UNAIDS Ethical Guidance (2012). Guidance point 19 stipulates that once an HIV 
                                                 
82 Indeed, the FACTS 001 study fills this function. 
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prevention intervention has been ‘demonstrated to be safe and effective’ it should be 
made available not just to trial participants but also to others at higher risk of HIV 
acquisition. The communities from which CAPRISA 004 participants were drawn had 
HIV incidences of 11% and 15% at the rural and urban sites respectively. In addition, 
former participants from HIV prevention trial that had not produced ‘safe and 
effective’ interventions were intended to be included – firstly, as their prior trial 
participation demonstrates that they have been assessed to be at high risk of HIV 
acquisition, and secondly as a gesture of reciprocity towards people who have 
contributed to clinical research. Of course the level efficacy of tenofovir gel is 
contested, and on that basis an argument can be made that limiting the trial population 
for CAPRISA 008 is protective – open label access to the gel might encourage risk 
taking, and the gel might provide inadequate protection.  This position however seems 
unnecessarily paternalistic, and ignores the reality that many of these women may not 
be able to negotiate condom use, regardless of trial participation. In other words, the 
partially protective gel, with enhanced adherence measures, might be their best 
option. 
Conclusion 
 
Building on the findings of Heise et al.,83 this study shows on the one hand that HIV 
prevention researchers recognise the importance of post-trial access to ARV for 
seroconverters, and have become increasingly adept at setting up the partnerships that 
facilitate this in instances where they do not directly provide ARV at trial sites. It also 
shows the complexity of post-trial access to successful products – ‘post’-trial being 
                                                 
83 L.  Heise, K. Shapiro and K. West Slevin. 2008. Mapping the Standards of Care at 
Microbicide Clinical Trial Sites. Washington DC: Global Campaign for Microbicides. 
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something of a misnomer, given that the most timely and effective mechanism 
appears to be cross-over trial designs where  participants on placebo arms are crossed 
over to active product, as in the instances of HPTN 052 and Partner PrEP. Extension 
studies commenced after trial results are released, as in the cases of TDF2 and 
CAPRISA 004, are sound in principle but in these instances were subject to delays 
beyond the control of investigators.  
The delays experienced in setting up these extension studies point to a systemic issue 
in the translation of research results. If communities that participate in research are to 
benefit from its results, governments must be prepared to support the implementation 
of those interventions within their policy framework. This is easier said than done. In 
the instance of tenofovir gel, the modest efficacy combined with the conflicting data 
from VOICE created a dilemma for regulators which could not reasonably have been 
predicted. It seems unjust, though, that participants in the trial have to had to wait 
over two years to secure access, despite the great international acclaim with which 
this study was hailed,84 due to issues regarding efficacy margins and breadth of the 
extension trial population. With regard to PrEP in Botswana, it is possible that a 
willingness to embrace ARV for prevention in HIV negative people has been affected 
by the stronger results of HPTN 052 showing the preventative efficacy of ARV when 
used earlier in positive people. While treatment-as-prevention does not provide the 
person at high risk of HIV acquisition with a new means of protection, it fulfils two 
functions simultaneously, and is easier to target than PrEP. 
                                                 
84 AIDS 2010. 2010. Webcast: Safety and effectiveness of 1% Tenofovir Vaginal Microbicide Gel in 
South African Women: Results of of the CAPRISA 004 Trial. XVIII International AIDS Conference 
Vienna, ed. Available at: http://pag.aids2010.org/session.aspx?s=13#6 [Accessed 1 September 2013]. 
. 
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Securing the reasonable availability of a successful intervention is intended to ensure 
that research conducted in lower income countries is responsive to needs, and does 
not exploit vulnerable population to test interventions for the consumption of those in 
high income countries. A major problem with this requirement, however, is the 
determining who is responsible for this form of access. It is clearly beyond the control 
of principal investigators, and is a matter for governments and their regulatory bodies 
– though sponsors certainly have a responsibility to actually apply for regulatory 
approval. The UNAIDS Guidance points to the engagement of ‘national government, 
international organisations, development partners, representatives from wider affected 
communities, local authorities, international and regional non-governmental 
organizations, and the private sector’ in addition to trial sponsors and researchers. 
Problems with post-trial access evidently occur when not all parties agree whether or 
not a new intervention should be made available for a given population at a particular 
time.  
Careful alignment of national HIV strategies with approval criteria for ethical review 
committees might be a mechanism for ensuring that the research that goes ahead tests 
interventions that the national government will be prepared, later down the line, to 
fund, should the intervention prove successful. Even with such safeguards, however, 
political expediency may hamper funding, promotion and uptake of proven 
interventions – consider for example the Ugandan president’s anti-circumcision 
statements,85 and the tragically slow uptake of harm reduction for injecting drug users 
in the US.  
                                                 
85 T. Kwidini. 2012. Uganda's president dismisses circumcision, HIV research. Zimeye 4 
August 2012.. 
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The inherent difficulties in achieving secure, ongoing access to effective interventions 
for trial participants and other communities at high risk of HIV acquisition does not 
mean it is unimportant. Rather, there is a need for further examination of when and 
how it works, and what factors are associated with failure so that procedural guidance 
can be refined and access maximised. 
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Abstract 
Published data show that new HIV prevention strategies including treatment-as-
prevention and pre-exposure prophylaxis (PrEP) using oral antiretroviral drugs 
(ARVs) are highly, but not completely, effective if regimens are taken as directed. 
Consequently, their implementation may challenge norms around HIV prevention. 
Specific concerns include the potential for ARV-based prevention to reframe 
responsibility, erode beneficial sexual norms and waste resources. This paper explores 
what rights claims uninfected people can make for access to ARVs for prevention, 
and whether moral claims justify the provision of ARV therapy to those who do not 
yet clinically require treatment as a way of reducing HIV transmission risk. An ethical 
analysis was conducted of the two strategies, PrEP and treatment-as-prevention, using 
a public health stewardship model developed by the Nuffield Council on Bioethics 
Council to consider and compare the application of PrEP and treatment-as-prevention 
strategies. We found that treating the person with HIV rather than the uninfected 
person offers advantages in settings where there are limited opportunities to access 
care. A treatment-as-prevention strategy that places all the emphasis upon the positive 
person’s adherence however carries a disproportionate burden of responsibility. PrEP 
remains an important option for receptive partners who face increased biological 
vulnerability. We conclude that the use of ARV for prevention is ethically justified, 
despite imperfect global to drugs for those in clinical need. The determination of 
which ARV-based HIV prevention strategy is ethically preferable is complex and 
must take into account both public health and interpersonal considerations.  
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Introduction 
Antiretroviral drugs (ARV) have been shown in several studies to be effective for 
HIV prevention, 1 using two quite different strategies. Treating people who have HIV 
with the specific goal of suppressing viral replication, and before they would normally 
need treatment for their own health, is known as ‘treatment-as-prevention’ (TasP) and 
reduces the risk of transmission to sexual partners by 96%2. Providing ARV to HIV 
negative people at high risk of acquiring HIV can occur either before the potential 
exposure as ‘pre-exposure prophylaxis’ (PrEP), which reduces the risk of becoming 
infected by 443-75%4 or after the exposure, as post-exposure prophylaxis (PEP).5 
This manuscript will only consider PrEP. The strategies differ, in that TasP puts the 
burden of HIV prevention onto the person with HIV, while PrEP puts it onto the HIV 
negative person, but they share many similarities.  In both, the ‘burden’ comprises 
having medication prescribed, adhering to a dosing schedule, perhaps experiencing 
side effects, and having periodic medical tests. 
 
                                                 
1 S.S. Abdool Karim & Q. Abdool Karim. Antiretroviral Prophylaxis: a Defining Moment in HIV 
control. Lancet 2011; 378(9809): e23-e25. 
2 M.S. Cohen, Y. Q. Chen, et al. Prevention of HIV-1 Infection with Early Antiretroviral Therapy. New 
Engl J Med 2011; 365(6): 493-505. 
3 R.M. Grant, J. R. Lama, et al. (2010). Preexposure Chemoprophylaxis for HIV Prevention in Men 
Who Have Sex with Men. New Engl J Med 2010; 363(27): 2587-2599. 
4 J.M. Baeten, D. Donnell, et al. Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men 
and Women. New Engl J Med 2012; 367: 399-410..  
5 I.M. Poynten, F.Y. Jin, et al. Non-occupational post-exposure prophylaxis, subsequent risk behaviour 
and HIV incidence in a cohort of Australian homosexual men. AIDS 2009; 23:1119–1126. 
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Despite their recognised efficacy, there is debate about how these prevention 
strategies should be implemented in public health programs. Concerns include their 
impact on established prevention approaches such as condom use, the side effects of 
widespread additional use of potent drugs, the potential for coercive application of the 
strategies, and the diversion of ARV away from people with infection who need 
treatment for their own health.  
 
Both HIV prevention and universal treatment access have been identified as global 
health priorities in the Millennium Development Goals6, the WHO Political 
Declaration on AIDS in 2006 and the UN General Assembly of 2011. It is clearer than 
ever that they are complementary goals, in that reducing the number of new infections 
will decrease the need for treatment, and increasing the access to treatment will 
reduce the viral load in the population, and hence the risk of new infections.  
However, there is inevitably a tension between the two goals at a number of levels, 
most obviously in regard to resource allocation. 
 
In this evolving context, we examined the perceived need for ARV-based prevention, 
in the form of PrEP and the moral claims that can be made for supplying ARV to 
people who are either HIV negative, or HIV positive but not at imminent risk of HIV-
related immune damage. We considered whether or not, from a moral perspective, 
                                                 
6 United Nations.  2008. The Millennium Development Goals Report. New York. Available at: 
http://www.un.org/millenniumgoals/pdf/The%20Millennium%20Development%20Goals%20Report%
202008.pdf [Accessed July 30 2012.] 
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PrEP and TasP are strategies that meet important public health goals, and the extent to 
which they complement or compete with universal treatment access goals. 
  
A public health stewardship framework  
 
We chose to analyse both PrEP and TasP using a public health stewardship 
framework that seeks to balance individual autonomy with utilitarian and collectivist 
concepts of a common good. This approach is particularly suited for HIV prevention 
interventions, which involve the linkage of public health outcomes and human rights 
protections7, thereby facilitating the active collaboration of people living with and 
affected by HIV.  The Nuffield Bioethics Council proposes a stewardship model that 
asserts that acceptable goals for public health activities are: 
 reducing the risks of ill health that result from other people’s actions; 
 reducing causes of ill health relating to environmental conditions;  
 protecting and promoting the health of children and other vulnerable people; 
 ensuring that it is easy for people to lead a healthy life; 
 ensuring that people have appropriate access to medical services; and 
 reducing unfair health inequalities. 
These goals are considered to be acceptable, provided that they: 
 do not attempt to coerce adults to lead healthy lives; 
 minimise the use of measures that are implemented without consulting people 
(either individually or using democratic procedures); 
                                                 
7 J. M .Mann. Medicine and Public Health, Ethics and Human Rights. Hastings Cent Rep 1997; 27(3): 
6-13. 
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 minimise measures that are very intrusive or conflict with important aspects of 
personal life, such as privacy.8 
This framework is directly applicable to access to communicable disease control and 
specifically to HIV biomedical prevention interventions, as it articulates an approach 
to public health agenda, while recognising the need to minimise the impact on 
individual autonomy. In so doing it allows for a public health approach that fosters 
human rights protections because it recognises the importance of both individual and 
collective health, resisting the ‘false dichotomy’ between human rights and public 
health identified by Barr et al.9 
 
Importantly, the framework recognises the ease with which an intervention facilitates 
‘a healthy life’ as a significant public health goal. Past public discourses on HIV 
prevention have extolled the ‘duty’ to use a condom, or to adopt restrictive 
behavioural prevention practices, as if they were moral virtues in and of themselves.10 
In fact the long history of contraception has shown the difficulties that people 
experience in adhering to this kind of regime, rendering them potentially quite 
ineffective as public health strategies. The arrival fifty years ago of the contraceptive 
pill taught us that taking a pill to prevent potential unwanted consequences of sex is 
                                                 
8 Nuffield Council on Bioethics. 2007. Public health: ethical issues. Chapter 2 (An Ethical Framework) 
Available at: 
http://www.nuffieldbioethics.org/sites/default/files/files/Public%20health%20Chapter%202%20-
%20An%20ethical%20framework.pdf  
9 D. Barr, J. J. Amon, M. Clayton. Articulating A Rights-Based Approach to HIV Treatment and 
Prevention Interventions. Current HIV Research 2011; 9(6): 396-404. 
10 M. Davis. The ‘loss of community’ and other problems for sexual citizenship in recent HIV 
prevention. Sociology of Health & Illness 2008; 30: 182-196. 
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far easier that using a barrier correctly and consistently for every penetrative sex act, 
and is consequently used, thereby yielding the public health benefit. Ease of use is 
integrally linked to the likelihood of effectiveness.11   
 
As an HIV preventive intervention, PrEP reduces the risks of ill health that result 
from other people’s actions  - sexual partners who don’t use barrier protection 
correctly or consistently12 and ‘environmental conditions’, such as population HIV 
incidence that is so high that exposure is virtually inevitable. PrEP also protects the 
health of vulnerable people, in that people at increased risk of HIV are vulnerable in 
that respect if not in many other aspects of their lives. It is an ‘appropriate medical 
service’ in that it is an effective risk reduction tool, and reduces the inequality of some 
people facing disproportionate risk of HIV acquisition. Because of the adherence 
required, PrEP effectiveness is linked with voluntary, motivated and informed use in 
line with the principle of autonomy. 
 
TasP also sits fairly comfortably in the stewardship framework. Like PrEP, TasP 
serves the public health goal of reducing risks of ill health resulting from other 
people’s behaviour: People with HIV may experience pressure to disclose their HIV 
                                                 
11 J.O. Kahn, J.N. Martin, M.E. Roland, J.D. Bamberger, M. Chesney, D. Chambers, K. Franses, T.J. 
Coates & M.H. Katz. Feasibility of Postexposure Prophylaxis (PEP) against Human Immunodeficiency 
Virus Infection after Sexual or Injection Drug Use Exposure: The San Francisco PEP Study. Journal of 
Infectious Diseases 2001; 183: 707-714. 
12 Where people have equal power, it is reasonable that they take equal responsibility for HIV/STI 
protection. However, condom use is not directly under the control of receptive sex partners, thus the 
receptive partner can be said to have less agency with regard to barrier protection. 
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status in situations where they feel it is unsafe to do so, such as negotiating condom 
use with a sexual partner, including a spouse; If they are effectively treated, the 
resulting viral suppression minimises the harm that can occur if positive people have 
unprotected sex. As TasP necessitates a focus on testing, more people knowing their 
HIV status and taking up the treatment option results in a lower ‘community viral 
load’, thus decreasing the overall environmental risk of HIV acquisition for others. It 
works to protect vulnerable people who fail to negotiate barrier protection and reduces 
the inequality of some people facing disproportionate risk of HIV acquisition by 
decreasing the risk itself, through reducing infectivity. Similarly to PrEP informed, 
motivated, voluntary uptake of TasP is an exercise in autonomy. However, lifelong 
adherence to medication is a huge commitment, particularly when started early. 
Unlike PrEP, the burden is unremitting once started, as taking breaks from treatment 
has been shown to lead to drug resistance and failure.13 This aspect means it does not 
fit the criterion of making it easy to live a healthy life.  The burden of treatment, 
however, is arguably offset by three factors: that some people with HIV prefer early 
treatment because it treats the ‘illness’ of being infectious, there is some preliminary 
evidence that suggests early treatment may be medically beneficial and that the point 
of diagnosis might be a critical juncture for linking in to treatment services, which in 
later HIV disease is crucial.  
                                                 
13 J.D. Lundgren, A. Babiker, W. El-Sadr et al. Inferior clinical outcome of the CD4+ cell count-guided 
antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV 
RNA levels during follow-up. J Inf Diseases 2008; 197: 1145-1155. 
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PrEP  
 
While the acquisition of HIV is preventable through the use of condoms and 
behavioural strategies such as celibacy or mutual monogamy, these strategies are of 
limited usefulness in many circumstances. Celibacy may be socially and/or 
economically impossible for many individuals. Mutual monogamy assumes that both 
partners are HIV negative from the outset, and that ongoing monogamy can be 
assured, whereas a body of evidence shows that this is unrealistic and many women 
worldwide have acquired HIV through their sole sexual partner14. Condom use 
requires the ability to both detect when there is a risk of HIV acquisition and negotiate 
condoms use for those acts, or use of condoms for all penetrative sex acts. While 
many commentators discuss the notion of ‘responsible’ sexual behaviour as a 
desirable moral norm, this overlooks the fact that HIV risk is largely determined by 
structural factors – the HIV prevalence in the demographic pool in which one has sex, 
rather than simply the sex one has, combined with the prevailing sexual mores. This is 
demonstrated by the fact that a woman from Kwa-Zulu Natal in South Africa faces a 
25% lifetime risk of HIV acquisition, while an Australian woman’s risk is less than a 
thousandth of that.15 Given the difficulty of negotiating condom use in a variety of 
sexual scenarios and the dampening of sexual pleasure and/or erectile dysfunction that 
                                                 
14 Jg Silverman et al.  Intimate Partner Violence and HIV Infection Among Married Indian women. JAMA  2008 
300(6): 703-710. 
 
15 B. Haire, J. Kaldor, C.J. Jordens.  How Good Is “Good Enough?” The Case for Varying Standards of 
Evidence According to Need for New Interventions in HIV Prevention. Am J  Bioeth 2012; 12(6): 21-
30. p 28 
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some experience when using condoms,16 additional strategies to reduce HIV 
acquisition are desperately needed. 
 
A particular appeal of PrEP is that it is the first regulator approved preventive 
intervention directly under the control of individuals at risk of HIV who have 
receptive vaginal or anal sex. The young women in southern Africa who are unable to 
insist upon condom use or faithfulness by their spouses, are equally unable to be able 
to prevail upon them to be tested for HIV, take up treatment, and ensure medication 
adherence to keep viral load suppressed, as would be required for TasP.17 The moral 
imperative to enable  the highest risk population in the world to protect themselves,  
requires a strategy that empowers them to be proactive on their own behalf, not one 
that positions them as hapless (or lucky) recipients of a fate determined by others’ 
actions. 
 
In summary, the moral argument for PrEP at an individual level rests on the need for 
preventive strategies in people facing an overwhelming risk. Existing tools are 
inadequate, particularly for the receptive sex partner who both faces a higher 
biological risk and has less control over the decision as to whether barrier protection 
is used. PrEP was developed for people in precisely this predicament. 18 
                                                 
16 N.S. Musacchio, M. Hartrich & R. Garofalo. Erectile Dysfunction and Viagra Use: What’s up with 
College-Age Males? J Adolescent Health 2006; 39: 452-454. 
17 S.S.Abdool Karim & Q. Abdool Karim. Antiretroviral prophylaxis for HIV prevention reaches a key 
milestone.  Lancet 2011 (online first). 
  
18 PrEP may however also entail some social harms, as a person taking it may be presumed to be HIV 
positive and thus experience stigma. Thanks to an anonymous reviewer for this observation. 
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Treatment-as-prevention 
 
Ongoing, secure access to ARV is critical for people with HIV, once a certain level of 
immune-system damage has been sustained.19  TasP approaches have been criticised 
for prioritising a public health benefit – the suppression of viral replication, reducing 
infectivity – over the health of the patient, potentially leading to coercive regimes of 
testing and treatment without informed voluntary participation. 20 
These criticisms rest on several premises. The first is that there is a period after HIV 
infection but before significant immune damage in which it is valuable for the person 
with HIV to not commence treatment. In the absence of definitive evidence21, this 
position is currently supported by several lines of reasoning. Specifically, it may be 
that starting ARV shortly after diagnosis extends the opportunity for poor adherence, 
for no clear benefit, which in turn can cause drug resistance, limiting treatment 
options later on. There is now clear evidence that interrupting treatment is associated 
with increased risk of disease progression and death22.  Even the safest ARV 
                                                 
 
20 Strubb, S. 2012. Public Health or Slippery Slope? Poz Blogs, Poz. 2012. Accessed July 31 2012 
Strubb, S. 2010. Medical Ethics and the Rights of People With HIV Under Assault. Poz Blogs, Poz. 
2012. Accessed July 31 2012 
21 It is not known whether there is a medical advantage is starting ARV very early in HIV infection. A 
randomised controlled trial, the START study, is evaluating this and results are expected within five 
years. http://www.niaid.nih.gov/volunteer/hivandinfectious/hivstudies/Pages/STARTStudy.aspx. 
Accessed July 31 2012 
22 The Strategies for Management of Antiretroviral Therapy Study Group. (2008). Major Clinical 
Outcomes in Antiretroviral Therapy (ART)–Naive Participants and in Those Not Receiving ART at 
Baseline in the SMART Study. J Inf Diseases 2008 197(8): 1133-1144. 
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regimens currently available can have serious short or long-term side effects, 
including altered lipids, reduced bone density and kidney damage.   
 
Clearly, these are important individual considerations to be weighed against the 
potential public health benefit of having reduced infectivity. Their importance for an 
individual depends on contextual factors such as whether or not an individual is 
confident about taking medicine consistently, whether an uninterrupted supply is 
assured, and whether there will be a good opportunity to take up ARV at a later point 
if it delayed.  
 
On the other hand, regardless of the medical implication of early treatment, 
suppressing viral load can also have the benefit of relieving the psychological burden 
that some people with HIV have expressed – the fear of potentially causing 
infection.23 
 
The second premise is that it is morally wrong to  situate the health of the person with 
HIV as secondary to the public health benefit of suppressing viral load, as occurs in a 
‘treatment-as prevention’ strategy. At the individual level there is a clear 
responsibility for the physician to explain that early therapy may not be directly 
beneficial to the patient, and to present reasons why the patient may choose to decline 
early ARV. People may however prefer early treatment, for its impact on 
infectiousness or other reasons. If there is genuine voluntariness, the objection that the 
                                                 
23 J. Gibbs. Verdict on a virus. IRMA Rectal Microbicides Advocacy blog. http://irma-
rectalmicrobicides.blogspot.com.au/2011/11/pros-and-cons-of-treatment-as.html  Accessed July 31 
2012. 
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person with HIV is being coerced for societal benefit is neutralised.  In addition, there 
is a sound rationale for offering early treatment: the risk of side effects is  arguably 
mitigated by benefits in terms of reduction of inflammation, and the risks relating to 
non-adherence  are under the patient’s control to some extent). The public health goal 
is clear: reducing the risk of ill health that could come from the person with HIV 
having unprotected sex. Thus the benefit justifies the risk (which has been voluntarily 
assumed by the person with HIV), satisfying ethical criteria.24 
 
Finally, there is the issue of coercion. Since the beginning of the HIV epidemic there 
have been periodic calls for coercive measures to isolate, control and in some cases 
criminalise people with HIV25. Coercive practices are unethical and specifically 
undermine effective HIV programs which ultimately rely upon people utilising 
services over lifetimes. Adherence to HIV treatment requires (at least) daily 
adherence to medication and this is only feasible when people voluntarily take on the 
responsibility.  
                                                 
24 Jaffe, H. W. and T. Hope (2010). "Treating for the Common Good: A Proposed Ethical Framework." 
Public Health Ethics 3(3): 193-198. 
25 R. Bayer, R. 1989. Isolating the infected: the politics of control . Private Acts, Social Consequences. 
New York, The Free Press: 169-206. 
Global Network of People Living with HIV. About the Global Criminalisation Scan. Available at: 
http://www.gnpplus.net/criminalisation. Accessed July 31, 2012. 
International Planned Parenthood Federation, Global Network of People Living with HIV/AIDS, 
International Community of Women Living with HIV/AIDS. HIV - Verdict on a Virus: Public Health, 
Human Rights and Criminal Law. 2008. Available at: 
http://www.gnpplus.net/images/stories/2008_verdict_on_a_virus.pdf. Accessed July 31, 2012. 
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Rationing 
 
A key concern is that expanding the criteria for treatment to include TasP for the 
newly diagnosed or PrEP for the HIV negative at high risk will reduce the availability 
of ARV for those who need it to maintain their health, meaning those who have 
symptomatic HIV disease or who are at imminent risk of disease progression.  
It is not clear, however, that expanding the criteria for ARV will undermine access to 
ARV for those who need it for immediate health needs. As Barr et al point out, 
sustainable use of ARV for either treatment or prevention depends upon people 
seeking out services and in the case of treatment, using it for a lifetime.26Stigma, 
discrimination and lack of human rights protections jeopardise ARV programs 
because people become afraid of the social and political consequences of using them. 
Expanding the criteria for access has the potential to dilute association between ARV 
and negative social stereotypes (even so, there remains an imperative to address these 
issues both in terms of law reform for those subject to discriminatory laws and social 
empowerment of HIV-affected communities).27 
 
In addition, many of the identified impediments to scaling up HIV treatment access 
are workforce and health system issues, including poor distribution systems, low 
remuneration for workers and accelerated migration of skilled workers28. Expanding 
                                                 
26 Note 9, op cit 
27 Ibid 
28 Schneider, H., D. Blaauw, et al. (2006). Health Systems and Access to Antiretroviral Drugs for HIV 
in Southern Africa: Service Delivery and Human Resources Challenges. Reproductive Health Matters 
2006; 14(27): 12-23. 
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the criteria for ARV access, provided it occurs in a fashion that strengthens rather 
than undermines existing health infrastructure, has the potential to make efficiency 
gains across HIV programs.29 
 
Mother-to-child prevention programs are a case in point.30 Importantly, and despite 
the fact that women access ARV at higher rates than men  in sub-Saharan Africa, 
mother-to-child prevention programs do not take treatment resources away from those 
in greater need – on the contrary, they have provided an important access point and 
facilitated the development of ARV services. 
 
The public health goal in mother-to-child prevention programs is protecting and 
promoting the health of children. They are also grounded in a rights framework - the 
right to health. In the case Minister of Health vs Treatment Action Campaign31, this 
right was upheld by the South African Constitutional Court, and the corresponding 
duty to provide the means to prevent the infection (ARV) was found to fall upon the 
South African Government. The responsibility of the government to intervene was 
because the risk was real – estimated as up to 30% without intervention – and 
effective risk mitigation was both available and feasible.  
 
                                                 
29 G. Hirnschall, G. & B. Schwartländer. Treatment 2.0: catalysing the next phase of scale-up. Lancet  
2012; 378(9787): 209-211. 
30 There are a wide range of these programs, ranging from comprehensive programs that link the 
mother to ongoing care regardless of her CD4 cell count, to sub-optimal ones that provide singles doses 
of ARV to the mother and infant. 
31 http://www.saflii.org/za/cases/ZACC/2002/16.html 
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Importantly, mother-to-child prevention programs have been a mechanism for getting 
people into treatment programs. While such programs were initially used just to cover 
the pre- and immediate post- natal period, World Health Organisation guidelines  now 
include an option for life-long access (known as the ‘B+ option’), in recognition that 
cycling on and off ARV may be harmful to women’s health, and that there are 
ongoing preventive benefits of continual treatment.32 
 
The same argument now holds for population use of ARV-based prevention in adults, 
given evidence of efficacy and the high likelihood of HIV exposure for sexually 
active people in hyper-endemic settings, with the public health goal being the 
protection of vulnerable people. While population level treatment-as prevention is 
considerably more expensive that mother-to-child programs, prevention HIV now 
reduces pressure on ARV in the immediate future, thus arguably making ARV more 
sustainable for people who need it for their health. Without a significant decline in 
incidence, sustainability of treatment programs will be threatened as demand 
increases. 
 
While governments can and must set spending priorities with regard to HIV treatment 
and prevention, supplying one group with ARV does not necessarily entail denying 
access to another group, if economies of scale are achieved. Clearly where the direct 
need of a person to be treated with HIV conflicts with the need of a negative person 
for PrEP, the health needs of the person with HIV must be addressed first because the 
                                                 
32World Health Organisation.April 2012. Programmatic Update: Use of Antiretroviral Drugs 
for Treating Pregnant Women and Preventing HIV Infection in Infants. Executive summary. Available 
at:  http://www.who.int/hiv/PMTCT_update.pdf [Accessed  20 November 2012] 
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life of that person depends on the supply of ARV, a need that trumps any potential 
prevention benefit. This does not imply, however, that the establishment of treatment-
as-prevention and PrEP programs should wait until governments meet their 
commitments to existing universal access targets. 
 
One of the fallacies in the 1990s debate over standards of care in research was that 
drug prices are immutable. The treatment access movement showed that drug prices 
do drop as a result of public pressure, and (some) pharmaceutical companies have 
shown themselves to be amenable to trade policies that facilitate access for those in 
low income countries, rather than adopting a  protectionist stances. PEPFAR and the 
Global Fund have demonstrated that while providing ARV access is complex it can be 
progressively realised, and that successful programs breed successful programs. 
Rather than ‘wasting’ funds earmarked for HIV, widening the pool of those eligible 
for ARV by adopting ‘treatment-as-prevention’ may decrease the wastage that 
currently occurs wastage not just of resources, but more importantly of human life.  
Voluntary HIV testing is a cornerstone of HIV programs, but testing in itself is 
useless unless it links people to care. As Barr et al assert, testing is a tool, not a goal.33 
Current testing regimes linked to delayed ARV programs are not working optimally, 
according to a meta-analysis of 28 trials looking at people diagnosed with HIV but not 
yet eligible for ARV in sub-Saharan Africa. This study showed that more than two 
thirds of people tested positive were lost to care, meaning they never accessed 
treatment34. This is sobering. It suggests that diagnosing people with HIV, then telling 
                                                 
33 Note 9 op cit 
34 S. Rosen & M. P. Fox. Retention in HIV Care between Testing and Treatment in Sub-Saharan 
Africa: A Systematic Review. PLoS Med 2011; 8(7): e1001056. 
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them to wait until their CD4 count drops, may not be a strategic use of resources in 
low and middle income countries. Diagnosing people with HIV and linking them to 
treatment, however, has twofold benefit: maintaining the health of the person with 
HIV, and protecting his or her sex partner/s35. 
Most-at-risk populations targeting 
 
Age, gender and nationality, however, are not the only determinants of HIV risk.  
Both PrEP and TasP should be deployed to ensure access by  those who most need 
them. This includes the most-at risk populations that exist within generalised 
epidemics, and care needs to be taken to ensure that the prevention programs do not 
further stigmatise these groups. 
 
While the trial that established TasP was in serodiscordant couples, its mechanism of 
action is to reduce infectiousness to sex partners, so it should be available to on the 
basis of a positive person being sexually active with a partner or partners of unknown 
or negative status. It should be available to heterosexually and homosexually active 
people alike – trials of TasP in gay and MSM populations are infeasible post-HPTN 
052, so the best that can be done is to extrapolate the findings, with the riser that as 
anal sex has a higher risk-per-act that vaginal, it might be somewhat less effective. 
Successful, cost-effective PrEP depends upon people who are at increased risk of HIV 
acquisition understanding this, seeking out PrEP, and adhering to the regimen for the 
period of time for which they are risk. This is complex, as even in sub-Saharan Africa 
there are heterogeneous risk factors in different regions.36  Imposing eligibility 
                                                 
35 Haire, B. (2011). Treatment-as-Prevention Needs to Be Considered in the Just Allocation of HIV 
Drugs. Am J Bioeth 2011; 11(12): 48-50. 
36 http://transition.usaid.gov/our_work/global_health/aids/Countries/africa/hiv_summary_africa.pdf 
 238
constraints on PrEP in regions where HIV is hyper-endemic is problematic from a 
human rights perspective, however, due to the prevalence of violence and 
discrimination towards gay men and other men who have sex with men (MSM) in 
many African countries37. For PrEP to be meaningfully accessible to men at highest 
risk of HIV, those who have receptive anal intercourse with other men, an avenue for 
access without identifying as MSM is necessary. The recommendation for eligibility 
then would have to be for women and men who identify as being at high risk of HIV, 
without elaborate targeting that requires sexuality disclosure, as that could 
paradoxically exclude those at highest risk. 
 
The situation for sex workers is complex, as their occupational health and safety is 
best protected by condoms.38 Great care needs to be taken not to undermine condom 
culture in sex work, while still facilitating access to the full range of options for HIV 
prevention which workers might require for either professional or private sex practice.  
Involving sex workers in policy development around new HIV prevention 
technologies is critical to getting the balance right. 
 
Targeting in concentrated epidemics 
 
In developed countries with concentrated epidemics, PrEP is much easier to target, 
and is arguably the most effective way of utilising ARV for HIV prevention. In 
countries with universal health care systems and a clearly identifiable at risk 
population – the subsection of gay men and other MSM who have unprotected sex 
                                                 
37Note 9 op cit 
38 C.C. O'Connor, G. Berry, R. Rohrsheim & B. Donovan. Sexual health and use of condoms among 
local and international sex workers in Sydney. Genitourinary Medicine 1996; 72: 47-51. 
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with partners of unknown status – it is arguably more efficient to target these men to 
utilise PrEP than to attempt ‘treatment-as prevention’. Recent Australian research has 
shown that men who identify themselves as being at high risk of HIV are willing to 
take PrEP, while those who perceive their risk as lower are less so39. The biological 
advantage of PrEP in a small epidemic is that it is more likely to provide protection in 
the highly infectious seroconversion period, when a person with newly acquired HIV 
has a high viral load but might not recognise that s/he has acquired HIV, and hence 
might not have yet accessed testing or treatment. That is not to say that treatment 
ought not to be available for people with HIV who perceive an advantage in early 
treatment, merely that in strategic terms, when the at-risk population is readily 
identifiable there are benefits both in terms of cost (the two drugs used in prevention 
being cheaper than three used in treatment) and in terms of providing protection on 
the basis of the negative person’s risk practice rather than the positive person’s 
apprehension of his need for treatment.  
 
Conclusion 
Both PrEP and treatment-as-prevention offer new ways to address HIV incidence.  
While ARV treatment is expensive, harnessing its preventative potential now will 
ultimately reduce demand on treatment resources. Treatment-as-prevention is more 
effective than PrEP, but its risks and benefits are likely to be weighed differently by 
individuals according to complex psychological rationale, and we consider that 
                                                 
39 M. Holt et al. Willingness to use HIV pre-exposure prophylaxis and the likelihood of decreased 
condom use are both associated with unprotected anal intercourse and the perceived likelihood of 
becoming HIV-positive among Australian gay and bisexual men. Sex Transm Infect, 2012; 88, 258-
263. 
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informed voluntary uptake is the only way for this option to be both ethical and 
effective. Wholesale uptake of treatment as prevention at the level required to make a 
major impact on the epidemic is therefore necessarily highly unlikely, at least until 
treatment regimens become more user-friendly or definite evidence emerges as to 
individual benefit of early treatment. PrEP offers a complementary modality than has 
the massive advantage of enabling people at risk to take control of their own 
protection, even if they are not so successful with condoms.  This is a particularly 
welcome development for those who have receptive vaginal or anal sex. 
 
In endemic or hyper-endemic settings, making both PrEP and treatment-as-prevention 
available, combined with  human rights protection and empowerment of HIV-affected 
communities, makes more sense than trying to scale up testing and treatment alone. 
Adding PrEP into the toolbox for people who recognise that they are at high risk  both 
supports the decline of HIV incidence while also changing the character of ARV 
access, disaggregating it from being a marker of HIV infection, which may assist in 
destigmatising it to some degree. 
 
We recognise that there will be instances where rationing decisions need to be made 
as to whether an HIV negative person, a healthy HIV positive person or an HIV 
positive person with immune suppression will receive a limited supply of ARV. 
Where there is direct competition like this, we affirm the right to the sick person’s 
need to be met above all other considerations. At the programmatic level, however, 
we argue that broadening the scope of ARV access to include both treatment as 
prevention and PrEP should occur now, and not wait until existing access targets are 
met, as the issue with ARV access is as much to do with infrastructure as it is with 
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supply, and new investment in ARV as treatment has the potential to increase 
efficiencies within the existing infrastructure, and complement the goal of universal 
access. 
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Abstract 
In 2010, randomised controlled trials (RCTs) of two different biomedical strategies to 
prevent HIV infection had positive findings. However, despite ongoing very high levels of 
HIV infection in some countries and population groups, it has been made clear by regulatory 
authorities that the evidence remains insufficient to support either product being made 
available outside of research contexts in the developing world for at least two years. In 
addition, prevention trials in endemic areas will continue to test new interventions against 
placebo. But the judgments of evidentiary standards are never value-neutral.  Using the 
recent trials and their contexts as case studies, we examine the basis for these decisions, 
which will potentially delay access to scientific innovation to the people who are most 
urgently in need of it. 
 
Introduction 
During 2010, in the space of five months, two landmark studies, CAPRISA 004 and iPrEX, 
showed convincing, positive results using related but different biomedical strategies to 
prevent HIV (Abdool Karim, Abdool Karim and Frolich et al.. 2010, Grant, Lama and 
Anderson et al.. 2010). Both studies found that their interventions had partial efficacy, 
meaning that they reduced, but did not eliminate the occurrence of new HIV infection. Both 
tested strategies involving antiretroviral drugs used in HIV negative people, but with 
different modes of administration – one a vaginally applied topical product, the other one 
orally administered.  But neither product will be made available outside of the research in the 
developing world for at least two years1. In addition, neither product will be used as 
‘standard of prevention’ in ongoing HIV prevention trials until confirmatory studies have 
been completed. In this article we examine the basis for these decisions, which will 
                                                 
1 This is the estimated completion time of confirmatory studies. See Mail & Guardian 2011. 
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potentially delay access to scientific innovation to the people who are most urgently in need 
of it. 
Reducing the incidence of HIV is both a public health priority and a moral 
imperative. Although World Health Organization (WHO) estimates of the extent of the 
international epidemic have declined slightly in recent years (UNAIDS  2010a), a number of 
southern African countries have estimated prevalence above 20% (UNAIDS  2010b) and 
current infection rates in the range of 1-5%. There are resurgent epidemics in gay men and 
men who have sex with men2 in the developed world (van Griensven & de Lind van 
Wijngaarden, et al.. 2009), and despite the galvanizing of international will to provide 
universal access to antiretroviral drugs (ARV) over the last decade, the reality of treatment 
for all who need it remains a distant goal, particularly with the Global Financial Crisis having 
a potential impact upon key donors such as the President’s Emergency Fund for AIDS 
(PEPFAR). Preventing HIV acquisition therefore, as well as treating those living with the 
virus, remains a critical public health goal in areas where HIV is endemic.  
New biomedical products of moderate efficacy have the potential to significantly 
slow the epidemic in these affected countries. Delay in introducing effective prevention 
strategies may result in hundreds of thousands of potentially avoidable infections.  It is 
therefore reasonable to ask on what basis was it decided a) that the two new trials do not 
provide sufficient evidence to support these products being made available outside research 
settings, and b) that they should not form part of the standard of care in the control arm of 
new trials, and replace placebos? The main sources of guidance available to make this 
judgement are specific ethical guidelines produced by UNAIDS/WHO (2007), the HIV 
Prevention Trials Network (2009) and UNAIDS/AVAC (2010), ethical analysis using the 
                                                 
2 We distinguish ‘gay’ men from ‘men who have sex with men’ to acknowledge that homosexually 
active men have distinct and different social identities. 
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concept of equipoise, and regulatory requirements, in particular those of the US Food and 
Drug Administration (FDA). 
 Application of FDA guidelines immediately raises the question as to whether the 
level of evidence being required for US or other rich country settings is in the best interests 
of people at risk of HIV, and participants in new trials, in developing countries with a high 
incidence of HIV.  
The recent trials 
In July 2010 the ground-breaking results of the CAPRISA 004 trial were released to 
international acclaim (AIDS 2010), showing 39% efficacy of a vaginal microbicide using 1% 
tenofovir gel in a large scale IIB trial (Abdool Karim, Abdool Karim and Frolich et al.. 
2010)3. 
In November 2010, the iPrEx results were published in the New England Journal of 
Medicine, showing a higher risk reduction than CAPRISA 004 (44%) using a combination of 
tenofovir and emtricitabine (TNF/FTC)4 taken orally each day (Grant, Lama and Anderson et 
al. 2010).  
                                                 
3 Microbicides are topical agents, in this case in the form of a gel, containing the antiretroviral drug 
tenofovir. They are designed to prevent HIV acquisition when applied inside the vagina (products are 
also being developed for rectal use). In theory a microbicide product could empower women to protect 
themselves from HIV, as it could be used at a women’s discretion and need not involve negotiation 
with a male sexual partner.  In practice, development of products in this field has been beset with 
unexpected difficulties. The first product ever evaluated in an efficacy trial was associated with 
increased risk of HIV acquisition, closely followed by several other products with negative (though not 
necessarily harmful) results (Padian, Buvé and Balkus 2008).  
 
4 The product consisted of tenofovir – the same active ingredient in the CAPRISA 004 product, 
together with a second antiretroviral drug, emtricitabine, taken orally. The combination is available as a 
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While the effects of both these products appear modest compared to some preventive 
measures, such as infant vaccines, they are substantial in the context of HIV prevention, 
where there have been few technological advances, apart from male circumcision (which is a 
long-established practice used for a new purpose), in a quarter of a century5.  Furthermore, 
the real benefit of these products might be substantially greater at the individual level, 
because the estimates found in the trials reflect the raw difference in HIV infection rates 
between the two randomised groups in each study, without regard to the extent to which 
participants actually used the study products.  
As pill-taking and gel use are user-controlled activities that require on-going 
adherence, both studies had strategies for testing adherence so that the efficacy of the product 
in high adherers could be compared that in to low adherers. In the topical trial, adherence was 
tested using a biomarker on the applicator gel that reacted to vaginal fluid (applicators were 
returned to researchers). In the iPrEX trial, adherence was tested by measuring blood levels 
of the drug. For both studies, step-wise increases in efficacy were associated with evidence of 
adherence. In iPReX, high adherers were 73% less likely to acquire HIV than the placebo 
group (Grant, Lama and Anderson et al. 2010), and in CAPRISA 004, were 54% less likely 
                                                                                                                                            
single pill under the brand name Truvada, and is currently used in the treatment of people with HIV. 
The advantages of an oral product are again that it can be taken discreetly, but more importantly – like 
modern hormonal contraception – the act of protection is removed from the sexual context (‘non 
coitally dependant’, in medical parlance). This makes it something that can be integrated into daily 
routine, arguably facilitating adherence. 
5 Another biomedical strategy prevention strategy was found effective in May 2011. The study 
HPTN052 showed that early initiation of treatment in a person with HIV prevented HIV acquisition by 
that person’s HIV uninfected sexual partner by 96%. Unlike PrEP and microbicide strategies, this 
approach works by reducing the infectivity of the index partner rather than directly blocking infection 
in the HIV negative partner. 
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to acquire HIV (Abdool Karim, Abdool Karim and Frolich et al. 2010). As adherence 
dropped, so too did efficacy in both studies. This strengthens the plausibility that reduction in 
HIV acquisition was due to the product, and suggests that the real efficacy of the products is 
very much higher than the estimate derived from the reported intent-to-treat analysis. 
Adherence is critical to real world effectiveness of user-dependent methods. As Heise 
et al. (2010) point out: 
[W]ith user-dependent methods like microbicides or condoms, focusing on the 
method's efficacy alone misses half the story. The protection that a prevention 
method confers is a function of both the inherent efficacy of the method and 
how consistently it is used. Indeed, given the particular transmission dynamics 
of HIV, consistency directly compensates for efficacy. In other words, using a 
low-efficacy method consistently for HIV protection can confer as much 
protection as using a high-efficacy method inconsistently. 
Taking a pill, for example, or using a gel that increases rather than dampens sexual 
pleasure (Stadler 2010) might prove to be more user-friendly than using a condom; and user-
friendliness would promote adherence and thereby increase the real-world effectiveness of 
PrEP and microbicides in HIV prevention. 
 
Ethical guidelines on standards of prevention and placebo 
Three sets of guidelines provide specific advice on the standard of prevention issue in HIV 
prevention trials: UNAIDS/WHO in their ‘Ethical considerations in biomedical HIV 
prevention trials’ of 2007, HIV Prevention Trials Network (HPTN) in their Ethics Guidance 
for Research (2009) and UNAIDS/AVAC Good Participatory Practice Guidelines for HIV 
prevention trials (2010 consultation draft).  
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The 2007 UNAIDS/WHO guidelines replace an earlier document that was specific to 
HIV preventive vaccines, broadening the scope to the wider field of emerging HIV 
prevention technologies and encompassing social changes, such as the increased availability 
of antiretroviral therapy. It is in these guidelines, indeed, that the term ‘standard of 
prevention’ was coined, to distinguish it from its sibling, ‘standard of care’. Guidance Point 
13 on ‘standard of prevention’ and Guidance Point 15, on ‘control groups’ are particularly 
relevant here as they specify respectively what participants should receive in HIV prevention 
trials as standard care in general and in control groups. 
Regarding the standard of prevention, Guidance Point 13 states: 
Researchers, research staff, and trial sponsors should ensure, as an integral 
component of the research protocol, that appropriate counselling and access to 
all state of the art HIV risk reduction methods are provided to participants 
throughout the duration of the biomedical HIV prevention trial. New HIV 
risk-reduction methods should be added, based on consultation among all 
research stakeholders including the community, as they are scientifically 
validated or as they are approved by relevant authorities. (Guidance point 13, 
Standard of Prevention, our italics.) 
UNAIDS /WHO guidelines make a normative statement – that researchers must 
ensure that participants in HIV biomedical prevention trials have access to all state of the art 
HIV risk reduction methods. It then goes onto make a procedural instruction, which is that 
researchers should negotiate the incorporation of new prevention methods into existing trials 
with research stakeholders, including the community. Negotiation, the guidelines state, 
should take into consideration feasibility, expected impact, and the ability to isolate the 
impact of the biomedical HIV modality being tested. Finally, the guidelines state that that 
new interventions should be added “as they are scientifically validated” (a concept that is left 
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undefined) or “as they are approved by relevant authorities”. Scientific validation could be 
defined as evidence of efficacy as shown in a clinical trial, while “approval by relevant 
authorities” introduces an inevitable delay that depends on regulatory processes.   
The normative statement in the UNAIDS Guidance Point 13 encapsulates a 
universalist stance in its directive to supply participants in HIV prevention trial with ‘state-
of-the-art’ prevention interventions in the control arms of studies. The procedural point that 
follows, however, has the effect of opening up the standard for negotiation – a negotiation 
that is tipped in favour of research funders, particularly with respect to the provision 
regarding feasibility of subsequent trials, which is a determination that that can only be made 
by the research elite, and involves judgments of value as much as objective judgements. 
So in effect, the UNAIDS Guidance Point 13 proposes a normative standard about 
how HIV prevention research is conducted,6 however in the commentary the interests of both 
science and society  are mentioned as factors that might provide reason not  to supply ‘state 
of the art’ HIV prevention technologies, even before getting into what ‘a proven intervention’ 
means. Given that adding in new partially effective prevention interventions  into trials 
testing other as yet unproven interventions will necessarily complicate research and require 
larger sample sizes and exponentially more funding, the commentary undercuts the norm. 
Guidance Point 15, on control groups, provides somewhat clearer guidance. It defines 
the ethically acceptable use of a placebo control, limiting its use to situations where “there is 
no HIV prevention modality of the type being studied that has been scientifically validated in 
comparable populations or approved by relevant authorities.” The accompanying 
commentary provides examples that recognise the limits to extrapolating assumptions about 
efficacy beyond the populations represented in available trial results. The wording however 
                                                 
6This follows from the principle that the interests of the research participant should take precedence 
over all other interests, in line with the Declaration of Helsinki (article 6).   
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still allows for the interpretation that a technology does not become standard of prevention 
until it has been ‘approved by relevant authorities’, an issue we will discuss further in the 
paper. 
The HIV Prevention Trials Network (HPTN) Ethics Guidance for Research (2009) 
avoids the apparent contradictions in the UNAIDS/WHO by taking a pragmatic line, in 
which it parses the ethical aspect of standard of prevention into obligatory and aspirational 
elements. The full guidance point (9) states:  
In partnership with key stakeholders, HPTN should establish a package of 
effective, comprehensive and locally sustainable prevention services to be 
offered to participants in each HPTN study. 
It then assigns ‘provision of prevention package’ to the status of ‘ethical obligation’ 
and ‘content of prevention package’ to the status of ‘ethical aspiration’. Down-shifting the 
content of the package to ‘aspirational’ is a minimalist approach. It obviously gives 
researchers much greater leeway in designing studies, and indicates a shift away from a strict 
obligation-based framework. These guidelines introduce the concept that a prevention 
package provided in a trial should be ‘locally sustainable’, which both points toward an 
intertwining of research ethics and public health intervention (as discussed in Macklin 2010), 
along with a whiff of  ethical relativism – that research participants are owed different duties 
according to where they live. 
The other very specific set of guidelines is the UNAIDS/AVAC Good Participatory 
Practice Guidelines for HIV prevention trials. There is a 2010 iteration of these up for public 
comment that also uses the language of negotiation regarding the addition of newly validated 
HIV prevention technologies. Researchers are asked to ‘review’ prevention packages, and to 
‘negotiate’ and ‘consult’. The standard for what constitutes a proven intervention is vague, 
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and the wording shifts between ‘scientifically validated’ and the stricter ‘approv[al] by 
relevant authorities’. 
None of the three sets of guidelines discussed here offers a clear normative standard 
for the content of the prevention package in HIV prevention research. The UNAIDS/WHO 
2007 guidelines come closest, with their statement that participants should be offered ‘state-
of-the-art’ prevention interventions. 
 
Guidance based on the requirement of “state of the art” prevention for all trial 
participants 
A central question posed by the both the CAPRISA 004 and iPrEx results is whether 
tenofovir gel and oral TNF/FTC must, as a result of their success in reducing HIV infection 
rates, now be considered ‘state-of-the-art’ HIV prevention, and thus be included in the 
control arms of subsequent prevention trials. In March 2009 USAID, in anticipation of such 
quandaries, the Global Campaign for Microbicides (GCM), UNAIDS and the Centers for 
Disease Control (CDC) met in Kampala, Uganda to discuss precisely how to determine when 
a prevention product should be deemed ‘state of the art’. They came up with a list of criteria 
that fall into four categories: the weight of evidence for a product and how this has been 
received by the broader scientific community; issues surrounding potential safety or cultural 
concerns; the feasibility of supplying the product; and the impact of adding the product to the 
enterprise of testing new HIV prevention modalities (McGrory et al. 2010). 
Unlike male circumcision, the other new prevention technologies to emerge so far in 
HIV prevention – i.e. vaginal or rectal microbicides and oral prophylaxis - do not appear to 
present fundamental cultural issues for implementation, and both offer a form of protection 
that has hitherto been lacking in HIV prevention: a technology whose use is controlled by the 
receptive sexual partner. Regarding issues of safety, there are considerable safety data 
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available from earlier trials (e.g. Peterson et al. 2007). Feasibility of supplying a new product 
is always challenging, but in the end, a matter of distribution logistics. Thus the remaining 
issues are the weight of evidence and the impact of adding new technologies to the enterprise 
of HIV prevention research. 
Large scale efficacy trials of new prevention technologies for HIV are generally 
powered to detect reductions in infection rates down to about 30%, the lowest level at which 
it is considered that an intervention would have an advantageous public health impact, based 
on mathematical modelling studies (WHO 2010). The absolute size of the impact in any 
particular region, however, depends upon the dynamics of the HIV epidemic in the region, its 
scale, and the extent to which other prevention interventions are being used. 
 
Guidance based on drug development standards 
Most drug development occurs in the developed world in an environment of intense 
commercial and academic competition. The United States’ Food and Drug Administration 
handles high numbers of applications for the approval of new drugs, including applications 
for drugs that are very similar to drugs already on the market (‘me too’ drugs). In response, 
the FDA has developed stringent standards for evidence of efficacy (Hamburg 2010). One of 
the key elements of these standards is the requirement that the efficacy of a product be 
proven in two separate trials each of which must have a p value of less than 0.05 (Stone 
2010, 25).  
A p value of 0.05 is the accepted threshold of statistical significance. A p value is a 
measure of statistical significance, and a p value of 0.05 means that there is 1 in 20 
probability that the results would have happened by chance if the factor being tested had in 
fact no effect – and the lower the number, the less likely that the result is due to chance. 
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Kopelman (1986) points out that while this is “a reasonable and well-established convention, 
it is none the less a moral choice” (Kopelman 1986, 322). 
Alan Stone, writing on behalf of WHO, adds that in theory a single trial that is 
statistically significant at the 0.001 level rather than two trial with p values of 0.05 would 
suffice (alongside other non-RCT evidence). Indeed, an earlier breakthrough in HIV 
prevention – the mother-to-child transmission trial, known as PACTG076 that established the 
use of antiretrovirals to dramatically reduce transmission from mother to infant – became 
standard of care on the basis of a single trial, the p value for which was 0.00006 (Connor et 
al. 1994). 
Stone identifies the requirement for two trials one after the other as potentially posing 
“insurmountable practical and ethical difficulties, particularly if the first trial showed 
evidence of protection with a p value well below 0.05.” (Stone 2010, 25).The p value for the 
overall CAPRISA result was 0.017, with the 95 percent confidence interval7 of 6 to 60%, 
placing this trial squarely in that realm identified by Stone as posing 
“insurmountable…difficulties”.  
The rationale for requiring confirmatory studies post CAPRISA is that the confidence 
intervals are wide. This is due in part to the fact that the trial was designed as a phase IIb 
study. Phase IIb studies have exponentially fewer participants that phase III efficacy studies, 
and these smaller sample sizes mean they are less likely to produce evidence of efficacy 
strong enough for regulatory approval. Essentially a phase IIb trial is an under-powered 
efficacy study designed to give preliminary evidence that a product works rather than an 
accurate estimate of its efficacy. 
                                                 
7 A confidence interval is a range around an interval that conveys how precise and how stable a 
measurement is (New York Department of Health 1999). Wider confidence intervals indicate 
instability, meaning that if the trial were repeated the results could vary within that wide range 
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The iPrEx results are considerably stronger, with a p value of 0.005, and 95% 
confidence intervals of 32-74%. This means there is a 5 in 1000 probability that the result 
would have occurred by chance if the agent had no effect, and even the lowest end of the 
confidence interval is a level of efficacy that would, according to mathematical modelling, 
have significant public health benefits not only in regions where HIV is endemic (Anderson 
et al. 1996, Vermund 1998). 
 On October 25, 2010, The United States’ Food and Drug Administration gave the go-
ahead for fast tracking its review of tenofovir 1% vaginal gel, the product used in CAPRISA 
004 (CONRAD 2010). This allows the product sponsors to  submit each section of their New 
Drug Application for ‘rolling review’, a process which is more time-efficient, as some 
aspects of the application can be completed and submitted for review as further data are 
being gathered. Without a ‘fast track’ approval, the New Drug Application could not be 
submitted until all sections were complete, then the review would begin. The FDA stipulated 
the need for more data based on its preference for two well-controlled studies to verify the 
safety and efficacy of 1% tenofovir gel”, so no final decision on licensure will be made until 
the results of another, confirmatory trial, which is due to end in 2013, are submitted (Global 
Campaign for Microbicides 2010).  
In the case of oral tenofovir/FTC, although only one trial had been completed, the 
FDA requirement for two studies did not seem to be an impediment to the development of 
new prevention guidelines based on the findings of the trial. On January 28, 2011 the US 
Centers for Disease Control (CDC) released Interim Guidance: Pre-exposure Prophylaxis for 
the Prevention of HIV Infection in Men Who Have Sex with Men (CDC 2011) two months 
after the publication of the iPrEx results. This document provides a summary of the iPrEx 
results, with eligibility criteria and details of the medication regimen and recommended 
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follow-up, written in a way that suggested that it was aimed at healthcare providers and 
research-literate members of at-risk populations.  
The interim Guidance follows an earlier CDC facts sheet, Pre-Exposure Prophylaxis 
(PrEP) for HIV Prevention: Promoting Safe and Effective Use in the United States which 
was released to coincide with the iPrEx publication. Despite the FDA’s stated preference for 
two positive trials before licensing (Stone 2009), the CDC seemed to draw a more definitive 
conclusion,  stating that  “The iPrEx trial findings offer a new tool to help combat HIV 
among MSM, one of the hardest hit populations in the U.S. and many areas of the world” 
(CDC 2010).  
The iPrEx product is a combination of the antiretroviral drugs tenofovir and 
emtricitabine (TNF/FTC), sold as the combination pill Truvada.  The TNF/FTC 
combination pill is already in use for the treatment of HIV, so it could potentially be 
prescribed for the indication of prevention rather than treatment – particularly with the 
interim guidelines in place (unlike tenofovir gel for vaginal administration, which is not yet 
manufactured in commercial quantities). For gay men and men who have sex with men8 in 
the US, access to this prevention technology is becoming a reality, although cost is currently 
a barrier.  
In issuing guidelines for the use of TNF/FTC in HIV prevention the CDC, as a public 
health agency, has acknowledged that as the drug combination is already approved for HIV 
treatment, off-label prescription is a likely consequence of iPrEx, even before the regulatory 
body, the FDA, has considered licensing for that indication.  
Despite recognition by the CDC that the TNF/FTC combination pill may now be used 
by MSM for HIV prevention purposes, it continues to be tested against a placebo comparator 
                                                 
 
 
 
256
in four out of five studies (AVAC 2010)9. The rationale for this is outlined by the US 
community advocacy organization AVAC (AIDS Vaccine Advocacy Coalition). 
These [iPrEx] data can’t be extrapolated to people at risk of HIV via heterosexual sex 
or injection drug use. Differences in biology of the vagina and rectum, and between 
HIV risk in sexual versus injection exposure make it essential that ongoing placebo-
controlled trials looking at PrEP in these contexts must continue. 
There will inevitably be an element of judgement involved in deciding whether 
evidence in one setting (protection against rectal HIV exposure in men) can be translated into 
another (vaginal exposure in women)10.   
The somewhat unexpected results of a recent HIV prevention trial, FEM-PrEP, show 
there may be a valid scientific rationale for testing HIV prevention technologies according to 
exposure routes (rectal, vaginal, penile, injection-associated) rather than extrapolating results 
from one exposure route to another. FEM-PrEP was a placebo-controlled trial looking at the 
same PrEP drug as iPrEX – TNF/FTC in women at higher risk of HIV in three African 
countries. It closed prematurely in April 2011 when a scheduled analysis by the independent 
Data Safety and Monitoring Board ruled that the trial as designed would be highly unlikely to 
answer the scientific question of whether the intervention prevented HIV in women. The trial 
had reached 56 endpoints (HIV seroconversions) which were divided even between the 
placebo and intervention groups. Accordingly, the trial was stopped due to futility. At this 
                                                 
9  The fifth study is a direct ‘follow-on’ study for iPrEx participants, which offers open label access to 
the drug for all, and provides less intensive counselling in order to get a more ‘real world’ result 
(AVAC 2010). 
10 While the premature closure of FEM-PrEP might suggest that there is a biological difference in the 
way that PrEP works in the setting of vaginal exposure, this presumption is premature until detailed 
information about drug adherence by FEM-PrEP participants becomes available.   
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stage it is unknown whether this unanticipated result was due to a biological difference 
(inadequate drug levels reaching the vagina) or some other factor, such as adherence (AVAC 
2011). 
Whether or not oral TNF/FTC is less effective, or ineffective, in women, there is now 
a range of prevention technologies for which there is RCT evidence that cover key sexual 
exposure routes: vaginal (tenofovir gel), penile (male circumcision and plausibly PrEP) and 
rectal (oral PrEP) – with two of these interventions evidenced by the result of a single trial.  
The question that needs to be addressed is whether there is any latitude for allowing 
different standards of evidence to come into play, depending on the urgency and magnitude 
of the public health problem being addressed11.  
It is entirely reasonable to ask this question, given that drug regulation is reactive, and 
its systems change. A brief history of the FDA shows that until 1962, drugs only had to show 
safety, not efficacy, before licensing. Later, in response to thalidomide, regulators became so 
risk-averse that women of childbearing age were banned from participating in early-stage 
clinical trials altogether. As Edgar and Rothman note (1990), the post-thalidomide FDA 
adopted an adversarial rigour not only in the level of safety data required, but also in their 
aversion to the Type1 error (a statistical blip that produces false positive result in a clinical 
trial, when the result was due to chance). This perspective, which led to the requirement that 
efficacy be proven to a very high degree of stringency, was then changed by the persuasion 
of AIDS activists, who asserted that access to emerging therapies – use of ‘any and all’ 
therapies – was justified in a deadly epidemic, even if the approval system let through some 
drugs that were not truly effective (Edgar and Rothman 1990).  
                                                 
11 Recall that from 1977 to 1993, women were not allowed in early stage FDA trials due to perceived 
risk, and data was routinely extrapolated from men.  
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This approach bore fruit. In 1987, pressure from AIDS advocates led the FDA to 
change its rules so that investigational drugs could be sold for serious or life-threatening 
diseases, well before they were proven to be effective according to the more demanding 
standards that had been previously in place (Edgar and Rothman 1990, 123). A year later, the 
FDA adopted a new regulation that involved the agency in the planning of research to assure 
a more efficient pathway through the regulatory system. 
Current caution surrounding the new HIV prevention technologies stands in stark 
contrast to the arguments advanced by AIDS activists in the late 1980s.  
The issues raised by new HIV prevention technologies are in some respects different 
to HIV treatment in the earlier years, in that there is already an effective prevention 
technology – the condom – and that effective treatments have become available so that 
infection is not a death sentence. Treatment, however, is expensive and inconvenient, has 
side effects, and may not be sustained in all contexts. Condoms require the willingness of the 
insertive partner to use one, and to use one correctly, in every instance in which exposure is 
possible. In southern Africa in particular there is an urgent need to break the cycle of 
infection through enabling receptive sex partners to control their own protection, thus 
microbicides and TNF/FTC offer a new avenue of risk reduction, and a chance to curtail the 
epidemic. It is also clear that for many people, the threat of infection remains as acute and 
irreducible as the threat of death was to people living with HIV in decades past. 
 
Control groups in clinical trials 
 Turning to the impact of adding new technologies to the current standard of 
prevention, some participants in the Kampala Standard of Prevention consultation argued for 
a particularly stringent standard of accepted efficacy before a new prevention strategy would 
be classed as state-of-the-art and therefore required to be offered to all trial participants. 
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Applying the most stringent interpretation of the UNAIDS Guidelines (2007), they suggested 
that a new technology needed endorsement by normative agencies and approval by national 
regulatory authorities and even inclusion in national prevention policies where the trial is 
taking place (McGrory et al. 2010, 34).  Each of these steps would involve at the very least 
several months, and more often several years, from the time of results being released to the 
point of licensure and inclusion in national strategic plans. The rationale for delaying the 
introduction of new prevention technologies in this manner rests on a utilitarian premise: that 
the development of maximally effective products justifies ongoing placebo-controlled trials. 
Delaying the introduction of partially effective technologies allows for simpler, faster and 
cheaper trials which maximise the opportunity for refinement of products and may expedite 
development of optimal prevention technologies. Better prevention technologies, the 
argument goes, would ultimately prevent more infections than addition on successive 
modestly effective interventions.  
This approach offsets infections that could be prevented by the earlier introduction of 
modestly effective new technologies against infections prevented in the future using as yet 
unknown prevention technologies. This is a gamble, as there is no assurance that prevention 
technologies will increase in efficacy at a rate that justifies delay. It disturbs the 
deontological underpinnings of contemporary research ethics and posits a utilitarian approach 
– and one where the calculus rests upon the gamble that research is successful. This moral 
framework would be unlikely to gain support in industrialised countries, raising the question 
of why it would be considered in developing nations.  
Setting the evidentiary bar high facilitates ongoing placebo-controlled trials, which 
makes research cheaper and more efficient. Faster research might result in finding more 
effective product more quickly. However there is no guarantee of this. 
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Universalism vs utilitarianism 
The argument that research participants should be supplied with state-of-the-art prevention 
comes from a deontological (duty-based) perspective; it is grounded in the duty that a doctor 
has to act in the medical best interests of patients. This philosophical perspective deems 
clinical research to be akin to clinical practice, and underpins documents such as the 
Declaration of Helsinki. Denying a research participant access to best practice treatment or 
prevention for the purposes of a research study would be exploiting that person for the 
putative future benefit of others (in Kantian terms, treating the person as ‘mere means’). This 
is a universalist perspective, which posits the duties owed to a person by merit of his or her 
personhood, as being the same as those owed to any other person, unless there are morally 
relevant differences. As Macklin (1999, 51) notes, universal principles ‘require interpretation 
in the light of relevant empirical facts and contexts before they can be applied’.  
A contrasting view is that those who participate in HIV prevention research studies usually 
reduce their risk of HIV acquisition and gain access to better medical services ( in a tenofovir 
trial, for example, self-reported condom use rose from 52% to 95%, Peterson 2007). 
Furthermore, adding in newly validated prevention technologies would necessitate increased 
sample sizes and make it more difficult to get a clear answer to the research question. This 
perspective privileges the enterprise of HIV prevention research over the protection of 
individual trial participants, using the rationale that participants are already better off than the 
general local community. A problem with this perspective is that it takes a minimalist view 
of justice, apparently accepting the HIV incidence in southern Africa for example, as a given 
rather than an instance of injustice. 
 
 
 
261
Clinical equipoise  
The concept of equipoise provides another way to consider whether it remains 
acceptable to conduct placebo controlled trials when studies such as CAPRISA and iPReX 
have established the efficacy of specific prevention products.  Equipoise posits that 
randomised controlled trials (RCTs) are morally justified where there is genuine uncertainly 
as to whether one therapy is superior to another (the received context is therapeutic rather 
than preventative). It is drawn from ‘the principle of therapeutic beneficence and non-
maleficence that apply in the traditional relationship between physician and patient’ (Jansen 
2005). Initially it was understood that the uncertainty needed to exist in the mind of the 
individual doctor (Fried 1974), but in 1987 a ground-breaking article by Freedman developed 
the concept that the ‘genuine uncertainty’ should be within the medical community, which he 
dubbed ‘clinical equipoise’. Clinical equipoise – defined as an honest, professional 
disagreement among expert clinicians – is frequently cited as normative standard12 of what 
remains a most contested concept (Ashcroft 1999).13 
If the determination of equipoise depends on consensus within the medical 
community, vexed questions arise. How should we determine which members of the expert 
community must reach consensus? How many members should be involved? How can we be 
sure that a sufficient number or the “right” members have determined whether consensus 
does or does not exist14? 
                                                 
 
13 Of note, Freedman would take a dim view of the purposeful under-powering of IIb studies: “the 
results of a successful clinical trial should be convincing enough to resolve the dispute among 
clinicians” (1987, 144). 
 
14 The authors are grateful to an anonymous reviewer for raising this point. 
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Furthermore, the validity of any form of equipoise in clinical trials has been 
challenged (Miller and Joffe 2011; Miller and Brody 2003; 2007), with the argument that 
research is fundamentally different from medical treatment, as its goals are the production of 
generalisable knowledge, not the best interests of the patient/participant. Miller and Brody 
propose that non-exploitation of participants should be the norm that regulates research, not 
equipoise. However what they propose in its stead is a minimal sketch of an anti-exploitation 
norm which, taken to its logical conclusion, would require that research participants be either 
altruistic actors, or handsomely compensated, neither of which is reasonable or likely in HIV 
prevention research in the developing world (Schüklenk 2010, London and Zollman 2010). 
So according to the Freedman model, neither CAPRISA 004 nor iPrEx disturbs 
clinical equipoise, because the medical and research community – which is made up of 
individuals who are directly invested in the ongoing project of HIV prevention research – has 
made this determination.  
It is clear however that Freedman did not anticipate that a study with a p value of 
0.017 – let alone one of 0.005 –  would be deemed unconvincing, as he defines a successful 
clinical trial as one that disturbs equipoise. 
In contrast to Freedman, Halpern (2006) offers a definition of equipoise that provides 
a seemingly objective standard:  
…that equipoise exists if well-designed studies have yet to answer the 
question as to which of the two interventions are to be preferred for a 
particular population of patients. 
Halpern’s definition is a neat, evidence-based solution that appears to avoid the 
consensus required by Freedman’s notion of clinical equipoise. When applying it to the 
CAPRISA 004 and iPrEx results, however, it is clear that interpretation still has a role. For 
example, did CAPRISA 004 answer ‘the question’, or was it underpowered?  
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 It is difficult to argue that iPrEx does not disturb equipoise, given that the level of 
evidence is deemed high enough for the CDC to issue interim guidelines for use (CDC 2011). 
The justification for ongoing placebo-controlled trials in this instance is that the trial 
population was limited to gay men and men who have sex with men. Adhering to literally to 
Halpern’s ‘particular population’ specification in this instance means limiting potential 
access not only by gender but by sexual orientation, despite the facts that women are also 
exposed to HIV through receptive anal intercourse, and both heterosexually active and 
homosexually active men may be exposed through insertive sex. Indeed, if TNF/FTC 
provides a level of protection for a man exposed to HIV through unprotected anal sex, it is 
biologically plausible that it must also protect a man exposed through insertive vaginal sex. 
This raises issues of whether the limitations are politically, let alone scientifically, valid. Can 
results from a trial in gay men and men who have sex with men be extrapolated to men more 
generally (consider that in the post-thalidomide era of the 1970s and 1980s, extrapolation 
form men to women the standard practice)?  
The apparent clarity of Halpern’s equipoise quickly leads back into the same, value-
laden territory.  
 
Impact on future HIV research 
Our key point about CAPRISA 004 and iPrEx is that different decisions could 
reasonably be made both regarding licensure and roll-out of the products in some areas where 
HIV is endemic, and in the composition of ‘standard of prevention’ in subsequent trials. For 
example, the South African regulators could have decided that, given South Africa’s high 
HIV incidence in women, licensure of tenofovir gel was justified (presumably with some 
follow-on open label studies to gather more data). If the 39% efficacy rate of CAPRISA 004 
translated into real-world effectiveness, this could have prevented 100,000 new infections per 
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year. While it could be argued that any modelling should be based on the lower end of the 
confidence interval, 6%, the higher level of efficacy shown in the more adherent trial 
participants is suggestive of higher, rather than lower, efficacy. 
As we have explained in our discussion of the ethical guidelines, licensure of 
tenofovir gel in any country would have the flow-on consequence of requiring that tenofovir 
gel would need to be added into various other prevention studies as part of the ‘standard 
prevention package’. 
 
Standard of prevention and standard of care – new terms, old debate 
In many respects, the issues raised in HIV prevention trial design as new technologies 
emerge are not new. ‘Standard of prevention’ is a new term for one aspect of the ‘standard of 
care’ debate that erupted in the 1990s. Briefly, ‘standard of care’ came to international 
attention in 1997 when placebo controlled trials of strategies for preventing mother-to-child 
HIV transmission in the developing world were criticised  (Angell 1997; Lurie and Wolfe 
1997).  A partially effective intervention that substantially reduced transmission rates had 
been established by the PACTG 076 trial in 1994, but trials conducted in the developing 
world continued to be designed with placebo-controls. Using a placebo rather than an active 
control was inconsistent with the Declaration of Helsinki on this issue, and arguably exposed 
women and their foetuses to avoidable harm (e.g. Lurie & Wolfe 1997). Proponents of the 
trials responded that when research was designed to be responsive to the health needs of a 
particular setting, use of a placebo was justified if that was the operational standard available 
in that setting (e.g.Varmus & Satcher 1997). As Macklin (2001) notes, the issue was never 
resolved, and there are reasonable, well-informed people on both sides of the argument.  
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At the heart of the issue is a conflict between the obligation of a researcher to have a 
physician-like duty-of-care to research participants, and the need to research interventions 
that are applicable to health problems in the circumstances of the developing world.   
This is salient to HIV prevention research, as introducing a newly validated 
intervention (tenofovir gel, TNF/FTC, or both) as ‘standard of prevention’ would require 
larger sample sizes and exponentially more funding and infrastructure for ongoing and 
planned trials.  If the first successful technology is only modestly effective, its introduction as 
the new standard of prevention might effectively inhibit the search for optimal much more 
effective, affordable and sustainable HIV prevention technology.  On the other hand, the 
populations enrolled in HIV prevention trials are among those at highest risk of acquiring 
HIV and it is not reasonable to withhold newly validated prevention technologies.  The 
questions common to both the debate from the 1990s and the current issues in HIV 
prevention research are: 
Are people exploited if they are exposed to sub-optimal treatment for the benefit of others? 
Should research participants have access to interventions that are significantly better than 
what is generally available in their countries? Are sub-optimal arms in research studies 
ethical if the research is intended to answer a significant question in global health? 
 
Unequal negotiation 
Current ethical guidance in HIV prevention trials places disproportionate emphasis on 
negotiation, which given the substantial inequities between the negotiating parties is likely to 
result in outcomes that suit the interests of research enterprise over the interests of the 
research participant. The rise of ‘proceduralism’ in ethics where processes of negotiation are 
privileged over setting normative standards, has been likened to “research at the auction 
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block” (London and Zollman 2010). The problem with auctions is that they enshrine the 
values of the market, not standards of fairness (Schüklenk 2010).  
An important contextual issue to address here is that the issue at stake is standards of 
prevention, rather than treatment for an illness, and whether this makes a difference to the 
putative obligations to participants. Two fallacious points are frequently made regarding 
participants in HIV prevention research – the first is that if people ‘engage in risky 
behaviour’ (e.g. Bloom 1998, Slack et al. 2005), that puts them at risk of HIV acquisition, 
this cannot be said to create an obligation for researchers. The second is that even the 
standard prevention package in HIV prevention trials – a combination of counselling, 
condom provision and treatment for sexually transmissible infections – sets the bar too high 
for research, as these interventions are not representative of the prevention options available 
outside trials and are not sustainable after their conclusion (Padian et al. 2008 p 593). 
 The problem with the first point is that it assumes a disproportionate level of 
personal responsibility for what is essentially a structural risk – a woman in Kwa Zulu Natal 
in South Africa, for example, faces a 25% lifetime risk of HIV acquisition, while an 
Australian woman’s risk is less than one thousandth of that (Camlin et al. 2010). Discourses 
of personal responsibility make no sense in the face of such odds, without even needing to go 
into issues of forced sex and sex as an economic imperative. 
The problem with the second claim is that the emphasis on local standards outside the 
trial and sustainability of interventions beyond trial completion ignore the fact that the 
research context is different from the outside world.  A duty of care is owed to research 
participants, hence ‘standard of prevention’ is pegged at international standards, rather than 
accepting the level of HIV risk and (lack of) access to risk-reduction in a trial community as 
an appropriate normative standard. 
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Conclusion 
Both the iPrEX and CAPRISA 004 resist black-and-white determinations as to 
whether or not they should be implemented either programmatically or as standard of 
prevention. The problem with iPrEx is that the trial was limited by both gender and sexual 
behaviour. The problem with CAPRISA 004 is that the lower end of the confidence interval 
for tenofovir gel – 6% efficacy – would not constitute a useful or cost-effective intervention. 
But waiting for the results of trials that will not be completed for several years can be viewed 
as an inadequate response to these very promising data, given the urgency of need in 
southern Africa for new risk reduction interventions, and in particular those that are 
controlled by women. 
As our discussion of the iPrEx and CAPRISA004 trials shows, evidentiary 
requirements and regulatory regimes are not objective standards, but involve moral decisions. 
Whether it is more important to eliminate any possibility of a Type 1 error, or to facilitate 
access to modestly effective, but imperfect, new technologies, is a question of values.  
The competing interests are particularly difficult to navigate. On one hand, the 
enterprise of HIV biomedical prevention research – which holds out the hope of cheap, 
effective, user-friendly products – might be threatened if the new technologies become 
‘standard of prevention’. Proving a new intervention against the background of these 
partially effective technologies would require an exponential increase in sample sizes and 
budgets, threatening feasibility. People at high risk of HIV who enter prevention trials 
generally reduce their risk as a result of their participation (e.g. Peterson 2007), and arguably, 
this discharges the obligation to protect participants. On the other hand is there is the 
(contested) tenet from the Declaration of Helsinki that the researcher’s primary obligation is 
to reduce risk for research participants, ahead of considerations of future beneficiaries of 
research. This is the basis upon which ‘standard of prevention’ packages are supplied – to 
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prevent the vulnerability of high risk populations being exploited for the future benefit of 
others, and to position the well-being of the research participant at the centre of the research 
endeavour.  
Current guidelines do not solve the dilemma, because while UNAIDS stipulates use 
of “state of the art’ interventions in the control arm of HIV prevention trials, the definition of 
this term is vague until the point that regulatory approval is granted, which delays any 
obligation to provide a new technology potentially for years. The guidelines other than 
UNAIDS are weaker still, with prevention packages being undefined, and negotiation and 
consultation being emphasised over normative standards. 
If the concept of equipoise is applied to the issues, the question then becomes, is there 
sufficient uncertainty regarding the results of CAPRISA 004 or iPrEx to continue with 
placebo-controlled trials?  We have argued that there is no easy answer to this, as received 
models of equipoise are inadequate umpires. The strength of the evidence from RCTs must 
ultimately be evaluated, and this again requires value judgments. 
Thus far, judgments have favoured the continuation of trials using placebo controls 
rather than the addition of one of both of the new technologies into the ‘standard of 
prevention’. This sits uncomfortably with the fact that the CDC is releasing interim guidance 
documents on TNF/FTC for US gay men and men who have sex with men (CDC 2011).  
The decision to continue using placebo controls while waiting for the results of 
confirmatory studies of CAPRISA 004 and iPrEx means that a high incidence of HIV is 
maintained in populations in the developing world for efficient testing of other new 
prevention technologies in future trials. This is a significant moral choice that weighs the 
potential benefit of delay over the benefits of immediate rollout in areas where HIV is 
endemic. The populations likely to gain from these decisions are those at lower risk of HIV 
who already have good access to condoms, for whom only a very highly effective product 
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would be advantageous. It might mean that we are more likely to find a highly effective HIV 
prevention technology faster — although this is a gamble). It certainly means that in the 
immediate future, infections will occur that could have been prevented by early uptake of 
new technologies. 
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Abstract  
 
In July 2012, based on evidence from two major trials, the United States Food and 
Drug Administration approved the use of combined oral tenofovir/emtricitabine as 
pre-exposure prophylaxis (PrEP) for people at high risk of HIV acquisition. PrEP 
effectiveness is marred by poor adherence, however, even in trial populations, thus it 
is not a magic bullet for HIV prevention. It is, however, the most effective biomedical 
HIV prevention intervention available for people at high risk of HIV, particularly 
those who have receptive sex and lack the power to negotiate condom use. 
Accordingly, there are compelling reasons to compare future experimental HIV 
prevention interventions against PrEP. The interests both of trial participants and of 
science are served by using PrEP as comparator: not only would HIV incidence be 
reduced, but also the question of whether new interventions  were superior to best 
proven interventions, in a given setting, would be answered comprehensively. 
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Introduction 
2012 saw a new optimism about ending AIDS, with the concept of ‘an AIDS-free 
generation’ becoming a concrete, if aspirational, goal (Knox and Doucleff 2012). This 
optimism is born of accumulating evidence that biomedical prevention interventions 
offer new approaches to preventing HIV infection, and that antiretroviral drug 
regimens (ARV) that are less toxic and more convenient stretch the life expectancy of 
people living with HIV toward ‘normal’ (May et al 2012). Despite a global decline in 
the incidence of HIV, global demand for ARV will continue to grow, however: of the 
estimated 34 million people with HIV, only eight million of these are on ARV, while 
another seven million require immediate treatment to which they do not have access 
(UNAIDS 2012). Of the 19 million remaining, they too will require treatment within 
the next six to ten years. Thus the number of people living with HIV, and needing 
treatment, continues to rise. Preventing new infections, and thereby not increasing the 
demand for ARV, remains critical. Research into new biomedical HIV prevention 
approaches needs to continue to expand the available options for people at high risk of 
acquiring HIV. New research into HIV prevention however needs to strike a balance 
between the urgent global need for new interventions and protection of the interests of 
people who participate in this research. This inevitably raises the issue of standards of 
care in trial design. 
 
In the last two years, two new ARV-based prevention strategies have been shown to 
be effective: pre-exposure prophylaxis (PrEP) and treatment-as-prevention. This 
makes it possible for wide-scale ARV-based prevention programs to complement 
behavioural, barrier and structural interventions (Baeten et al 2012; Grant et al 2010; 
Thigpen et al 2012; Cohen et al 2011). A third strategy, an ARV-based microbicide, 
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awaits results of a confirmatory trial (Abdool Karim et al 2010)1. In short, what is 
possible in HIV prevention has changed dramatically in a short period of time – but 
what does this mean for the conduct of future research studies? Recent research 
findings pose a series of significant ethical quandaries for the design of new HIV 
prevention trials, particularly those that fall under the heading of ‘standard of care’. 
With a swathe of partially effective options now proven, what should be in the control 
arm in new trials? What should the standard prevention package be for all 
participants?  
 
This article considers standard of care in HIV prevention trial in the light of the recent 
announcement that the United States Food and Drug Administration (FDA) has 
approved combined tenofovir/FTC as pre-exposure prophylaxis (PrEP) (FDA 2012). 
 
The efficacy trials 
The series of positive trial results for the use of antiretroviral drugs (ARV) for HIV 
prevention began in 2010, with CAPRISA 004. This trial looked at the efficacy of 1% 
tenofovir gel formulated as a topical agent for intravaginal application (a 
microbicide), with coitally dependant dosing (before and after sex).  Tenofovir is an 
ARV drug also used in HIV treatment. The study showed 39% efficacy which 
increased stepwise in participants who used the gel as directed (Abdool Karim et al 
2010). This approach awaits results of a confirmatory trial, as the trial was designed 
as a ‘proof of concept’ study and lacked the statistical power for regulatory approval. 
Only months later, results from iPrEX were published, showing that combination 
                                                 
1 Tenofovir gel works at a biological level as a form of topical pre- and post-exposure prophylaxis, but 
as taking an oral tablet is distinct from inserting a vaginal gel, the gel form and the oral form are 
usually seen as separate strategies. 
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tenofovir/FTC in tablet form (PrEP) reduced HIV acquisition by 44% in a population 
of men who have sex with men (MSM) and transgender women who have sex with 
men at high risk of HIV. Again, efficacy increased stepwise with good adherence to 
the study product to more than 90% (Grant et al 2010; Anderson et al 2012). Further 
evidence regarding tenofovir/FTC as PrEP came in 2011 from two trials in 
heterosexual people in Africa. The Partners PrEP study showed a 75% reduction in 
HIV incidence in couples where one partner was HIV negative and the other positive 
(serodiscordant couples), with tenofovir-only PrEP showing a 67% reduction (Baeten 
et al 2012). Finally the TDF2 study, which tested combined TDF/FTC PrEP 
conducted in heterosexual men and women in Botswana, showed a 62% reduction in 
HIV acquisition (Thigpen et al 2012). 
 
In addition, a study testing the efficacy of early2 ARV treatment for the HIV positive 
partner in serodiscordant couples (a strategy known as ‘treatment-as-prevention’) 
reduced HIV acquisition be a striking 96% (Cohen et al 2012).  
 
These successes in ARV-based prevention sit alongside three randomised controlled 
trials which have shown that male circumcision can reduce HIV acquisition in 
heterosexual men by around 50% (Auvert et al 2005, Bailey et al 2007, Gray et al 
2007), and a single vaccine trial that showed a modest 26% reduction in HIV 
acquisition (Rerks-Ngarm et al 2009). 
 
                                                 
2 ARV treatment is defined as ‘early’ when it is administered in people whose CD4 cell levels are 
above 350. 
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This block of evidence means that HIV prevention has now advanced well beyond 
behavioural and barrier modalities alone, and this has ethical implications for the 
design of future studies. 
 
Alongside the positive efficacy results, however, both PrEP (tenofovir alone and 
tenofovir/FTC) and tenofovir gel did not protect participants in the Fem-PrEP or 
VOICE trials, due to poor adherence (Van Damme et al 2012, MTN 2013). This 
suggests that there is still work to be done to establish an optimal prevention strategy 
that will be acceptable and usable for women at high risk of HIV acquisition. 
 
Standard of Care and study design 
‘Standard of care’ means the level of care provided to participants in a clinical trial. In 
HIV prevention trials, it can be used to describe four different aspects of care. Firstly, 
there is the ‘standard of prevention’, which is the risk-reduction package provided to 
all participants in the trial.3 Secondly, ‘standard of care’ may be used to refer to the 
care provided to participants randomised to the comparator arm of a trial (van der 
Graff and van Delden 2009). Thirdly, there is ancillary care – health care that is 
provided to trial participants that is indirectly associated with the research, such as 
contraception and reproductive health care, cervical cancer screening and treatment 
for illnesses that arise during trial participation (Richardson 2007; Belsky and 
Richardson 2004). Finally, there is access to ARV for trial participants who acquire 
HIV on the trial (Macklin 2006). 
 
                                                 
3 This term was coined in 2007 in the UNAIDS Ethical Considerations document to end the confusion caused my multiple 
meanings of ‘standard of care’. 
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Both the standard of prevention (the care provided to all participants) and the choice 
of a comparator arm (the standard of care against which an experimental intervention 
is measured), have profound impact on the design of HIV prevention studies. For 
reasons of efficiency and cost-effectiveness, HIV prevention studies are conducted in 
populations of high HIV incidence (and these populations are usually in specific 
geographic areas), because this allows an expeditious answer to the research question. 
The studies need to enrol sufficient numbers of people to provide a statistically 
significant result, calculated using the background HIV incidence. The introduction of 
a highly effective standard of prevention – such as treatment-as-prevention, which has 
been shown to reduce HIV acquisition by 96% – would require such exponential 
expansion of the sample size as to make a trial impracticable.4 For this reason, and 
because it is hard to justify withholding such an effective intervention in a study 
setting, it is likely that HIV prevention research targeting the specific population of 
serodiscordant couples will cease, and the focus fall on others at high risk of HIV 
acquisition. This article will therefore focus on people at high risk of HIV acquisition 
who are not in long-standing serodiscordant sexual partnerships. 
 
The guidelines 
There are several guidance documents that are relevant to the standard of care issue in 
HIV prevention trials.  
 
                                                 
4 It could be argued that given such an effective intervention, the time has come to stop testing new approaches and to fully fund 
the global roll-out of early treatment for all people with HIV. This approach does not satisfy the requirement for HIV negative 
people at high risk to be able to protect themselves, however, and research is likely to continue until this need has been met. 
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The Declaration of Helsinki is a general guide to research ethics produced by the 
World Medical Association (WMA 1964; as amended in 2008), an international non-
profit association of voluntary national medical associations formed in 1947. The 
Declaration drew upon the 10 points articulated in the Nuremberg Code and tied them 
in with physicians’ obligations under the Declaration of Geneva (1948). It has since 
been revised six times, most recently in 2008.  
 
The Declaration states in clause 6 that ‘In medical research involving human subjects, 
the well-being of the individual research subject must take precedence over all other 
interests’. Clause 32 goes on to address standard of care specifically: 
The benefits, risks, burdens and effectiveness of a new intervention must be 
tested against those of the best current proven intervention, except in the 
following circumstances: 
The use of placebo, or no treatment, is acceptable in studies where no current 
proven intervention exists; or 
Where for compelling and scientifically sound methodological reasons the use 
of placebo is necessary to determine the efficacy or safety of an intervention 
and the patients who receive placebo or no treatment will not be subject to any 
risk of serious or irreversible harm. Extreme care must be taken to avoid 
abuse of this option. 
Thus the Declaration of Helsinki adopts a universalist position that prescribes a best 
current standard for research participants in all cases where the risk is serious or 
irreversible, such as the risk of HIV acquisition. 
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The International Ethical Guidelines for Biomedical Research Involving Human 
Subjects adopts a more pragmatic position. These guidelines were developed by the 
Council for International Organizations of Medical Sciences (CIOMS) in 1993, and 
revised in 2002. They were intended to assist developing countries to define national 
policies on the ethics of biomedical research involving humans, to apply ethical 
standards in local circumstances, and to establish or improve ethical review 
mechanisms. The CIOMS guidelines offer extensive commentary on the issue of 
standards of care in general and whether or not an active comparator or a placebo 
control may be used. The actual guideline (#11) is strict about the use of placebo were 
an established intervention exists, but it does not insist on the active comparator being 
the ‘best’. Rather, it has to show some efficacy, allowing for the use of lower 
standards – or more technologically appropriate interventions – in specific instances, 
rather than a universal best practice. Guideline 11 states: 
As a general rule, research subjects in the control group of a trial of a 
diagnostic, therapeutic, or preventive intervention should receive an 
established effective intervention. In some circumstances it may be ethically 
acceptable to use an alternative comparator, such as placebo or ‘‘no 
treatment’’ 
Placebo may be used: 
 when there is no established effective intervention; when withholding 
an established effective intervention would expose subjects to, at most, 
temporary discomfort or delay in relief of symptoms;  
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 when use of an established effective intervention as comparator would 
not yield scientifically reliable results and use of placebo would not 
add any risk of serious or irreversible harm to the subjects. 
The CIOMS guideline is less prescriptive than the Declaration of Helsinki’s clause 32 
in that ‘an established effective intervention’ may be a local standard whereas the 
‘best current proven intervention’ calls for an optimal standard. The gap between the 
two becomes apparent when considering the HIV prevention context: in a prevention 
trial in heterosexual serodiscordant couples, for example, the CIOMS guidelines 
would permit condom-based prevention only, while the Declaration of Helsinki could 
be used to argue for condom-based prevention, plus PrEP for the negative partner, 
early treatment for the positive partner, and access to male circumcision for HIV-
negative male partners. 
In addition to these general research guidelines, there are two set of ethical guidelines 
that deal specifically with HIV prevention trials, the UNAIDS Ethical Considerations 
in HIV Biomedical Prevention trials (updated in 2012) and the HIV Prevention Trials 
Network Ethics Guidance for Research (2009). These documents are complementary 
in some respects but they differ in the way that they outline the obligations regarding 
standards of prevention and care. 
 
Guidance point 13 of the UNAIDS document, on standards of prevention, stipulates 
that there is an obligation to provide:  
…access to all state of the art HIV risk reduction methods … to participants 
throughout the duration of the biomedical HIV prevention trial. New HIV-risk-
reduction methods should be added, based on consultation among all research 
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stakeholders including the community, as they are scientifically validated or 
as they are approved by relevant authorities. 
Like the Declaration of Helsinki, the UNAIDS/WHO guidance takes a universalist 
perspective, prescribing state of the art prevention interventions as standard of 
prevention. Morally relevant criteria, including scientific validation, approval by 
normative bodies and the impact on research feasibility, may influence whether or not 
a new modality is considered standard of prevention. 
 
In addition to addressing standard of prevention, it also stipulates standards for 
ancillary care, specifically reproductive health care, treatment for sexually 
transmissible infections (STIs) and programs to address domestic violence.  
Guidance point 15 of the UNAIDS document, on the control arm, supports  point 13 
by reiterating that “participants in both the control arm and the intervention arm 
should receive all established effective HIV risk reduction measures”. In other words, 
experimental new interventions should be layered on top of what is already known to 
work. The allowable exceptions mentioned include instances where there is a sound 
biological rational for considering that  an intervention shown effective in one 
population cannot be generalised to another, such as a vaccine tested against a 
particular subtype, or a product tested vaginally that cannot be extrapolated to rectal 
use. 
 
The HPTN Guidance takes a different approach these issues. To begin with, it 
distinguishes between an ethical obligation and an ethical aspiration. Guidance point 9 
on the standard of prevention identifies the provision of an effective prevention 
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package for trial participants as obligatory. The content of that package, however, is 
undefined except insofar as there must be established evidence of efficacy and the 
prevention interventions must be practically achievable and reasonably accessible in 
the trial setting. Using this framework, in settings where particular risk reduction 
methods are deemed culturally inappropriate or illegal, they need not be offered so 
long as some other effective form of prevention is offered. Provision of voluntary 
medical male circumcision or needle exchange programs are not required under these 
guidelines even if trials enrol HIV negative uncircumcised men or injecting drug 
users, if these are not reasonably available in local communities5.  
 
The HPTN document also provides guidance on aspects of research not detailed in the 
UNAIDS document, including specifying processes of community engagement, 
building capacity and partnerships, and attention to ancillary care.6 Importantly, a 
new category of people to whom researchers have obligations is introduced – the 
‘screened out’. These are people who volunteer to participate in prevention trials but 
are found ineligible for reasons such as pre-existing undiagnosed HIV infection. 
                                                
 
In addition to these two sets of guidelines, there is a set of consensus points developed 
by a group of HIV prevention researchers and bioethicists in 2009 that require 
consideration, from the ‘Standard of Prevention’ consultation in Uganda (McGrory et 
al 2010). These consensus points articulate that a new intervention is considered ‘state 
 
5 While in-depth discussion of these issues are beyond the scope of this paper, conducting a trial in an 
area where participants are denied access to a proven safe and effective intervention for social or 
political reasons is both inappropriate and exploitative. 
6 UNAIDS deals with community engagement processes in detail in a separate document co-authored 
by UNAIDS and AVAC, the Good Participatory Practice Guidelines, first published in 2007. 
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of the art’ when it is approved by a relevant regulatory authority or included in 
normative guidelines. They also stipulated that there was a strategic set of trials using 
PrEP in different populations that should be allowed to continue without alteration, 
regardless of whether early results showed efficacy, in order to get maximum 
information about PrEP in different populations.   
The UNAIDS and HPTN documents will be discussed in detail in this chapter. 
 
Key differences 
The HPTN document was developed specifically to meet the needs of a research 
network undertaking HIV prevention work. It defines itself as ‘pragmatic’ rather than 
idealistic in its approach, and sets out to address ‘limitations, gaps and 
inconsistencies’ perceived in existing guidelines. It is structured to address issues that 
arise sequentially from before the trial to its aftermath, and it identifies which 
stakeholders are responsible for implementing which guidance points as well as 
defining the strength of guidance as ‘obligatory’ or ‘aspirational’, as noted above. In 
addition, it specifies a limited conception of justice in its underpinning principles – 
‘social justice’, defined as “the ethical concerns related to treating people equally, 
avoiding exploitation, and trying to reduce health disparities” (Rennie and Sugarman 
2010). Defining and limiting justice in this way prioritises equality between trial 
participants and their local communities rather than aiming to reduce health 
disparities between trial participants in high income countries and those in low and 
middle income countries. 
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While the UNAIDS guidelines impose duties on researchers to adopt international 
best practice, the HPTN document allows a looser standard to be adopted. The 
rationale for this is threefold: ‘state-of-the-art’ risk reduction methods that are not 
available outside the trial could constitute undue inducement to participate; to prevent 
research practices that would compromise ‘real world’ significance of data; and to 
guard against people within a trial having access to a higher standard of prevention 
than those outside it; (Rennie and Sugarman 2010).  The focus on current local 
capacity reframes the discourse about double standards, generally understood to mean 
disparities between high income countries and developing countries, to one that 
centres on the local research community. 
 
This brings us to the crux of the difference between the two sets of guidelines. With 
the FDA now having approved PrEP for HIV prevention, under the UNAIDS 
guidelines there is a prima facie requirement to provision PrEP as standard of 
prevention, as PrEP clearly meets the definition of ‘state-of-the-art’, having been 
approved by a normative body. Were this to occur, it would require much larger, more 
expensive and highly complex trials for subsequent experimental interventions – but 
these trials could dramatically decrease HIV acquisition in the trial populations. An 
argument against a ‘state-of the art’ PrEP-containing prevention package is that it  
could create serious inequities between trial participants and their communities in 
which PrEP is not available, though this could be rebutted on the ground that such 
provision would be a capacity building-enabler of better services in communities. 
Sustainability of the intervention is also an issue. 
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 Under the HPTN guidelines, no such change is required, as these guidelines define a 
minimum standard that is amenable to ongoing research studies using the currently 
established standard of prevention (i.e. condoms, behavioural counselling and 
treatment for sexually transmissible infections), despite the fact that in the 
communities that have high HIV incidence, the inadequacy of existing methods is 
arguably well established. There is a clear tension between the imperative to protect 
participants and the imperative to find a cheap, effective user-friendly HIV prevention 
technology. Who gains from such studies is an important consideration – people in 
high incidence populations in low and middle income countries, or those in high 
income countries? 
The mother-to-child transmission controversy revisited 
These questions revisit the debate from the late 1990s about alleged doubled standards 
in mother-to-child prevention trials. A major ethical controversy erupted in 1997, 
when an article in the New England Journal of Medicine called into question placebo-
based trials for mother-to-child HIV prevention in Africa and Asia, despite a proven 
effective intervention being published in 1994.The critics pointed out that the 
placebo-controlled trials violated the Declaration of Helsinki. They alleged that an 
unacceptable double standard regarding research ethics was operating, reminiscent of 
the notorious Tuskegee trial (Angell 1997; Lurie and Wolf 1997). Defenders of the 
trials argued the ‘standard of care’ established in the 1994 was not feasible in 
developing countries, that the placebo-based trials addressed a significant public 
health issue in those countries, and that the question that needed to be answered was 
whether the experimental therapy was better than nothing, not whether it was as good 
as an unattainable standard (Varmus and Satcher 1997). 
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The controversy led to a redrafting of the Declaration of Helsinki, but in the end the 
revised version(s) maintained that new interventions for serious conditions should not 
be tested against placebo when established treatment exists. Regardless of this 
outcome, bioethicists and researchers remain polarised on this issue (Macklin 2001). 
With respect to HIV prevention, the debate has slumbered as provision of behavioural 
and barrier prevention has been accepted by researchers and communities alike, and 
until very recently circumcision was the only proven biomedical intervention, which 
has a very specific population (heterosexual men) and is subject to profound social 
and cultural mores (Macklin 2008). The advent of ARV-based prevention reignites 
the issues. 
Practical aspects 
Amidst philosophical disagreement about standards, a focus on consensus-building 
processes among stakeholders including communities and actual and potential trial 
participants has emerged as a means for getting broad agreement of how research 
should be conducted in particular settings (for example, Vallely et al 2007). In 2007 
UNAIDS and AVAC  developed Participatory Practice guidelines (revised in 2012) 
that detail expected engagement with communities and the setting up of mechanisms 
that give communities  opportunities for input throughout the research. 
 
This is a very significant move, catalysed by the premature closure of PrEP trials in 
the early 2000s that were perceived to have been insufficiently consultative with trial 
communities, and which were perceived to be not sufficiently responsive the 
participants’ needs (Forbes and Mudaliar 2009; Haire 2011; McGrory et al 2009; 
Ukpong and Peterson 2009). 
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Direct two-way communication with communities and giving community 
stakeholders real power to influence aspects of the research is a very important 
development. Community members do not meet with international researchers on an 
equal basis, however: there are vast power differentials at play. Indeed, the 
relationship has been defined as one of structural inequality, such that the researcher 
has a fiduciary responsibility to the research participant (Miller and Weijer 2006). 
Accordingly, while community collaboration with HIV prevention research is 
essential for best practice, it is no substitute for clear standards. 
 
Making the call 
The evidence that treatment-as-prevention, circumcision and PrEP are effective in 
preventing HIV acquisition means that it is no longer ethically appropriate to design 
HIV prevention without securing access to these interventions. Each of these 
strategies has been approved by a regulatory authority or in a normative guideline (the 
WHO in the case of circumcision, the International Antiviral Society, USA panel in 
the case of treatment-as-prevention, and the FDA in the case of PrEP).  
 
Despite the recent advances in biomedical prevention, however, the need to develop 
new interventions remains. Longer-acting products in particular are required to avoid 
the problem of suboptimal adherence. A balance therefore needs to be struck between 
prioritising the protection of trial participants and facilitating ongoing research into 
new HIV prevention technologies that might be cheaper, more effective and more 
feasible in low- and middle-income countries.  
 
 316
Several different solutions have been proposed for the design of future prevention 
trials. Firstly, PrEP could be added into the standard of prevention and made available 
to all trial participants, who would be randomised to receive the experimental 
intervention or placebo on top of this background. The advantage of this is that it 
would be highly likely to reduce HIV acquisition very significantly in the trial 
population.  The problem is that it would require very large sample sizes to obtain a 
result, and it might be difficult to untangle the efficacy (or not) of the experimental 
intervention from PrEP efficacy (which would likely be affected by differential 
adherence, as in trials to date). 
 
A variation on this approach would be to allow PrEP in standard of prevention 
packages only where it is available in the community – namely, the US and at PrEP 
demonstration sites7 – and not in other trial sites. There are serious objections to this. 
If the trial were only conducted in sites where PrEP was available, the same problems 
with very large sample size and difficulty in discerning the impact of the experimental 
intervention would apply. If some sites had PrEP access and others did not, a stark 
double standard would be in evidence, with the majority of HIV seroconversions 
likely to occur in the non-PrEP sites. 
 
Alternatively, new trials could seek volunteers from amongst those who opt not to 
take PrEP, who could thus be randomised to experimental intervention or placebo.  If 
it were the active choice of the volunteers not to take PrEP, there could be no ethical 
                                                 
7 At the time of writing, the only demonstration sites launched were in the US, with others planned in 
two or three cities in Brazil. 
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objection. There are two problems with this, however. Firstly, in order for the choice 
to opt out of PrEP to be free, these studies would need to take place in setting where 
PrEP is available, which is a major constraint. Secondly, available research suggests 
that people who recognise themselves to be at high risk of HIV acquisition tend to be 
amenable to taking PrEP (Wheelock et al 2013, Holt et al 2011). People who don’t 
wish to take PrEP may therefore be at lower risk, which would then require larger 
sample sizes to get a result, with the risk of a futile result. 
Finally, there is the option of using PrEP as the active comparator. Again, there are 
several issues here. For this to be ethical, there would need to be strong preliminary 
evidence to suggest that the experimental intervention would be of comparative 
efficacy, so as to ensure equipoise (i.e. uncertainty as to whether one arm would be 
better than the other) between the two arms of the trial. The scientific objection to 
using PrEP as a comparator is the lack of precision regarding the preventative efficacy 
of TDF/FTC, with point estimates from randomised control trials ranging from 6% 
(FEM-PrEP) to 75% (Partners PrEP). An active comparator is usually required to 
have a substantial magnitude of effect, precisely estimated, with that estimate relevant 
to the trial population (Fleming 2013). This is not an insurmountable barrier, 
however. Further analyses of high adherers from iPrEx have shown efficacy of around 
90% (Anderson et al 2012). Regrettably, similar information is not yet available 
regarding high adherence in women. Further, the requirement for a ‘precise estimate’ 
is questionable in this context, given that it has been well established that PrEP 
reduces HIV acquisition significantly when it is taken, but its effectiveness is 
attenuated by poor adherence (Mayer 2013). A long-acting intervention that had lower 
biological efficacy might work better than PrEP in one population and worse in 
another, more adherent one. Head-to-head studies are an opportunity to discover this. 
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Active comparator studies using PrEP also offer an opportunity to study further 
factors that relate to adherence in specific populations, and potential strategies for 
improvement. 
 
PrEP is the appropriate comparator because there is good evidence that it works if 
people adhere to it. Adherence is a significant issue (Van Damme et al 2012; Beaten 
et al 2012), however, as is cost. It is not ideal, but in combination with existing barrier 
methods it is the best technology available for HIV negative women or men who have 
receptive sex. Finding an intervention that works as well as PrEP without requiring 
daily adherence would be a breakthrough. If a new experimental intervention failed to 
be as good as PrEP, then the trial would still be useful for getting further information 
about PrEP adherence in settings where HIV is hyper-endemic. 
Voluntary circumcision for HIV negative heterosexual men should be offered as 
standard of prevention in studies that include this population, as it is feasible and cost-
effective. Uptake of this option is likely to differ according to social and religious 
factors, but HIV negative heterosexual male participants in research studies should be 
allowed to make up their own minds, based on the evidence of safety and efficacy and 
their own personal values as to whether it is appropriate for them. The option should 
not be censored on the presumption of unilateral social and religious values in a 
community.  
 
The recommendation to use PrEP as an active comparator arm, with circumcision 
offered as appropriate as standard of prevention, applies to trials that are in design 
phases. It would be counterproductive, for example, to try to add extra arms to trials 
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like FACTS 001, which is designed to meet the requirement of the South African 
regulatory authorities, and without which the question of how effective tenofovir gel 
is may never be answered comprehensively. Continuation of this trial should be 
supported for this reason. The continuance of PopART should also be supported, as 
this is a cluster trial testing an approach to the implementation of circumcision and 
treatment-as-prevention in a series of communities. PopART is not testing an 
experimental technology, but a particularly intensive approach to engaging people 
with proven HIV prevention practices, male circumcision and treatment-as-
prevention. 
Conclusion 
In the absence of a universally acceptable, highly effective, cheap and user-friendly 
vaccine, HIV prevention research will continue to be an important component in the 
struggle to eliminate HIV. Despite its seemingly high biological efficacy, TDF/FTC 
PrEP is far from an ideal intervention, particularly given the serious problems with 
adherence shown in several of the trials to date. Even if adherence can be improved 
significantly in high-incidence populations through specialised programs, a short-
acting user-dependent prevention technology is vulnerable to a range of potential 
disruptions. For people who are at high risk of HIV acquisition (from risk factors 
other than a serodiscordant regular sex partner), however, PrEP is the best adjunct to 
barrier and behavioural prevention that we have. Certainly there needs to be better 
data on how to use it optimally, but this can be gathered in studies that use PrEP as a 
comparator against which other experimental interventions are tested.  
 
The goals of HIV prevention research must be to find the most effective ways of 
using existing tools, including PrEP, and to establish the effectiveness of new tools. 
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Randomised controlled trials are an important part of this, but they need to be 
designed in such a way as to ensure that all participants receive effective 
interventions, even though this necessarily means that trials will need larger sample 
sizes. HIV prevention trial participants are among the most vulnerable to HIV in the 
world, and need to be protected. 
 
Incorporating TDF/FTC PrEP as the comparator arm in forthcoming HIV prevention 
trials balances the need for ongoing research with appropriate protection for research 
subjects. While a daily tablet is not an ideal prevention intervention, as it is vulnerable 
to stock-outs and to individual forgetfulness, it has the advantages of being separable 
from each sex act and appropriate for receptive sex partners. For HIV negative people 
at high risk of HIV acquisition, it is the best protection currently available. If we take 
seriously the moral imperative to address HIV incidence in those populations most 
vulnerable to HIV acquisition, then PrEP needs to be the comparator in forthcoming 
research. 
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Abstract  
 
In July 2012, based on evidence from two major trials, the United States Food and 
Drug Administration approved the use of combined oral tenofovir/emtricitabine as 
pre-exposure prophylaxis (PrEP) for people at high risk of HIV acquisition. PrEP 
effectiveness is marred by poor adherence, however, even in trial populations, thus it 
is not a magic bullet for HIV prevention. It is, however, the most effective biomedical 
HIV prevention intervention available for people at high risk of HIV, particularly 
those who have receptive sex and lack the power to negotiate condom use. 
Accordingly, there are compelling reasons to compare future experimental HIV 
prevention interventions against PrEP. The interests both of trial participants and of 
science are served by using PrEP as comparator: not only would HIV incidence be 
reduced, but also the question of whether new interventions  were superior to best 
proven interventions, in a given setting, would be answered comprehensively. 
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Introduction 
2012 saw a new optimism about ending AIDS, with the concept of ‘an AIDS-free 
generation’ becoming a concrete, if aspirational, goal (Knox and Doucleff 2012). This 
optimism is born of accumulating evidence that biomedical prevention interventions 
offer new approaches to preventing HIV infection, and that antiretroviral drug 
regimens (ARV) that are less toxic and more convenient stretch the life expectancy of 
people living with HIV toward ‘normal’ (May et al 2012). Despite a global decline in 
the incidence of HIV, global demand for ARV will continue to grow, however: of the 
estimated 34 million people with HIV, only eight million of these are on ARV, while 
another seven million require immediate treatment to which they do not have access 
(UNAIDS 2012). Of the 19 million remaining, they too will require treatment within 
the next six to ten years. Thus the number of people living with HIV, and needing 
treatment, continues to rise. Preventing new infections, and thereby not increasing the 
demand for ARV, remains critical. Research into new biomedical HIV prevention 
approaches needs to continue to expand the available options for people at high risk of 
acquiring HIV. New research into HIV prevention however needs to strike a balance 
between the urgent global need for new interventions and protection of the interests of 
people who participate in this research. This inevitably raises the issue of standards of 
care in trial design. 
 
In the last two years, two new ARV-based prevention strategies have been shown to 
be effective: pre-exposure prophylaxis (PrEP) and treatment-as-prevention. This 
makes it possible for wide-scale ARV-based prevention programs to complement 
behavioural, barrier and structural interventions (Baeten et al 2012; Grant et al 2010; 
Thigpen et al 2012; Cohen et al 2011). A third strategy, an ARV-based microbicide, 
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awaits results of a confirmatory trial (Abdool Karim et al 2010)1. In short, what is 
possible in HIV prevention has changed dramatically in a short period of time – but 
what does this mean for the conduct of future research studies? Recent research 
findings pose a series of significant ethical quandaries for the design of new HIV 
prevention trials, particularly those that fall under the heading of ‘standard of care’. 
With a swathe of partially effective options now proven, what should be in the control 
arm in new trials? What should the standard prevention package be for all 
participants?  
 
This article considers standard of care in HIV prevention trial in the light of the recent 
announcement that the United States Food and Drug Administration (FDA) has 
approved combined tenofovir/FTC as pre-exposure prophylaxis (PrEP) (FDA 2012). 
 
The efficacy trials 
The series of positive trial results for the use of antiretroviral drugs (ARV) for HIV 
prevention began in 2010, with CAPRISA 004. This trial looked at the efficacy of 1% 
tenofovir gel formulated as a topical agent for intravaginal application (a 
microbicide), with coitally dependant dosing (before and after sex).  Tenofovir is an 
ARV drug also used in HIV treatment. The study showed 39% efficacy which 
increased stepwise in participants who used the gel as directed (Abdool Karim et al 
2010). This approach awaits results of a confirmatory trial, as the trial was designed 
as a ‘proof of concept’ study and lacked the statistical power for regulatory approval. 
Only months later, results from iPrEX were published, showing that combination 
                                                 
1 Tenofovir gel works at a biological level as a form of topical pre- and post-exposure prophylaxis, but 
as taking an oral tablet is distinct from inserting a vaginal gel, the gel form and the oral form are 
usually seen as separate strategies. 
 303
tenofovir/FTC in tablet form (PrEP) reduced HIV acquisition by 44% in a population 
of men who have sex with men (MSM) and transgender women who have sex with 
men at high risk of HIV. Again, efficacy increased stepwise with good adherence to 
the study product to more than 90% (Grant et al 2010; Anderson et al 2012). Further 
evidence regarding tenofovir/FTC as PrEP came in 2011 from two trials in 
heterosexual people in Africa. The Partners PrEP study showed a 75% reduction in 
HIV incidence in couples where one partner was HIV negative and the other positive 
(serodiscordant couples), with tenofovir-only PrEP showing a 67% reduction (Baeten 
et al 2012). Finally the TDF2 study, which tested combined TDF/FTC PrEP 
conducted in heterosexual men and women in Botswana, showed a 62% reduction in 
HIV acquisition (Thigpen et al 2012). 
 
In addition, a study testing the efficacy of early2 ARV treatment for the HIV positive 
partner in serodiscordant couples (a strategy known as ‘treatment-as-prevention’) 
reduced HIV acquisition be a striking 96% (Cohen et al 2012).  
 
These successes in ARV-based prevention sit alongside three randomised controlled 
trials which have shown that male circumcision can reduce HIV acquisition in 
heterosexual men by around 50% (Auvert et al 2005, Bailey et al 2007, Gray et al 
2007), and a single vaccine trial that showed a modest 26% reduction in HIV 
acquisition (Rerks-Ngarm et al 2009). 
 
                                                 
2 ARV treatment is defined as ‘early’ when it is administered in people whose CD4 cell levels are 
above 350. 
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This block of evidence means that HIV prevention has now advanced well beyond 
behavioural and barrier modalities alone, and this has ethical implications for the 
design of future studies. 
 
Alongside the positive efficacy results, however, both PrEP (tenofovir alone and 
tenofovir/FTC) and tenofovir gel did not protect participants in the Fem-PrEP or 
VOICE trials, due to poor adherence (Van Damme et al 2012, MTN 2013). This 
suggests that there is still work to be done to establish an optimal prevention strategy 
that will be acceptable and usable for women at high risk of HIV acquisition. 
 
Standard of Care and study design 
‘Standard of care’ means the level of care provided to participants in a clinical trial. In 
HIV prevention trials, it can be used to describe four different aspects of care. Firstly, 
there is the ‘standard of prevention’, which is the risk-reduction package provided to 
all participants in the trial.3 Secondly, ‘standard of care’ may be used to refer to the 
care provided to participants randomised to the comparator arm of a trial (van der 
Graff and van Delden 2009). Thirdly, there is ancillary care – health care that is 
provided to trial participants that is indirectly associated with the research, such as 
contraception and reproductive health care, cervical cancer screening and treatment 
for illnesses that arise during trial participation (Richardson 2007; Belsky and 
Richardson 2004). Finally, there is access to ARV for trial participants who acquire 
HIV on the trial (Macklin 2006). 
 
                                                 
3 This term was coined in 2007 in the UNAIDS Ethical Considerations document to end the confusion caused my multiple 
meanings of ‘standard of care’. 
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Both the standard of prevention (the care provided to all participants) and the choice 
of a comparator arm (the standard of care against which an experimental intervention 
is measured), have profound impact on the design of HIV prevention studies. For 
reasons of efficiency and cost-effectiveness, HIV prevention studies are conducted in 
populations of high HIV incidence (and these populations are usually in specific 
geographic areas), because this allows an expeditious answer to the research question. 
The studies need to enrol sufficient numbers of people to provide a statistically 
significant result, calculated using the background HIV incidence. The introduction of 
a highly effective standard of prevention – such as treatment-as-prevention, which has 
been shown to reduce HIV acquisition by 96% – would require such exponential 
expansion of the sample size as to make a trial impracticable.4 For this reason, and 
because it is hard to justify withholding such an effective intervention in a study 
setting, it is likely that HIV prevention research targeting the specific population of 
serodiscordant couples will cease, and the focus fall on others at high risk of HIV 
acquisition. This article will therefore focus on people at high risk of HIV acquisition 
who are not in long-standing serodiscordant sexual partnerships. 
 
The guidelines 
There are several guidance documents that are relevant to the standard of care issue in 
HIV prevention trials.  
 
                                                 
4 It could be argued that given such an effective intervention, the time has come to stop testing new approaches and to fully fund 
the global roll-out of early treatment for all people with HIV. This approach does not satisfy the requirement for HIV negative 
people at high risk to be able to protect themselves, however, and research is likely to continue until this need has been met. 
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The Declaration of Helsinki is a general guide to research ethics produced by the 
World Medical Association (WMA 1964; as amended in 2008), an international non-
profit association of voluntary national medical associations formed in 1947. The 
Declaration drew upon the 10 points articulated in the Nuremberg Code and tied them 
in with physicians’ obligations under the Declaration of Geneva (1948). It has since 
been revised six times, most recently in 2008.  
 
The Declaration states in clause 6 that ‘In medical research involving human subjects, 
the well-being of the individual research subject must take precedence over all other 
interests’. Clause 32 goes on to address standard of care specifically: 
The benefits, risks, burdens and effectiveness of a new intervention must be 
tested against those of the best current proven intervention, except in the 
following circumstances: 
The use of placebo, or no treatment, is acceptable in studies where no current 
proven intervention exists; or 
Where for compelling and scientifically sound methodological reasons the use 
of placebo is necessary to determine the efficacy or safety of an intervention 
and the patients who receive placebo or no treatment will not be subject to any 
risk of serious or irreversible harm. Extreme care must be taken to avoid 
abuse of this option. 
Thus the Declaration of Helsinki adopts a universalist position that prescribes a best 
current standard for research participants in all cases where the risk is serious or 
irreversible, such as the risk of HIV acquisition. 
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The International Ethical Guidelines for Biomedical Research Involving Human 
Subjects adopts a more pragmatic position. These guidelines were developed by the 
Council for International Organizations of Medical Sciences (CIOMS) in 1993, and 
revised in 2002. They were intended to assist developing countries to define national 
policies on the ethics of biomedical research involving humans, to apply ethical 
standards in local circumstances, and to establish or improve ethical review 
mechanisms. The CIOMS guidelines offer extensive commentary on the issue of 
standards of care in general and whether or not an active comparator or a placebo 
control may be used. The actual guideline (#11) is strict about the use of placebo were 
an established intervention exists, but it does not insist on the active comparator being 
the ‘best’. Rather, it has to show some efficacy, allowing for the use of lower 
standards – or more technologically appropriate interventions – in specific instances, 
rather than a universal best practice. Guideline 11 states: 
As a general rule, research subjects in the control group of a trial of a 
diagnostic, therapeutic, or preventive intervention should receive an 
established effective intervention. In some circumstances it may be ethically 
acceptable to use an alternative comparator, such as placebo or ‘‘no 
treatment’’ 
Placebo may be used: 
 when there is no established effective intervention; when withholding 
an established effective intervention would expose subjects to, at most, 
temporary discomfort or delay in relief of symptoms;  
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 when use of an established effective intervention as comparator would 
not yield scientifically reliable results and use of placebo would not 
add any risk of serious or irreversible harm to the subjects. 
The CIOMS guideline is less prescriptive than the Declaration of Helsinki’s clause 32 
in that ‘an established effective intervention’ may be a local standard whereas the 
‘best current proven intervention’ calls for an optimal standard. The gap between the 
two becomes apparent when considering the HIV prevention context: in a prevention 
trial in heterosexual serodiscordant couples, for example, the CIOMS guidelines 
would permit condom-based prevention only, while the Declaration of Helsinki could 
be used to argue for condom-based prevention, plus PrEP for the negative partner, 
early treatment for the positive partner, and access to male circumcision for HIV-
negative male partners. 
In addition to these general research guidelines, there are two set of ethical guidelines 
that deal specifically with HIV prevention trials, the UNAIDS Ethical Considerations 
in HIV Biomedical Prevention trials (updated in 2012) and the HIV Prevention Trials 
Network Ethics Guidance for Research (2009). These documents are complementary 
in some respects but they differ in the way that they outline the obligations regarding 
standards of prevention and care. 
 
Guidance point 13 of the UNAIDS document, on standards of prevention, stipulates 
that there is an obligation to provide:  
…access to all state of the art HIV risk reduction methods … to participants 
throughout the duration of the biomedical HIV prevention trial. New HIV-risk-
reduction methods should be added, based on consultation among all research 
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stakeholders including the community, as they are scientifically validated or 
as they are approved by relevant authorities. 
Like the Declaration of Helsinki, the UNAIDS/WHO guidance takes a universalist 
perspective, prescribing state of the art prevention interventions as standard of 
prevention. Morally relevant criteria, including scientific validation, approval by 
normative bodies and the impact on research feasibility, may influence whether or not 
a new modality is considered standard of prevention. 
 
In addition to addressing standard of prevention, it also stipulates standards for 
ancillary care, specifically reproductive health care, treatment for sexually 
transmissible infections (STIs) and programs to address domestic violence.  
Guidance point 15 of the UNAIDS document, on the control arm, supports  point 13 
by reiterating that “participants in both the control arm and the intervention arm 
should receive all established effective HIV risk reduction measures”. In other words, 
experimental new interventions should be layered on top of what is already known to 
work. The allowable exceptions mentioned include instances where there is a sound 
biological rational for considering that  an intervention shown effective in one 
population cannot be generalised to another, such as a vaccine tested against a 
particular subtype, or a product tested vaginally that cannot be extrapolated to rectal 
use. 
 
The HPTN Guidance takes a different approach these issues. To begin with, it 
distinguishes between an ethical obligation and an ethical aspiration. Guidance point 9 
on the standard of prevention identifies the provision of an effective prevention 
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package for trial participants as obligatory. The content of that package, however, is 
undefined except insofar as there must be established evidence of efficacy and the 
prevention interventions must be practically achievable and reasonably accessible in 
the trial setting. Using this framework, in settings where particular risk reduction 
methods are deemed culturally inappropriate or illegal, they need not be offered so 
long as some other effective form of prevention is offered. Provision of voluntary 
medical male circumcision or needle exchange programs are not required under these 
guidelines even if trials enrol HIV negative uncircumcised men or injecting drug 
users, if these are not reasonably available in local communities5.  
 
The HPTN document also provides guidance on aspects of research not detailed in the 
UNAIDS document, including specifying processes of community engagement, 
building capacity and partnerships, and attention to ancillary care.6 Importantly, a 
new category of people to whom researchers have obligations is introduced – the 
‘screened out’. These are people who volunteer to participate in prevention trials but 
are found ineligible for reasons such as pre-existing undiagnosed HIV infection. 
                                                
 
In addition to these two sets of guidelines, there is a set of consensus points developed 
by a group of HIV prevention researchers and bioethicists in 2009 that require 
consideration, from the ‘Standard of Prevention’ consultation in Uganda (McGrory et 
al 2010). These consensus points articulate that a new intervention is considered ‘state 
 
5 While in-depth discussion of these issues are beyond the scope of this paper, conducting a trial in an 
area where participants are denied access to a proven safe and effective intervention for social or 
political reasons is both inappropriate and exploitative. 
6 UNAIDS deals with community engagement processes in detail in a separate document co-authored 
by UNAIDS and AVAC, the Good Participatory Practice Guidelines, first published in 2007. 
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of the art’ when it is approved by a relevant regulatory authority or included in 
normative guidelines. They also stipulated that there was a strategic set of trials using 
PrEP in different populations that should be allowed to continue without alteration, 
regardless of whether early results showed efficacy, in order to get maximum 
information about PrEP in different populations.   
The UNAIDS and HPTN documents will be discussed in detail in this chapter. 
 
Key differences 
The HPTN document was developed specifically to meet the needs of a research 
network undertaking HIV prevention work. It defines itself as ‘pragmatic’ rather than 
idealistic in its approach, and sets out to address ‘limitations, gaps and 
inconsistencies’ perceived in existing guidelines. It is structured to address issues that 
arise sequentially from before the trial to its aftermath, and it identifies which 
stakeholders are responsible for implementing which guidance points as well as 
defining the strength of guidance as ‘obligatory’ or ‘aspirational’, as noted above. In 
addition, it specifies a limited conception of justice in its underpinning principles – 
‘social justice’, defined as “the ethical concerns related to treating people equally, 
avoiding exploitation, and trying to reduce health disparities” (Rennie and Sugarman 
2010). Defining and limiting justice in this way prioritises equality between trial 
participants and their local communities rather than aiming to reduce health 
disparities between trial participants in high income countries and those in low and 
middle income countries. 
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While the UNAIDS guidelines impose duties on researchers to adopt international 
best practice, the HPTN document allows a looser standard to be adopted. The 
rationale for this is threefold: ‘state-of-the-art’ risk reduction methods that are not 
available outside the trial could constitute undue inducement to participate; to prevent 
research practices that would compromise ‘real world’ significance of data; and to 
guard against people within a trial having access to a higher standard of prevention 
than those outside it; (Rennie and Sugarman 2010).  The focus on current local 
capacity reframes the discourse about double standards, generally understood to mean 
disparities between high income countries and developing countries, to one that 
centres on the local research community. 
 
This brings us to the crux of the difference between the two sets of guidelines. With 
the FDA now having approved PrEP for HIV prevention, under the UNAIDS 
guidelines there is a prima facie requirement to provision PrEP as standard of 
prevention, as PrEP clearly meets the definition of ‘state-of-the-art’, having been 
approved by a normative body. Were this to occur, it would require much larger, more 
expensive and highly complex trials for subsequent experimental interventions – but 
these trials could dramatically decrease HIV acquisition in the trial populations. An 
argument against a ‘state-of the art’ PrEP-containing prevention package is that it  
could create serious inequities between trial participants and their communities in 
which PrEP is not available, though this could be rebutted on the ground that such 
provision would be a capacity building-enabler of better services in communities. 
Sustainability of the intervention is also an issue. 
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 Under the HPTN guidelines, no such change is required, as these guidelines define a 
minimum standard that is amenable to ongoing research studies using the currently 
established standard of prevention (i.e. condoms, behavioural counselling and 
treatment for sexually transmissible infections), despite the fact that in the 
communities that have high HIV incidence, the inadequacy of existing methods is 
arguably well established. There is a clear tension between the imperative to protect 
participants and the imperative to find a cheap, effective user-friendly HIV prevention 
technology. Who gains from such studies is an important consideration – people in 
high incidence populations in low and middle income countries, or those in high 
income countries? 
The mother-to-child transmission controversy revisited 
These questions revisit the debate from the late 1990s about alleged doubled standards 
in mother-to-child prevention trials. A major ethical controversy erupted in 1997, 
when an article in the New England Journal of Medicine called into question placebo-
based trials for mother-to-child HIV prevention in Africa and Asia, despite a proven 
effective intervention being published in 1994.The critics pointed out that the 
placebo-controlled trials violated the Declaration of Helsinki. They alleged that an 
unacceptable double standard regarding research ethics was operating, reminiscent of 
the notorious Tuskegee trial (Angell 1997; Lurie and Wolf 1997). Defenders of the 
trials argued the ‘standard of care’ established in the 1994 was not feasible in 
developing countries, that the placebo-based trials addressed a significant public 
health issue in those countries, and that the question that needed to be answered was 
whether the experimental therapy was better than nothing, not whether it was as good 
as an unattainable standard (Varmus and Satcher 1997). 
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The controversy led to a redrafting of the Declaration of Helsinki, but in the end the 
revised version(s) maintained that new interventions for serious conditions should not 
be tested against placebo when established treatment exists. Regardless of this 
outcome, bioethicists and researchers remain polarised on this issue (Macklin 2001). 
With respect to HIV prevention, the debate has slumbered as provision of behavioural 
and barrier prevention has been accepted by researchers and communities alike, and 
until very recently circumcision was the only proven biomedical intervention, which 
has a very specific population (heterosexual men) and is subject to profound social 
and cultural mores (Macklin 2008). The advent of ARV-based prevention reignites 
the issues. 
Practical aspects 
Amidst philosophical disagreement about standards, a focus on consensus-building 
processes among stakeholders including communities and actual and potential trial 
participants has emerged as a means for getting broad agreement of how research 
should be conducted in particular settings (for example, Vallely et al 2007). In 2007 
UNAIDS and AVAC  developed Participatory Practice guidelines (revised in 2012) 
that detail expected engagement with communities and the setting up of mechanisms 
that give communities  opportunities for input throughout the research. 
 
This is a very significant move, catalysed by the premature closure of PrEP trials in 
the early 2000s that were perceived to have been insufficiently consultative with trial 
communities, and which were perceived to be not sufficiently responsive the 
participants’ needs (Forbes and Mudaliar 2009; Haire 2011; McGrory et al 2009; 
Ukpong and Peterson 2009). 
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Direct two-way communication with communities and giving community 
stakeholders real power to influence aspects of the research is a very important 
development. Community members do not meet with international researchers on an 
equal basis, however: there are vast power differentials at play. Indeed, the 
relationship has been defined as one of structural inequality, such that the researcher 
has a fiduciary responsibility to the research participant (Miller and Weijer 2006). 
Accordingly, while community collaboration with HIV prevention research is 
essential for best practice, it is no substitute for clear standards. 
 
Making the call 
The evidence that treatment-as-prevention, circumcision and PrEP are effective in 
preventing HIV acquisition means that it is no longer ethically appropriate to design 
HIV prevention without securing access to these interventions. Each of these 
strategies has been approved by a regulatory authority or in a normative guideline (the 
WHO in the case of circumcision, the International Antiviral Society, USA panel in 
the case of treatment-as-prevention, and the FDA in the case of PrEP).  
 
Despite the recent advances in biomedical prevention, however, the need to develop 
new interventions remains. Longer-acting products in particular are required to avoid 
the problem of suboptimal adherence. A balance therefore needs to be struck between 
prioritising the protection of trial participants and facilitating ongoing research into 
new HIV prevention technologies that might be cheaper, more effective and more 
feasible in low- and middle-income countries.  
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Several different solutions have been proposed for the design of future prevention 
trials. Firstly, PrEP could be added into the standard of prevention and made available 
to all trial participants, who would be randomised to receive the experimental 
intervention or placebo on top of this background. The advantage of this is that it 
would be highly likely to reduce HIV acquisition very significantly in the trial 
population.  The problem is that it would require very large sample sizes to obtain a 
result, and it might be difficult to untangle the efficacy (or not) of the experimental 
intervention from PrEP efficacy (which would likely be affected by differential 
adherence, as in trials to date). 
 
A variation on this approach would be to allow PrEP in standard of prevention 
packages only where it is available in the community – namely, the US and at PrEP 
demonstration sites7 – and not in other trial sites. There are serious objections to this. 
If the trial were only conducted in sites where PrEP was available, the same problems 
with very large sample size and difficulty in discerning the impact of the experimental 
intervention would apply. If some sites had PrEP access and others did not, a stark 
double standard would be in evidence, with the majority of HIV seroconversions 
likely to occur in the non-PrEP sites. 
 
Alternatively, new trials could seek volunteers from amongst those who opt not to 
take PrEP, who could thus be randomised to experimental intervention or placebo.  If 
it were the active choice of the volunteers not to take PrEP, there could be no ethical 
                                                 
7 At the time of writing, the only demonstration sites launched were in the US, with others planned in 
two or three cities in Brazil. 
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objection. There are two problems with this, however. Firstly, in order for the choice 
to opt out of PrEP to be free, these studies would need to take place in setting where 
PrEP is available, which is a major constraint. Secondly, available research suggests 
that people who recognise themselves to be at high risk of HIV acquisition tend to be 
amenable to taking PrEP (Wheelock et al 2013, Holt et al 2011). People who don’t 
wish to take PrEP may therefore be at lower risk, which would then require larger 
sample sizes to get a result, with the risk of a futile result. 
Finally, there is the option of using PrEP as the active comparator. Again, there are 
several issues here. For this to be ethical, there would need to be strong preliminary 
evidence to suggest that the experimental intervention would be of comparative 
efficacy, so as to ensure equipoise (i.e. uncertainty as to whether one arm would be 
better than the other) between the two arms of the trial. The scientific objection to 
using PrEP as a comparator is the lack of precision regarding the preventative efficacy 
of TDF/FTC, with point estimates from randomised control trials ranging from 6% 
(FEM-PrEP) to 75% (Partners PrEP). An active comparator is usually required to 
have a substantial magnitude of effect, precisely estimated, with that estimate relevant 
to the trial population (Fleming 2013). This is not an insurmountable barrier, 
however. Further analyses of high adherers from iPrEx have shown efficacy of around 
90% (Anderson et al 2012). Regrettably, similar information is not yet available 
regarding high adherence in women. Further, the requirement for a ‘precise estimate’ 
is questionable in this context, given that it has been well established that PrEP 
reduces HIV acquisition significantly when it is taken, but its effectiveness is 
attenuated by poor adherence (Mayer 2013). A long-acting intervention that had lower 
biological efficacy might work better than PrEP in one population and worse in 
another, more adherent one. Head-to-head studies are an opportunity to discover this. 
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Active comparator studies using PrEP also offer an opportunity to study further 
factors that relate to adherence in specific populations, and potential strategies for 
improvement. 
 
PrEP is the appropriate comparator because there is good evidence that it works if 
people adhere to it. Adherence is a significant issue (Van Damme et al 2012; Beaten 
et al 2012), however, as is cost. It is not ideal, but in combination with existing barrier 
methods it is the best technology available for HIV negative women or men who have 
receptive sex. Finding an intervention that works as well as PrEP without requiring 
daily adherence would be a breakthrough. If a new experimental intervention failed to 
be as good as PrEP, then the trial would still be useful for getting further information 
about PrEP adherence in settings where HIV is hyper-endemic. 
Voluntary circumcision for HIV negative heterosexual men should be offered as 
standard of prevention in studies that include this population, as it is feasible and cost-
effective. Uptake of this option is likely to differ according to social and religious 
factors, but HIV negative heterosexual male participants in research studies should be 
allowed to make up their own minds, based on the evidence of safety and efficacy and 
their own personal values as to whether it is appropriate for them. The option should 
not be censored on the presumption of unilateral social and religious values in a 
community.  
 
The recommendation to use PrEP as an active comparator arm, with circumcision 
offered as appropriate as standard of prevention, applies to trials that are in design 
phases. It would be counterproductive, for example, to try to add extra arms to trials 
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like FACTS 001, which is designed to meet the requirement of the South African 
regulatory authorities, and without which the question of how effective tenofovir gel 
is may never be answered comprehensively. Continuation of this trial should be 
supported for this reason. The continuance of PopART should also be supported, as 
this is a cluster trial testing an approach to the implementation of circumcision and 
treatment-as-prevention in a series of communities. PopART is not testing an 
experimental technology, but a particularly intensive approach to engaging people 
with proven HIV prevention practices, male circumcision and treatment-as-
prevention. 
Conclusion 
In the absence of a universally acceptable, highly effective, cheap and user-friendly 
vaccine, HIV prevention research will continue to be an important component in the 
struggle to eliminate HIV. Despite its seemingly high biological efficacy, TDF/FTC 
PrEP is far from an ideal intervention, particularly given the serious problems with 
adherence shown in several of the trials to date. Even if adherence can be improved 
significantly in high-incidence populations through specialised programs, a short-
acting user-dependent prevention technology is vulnerable to a range of potential 
disruptions. For people who are at high risk of HIV acquisition (from risk factors 
other than a serodiscordant regular sex partner), however, PrEP is the best adjunct to 
barrier and behavioural prevention that we have. Certainly there needs to be better 
data on how to use it optimally, but this can be gathered in studies that use PrEP as a 
comparator against which other experimental interventions are tested.  
 
The goals of HIV prevention research must be to find the most effective ways of 
using existing tools, including PrEP, and to establish the effectiveness of new tools. 
 320
Randomised controlled trials are an important part of this, but they need to be 
designed in such a way as to ensure that all participants receive effective 
interventions, even though this necessarily means that trials will need larger sample 
sizes. HIV prevention trial participants are among the most vulnerable to HIV in the 
world, and need to be protected. 
 
Incorporating TDF/FTC PrEP as the comparator arm in forthcoming HIV prevention 
trials balances the need for ongoing research with appropriate protection for research 
subjects. While a daily tablet is not an ideal prevention intervention, as it is vulnerable 
to stock-outs and to individual forgetfulness, it has the advantages of being separable 
from each sex act and appropriate for receptive sex partners. For HIV negative people 
at high risk of HIV acquisition, it is the best protection currently available. If we take 
seriously the moral imperative to address HIV incidence in those populations most 
vulnerable to HIV acquisition, then PrEP needs to be the comparator in forthcoming 
research. 
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Part 4, Chapter 1 
Summary and conclusions 
 Summary and conclusions 
Broad aim of this thesis 
The broad aim of this thesis was to explore the ethical issues relating to the standards 
of care in HIV biomedical prevention research, with a specific focus on how benefits 
for participants are negotiated. It had empirical and normative components.  The 
empirical component was a mixed-methods study that surveys principal investigators 
of HIV prevention trials and the ethics committees that review them, and in-depth 
interviews with principal investigators of HIV prevention trials. The normative 
component first explored the moral basis for ARV-based prevention in the absence of 
true universal access for treatment and then examined how debates on standards of 
care apply in the evolving context of partially effective HIV prevention interventions. 
 
The study took place at a dynamic period of HIV prevention research. Between 2009 
and 2012 positive efficacy results were reported from six large, randomised controlled 
trials (RCTs) of HIV prevention interventions. One of these trials tested a candidate 
vaccine, while the other five tested three different, but related, preventive strategies 
that use antiretroviral drugs in different ways: topical use (a vaginal microbicide); pre-
exposure prophylaxis using either tenofovir alone or emtricitabine/tenofovir 
combined; and treatment-as-prevention (treating HIV positive people with ARV 
earlier than medically required in order to prevent transmission to sexual partners).  
These trials added to existing evidence that medical male circumcision is partially 
effective in preventing HIV infection. 
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Alongside these positive efficacy results, the results of the FEM-PrEP and VOICE 
trials were reported. These demonstrated the importance of adherence in trials of user-
dependent technologies. Neither trial showed efficacy, and subsequent studies 
revealed that less than a third of participants were taking their drugs, as shown by 
blood level analysis (Van Damme et al 2012; Microbicide Trials Network 2013). 
Added to the lower-than ideal adherence in iPrEX (Grant et al 2010), these trials 
signal that adherence is the next big issue in HIV prevention research. This will 
impact on the conduct of future HIV prevention research by increasing sample sizes, 
by imposing directly observed therapy, or by discouraging the research and 
development of daily use products. 
 
Key empirical findings 
This thesis has several key empirical findings.  Firstly, there is no consensus as to 
how standards of prevention should change in response to emerging partially effective 
interventions. While some investigators argue that new experimental interventions 
should be tested against optimised background prevention, others are adamant that 
prevention options for trial participants should not exceed those available to 
community members outside the trial. Some investigators argue that optimised 
prevention within trials will ensure that trials require larger sample sizes, and hence 
the benefits of participation shared amongst larger populations; others argue that that 
basic prevention packages are sufficient and that these benefit the HIV prevention 
endeavour by expediting research results. 
 
With regard to implementing new research findings, investigators had significantly 
different approaches as can be seen most clearly with the example of medical male 
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circumcision. One research group proactively added voluntary male circumcision to 
standard of prevention based of the strength of the data, others had information and 
referral processes that worked with national guidelines, but one major study had no 
systematic approach to the issue at all.  
 
Controversy over provisions of ARV for seroconverters, however, has vanished. The 
exponential growth of ARV access programs, both nationally based and donor-
funded, and successful partnerships between access programs and research sites have 
made access to care for seroconverters the norm. 
 
 
Investigators saw it as necessary, for both ethical and practical reasons, to provide 
some level of ancillary care that complemented other local health services. This 
sometimes created ethical conflict due to constraints of either funding or local 
infrastructure. With the emphasis on delivery of ancillary care, researchers generally 
described their focus broadly in terms of having a beneficial impact on individuals and 
communities, rather than a narrow focus on simply answering a research questions. Even so, 
the best medical interests of individual participants were generally not the key priority 
for the informants, but one factor to be balanced with several others. The competing 
factors included the scientific integrity of the trial, limitations imposed by funders, 
and the constraints of local infrastructure.  
 
Regarding post-trial access, each of the nine HIV prevention trials that had positive 
efficacy results had undertaken access planning in the event that their trial produced 
an effective intervention. This suggests that post-trial access is considered normative. 
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Differences were evident however in the mechanisms for providing access, the 
timeframes in which this was achieved, and the length of time it was sustained. The 
surprising aspect of the post-trial access is firstly that the key mechanism for 
delivering it is, in fact, a clinical trial, so it is actually a form of intra-trial rather than 
post trial access. Cross-over mechanisms (where participants on placebo are switched 
to active drug) appear to offer major advantages in terms of timeliness over new 
formal extension trials that can take months or years to get the necessary approvals. 
Secondly, even though the obligation to provide access is a shared one in which 
investigators have only a limited role, the advocacy efforts of investigators appear to 
be very important for securing access, particularly when there might be issues in 
securing population-wide regulatory approval. 
 
Finally, the reported duration and depth of community engagement and consultation 
increased over time, with later trials generally entailing more community engagement 
from earlier stages of the research process. 
 
Key normative findings 
Moral basis for ARV as prevention 
In Chapter 1, Ethics of ARV-based HIV prevention I argue that there is a sound moral 
basis for using ARV for prevention, even though some seven million people who need 
treatment for their health do not have access to it. Firstly I propose that that HIV risk 
is largely determined by structural factors – the HIV prevalence in the demographic 
pool in which one has sex rather than individual behaviour. Secondly,   while the 
acquisition of HIV is preventable through the use of condoms and behavioural 
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strategies such as celibacy or mutual monogamy, these strategies are of limited 
usefulness in many circumstances. 
 
Using two different ethical frameworks – principle-ism and a public health 
stewardship framework – Ethics of ARV-based HIV prevention considers both 
treatment-as-prevention and PrEP.  
Treatment-as-prevention involves treating people with HIV earlier than would be 
required to maintain their own health for the purpose of reducing their infectivity to 
sexual partners. It has the potential advantage of offering as yet speculative health 
benefits to the positive person, but also exposes him or her to the known risks that 
come with longer term-exposure to ARV. This includes drug toxicities, and perhaps 
more importantly, the risk of drug resistance developing if adherence is inadequate, 
which could compromise later treatment options. Treatment-as-prevention approaches 
have been criticised for prioritising a public health benefit (i.e. the suppression of 
viral replication, reducing infectivity) over the health of the patient, potentially 
leading to coercive regimes of testing and treatment without informed voluntary 
participation. 
 
PrEP on the other hand requires HIV negative people to take ARV for preventive 
purposes, but is the first preventive intervention directly under the control of 
individuals at risk of HIV who have receptive vaginal or anal sex. As such it offers a 
new prevention modality for population that is at highest risk of HIV acquisition – 
young women in southern Africa.  
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Ethics of ARV-based HIV prevention argues that each strategy has risks and benefits, 
but that each has a place in the epidemic. One enables the person with HIV to be less 
infectious to partners, while the other enables highest risk populations in the world to 
protect themselves through a strategy that empowers them to be proactive on their 
own behalf, not one that positions them as hapless (or lucky) recipients of a fate 
determined by others’ actions. 
 
How good is good enough? 
In Chapter 2 How good is ‘good enough’? my co-authors and I argue that the standards of 
evidence required for licensure applied to tenofovir gel and tenofovir/emtricitabine PrEP may 
be inappropriate measures of how useful new modestly effective HIV prevention products 
might be in the generalised epidemics in southern Africa. We argue that reducing the 
incidence of HIV is both a public health priority and a moral imperative, and question the 
need for lengthy confirmation trials before licensure.  
 
As new biomedical products of moderate efficacy have the potential to significantly slow the 
epidemic in these affected countries, delay in introducing effective prevention strategies may 
result in hundreds of thousands of potentially avoidable infections.  We therefore ask on what 
basis was it decided a) that the two new trials do not provide sufficient evidence to support 
these products being made available outside research settings, and b) that they should not 
form part of the standard of care in the control arm of new trials, and replace placebos. 
Setting the evidentiary bar high facilitates ongoing placebo-controlled trials, which makes 
research cheaper and more efficient. Faster research might result in finding more effective 
product more quickly. However there is no guarantee of this and, as we argue, it entails a 
substantial human cost. 
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 The key point about CAPRISA 004 and iPrEx is that different decisions could reasonably be 
made both regarding licensure and roll-out of the products in some areas where HIV is 
endemic, and in the composition of ‘standard of prevention’ in subsequent trials. For 
example, the South African regulators could have decided that, given South Africa’s high 
HIV incidence in women, licensure of tenofovir gel was justified (presumably with some 
follow-on open label studies to gather more data). While the failure of VOICE gives pause 
for thought, the low adherence to all study products in that trial suggests that there was 
something specific in that population context that dramatically affected adherence, rather 
than an efficacy issue per se. If the 39% efficacy rate of CAPRISA 004 translated into real-
world effectiveness it could have prevented 100,000 new infections per year.  
 
Standard of Prevention 
Chapter 3, on the standard of prevention, discusses the issues that arise in considering 
appropriate standards in the light of evolving evidence.  
 
Antiretroviral (ARV) drugs can be used in diverse ways to reduce HIV acquisition or 
transmission risks, taken either as pre-exposure prophylaxis (PrEP) by those who are 
uninfected, or as early treatment for prevention (T4P) by those living with HIV. This 
expands the armamentarium of existing HIV prevention tools. These findings also 
have implications for the design of future HIV prevention research trials. With the 
advent of multiple effective HIV prevention tools, discussions about the ethics and the 
feasibility of future HIV prevention trial designs have intensified.  Determining the 
appropriate trial design and prevention package for a particular study in a specific 
HIV risk population requires careful consideration, taking account of  national and 
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international guidelines, ARV programme coverage, and the perspectives of 
researchers, ethics committees, trial sponsors, regulators, communities, and other HIV 
prevention trial stakeholders. There is currently no documented evidence on 
consultative decision-making processes for defining the standard of prevention 
packages for HIV prevention research. The field needs to develop processes that 
engage all stakeholders in realistic and practical decision-making in a time-sensitive 
manner, without undue prioritisation of financial considerations above the interests of 
trial participants. 
 
Time for change 
Chapter 4, It’s time, uses both the evidence form clinical trial and the U.S FDA 
approval of PrEP to argue for new standards. 
In July 2012, based on evidence from two major trials, the United States Food and 
Drug Administration approved the use of combined oral tenofovir/emtricitabine as 
pre-exposure prophylaxis (PrEP) for people at high risk of HIV acquisition. PrEP 
effectiveness is marred by poor adherence, however, even in trial populations, thus it 
is not a magic bullet for HIV prevention. Inclusion as a comparator also offers unique 
opportunities to study factors that related to adherence in different populations. 
Despite the adherence conundrum, PrEP remains the most effective biomedical HIV 
prevention intervention available for people at high risk of HIV, particularly those 
who have receptive sex and lack the power to negotiate condom use. Accordingly, 
there are compelling reasons to compare future experimental HIV prevention 
interventions against PrEP. Using PrEP as a comparator serves the interests both of 
trial participants and of scientific research: not only would HIV incidence be reduced, 
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but also the question of whether new interventions were superior to best proven 
interventions, in a given setting, would be answered comprehensively. 
 
Situating this study historically 
At the beginning of this study (mid-2009) there was a ‘practical consensus’ about the 
standard of prevention and care in HIV prevention trials. Condom-based prevention 
with counselling and STI treatment were the preventative standard, with some form of 
linkage to care for seroconverters, most often though not always through a separate 
agency. Access to hormonal contraception – particularly the oral contraceptive pill 
and injectables – was frequently facilitated or directly provided in studies that 
included female participants, to avoid pregnancies complicating or confounding the 
trials (research ethics prevent pregnant women from taking experimental products 
until there is good safety and efficacy data in other populations). Other forms of 
ancillary care depended on the sites, the sponsors and the trial populations, and post-
trial access to successful intervention was limited to access to voluntary medical male 
circumcision1. 
 
This was a ‘practical’ rather than a true consensus: from approximately 2006, the 
above had become the standard practices, though differences in implementation could 
still mean that the levels of prevention and care received by trial participants could 
differ significantly. Some principal investigators however criticised the level of 
prevention offered within trials as being too far above the locally available standards 
                                                 
1 The HIV prevention benefit of voluntary medical male circumcision only applies to HIV negative 
heterosexually active men living in countries with generalised epidemics. 
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within trial communities, with better standards of prevention within trial potentially 
masking the efficacy of some products.  
 
The local standard compared with the best proven first plays out with regard to 
medical male circumcision, where some trials provide or facilitate provisions 
proactively, while others await the establishment of government programs. 
 
Two major contextual elements affect the negotiation of benefits for trial participants: 
the universal access movement for ART, and increasing recognition of the role of 
community participation and collaboration in HIV prevention research. As discussed 
in Pt 1 Chapter 2, Because we can, four major PrEP trial sites2 were closed in the 
early 2000s amidst assertions that the research processes were unacceptable to the 
communities in which they were to occur. The specific allegations across the sites 
were of insufficient informed consent practices, a perceived lack of access to ART for 
seroconverters, inadequate provision of HIV prevention counsellors, no provision for 
post-trial access, lack of insurance in the event of illness induced by the study drugs 
and limited involvement of the affected communities in trial design. The closure of 
these trials focused attention on the importance of community perception and 
community collaboration for ensuring the successful completion of research. Indeed, 
it showed that clinical trials could fail at a social level, despite being scientifically 
robust. This resulted in the Good Participatory Practice Guidelines, which provides a 
                                                 
2 I am referring to ‘sites’ rather than trials as it’s easier to be accurate. Sites were closed in Cambodia, 
Cameroon, Nigeria and Malawi; Cambodia and Malawi were distinct trials, while Nigeria and 
Cameroon were part of a larger trial that also had a site in Ghana, which did not close. 
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guide to community collaboration and addresses the need for access to ART for 
seroconverters. 
 
As I argue in Pt 1 Chapter 2, Because we can, recognition that there is a duty of care 
or moral obligation to provide access to ART to seroconverters is significant because 
it broadens the role of research in the developing world. Rather than functioning as a 
dislocated, disinterested machine for the production of knowledge, this obligation 
creates a new role for research as part of a capacity building project that can help to 
redress health disparities. This view is similar to the views published by Soloman 
Benatar and colleagues (2001; Singer and Benatar 2001; Shapiro and Benatar 2005), 
in that it recognises an obligation for research projects to play a role advancing social 
goals more broadly than simply focusing on benefits for participants.  It differs from 
those views in that I consider that the obligation to provide the participant with a 
universal standard of care – insofar as that is possible – remains. Participant benefits 
can be the entry point that helps leverage prevention and care services for the wider 
community. As Macklin argues (2012 personal communication), access has to start 
somewhere. 
 
By the end of the study in 2013, the focus in HIV prevention has once more swung 
around toward socio-behavioural issues, with the release of VOICE data on 4 March, 
2013. Rather than confirming the efficacy of any of the three intervention it tested, the 
interventions in VOICE showed no efficacy against HIV, due to the fact that less than 
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30% of the participants3 adhered to the trial protocol. This result has once more 
focused attention on the large-scale clinical HIV prevention trial as a complex social 
hub involving many different people with different aims, interests and values whose 
investment in the trial process may be for totally different reasons than those assumed 
by those who designed the trial.  
 
An interesting side effect of the VOICE result has been increased emphasis upon the 
original trials (such as iPrEX) that provided evidence of biological efficacy of ARV 
for prevention in negative people – those very trials that, it was argued, required  
extensive confirmation. This turn supports the arguments made in Pt 3 Chapter 2, 
How good is good enough, that the initial trials contained enough data on biological 
efficacy, and hence obviated the need for further placebo controls.  
 
Specific aims of the thesis 
The specific aims of the study were: 
1. To gather evidence on how benefits to participants are negotiated in efficacy 
trials of biomedical HIV prevention technologies; 
2. To re-consider the debates about obligations to trial participants in the light of 
the positive trial results (what are the ethical issues in HIV prevention research 
in the age of partially effective HIV prevention modalities?); 
                                                 
3 Drug was detected in 29 percent of blood samples from women in the 
tenofovir/emtricitabine group, 28 percent of samples in the oral tenofovir group and 23 
percent among those in the tenofovir gel group. 
http://www.mtnstopshiv.org/news/studies/mtn003 
 340
3. To understand how principal investigators and ethics committees navigate this 
territory, and how experience in conducting HIV prevention trials shapes 
views on how they should be conducted in the future; 
4. To explore the factors that affect how and when positive research findings are 
implemented; and 
5. To ask whether there are ethical issues that arise from the empirical research 
that are not present in the current normative literature. 
 
Aim 1: To gather evidence on how benefits to participants are negotiated in efficacy 
trials of biomedical HIV prevention technologies in the developing world. 
The surveys of principal investigators and ethics committee members showed that 
both sets of stakeholders draw on multiple forms of formal ethical guidance in their 
decision-making processes. With regard to principal investigators, however, the 
survey showed significant variation in the ways that standards of prevention and care 
are conceived, designed and implemented, despite considerable attention given to 
normative ethics guidance. This was borne out in investigator interviews, in which a 
spectrum of views was given by informants as to how standards of prevention should 
be determined. Perceptions ranged from an ethical impetus to include newly validated 
technologies as soon as feasible to a desire to reduce the prevention package to make 
it more like “real life”, thus enabling subsequent trials to test interventions against 
basic prevention packages.  
 
Informants were divided as to whether ‘equity’ meant people having access to the 
same basic goods within a trial and in the community outside it, or whether ‘equity’ 
was about equal access for goods for people participating in trials regardless of where 
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the trials occur. These competing concepts of social justice are discussed in Pt 3 
Chapter 3 Ethical considerations in determining standard of prevention packages for 
HIV prevention trials. 
 
Survey data showed that the ARV access movement has had a decisive impact on the 
care made available to both seroconverters from trials and, to a lesser extent, 
volunteers screened out due to pre-existing HIV infection. The impact of broader 
access to ARV was the key change over time discussed in the interviews, and it was 
universally welcomed. Investigators permanently based in the countries in which they 
conducted research tended to be more confident of their ARV access linkages and 
mechanisms than those who were present in the host country for the duration of the 
trial only and were reliant upon partners to implement access. 
   
As discussed in Pt 2 Chapter 3, Ethics of medical care and clinical research some 
investigators perceived a stronger obligation to ensure access to ARV for the 
‘screened out’ than they did to people who seroconverted during trial due to the likely 
more acute medical need of those who discover their HIV infection when enrolling in 
a trial compared with those who recently seroconverted. 
 
Investigators generally did not report major issues with sponsor policies limiting the 
way that budgets could be spent on ancillary care and infrastructure in the surveys 
(particularly those who had conducted recent trials), but containing cost was the major 
issue raised when the question of adding new interventions to the standard of 
prevention was discussed. In interviews with those who conducted trials in the early 
2000s, informants reported major issues with sponsor policies precluding activities 
 342
that investigators deemed warranted particularly with regard to open access to 
protocols and insurance funds to cover trial-related injury. 
 
Aim 2. To re-consider the debates about obligations to trial participants in the light 
of the positive trial results (what are the ethical issues in HIV prevention research in 
the age of partially effective HIV prevention modalities?). 
There are two main issues here: How partial efficacy affects the obligation for post-
trial access, and how the partial efficacy of a particular intervention should affect the 
design subsequent trials. 
 
As discussed in Pt 2 Chapter 5, Mind the gap, principle investigators’ obligation to 
provide post-trial access is limited by their capacity to do so, and the responsibility is 
shared with other actors including sponsors, government bodies and regulators. 
Problems with post-trial access evidently occur when not all parties agree whether or 
not a new intervention should be made available for a given population at a particular 
time. Interventions that show modest efficacy and are deemed to require confirmatory 
trials are inherently problematic: participants have a reasonable expectation of getting 
access, but regulators and governments may be conflicted over potential political 
consequences of allowing access to a modestly effect product that might have 
unknown social impacts and that might later be deemed not cost effective in a 
particular epidemic. Thus the role of the investigator as advocate is an important one. 
How newly validated interventions should be incorporated into the design of new 
trials is discussed in Pt 3 Chapter 3, Ethical considerations in determining standard of 
prevention packages for HIV prevention trials, Pt 3 Chapter 2, How good is ‘good 
enough’ and Pt 3 Chapter 4, It’s time. These chapters explore the evidentiary, 
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normative and regulatory bases for determining when a new intervention can be 
considered ‘validated’ and argue that there is a particularly compelling case for 
ensuring both that people at the highest risk of HIV receive optimised prevention 
packages, and that ongoing HIV prevention research into more user-friendly products 
is facilitated. The conclusion reached in Pt 3 Chapter 4, It’s time is that PrEP should 
become not the standard of prevention but a comparator, so that new experimental 
interventions that might offer similar biological efficacy to PrEP but have other 
properties such as being longer acting and hence less adherence-dependent can be 
measured against an active comparator.   
 
Aim 3. To understand how principal investigators and ethics committees navigate 
this territory, and how experience in conducting HIV prevention trials shapes views 
on how they should be conducted in the future. 
As discussed in Pt 2 Chapter 4 Standard of prevention in the real world there was no 
consensus as to how principal investigators viewed the way forward in designing HIV 
prevention trials with active comparators or newly validated interventions added to 
the standard of prevention.  Threads of scientific and ethical argumentation together 
were used to justify responses. As discussed in Pt 3 Chapter 3 Ethical considerations 
in determining standard of prevention packages for HIV prevention trials, the HPTN 
guidance validates the use of an effective, but not necessarily optimal, prevention 
package. Those taking a cautious perspective toward change tended to argue that it 
would be paradoxical to insist on optimal prevention in trials, as it would slow the 
speed and increase the cost of research and give trial participants access to a higher 
level of prevention services than those from the same communities who did not 
participate. Others saw optimal packages as being of scientific value, in that an 
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intervention tested against an optimal background is shown to work over and above 
and above that background, hence offering a genuine advance. In addition, optimal 
packages could effectively pilot the scale-up of new interventions in a local setting. 
 
There is a broad consensus that for all HIV prevention trials, all study participants 
should receive a standard HIV prevention package including male and female 
condoms, STI treatment, and behaviour change communication, as well as education 
and referral for VMMC in the instance of heterosexual men who are at particular risk 
of HIV exposure (though in practice this depends on national guidelines, and in at 
least one major trial did not occur). However, there is a lack of consensus regarding 
whether PrEP should be part of the standard of prevention package in HIV prevention 
trials and whether it could be used as a comparator arm. Decisions by country 
regulatory authorities are not the only factors in making this determination.   
 
. 
 
 
Aim 4. To explore the factors that affect how and when positive research findings are 
implemented. 
Positive research findings on three different biomedical HIV prevention modalities 
were implemented to some degree during this study – medical male circumcision 
(MMC) in countries with generalised epidemics, oral tenofovir/emtricitabine as PrEP 
in the United States and earlier ARV treatment for its preventative benefit in various 
countries.  
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As discussed in Pt 3 Chapter 3, Ethical considerations in determining standard of 
prevention packages for HIV prevention trials,  voluntary MMC was added to the 
standard of prevention in the Phambili vaccine trial following the release of trial data, 
well before it was incorporated into either World Health Organisation or national 
guidelines. Subsequent trials that enrolled HIV negative men from areas with 
generalised epidemics, however, have not necessarily followed suit. The Partners 
PrEP study had a detailed protocol concerned with providing information and 
facilitating access to services, but as discussed in Pt 2 Chapter 4, Standard of 
prevention in the real world access depended on government programs, and this 
happened faster in Kenya than in Uganda. The TDF-2 trial provided information on 
medical male circumcision once the Botswana government made its recommendation 
in favour of the practice. HPTN 052 did not provide any systematic information or 
referral regarding male circumcision at all. 
 
The United States’ Food and Drug Administration’s approval of oral 
tenofovir/emtricitabine PrEP is discussed in Pt 2 Chapter 4, Standard of prevention in 
the real world, Pt 3 Chapter 3 Ethical considerations in determining standard of 
prevention packages for HIV prevention trials, Pt 3 Chapter 1 Ethics of ARV-based 
prevention and Part 3 Chapter 4, It’s time.  Several ‘demonstration sites’ have been set 
up in the US to both provide PrEP and to monitor its use in terms of efficacy, 
adherence, toxicities and impact on HIV risk.  
 
The other countries that participated in the iPrEx and Partners PrEP trials, upon which 
the FDA approvals was based, have made no move to approve PrEP, though short-
term access programs have been put in place, as detailed in Mind the gap and 
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demonstration sites have commenced in Kenya and Uganda, with further sites planned 
in Brazil, Kenya, Nigeria and South Africa (AVAC Report 2012). This raises a set of 
compelling questions about appropriate technology, the commitment to transform 
successful research into programmatic interventions in the communities that 
participated in that research and evidentiary standards. To complicate matters, 
following the success of iPrEX, Partners PrEP and TDF-2, two subsequent trials 
featuring PrEP in African women have since failed due to very low adherence, giving 
rise to speculation that a daily preventative pill regimen may be inappropriate for at-
risk some communities or populations. 
 
Treatment-as-prevention has been implemented in the US, in that the federal ARV 
guidelines have changed to recommend treatment upon diagnosis of HIV infection 
(Panel on Antiretroviral Guidelines for Adults and Adolescents. 2012). In Zambia, the 
HIV positive partner in a serodiscordant relationship can access ARV irrespective of 
CD4 count, and Rwanda and Mozambique are moving towards this. In Britain and 
Europe, guidelines promote ‘considering’ ARV irrespective of CD4. China has an 
official treatment-as-prevention strategy for sero-discordant couples. Elsewhere, a 
range of countries including Australia4 promote ARV access at CD4 counts between 
350 and 500 (WHO 2012).  
 
Aim 5. To ask whether there are ethical issues that arise from the empirical research 
that are not present in the current normative literature. 
One of the key findings of this study, discussed in Pt 3 Chapter 1, Ethics of medical 
care and clinical research, was that that the principal investigators expressed 
                                                 
4 There are current advocacy efforts aimed at removing any CD4 limit to ARV access in Australia. 
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considerable identification with the idea of a therapeutic obligation to trial 
participants – or more broadly, to the communities that facilitated the trial, including 
individuals who volunteered but were ineligible due to pre-existing HIV infection. 
The identification of the ‘screened out’ is a significant case in point, as the perceived 
obligation to this group is built on  doctor-like moral premise that care is owed to 
those who most need it, rather than stratifying obligations by the depth of the 
researcher/participant relationship. 
 
For researchers establishing projects in host countries, negotiating the ways that the 
research site can support existing infrastructure and provide health services in a way 
that complements rather than replicates local service provision was central to their 
understanding of their work. For researchers who lived and worked in communities in 
which they conducted research, HIV prevention and care were part of a continuum 
rather than disparate activities. For both, the ‘therapeutic orientation’ in HIV 
prevention trials  appeared indivisible from competent research practice, which 
challenges the school of bioethics that seeks to further distinguish the activities and 
goals of research from those of clinical care (e.g. Miller and Brody 2003; Miller and 
Joffe 2011). Provision of routine primary care in resource-limited setting can 
ultimately save lives, in addition to the instrumental value of earning the trust that is 
essential to run such trials.  
 
While researchers were clear that answering the research question remained 
paramount, the process of conducting a large-scale HIV prevention trial involves 
complex negotiation with communities and existing health services and ultimately 
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impacts on the health status of the communities involved and on the surrounding 
health infrastructure. 
 
These findings are consistent with the concept of clinical research in lower income 
countries operating as a health intervention that delivers health goods for participants 
rather than merely as an experiment that produces outcomes in terms of knowledge. 
 
What does this thesis add? 
This thesis contributes to the existing empirical on standards of care in HIV 
prevention trials in the papers Pt 2 Chapter 3, Ethics of medical care and clinical 
research, Pt 2 Chapter 4 Standard of prevention in the real world, and Pt 2 Chapter 5 
Mind the gap. The first two papers provide qualitative data on how principal 
investigators report making key decisions about ethically sensitive standard of 
prevention and care issues, with qualitative data on ancillary care considered in the 
light of different models proposed in existing ethics literature. Mind the gap is the 
first comprehensive account of post-trial access to successful products in the context 
of HIV prevention, and it highlights what experience proved to be the most effective 
process for ensuring access to as-yet unapproved products. This is likely to be useful 
for researchers planning HIV prevention trial who seek to minimise the access 
problems that other researchers have experienced, as documented in this paper.  
 
This thesis also makes a conceptual, and normative, contribution to the literature. 
Pt 3 Chapter 1, Ethics of ARV-based prevention argues that not only is ARV-based 
prevention justified in terms of both individual and public health ethical frameworks, 
but that each has specific validity in different circumstances, and addresses particular 
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moral claims of individuals and community. Accordingly, each strategy has a place – 
PrEP for HIV negative people at very high risk of HIV acquisition who are 
inadequately served by exiting technologies, and treatment as prevention for the 
sexual partners (whether regular or casual) of HIV positive people. 
 
Pt 3 Chapter 2, How good is good enough, provides a critical analysis of the 
evidentiary regimes that determine drug licensure. It also criticises Freedman’s 
definition of clinical equipoise on the basis that it is an evidence-free social standard 
prone to manipulation in instances where the experts have conflicts of interest. This 
analysis has already been used to support the activist group Warning, which seeks to 
close the placebo arm in the French trial Ipergay, which tests intermittent PrEP in gay 
men (Olivier Jablonski, personal email communication 8 November 2012). 
 
Finally, Pt 3 Chapter 4 It’s time makes a clear and carefully nuanced argument that 
given the both the acknowledged difficulties of PrEP adherence and its high 
biological efficacy, that PrEP should be the comparator for testing promising new 
experimental interventions. This would both enable further studies of the factor that 
affect PrEP adherence and how they may be improved and establish whether or not 
other experimental interventions offer a real improvement in terms of outcomes. 
 
Clinical trials ought not to be the primary means of delivering health care and 
prevention justice in countries with endemic HIV. Trials that involve hundreds or 
thousands of people are however major social enterprises that affect the communities 
in which they are situated, as well as the participants themselves. While the primary 
purpose of a trial is to answer a research question, the impact of a trial goes beyond 
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that – it can increase the research literacy and skill base of the community and 
strengthen health care infrastructure, for example, and well as directly providing 
services.  
 
Surprising as it is that two trials have shown no additive effect from PrEP (the VOICE 
and Fem-PrEP trials where adherence rate were so low that the experimental 
intervention was futile), it is in some respects the adherence problem associated with 
PrEP that makes it a good comparator. It is fair to test a promising long-acting 
intervention of unknown efficacy against one that has high efficacy, but depends 
entirely upon excellent adherence for effectiveness.   
 
We need to know what works to prevent HIV acquisition and how to maximise the 
uptake of effective interventions. To continue to test new interventions against 
placebo at a time when there are imperfect but efficacious interventions like PrEP 
available exploits the vulnerability of trial populations for the future benefit of others. 
 
Depriving the people at highest risk of HIV acquisition of proven effective prevention 
options is not the way to obtain prevention justice.  
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This proposed research program will examine the interface between ethical constructs at a 
personal and societal level and a range of issues related to infectious disease control. It will 
address three distinct, but related issues in sexual health: the ethics of mass drug 
administration, personal ethics and sexual health, and the ethics of sexual representation.  
Aims 
1. Mass drug distribution: This project will explore the acceptability and feasibility of 
population-based distribution of drugs for endemic curable sexually transmissible 
infections (STIs) and pre-exposure prophylaxis for HIV. It will address the timely 
question of whether mass drug administration – an intervention proposed in populations 
at high risk of STIs, HIV and parasitic disease acquisition – is an acceptable and 
appropriate mechanism for controlling endemic STIs and their consequences in selected 
populations. 
2. Personal ethics and understandings of sexual health: This project will ask how people 
at high risk of STIs understand ‘sexual health’, how they formulate their personal sexual 
ethics, and how this influences their sexual attitudes and practice.   
3. Ethics of sexual representation: This project will consider how participants perceive 
mass media representations of bodies and sexuality, including pornographic genres, to 
affect their sexual attitudes, practice, ethics and self-image.  
Rationale: These questions are important for policy development, particularly as it relates to 
the design and development of targeted sexual health interventions. Findings will guide such t 
interventions, ensuring they are framed in ways that make sense to the people for whom they 
are designed, avoid reinforcing negative stereotypes.  
Background 
1. Mass drug administration for curable STIs.  
Mass drug administration is defined as the provision of a pharmacological agent that is 
therapeutically active against a particular infection to all members of a population, regardless 
of the individual presence of infection, with the goal of reducing transmission and prevalence 
of infection in the population.  The strategy has appeal when health authorities are faced with 
endemic infections that do not respond to other forms of prevention, and or conventional 
approaches to treatment that target those in whom infection has actually been diagnosed. 
They are also controversial because they are seen as taking away autonomy of both patient 
and clinician, and undermining the individual’s role and responsibility in disease control. 
Whether or not this loss of autonomy is balanced by the health benefits of reducing STI rates, 
is ultimately not a call that can be made by policy makers from outside the affected 
communities – these communities need to debate the issues and contribute to making a 
decision based on their own value systems.  
Internationally, mass drug administration is widely used for endemic parasitic 
diseases. In Australia its role has so far been limited to endemic trachoma in remote 
Aboriginal communities, but it has been variously proposed and investigated for sexually 
transmitted infections, scabies and other conditions. However, there has been little research 
on attitudes and perceptions related to mass drug administration, either in Australia or the 
Asia-Pacific region. 
Prior research also shows that mass drug distribution can control endemic STIs (e.g. 
Bollen et al 2010, Wiet al 2006; Mayaud and Mabey 2004; Wawer 1999). Mass drug 
distribution for STIs is an ‘elimination of choice’ public health strategy that requires strong 
justification to balance the diminution of autonomy that such a strategy necessarily involves. 
Other values may be more important than autonomy in particular circumstance, however, 
such as the lack of stigma associated with a community-wide program rather than 
individualised diagnosis and treatment of a disease perceived to be stigmatised. A mass drug 
distribution strategy cannot succeed without community consent. Its feasibility depends on 
whether communities will use the intervention, and recent experience in HIV research shows 
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that communities may now take up pill-taking intervention when there is no evident disease 
(Marrazzo et al 2013; van Damme et al 2012).  
2. Understandings of sexual health. 
 How people understand their responsibility to sexual partners and how they then enact these 
understandings is critical to the control of STIs and HIV. Between 1975 and 2002, eight 
different definition of ‘sexual health’ have been identified in the literature, with more recent 
ones adding concepts of mental health, responsibility and sexual rights (Edwards and 
Coleman 2004). Concepts of personal responsibility, shared responsibility and ‘special’ 
responsibility have been debated at length over the three decades of the HIV epidemic (e.g. 
Bayer 1996, Adam 2005) but changes in treatment efficacy and the relationship between 
treatment and prevention have changed the way that HIV is understood, which may impact 
on ethical deliberations.   
3.Relationships between representations of sex and sexuality in relation to sexual health. 
Representation of sexual practice is a vexed issue in health. Pornography has been linked 
with social harm in some studies (e.g. Perrin et al 2008), but exonerated from it in others 
(Luder et al 2011).  Critiques of health promotion campaigns and advertising generally, 
however, show that non-sexually explicit material may also be objectifying, demeaning and 
shaming (Carter et al 2011), or, conversely, portray idealised and exoticised images that may 
be experienced as deeply disenfranchising (Borgerson, J. L. and Schroeder, J. E. 2005). 
Sexual representation has been implicated in public health interventions in Australia and the 
US, including banning of pornography under the Northern Territory Intervention and the LA 
county law banning the making of pornography in which condoms are not used by the actors 
(Grudzen and Kerndt 2007). Sexualised representation is frequently used in health promotion 
targeting gay men, including images taken directly from pornography (Batrouney, personal 
communication) which raises profound ethical questions about objectification in health 
promotion. Strong negative connotations have been alleged between explicit pornography 
and sexual abuse, and censorship of such material has formed a part of the controversial 
Northern Territory Intervention that commenced under the Howard Government (Human 
Rights Watch 2007). Whether or not this aspect of the intervention was justified is unknown, 
however, and in addition, there are other genres, such as romance fiction, music videos and 
mass media, for example, that could have negative impacts upon understandings of gender 
roles, identity and sexual practice (Borgerson, J. L. and Schroeder, J. E. 2005).  
Proposed research program  
I will initiate and undertake a collaborative research program using qualitative research 
methods to investigate:  
1. The understanding and perception of mass drug administration strategies; and the 
barriers and incentives to the uptake of the mass drug administration strategies for 
different infections (STIs, HIV and parasitic diseases) and populations (gay men, 
women involved in sex work and communities in the Pacific region). 
2. Understandings and perception of sexual health and sexual health ethics; and 
3. Sexual representation and its perceived impacts upon self-image, personal ethics, 
sexuality and sexual practice.  
Methods 
Each element of the program will involve interviews and focus groups with members of 
communities at high risk of STIs, HIV or parasitic disease acquisition, predominantly gay 
men and communities in the Pacific region including female sex workers. The mass drug 
distribution component will also involve interviews and focus groups with policy makers, 
clinicians and representatives of affected communities.  
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The sexual health and personal ethics component will use the eight different 
definitions of ‘sexual health’ identified by Edwards and Coleman (2004) to prompt 
discussion of key concepts including sexual rights, agency and responsibility. 
The sexual representation component will recruit participants from communities who 
read gay and lesbian print media, and participants will be asked to view and respond to a 
range of images, including health promotion campaigns that use imagery sourced from 
pornography, and mainstream advertising for vodka and hosiery that includes sado-
masochistic imagery and sexual violence. Analytic categories and concepts defined by Carter 
et al (2011), and Borgerson and Schroeder (2005) will also be used in the analysis of the 
ethics of sexual representation. 
Reference groups consisting of members of the communities to be included in the 
research will be formed to guide the research, and this will occur in a timely fashion so that 
the reference groups can have real and meaningful input into the design of the research tools, 
in particular the semi-structured interview protocol.  Involving the relevant communities in 
discussion about the proposed program and taking heed of their responses is a respectful and 
appropriate way of addressing ethical issues in sexual health. 
Data will be coded using NVivo9 software and analysed using an inductive grounded 
theory approach. Descriptive data will be analysed using three different ethical constructs: the 
Nuffield public health stewardship approach (Nuffield Council of Bioethics 2007), principle-
ism (Beauchamp and Childress 1994) and Martha Nussbaum’s capabilities approach (2000).  
Each of these three ethical frameworks seeks to balance communitarian and individual 
benefits. 
Significance 
1. This mass drug distribution component of this proposal will answer a question of public 
health significance that is in some respects confounded by its ethical sensitivity. The ethical 
issues around pre-exposure prophylaxis (PrEP) for HIV and population-based presumptive 
treatment are quite distinct. With regard to PrEP, the issue is whether provision of this form 
of HIV prevention to individuals at particularly high risk of HIV acquisition could result in 
community harm through the undermining of safe sex cultures and a growing dependency 
upon a prevention strategy of lower biological efficacy than condom-based prevention. The 
issue with population-based STI treatment is that it undermines individual agency and 
subjects some individuals to an unnecessary pharmacological intervention, with its attendant 
risks, for the presumed benefit of others. While there is evidence that PrEP is biologically 
effective (Grant et al 2010, Anderson et al 2012,  Baeten et al 2012), it has also failed in some 
trial settings due to poor compliance (van Damme 2012, Marrazzo 2013). This raises an 
additional ethical issue of appropriate health resource allocation. 
2. Enquiry into the meaning of sexual health and sexual health ethics is necessary if we are to 
understand the complexity of human sexual behaviour. This study explores ethical 
frameworks perceived and described by participants –their own, and those they perceive to be 
dominant in their social worlds, prompted as necessary with key concepts in sexual health 
definition that have emerged since the first (now supplanted) definition adopted by the World 
Health Organisation in 1975. The results of this study will inform other targeted health 
interventions. 
3. This study will address the question of how participants view sexual representation, both as 
targets of advertising and/or as consumers of pornography if appropriate and their perceptions 
of how this affects their sexual identity and practice.  
Sexual health research is sensitive and requires a partnership approach with the communities 
in question. Specific collaborative arrangements including reference groups will be put in 
place to ensure the relevance of the questions being investigated, the suitability of the 
recruitment processes, the appropriateness of ‘stakeholder’ representatives and the 
comprehensive dissemination of findings.  Importantly, the reference groups will be involved 
in discussing the final interpretation of the data, the weighing up of the benefits and harms to 
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determine the appropriate course of action with regard to whether mass drug distribution 
should go ahead. 
Insights provided by this research program will facilitate better targeted health 
interventions. The specific component that addresses the acceptability of mass drug 
distribution will provide a direct answer as to whether this approach to STIs is acceptable and 
thus potentially feasible, or whether other approaches should be prioritised. The results of the 
mass drug dissemination component will inform future policy and funding decisions 
regarding targeted sexual health interventions for populations at high risk in Australia. These 
data will also provide important insights into the community concerns that will be relevant, 
though not necessarily directly applicable, to policy makers considering mass drug 
administration in other settings. 
 The strength of open-ended qualitative research as an empirical ethics methodology 
is that it can produce surprising results that could not be foreseen by researchers, thus it can 
change the parameters of how particular issues are understood, and open up new realms for 
research. Qualitative research into sexual health conducted in one population will not produce 
results that can be extrapolated directly to other settings, however, but it may provide relevant 
insights. 
Priority  
Addressing HIV and other communicable, sexually transmissible infections is a health 
priority, addressed in six successive national strategies on HIV, two on STIs, and three on 
STIs and blood borne viruses in Aboriginal and Torres Strait Islander people. Incidence 
and/or diagnosis of these infections is rising, however. HIV incidence has increased by 8.2% 
from 2010 with the majority of infections in men who have sex with men; diagnosis of 
chlamydia increased by 7% from 2010 and diagnosis of gonorrhoea increased by 45% since 
2007. Infectious syphilis rates vary by state, but remain a problem both in men who have sex 
with men and Aboriginal populations (Kirby Institute 2012, 7-8). In the immediate Pacific 
region, women working in the sex or ‘entertainment’ industry who were not registered as sex 
workers had curable STI prevalence of 38% (Wi et al 2006). 
These data show an unacceptable disease burden in particular populations that may 
have serious social effects. Both chlamydia and gonorrhoea if left untreated are implicated in 
causing pelvic inflammatory disease and infertility (Haggerty et al 2010), while untreated 
syphilis can cause a range of serious health problems, can be transmitted congenitally, an 
increases risk of HIV acquisition. HIV, while treatable, is a life-long infection that is life 
threatening without treatment, or with inadequate treatment.  
Finding ways of intervening in cycles of infection that are acceptable and that enhance rather 
than diminish wellbeing is the ultimate sequelae of this research.  
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PARTICIPANT CONSENT FORM 
 
I, .............................................................................[PRINT NAME], give consent to my 
participation in the research project 
 
TITLE: Standards of care in HIV biomedical prevention research in the developing 
world: the negotiation of benefits 
In giving my consent I acknowledge that: 
 
1. The procedures required for the project and the time involved (including any 
inconvenience, risk, discomfort or side effect, and of their implications) have 
been explained to me, and any questions I have about the project have been 
answered to my satisfaction. 
 
 
2. I have read the Participant Information Statement and have been given the 
opportunity to discuss the information and my involvement in the project with the 
researcher/s. 
 
 
3. I understand that I can withdraw from the study at any time, without affecting my 
relationship with the researcher(s) or the University of Sydney now or in the 
future. 
 
 
4. I understand that my involvement is strictly confidential and no information about 
me will be used in any way that reveals my identity. 
 
 
5. I understand that being in this study is completely voluntary – I am not under any 
obligation to consent. 
 
 
6. I understand that I can stop the interview at any time if I do not wish to continue, 
the audio/video recording will be erased and the information provided will not be 
included in the study.  
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If you answered YES to the “Receiving Feedback Question (iii)”, please 
provide your details i.e. mailing address, email address. 
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Address:  _______________________________________________________ 
 
_______________________________________________________ 
 
Email: _______________________________________________________ 
 
 
 
 
Signed: ...............................................................................................................................  
 
Name:  ............................................................................................................................... 
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RESEARCH STUDY 
 Standards of care in HIV biomedical prevention research in the developing 
world: the negotiation of benefits 
 
PARTICIPANT INFORMATION STATEMENT  
 
You are invited to take part in a research study into Standards of care in HIV 
biomedical prevention research in the developing world: the negotiation of benefits. 
The object is to investigate the benefits provided to participants in HIV biomedical 
prevention research, and to tease out the factors that affect the negotiation of 
benefits offered to participants. The study is being conducted by Bridget Haire and 
will form the basis for the degree of Doctor of Philosophy at the University of Sydney 
under the supervision of Dr Chris Jordens, Senior Lecturer at the Centre for Values, 
Ethics and Law in Medicine (VELiM). 
 
If you agree to participate in this phase of the study, you will be asked to complete a 
questionnaire that will be emailed to you by the researchers. The questionnaire will 
ask questions regarding the process by which benefits to participants (standard of 
care, ancillary care and access to antiretrovirals) were determined in the study or 
studies in which you have been involved as a researcher, community liaison officer 
or ethical reviewer. The questionnaire will take about 15 minutes to complete. 
 
All aspects of the study, including results, will be strictly confidential and only the 
investigators named above will have access to information on participants. A report 
of the study may be submitted for publication, but individual participants will not be 
identified in such a report. It is possible however that the identity of some participants 
may be inferred by readers of the subsequent thesis or other reports of this research. 
This is unlikely to be a problem for you, as the study is investigating the basis upon 
which decisions were made, while the outcomes of those decisions are already in 
the public domain. 
 
Being in this study is completely voluntary and you are not under any obligation to 
consent to complete the questionnaire.  Submitting a completed questionnaire is an 
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indication of your consent to participate in the study.  You can withdraw any time 
prior to submitting your completed questionnaire.  Once you have submitted your 
questionnaire anonymously, your responses cannot be withdrawn. 
 
You may also be invited to participate in a second phase of this study, consisting of 
telephone interviews exploring in-depth the themes raised in the questionnaire. 
Completing the questionnaire does not oblige you in any way to participate in the 
second phase of the study. 
 
If you would like to know more at any stage, please feel free to contact Bridget Haire, 
PhD candidate, on +61 2 9036 3424, email bridget.haire@sydney.edu.au  or Chris 
Jordens, Senior Lecturer, on +61 2 9036 3406, email: chris.jordens@sydney.edu.au 
 
Survey link: http://www.surveymonkey.com/s/ethics_negotiation_of_benefits 
 
 
 
 
 
 
 
Any person with concerns or complaints about the conduct of a research study 
can contact the Deputy Manager, Human Ethics Administration, University of 
Sydney on +61 2 8627 8176 (Telephone); +61 2 8627 8177 (Facsimile) or 
ro.humanethics@sydney.edu.au (Email). 
 
This information sheet is for you to keep. 
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PARTICIPANT INFORMATION STATEMENT  
 
You are invited to take part in a research study into Standards of care in HIV 
biomedical prevention research in the developing world: the negotiation of benefits. 
The object is to investigate the benefits provided to participants in HIV biomedical 
prevention research, and to tease out the factors that affect the negotiation of 
benefits offered to participants. The study is being conducted by Bridget Haire and 
will form the basis for the degree of Doctor of Philosophy at the University of Sydney 
under the supervision of Dr Chris Jordens, Senior Lecturer at the Centre for Values, 
Ethics and Law in Medicine (VELiM). 
 
If you agree to participate in this phase of the study, you will be asked to participate 
in an interview of approximately one hour duration during which you will be asked 
questions regarding the process by which benefits to participants (standard of care, 
ancillary care and access to antiretrovirals) were determined in the study or studies 
in which you have been involved as a researcher, community liaison officer or ethical 
reviewer. You will need to negotiate a convenient time with the study investigator.   
 
The interview will be recorded on audiotape. 
 
All aspects of the study, including results, will be strictly confidential and only the 
investigators named above will have access to information on participants. A report 
of the study may be submitted for publication, but individual participants will not be 
identified in such a report.  
 
It is possible that the identity of some participants may be inferred by readers of the 
subsequent thesis or other reports of this research. You will be de-identified with 
regard to your gender and institution, and the prevention modality and research 
location, except where the latter is salient to the research. The interviewer will 
discuss ways of further de-identifying your data during the course of your interview. 
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Participation in this study is entirely voluntary: you are not obliged to participate and - 
if you do participate - you can withdraw at any time. Whatever your decision, it will 
not affect your relationship with University of Sydney staff.  
 
You may stop the interview at any time if you do not wish to continue, the audio 
recording will be erased and the information provided will not be included in the 
study. 
 
 
When you have read this information, Bridget Haire will discuss it with you further 
and answer any questions you may have.  If you would like to know more at any 
stage, please feel free to contact Bridget Haire, PhD candidate, on +61 2 90363424 
or Chris Jordens, Senior Lecturer, on +61 2 9036 3406. 
 
 
 
 
 
 
Any person with concerns or complaints about the conduct of a research study 
can contact the Deputy Manager, Human Ethics Administration, University of 
Sydney on +61 2 8627 8176 (Telephone); +61 2 8627 8177 (Facsimile) or 
ro.humanethics@sydney.edu.au (Email). 
 
This information sheet is for you to keep. 
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RESEARCH STUDY 
 Standards of care in HIV biomedical prevention research in the developing 
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PARTICIPANT INFORMATION STATEMENT  
 
You are invited to take part in a research study into Standards of care in HIV 
biomedical prevention research in the developing world: the negotiation of benefits. 
The object is to investigate the benefits provided to participants in HIV biomedical 
prevention research, and to tease out the factors that affect the negotiation of 
benefits offered to participants. The study is being conducted by Bridget Haire and 
will form the basis for the degree of Doctor of Philosophy at the University of Sydney 
under the supervision of Dr Chris Jordens, Senior Lecturer at the Centre for Values, 
Ethics and Law in Medicine (VELiM). 
 
If you agree to participate in this phase of the study, you will be asked to participate 
in an interview of approximately one hour duration during which you will be asked 
questions regarding the process by which benefits to participants (standard of care, 
ancillary care and access to antiretrovirals) were determined in the study or studies 
in which you have been involved as a researcher, community liaison officer or ethical 
reviewer. You will need to negotiate a convenient time with the study investigator.   
 
The interview will be recorded on audiotape. 
 
All aspects of the study, including results, will be strictly confidential and only the 
investigators named above will have access to information on participants. A report 
of the study may be submitted for publication, but individual participants will not be 
identified in such a report.  
 
It is possible that the identity of some participants may be inferred by readers of the 
subsequent thesis or other reports of this research. You will be de-identified with 
regard to your gender and institution, and the prevention modality and research 
location, except where the latter is salient to the research. The interviewer will 
discuss ways of further de-identifying your data during the course of your interview. 
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Participation in this study is entirely voluntary: you are not obliged to participate and - 
if you do participate - you can withdraw at any time. Whatever your decision, it will 
not affect your relationship with University of Sydney staff.  
 
You may stop the interview at any time if you do not wish to continue, the audio 
recording will be erased and the information provided will not be included in the 
study. 
 
 
When you have read this information, Bridget Haire will discuss it with you further 
and answer any questions you may have.  If you would like to know more at any 
stage, please feel free to contact Bridget Haire, PhD candidate, on +61 2 90363424 
or Chris Jordens, Senior Lecturer, on +61 2 9036 3406. 
 
 
 
 
 
 
Any person with concerns or complaints about the conduct of a research study 
can contact the Deputy Manager, Human Ethics Administration, University of 
Sydney on +61 2 8627 8176 (Telephone); +61 2 8627 8177 (Facsimile) or 
ro.humanethics@sydney.edu.au (Email). 
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PARTICIPANT INFORMATION STATEMENT  
 
You are invited to take part in a research study into Standards of care in HIV 
biomedical prevention research in the developing world: the negotiation of benefits. 
The object is to investigate the benefits provided to participants in HIV biomedical 
prevention research, and to tease out the factors that affect the negotiation of 
benefits offered to participants. The study is being conducted by Bridget Haire and 
will form the basis for the degree of Doctor of Philosophy at the University of Sydney 
under the supervision of Dr Chris Jordens, Senior Lecturer at the Centre for Values, 
Ethics and Law in Medicine (VELiM). 
 
If you agree to participate in this phase of the study, you will be asked to complete a 
questionnaire that will be emailed to you by the researchers. The questionnaire will 
ask questions regarding the process by which benefits to participants (standard of 
care, ancillary care and access to antiretrovirals) were determined in the study or 
studies in which you have been involved as a researcher, community liaison officer 
or ethical reviewer. The questionnaire will take about 15 minutes to complete. 
 
All aspects of the study, including results, will be strictly confidential and only the 
investigators named above will have access to information on participants. A report 
of the study may be submitted for publication, but individual participants will not be 
identified in such a report. It is possible however that the identity of some participants 
may be inferred by readers of the subsequent thesis or other reports of this research. 
This is unlikely to be a problem for you, as the study is investigating the basis upon 
which decisions were made, while the outcomes of those decisions are already in 
the public domain. 
 
Being in this study is completely voluntary and you are not under any obligation to 
consent to complete the questionnaire.  Submitting a completed questionnaire is an 
indication of your consent to participate in the study.  You can withdraw any time 
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prior to submitting your completed questionnaire.  Once you have submitted your 
questionnaire anonymously, your responses cannot be withdrawn. 
 
You may also be invited to participate in a second phase of this study, consisting of 
telephone interviews exploring in-depth the themes raised in the questionnaire. 
Completing the questionnaire does not oblige you in any way to participate in the 
second phase of the study. 
 
If you would like to know more at any stage, please feel free to contact Bridget Haire, 
PhD candidate, on +61 2 9036 3424, email bhai0415@uni.sydney.edu.au; or Chris 
Jordens, Senior Lecturer, on +61 2 9036 3406 email cjordens@med.usyd.edu.au 
 
Survey link: http://www.surveymonkey.com/s/HIV_NPT_standards_of_care 
 
 
 
 
 
 
 
 
Any person with concerns or complaints about the conduct of a research study 
can contact the Deputy Manager, Human Ethics Administration, University of 
Sydney on +61 2 8627 8176 (Telephone); +61 2 8627 8177 (Facsimile) or 
ro.humanethics@sydney.edu.au (Email). 
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PARTICIPANT CONSENT FORM 
 
I, .............................................................................[PRINT NAME], give consent to my 
participation in the research project 
 
TITLE: Standards of care in HIV biomedical prevention research in the developing 
world: the negotiation of benefits 
In giving my consent I acknowledge that: 
 
1. The procedures required for the project and the time involved (including any 
inconvenience, risk, discomfort or side effect, and of their implications) have 
been explained to me, and any questions I have about the project have been 
answered to my satisfaction. 
 
 
2. I have read the Participant Information Statement and have been given the 
opportunity to discuss the information and my involvement in the project with the 
researcher/s. 
 
 
3. I understand that I can withdraw from the study at any time, without affecting my 
relationship with the researcher(s) or the University of Sydney now or in the 
future. 
 
 
4. I understand that my involvement is strictly confidential and no information about 
me will be used in any way that reveals my identity. 
 
 
5. I understand that being in this study is completely voluntary – I am not under any 
obligation to consent. 
 
 
6. I understand that I can stop the interview at any time if I do not wish to continue, 
the audio/video recording will be erased and the information provided will not be 
included in the study.  
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7. I consent to: –  
 
i) Audio-taping YES  NO  
ii) Receiving Feedback YES  NO  
If you answered YES to the “Receiving Feedback Question (iii)”, please 
provide your details i.e. mailing address, email address. 
 
Feedback Option 
 
Address:  _______________________________________________________ 
 
_______________________________________________________ 
 
Email: _______________________________________________________ 
 
 
 
 
Signed: ...............................................................................................................................  
 
Name:  ............................................................................................................................... 
 
Date:  ............................................................................................................................... 
 
 
This article was downloaded by: [University of Sydney]
On: 28 April 2013, At: 23:51
Publisher: Routledge
Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House,
37-41 Mortimer Street, London W1T 3JH, UK
The American Journal of Bioethics
Publication details, including instructions for authors and subscription information:
http://www.tandfonline.com/loi/uajb20
Back to Basics in Clinical Research Ethics
Bridget Haire a
a University of Sydney,
Version of record first published: 26 Feb 2009.
To cite this article: Bridget Haire (2009): Back to Basics in Clinical Research Ethics, The American Journal of Bioethics, 9:3,
48-49
To link to this article:  http://dx.doi.org/10.1080/15265160802654194
PLEASE SCROLL DOWN FOR ARTICLE
Full terms and conditions of use: http://www.tandfonline.com/page/terms-and-conditions
This article may be used for research, teaching, and private study purposes. Any substantial or systematic
reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to
anyone is expressly forbidden.
The publisher does not give any warranty express or implied or make any representation that the contents
will be complete or accurate or up to date. The accuracy of any instructions, formulae, and drug doses should
be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims,
proceedings, demand, or costs or damages whatsoever or howsoever caused arising directly or indirectly in
connection with or arising out of the use of this material.
The American Journal of Bioethics
Back to Basics in Clinical Research
Ethics
Bridget Haire, University of Sydney
The goal of restoring some uniformity to international
guidelines about standards of care in research is a laud-
able one, but I remain unconvinced that Van der Graaf and
Van Delden’s (2009) proposed universal language will do
the trick. The standard of care debate in the late 1990s was, I
contend, more about the fundamental values that underlie
clinical research than about how to choose the appropri-
ate control arm in a randomized controlled trial, despite
the obsessive focus that was devoted to the latter. Instead
of rewording clauses (again) in an attempt to find a com-
promise between dyed -in-the-wool universalists and rela-
tivists, I suggest that a clear statement that the interests of
research participants must always take precedence over the
interests of science and society with regard to research de-
sign provide maximum protection with sufficient room for
exceptional cases to be justified according to their merits.
In 2000, amidst great pressure to change ethical guide-
lines stipulating that the experimental therapies in clinical
trials needed to be tested against the “best proven” ther-
apeutic, preventive, or diagnostic method—an objective,
clear standard—the Declaration of Helsinki changed to the
similar but slightly more ambiguous wording, the “best cur-
rent” method (Wolinsky 2006). This uneasy, and rather un-
clear, compromise was insufficient for the purposes of the
relativist faction, who wanted ethical imprimatur to con-
duct research in the developing world to meet identified
health needs, which may nevertheless fall below therapeu-
tic standards in the developed world (Levine 1999).
Universalists opposed the weakening of the partici-
pants’ protection that this entailed, arguing that it created a
double standard, and most importantly subjugated the best
interests of the research participants to those of science and
society (Lurie and Wolfe 1997; Schu¨klenk 2004).
This ideological clash resulted in the reviewing and
rewriting of a swathe of guidelines to include wording such
as “the highest attainable,” “the best available,” “the best
current,” “a proven” or “an established effective treatment.”
The aim of these revisions was to provide decent subject pro-
tection but allow some regard for the context and the aims
of research to influence study design (Mackin 2001).
Van de Graaf and van Delden’s (2009) suggested re-
placement wording, which requires that participants in a
control group should be assured of a treatment of “net clin-
ical relevance for a specific condition that is under study for
the population that the control group represents” is clear,
precise and objective. I am unconvinced, however, that it
offers any real advantage over the former Helsinki stan-
Address correspondence to Bridget Haire, University of Sydney, NSW, Australia, 2006. E-mail: bhai0415@mail.usyd.edu.au
dard, the “best proven,” and on that basis I suspect it will
be rejected by anyone seeking to find leeway in research
design.
Van der Graaf and van Delden (2009) begin with two
questions. They ask whether a placebo is permissible where
a proven or known effective therapy exists and whether it
is acceptable to provide the control group in a developing
country a level of care that is different or lower than the
level that would be provided in the sponsoring country.
I suggest that the answers to these questions are already
established: it is permissible to use a placebo despite es-
tablished proven therapy when there is no increased risk
or harm associated with it—that is, when the option of ‘no
treatment’ is a valid therapeutic strategy. As to when it is
acceptable to use a different standard in a developing coun-
try to that provided in the sponsoring country, the obvious
answer is when the standard in the developing country is
better for that population.
Solomon Benatar wrote in 1998, “It seems somewhat
imperialistic to suggest that a drug regimen shown to be
of value in some of the wealthiest countries in the world is
necessarily the best proven regimen for some of the poor-
est” (221). In the context in which he wrote it, I disagree,
in that he was apparently suggesting that the 076 regimen
to reduce vertical HIV transmission might bring unforeseen
harms—other than its rapacious cost—to developing world
populations. In principle, however, he is right. ‘Care’ con-
tains sociocultural and well as medical elements, and these
aspects should certainly change in ways that are appro-
priate to context. The risk/benefit analyses for some pro-
cedures depend on the context in which care is delivered,
with caesarean delivery being an obvious case-in-point—if
a woman intends to have more children and cannot gener-
ally access hospital care, it may be a last resort only, whereas
the recommendation may be different for a woman in other
circumstances.
To illustrate the dilemmas of developing world research,
Van der Graaf and van Delden (2009) cite the example of
women in the contentious zidovudine trials not receiving
the longer course because they would have been "forced...
to abstain from breastfeeding” (35), which they describe
as potentially “violating local [cultural] healthcare norms”
(35). I agree that requiring women to artificially feed their
infants in contexts where such feeding may be unsafe or un-
acceptable is highly problematic, but this example requires
more analysis. Women in the PACTG 076 trial artificially
fed their infants, and this method was a contributing factor
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to the low rate of HIV transmission postnatally, but it was
not an element of the treatment protocol per se (Connor
et al. 1994). There was no reason to suppose that a longer
course of AZT prenatally, nor indeed as supplied to infants
as post-exposure prophylaxis as stipulated in the 076 reg-
imen, would be any riskier for either mother or baby in a
breastfeeding context than the shorter zidovudine courses.
Therefore I suggest that testing the 076 regimen against
other, simpler regimens, in breastfeeding women would
have been both scientifically and ethically valid.
We also need to be careful about invoking ’violation of
cultural healthcare norms’, given that developing countries is
a phrase that involves an enormous range of social, cultural,
economic and healthcare contexts, and that “culture” is a
dynamic entity. Medicalized male circumcision may also
’violate healthcare norms’ in some communities, but those
norms can and arguably might need to change in response
to HIV prevention imperatives. Obviously cultural change
cannot be forced and needs to evolve from within rather
than without, but it is possible—witness the widespread
uptake of condoms in gay communities in the 1980s.
The goal of clinical research in the developing world
must be to address health disparities—this is a point on
which relativists and universalists agree. The difference, as
illustrated in the debate over vertical transmission trial a
decade ago, is how to achieve that.
The placebo-controlled short-course zidovudine trials
were justified by some on the basis of putative outcomes to
be enjoyed by later populations rather than the participants,
and the harms that befell the participants—the higher than
necessary rate of HIV transmission to infants—was ratio-
nalized as being not directly caused by the research, in that
it would have occurred without the intervention. No direct
benefits were granted to the women who had the misfor-
tune to be randomized to placebo—neither they nor their
infected infants were offered treatment, and there was no
provision for ensuring that they had access to the proven
regimen in any subsequent pregnancy. Indeed, the proven
short-course zidovudine regimens were not widely imple-
mented in the countries that ran the trials. While the reasons
for this are complex and involve the development of cheaper
and more effective nevirapine regimen, a consequentialist
rationale demands to be judged by its consequences—and
the short-course zidovudine failed to be implemented in the
populations in which it was studied.
As Florencia Luna (2001) points out, the economic and
political variables that determine access to therapies post-
research are hard to control. The difficulty of achieving the
expected benefits of research is in many respects as fore-
seeable and outcome as the harms that occur through not
giving adequate care. How then can we justify conduct-
ing research that sacrifices the best interests of research
participants—involving some deaths, and allowing other
to go on with what Luna describes as the illness and hand-
icaps produced by that research—to some uncertain end?
The utilitarian spirit of this endeavor is in stark contrast to
the guiding principle from the Declaration of Helsinki to
place the interests of the subject above that of science and
society.
To that end, I advocate that instead of quibbling over
the wording of procedural clauses about specific trial de-
sign in guideline documents, that we re-embrace the pro-
tection of the research subject and the promotion of his or
her best interests as being the principle obligation of the re-
searcher. With that as the highest priority, “best proven”
would once again become the default control arm stan-
dard, with variation only occurring when it was demon-
strably in the subjects best interests—not the interests of
the population more broadly, or the scientific endeavor—to
do so. 
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Treatment-as-Prevention Needs to Be
Considered in the Just Allocation
of HIV Drugs
Bridget Haire, University of Sydney
Since the beginning of the HIV epidemic, HIV advocates
have resisted the competitive compartmentalisation of HIV
programs into treatment versus prevention. Early resistance
to HIV testing in gay male communities in the 1980s was
predicated on the fact that in the absence of treatment,
knowledge of asymptomatic HIV positive status could only
be harmful (Bayer 1989). Once treatments were identified
and made available, HIV testing became part of self-care,
and the ethos thatHIV research needed to address the needs
of people living with the virus was enshrined in documents
such as the Paris Declaration (1994). Nevertheless, polariz-
ing of treatment versus prevention has persisted in some
quarters.
Johansson and Norheim (2011) argue that the use of the
Atkinson index may help to clarify the ethics of health pol-
icy choice. They demonstrate the strengths of this approach
with four hypothetical cases studies where there are legit-
imate conflicts over prioritizing access to HIV resources:
urban versus rural treatment access, HIV prevention ver-
sus treatment, treating adults compared with children, and
treating more people compared with providing more ex-
pensive (complex) care.
In this commentary I consider how new research data
that show that early HIV treatment has a significant treat-
ment effect impact the treatment–prevention dichotomy,
and I argue that there is a deceptive simplicity about the
Atkinson index that may promote poor decision making,
using the real-life examples of mother-to-child prevention
programs, and the provision of more expensive second-line
therapy to people with HIV who have developed drug re-
sistance.
HPTN 052: TREATMENT AS PREVENTION
Paradoxically, new research results demonstrating the effi-
cacy of HIV treatment as prevention may initially inten-
sify health policy debates about pitting cost efficacy of
HIV prevention against HIV treatment for those most in
need—those with symptomatic disease.
HPTN 052 was a randomized controlled trial that
showed that providing treatment to HIV-positive people
1. CD4 cell counts provide a marker of immune function. They are progressively destroyed by HIV replication, and when the count
drops to below 200, the risk of opportunistic infections rises exponentially. A person with an intact immune system would have in excess
of 500 CD4 cells per cubic millimeter of blood.
Address correspondence to Bridget Haire, Centre for Values, Ethics and the Law in Medicine, University of Sydney, Camperdown NSW,
2050, Australia. E-mail: bridget.haire@sydney.edu.au
prior to severe immune damage (at or above 350 CD4 cells1)
was 96% effective in reducingHIV acquisition by their HIV-
negative partners (Cohen et al. 2011). These results are wel-
come and provide an additional rationale for the scale-up
of access to life-prolonging treatment in the resource-poor
world.
At a time of shrinking HIV budgets on a global scale,
however, it is inevitable that debates have begun as to
whether the preventive effect of early treatment means that
scarce treatment resources in developing countries will be
diverted away from the sick toward expensive programs
to test, and subsequently treat, people with asymptomatic
HIV infection.
A person with a CD4 count of 350 or above is usually
well, without symptoms of immune suppression, whereas
in resource-poor countries, many people only seek HIV
treatment when they are experiencing symptoms of HIV
disease, usually when the CD4 cell count is well below 200.
If treatment is a finite resource and there is an additional pre-
ventive benefit in treating a personwith a higherCD4 count,
that potentially deprives the sick person of life-prolonging
treatment. In this schema the principle of providing treat-
ment to those who would benefit most—the sickest—thus
comes into conflict with the principle of health maximiza-
tion,where both the personwithHIVandhis or her partners
may benefit.
Denying treatment for the ill in order to prioritize those
with the same condition at an asymptomatic stage, however,
would endanger HIV programs. Though HIV is a stigma-
tized disease, effective antiretroviral therapy disaggregates
HIV infection and death. Its impact is never as clear aswhen
a sick person commences treatment and becomes well, the
so-called “Lazarus” effect (Koenig et al. 2004). The prospect
of treatment is what makes testing acceptable. Leaving the
sick to diewhen they could access effective treatmentwould
thus profoundly destabilize HIV programs.
I suggest that the slow uptake at operational level of the
2010 WHO Antiretroviral Treatment Guidelines attests to
the primacy of treating the sick first. While the 2010 Guide-
lines raised the CD4 eligibility from 200 to 350 in response
to cohort studies showing benefits of earlier treatment prior
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Problems With Prioritization
to the evidence provided by HPTN 052, those in medical
need of treatment remained the priority.
But does this competition for treatment between the
symptomatic person with HIV and the asymptomatic
present a realistic picture of the challenges of resource dis-
tribution in the resource-poor world? I would argue that
it does not. A meta-analysis of 28 trials looking at pre-
antiretroviral care in Sub-Saharan Africa showed that more
than two-thirds of those diagnosed as HIV positive but not
yet treatment eligiblewere lost to care (Rosen and Fox 2011).
Hence, the investment in identifying people with HIV is
wasted if that does not lead to accessing treatment. If the
diagnosis leads to treatment, however, the return on the
investment in testing infrastructure is potentially twofold,
both in sustaining the productive life of the healthy person
with HIV, and in potentially protecting his or her partner
from infection. The new data show that treating at a higher
CD4 count does not have to occur at the expense of treating
the sick to make economic, as well as moral, sense.
A further concern with the implementation of HPTN
052 into health policy is that people in stable serodiscordant
relationships (where one is HIV positive and the other neg-
ative, as in the trial population) may be prioritized for early
treatment, with its attendant benefits, over those who have
less stable relationships or are single (Mayer 2011). This is
clearly challenging from a health equity perspective. Think-
ing about the mechanism of the preventive effect of earlier
treatment, it reduces infectivity. The HIV-negative sexual
partner of an HIV-positive person taking treatment, who
does not use other protection such as condoms, would ben-
efit from that reduced infectivity. While it may be difficult
to demonstrate this effect outside a stable relationship for
logistical reasons, this should not alter the biological benefit
to any partner, whether casual or regular.
CHEAP VERSUS EXPENSIVE INTERVENTIONS
Johannson and Norheim also apply the Atkinson index
to the dilemma of whether to invest in low-cost drugs
or high-cost drugs, in a scenario that is analogous to the
resource allocation decisions about the level of treatment
supplied to prevent mother-to-child transmission (PMTCT
programs), and the supply of more expensive second-line
HIV treatment for people failing2 first-line treatment. Again
Johannson and Norheim present these as ethical dilem-
mas related to potentially conflicting principles: health
maximization, which favors quantitative outcomes, and
health equity, which favors equitable distribution of health
goods/equality in the age of death.
The trouble with both PMTCT programs and allocation
of second-line therapy is that they are rather more complex
than a choice between taking one pill (the cheap option) and
taking two to achieve the same end.
Mother-to-childHIV transmission in high-income coun-
tries has reduced to below 2% through voluntary antena-
2. “Failing” meaning that the first-line drugs are not suppressing
viremia.
tal testing, provision of optimal combination antiretrovi-
ral therapy, and alternatives to breastfeeding. According
to UNAIDS estimates, however, only an estimated 53%
of pregnant women with HIV received any therapy, and
30% of these receive a cheap and efficient, but subopti-
mal, therapy—a single does of nevirapine (UNAIDS 2010,
78–80).
The simplicity and cost of the nevirapine regimenmade
it attractive from the perspective of health maximization
when antiretroviral roll-out in low income countries was in
its infancy. A decade or so on, the shortcomings are stark:
Drug resistance can develop in the mother from a single
dose, which then dramatically reduces its effectiveness for
subsequent pregnancies; drug resistance to nevirapine im-
pacts on any subsequent antiretroviral therapy provided for
the mother’s own health, and nevirapine is less effective in
preventingHIV transmission than a complex regimen in the
first place (Johnson et al 2005). Mothers with drug-resistant
virus are more likely to fail first-line therapy, meaning ei-
ther that they require more expensive second-line therapy,
or that they die, and potentially leave orphans who are less
likely to survive without a mother.
Similarly, constraining the use of second-line therapy in
order to maximize health (supplying more first line ther-
apy to more people) creates more complex health issues
in the foreseeable future. Second-line HIV therapy is de-
signed to be efficacious in people who have resistance to,
or intolerance of, first-line therapy. Failure to switch a pa-
tient onto second-line therapy both seriously jeopardizes
her health (squandering the initial investment in first-line
therapy) and promotes the development of drug-resistant
HIV, which is transmissible and has the potential to render
first-line therapy ineffective.
Treatment-as-prevention, PMTCT programs, and first-
and second-lineHIV therapy raise complex issues for health
policy in the context of limited resources, and indeed, I
have not even touched on pertinent implementation issues.
There is dynamic interplay among donors, governments,
and communities about what is an acceptable minimum
standard, with universal access being the stated goal. In
the meantime, it is necessary to be transparent about the
rationale for prioritization, and that discussionneeds to take
place with a full understanding of both the social and the
public health consequences of inequitable or suboptimal
programs. 
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Abstract. The most recent estimates indicate that in 2011, 34million people were living with HIV, the majority in sub-
Saharan Africa. Even though the estimated number of new infections is decreasing, there remains an urgent need for new
prevention technologies, particularly those controlled by women and men who have receptive sex. Microbicides are
products designed to be applied vaginally or rectally to prevent acquisition of HIV and other sexually transmissible
infections and, as such, provide a great hope for female-controlled HIV prevention. Oral prevention drugs are a more recent
development that also has great potential. The ﬁeld changed radically in 2010–2011 with the ﬁrst trials demonstrating
effectiveness of a microbicide and oral prevention drugs. The seventh biannual Microbicides conference, which took place
in Sydney, Australia, in April 2012, was the ﬁrst conference in this series since these new results and represented a
transition from the discovery phase of research to considerations of implementation. Researchers, advocates, community
representatives, funders and the media came together over 3 days to talk about the realities of implementation, particularly
in regard to challenges in adherence and funding, and also examined early ﬁndings for new prevention technologies. This
report of the 2012 International Microbicides Conference provides a summary of recent developments and ongoing
challenges in the ﬁeld of microbicides research.
Additional keywords: female-controlled prevention, HIV, oral prevention drugs, pre-exposure prophylaxis.
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Introduction
According to the latest estimates from UNAIDS, there were
2.5million new HIV infections in 2011, representing a decrease
of 20% compared with 2001.1 Nevertheless, the total number of
people living with HIVworldwide is estimated to have increased
to 34million in 2011,1 reﬂecting both the new infections and
the reduction in deaths due to improved access to antiretroviral
therapy.1 Globally, the proportion of women infected has
remained stable at 50%, but they represent the majority of
infections in sub-Saharan Africa (59%) and the Caribbean
(53%).1 The recent policy emphasis on the use of treatment
as prevention, driven largely by the ﬁndings of the HIV
Prevention Trials Network (HPTN) 052 trial released in
2011, will require a massive expansion of diagnosis and
treatment services, and will not protect the partners of those
whose HIV infection has not yet been diagnosed and controlled
by treatment.
In April 2012, the seventh conference in the biennial
Microbicides series, the 2012 International Microbicides
Conference (M2012), was held in Sydney, Australia. Its
objective was to consider new ﬁndings and their implications
in the ﬁeld of microbicides and oral pre-exposure prophylaxis
(PrEP) for HIV prevention. With support from the United States
National Institutes of Health Ofﬁce of AIDS Research, the Bill
andMelinda Gates Foundation and other agencies, the conference
attracted over 600 delegates from around the world, including
some 300 scholarship recipients, predominantly from sub-
Saharan Africa, the region most affected by the HIV epidemic.
The conference theme ‘From discovery to delivery’ reﬂected
the evolving nature of the ﬁelds of microbicides and oral PrEP.
Striking new developments since the previous conference in the
series (Microbicides 2010 in Pittsburgh) provided renewed
momentum after some earlier trial disappointments (see
Fig. 1 for a summary of recent HIV prevention trials). In the
second half of 2010, the Centre for the AIDS Programme of
Research In South Africa (CAPRISA) 004 trial showed that
tenofovir gel reduced the risk of infection in women using the
product, and the Preexposure Prophylaxis Initiative (iPREX)
trial demonstrated prevention success for daily oral tenofovir
and emtricitabine in gay men. During 2011, two new trials,
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Partners PrEP and Botwsana TDF/FTC Oral HIV Prophylaxis
Trial (TDF2), also found in favour of oral chemoprevention as a
prevention strategy for both heterosexual men and women,
although two other trials (FEM-PrEP and VOICE) failed to
ﬁnd beneﬁt for women, and a trial of tenofovir gel in one arm
of the VOICE study, using a daily dosing strategy that differed
from the one used in CAPRISA 004, also found no protection.
Along with the HPTN 052 trial, which showed that effective
treatment of people with HIV infection decreased their
infectiousness by over 95%, and the existing evidence for
male circumcision as a means of protecting men, HIV
prevention is now a complex ﬁeld of biomedical, behavioural
and structural strategies, bringing with them the challenges of
delivery in a wide variety of settings and the difﬁcult choices that
will need to be made when allocating limited resources. The
challenges of discovery also continue, as the currently available
agents are far from fully effective, and continuing development
is needed to improve the potency of prevention products at the
same time as ensuring that they are safe and acceptable for all
those who stand to beneﬁt.
M2012 explored issues of access to prevention technologies,
adherence in clinical trials, multipurpose prevention
technologies, the ethical challenges of future prevention trials
and new methods of preventing the rectal transmission of HIV.
We report here on the proceedings of M2012, with respect to
discussions and outcomes under the four theme areas of basic
science, community and advocacy, clinical science, and social
and behavioural science.
The biology of mucosal transmission
With adherence emerging as a key issue (see below), the basic
science focus at M2012 was largely in the area of
pharmacodynamics. Connie Celum from the University of
Washington presented data from Microbicide Trials Network
(MTN)-001, which examined the pharmacokinetic and
pharmacodynamics of oral tenofovir in women, revealing that
there were far lower levels of the drug in the vagina compared
with the rectum.2 Complementary ﬁndings in pigtailed
macaques were presented by Walid Heneine from the Centers
from Disease Control and Prevention, indicating the utility of
this model for evaluating the pharmacology and efﬁcacy of
PrEP.3 Several presentations considered the biological basis for
the apparent differences in PrEP efﬁcacy observed in women.
Salim Abdool Karim from the University of KwaZulu-Natal
opened the conference with an inspirational overview of the
trials and tribulations of the microbicide ﬁeld over the past
20 years. He outlined lessons learned in the quest to develop
an efﬁcacious microbicide, culminating in the success of the
CAPRISA 004 trial.4 The key messages included the need for
diversity in product development and for genuine community
partnerships in trial planning and implementation. New data
from CAPRISA 004 showed that, irrespective of tenofovir
use, women who acquired HIV had signiﬁcantly higher levels
of systemic innate immune activation before HIV infection
compared with women who remained free of infection.4
Furthermore, the protective effect of tenofovir gel was
weaker in women who were found to have genital
inﬂammation, as detected by raised cytokine levels following
gel use.
Betsy Herold from the Albert Einstein College of Medicine
showed how the design of effective PrEP can be informed by
an understanding of the biology of HIV transmission.5,6 She
emphasised that HIV transmission via sex is an inefﬁcient
process due to physical barriers, mucus, innate antiviral
factors and products produced by healthy microbes present in
the female genital tract. However, the balance can be tipped
towards promotion of HIV infection, even in the presence of an
antiviral drug, by several factors, including the act of sex, the
presence of semen, high viral load in the partner, the virulence of
the virus, sex hormones and immune activation, such as might
Fig. 1. Effect sizes and 95% conﬁdence intervals from recent HIV prevention trials.39–41 HPTN 052, treatment
as prevention in discordant couples; Partners PrEP, oral Truvada or Viread in discordant heterosexual couples;
TDF2, oral Truvada in high-risk heterosexuals; iPrEX, oral Truvada in men who have sex with men; CAPRISA
004, topical tenofovir gel; FEM-PrEP, oral Truvada in high-risk women.
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arise through a sexually transmissible infection or bacterial
vaginosis. A greater understanding of the basic biology of
HIV transmission in genital tissue is required to inform PrEP
development and formulation, and to develop better preclinical
models for predicting PrEP’s safety and efﬁcacy in vivo.
A recurring theme at the conference was the role of
inﬂammation in enhancing HIV infection in the female
genital tract. In a symposium dedicated to this topic, Jeanne
Marrazzo from the University of Washington, Alan Landay
from Rush University Medical Center and Richard Cone
from Johns Hopkins University reviewed our current
knowledge of the vaginal microbiome in healthy women of
reproductive age, the microbiome in women with bacterial
vaginosis, and changes in the microbiome that could either
enhance or diminish HIV acquisition.7–9 Marrazzo reported
from a prospective cohort study conducted in East Africa
demonstrating a three-fold increased risk of female-to-male
HIV transmission among men whose female partners had
bacterial vaginosis compared with women with normal
vaginal ﬂora.7 Cone presented data on lactic acid produced
by Lactobacilli sp., which is responsible for acidifying the
female vagina as an antimicrobial defence mechanism.9
Steven Zeichner from George Washington University showed
that the failed microbicide candidates nonoxynol-9 and cellulose
sulfate mediate changes in the vaginal microbiota towards
nonlactobacilli-containing communities.10 Intriguingly, these
microbial communities are not generally associated with the
elevated Nugent scores that are conventionally used to diagnose
bacterial vaginosis, suggesting that this scoring system might be
inadequate for assessing the safety of candidate microbicides
and that a DNA method of sequencing (pyrosequencing) may
be a preferable means of deﬁning the vaginal microbiota (i.e.
bacterial communities).
Helen Rees from the Wits Reproductive Health & HIV
Institute dissected the recent controversy surrounding the role
of progestogen-only injectable contraceptives in the risk of HIV
acquisition.11 Analysis of the studies as a whole indicates that
although there is some indication of increased risk, the data
were not sufﬁciently conclusive to change current guidelines
that permit their use. On a related topic, there was considerable
enthusiasm for ‘multipurpose prevention technology’ as
reviewed by Joseph Romano from the NWJ Group.12,13
Multipurpose prevention technologies can take several forms
including drugs or drug combinations that target more than one
sexually transmissible infection such as HIV and the herpes
simplex virus, or a device such as a diaphragm to prevent
pregnancy that also releases an antiviral and multi-indication
vaccines. Romano described proposed multipurpose prevention
technology products consistent with the ‘target product proﬁle’
that are under development and acknowledged that multipurpose
prevention technologies will present new challenges to
regulators, researchers and communities.
The role of community and advocacy
The promise of microbicides and PrEP demonstrated by the
recent successful trials, together with the caution raised by
the negative ﬁndings from others, provided a context for
implementing questions of great concern to communities,
such as which populations will really beneﬁt from new
prevention technologies and how people will incorporate
them into their sexual practices.
Dean Murphy from the Australian Federation of AIDS
Organisations presented results from PrEPARE, an online
survey of Australian HIV-positive and HIV-negative men
intended to gather information pertinent to PrEP
implementation.14 The study found that two-thirds of all anal
sex was unplanned, suggesting that event-based dosing may not
be effective, and that intermittent plus post-sex dosing strategies
may be a more achievable strategy in this population.
Sexual practice within microbicide trials and the cultural
framing of the investigational product was examined by
researchers from the Microbicides Development Programme
(MDP) 301 study in several presentations. Shelley Lees from
the London School of Hygiene and Tropical Medicine reported
on qualitative research conducted at the Mwanza, Tanzania, site
of the MDP 301 clinical trial with women working in the local
hospitality industry who may engage in transactional sex.15 Lees
found that although these women were aware of their
vulnerability to HIV, their discussions of sexuality were more
complex than a focus on risk. For them, ‘traditional’ sexuality
represented respect combined with men’s sexual control of
women, whereas ‘modern’ sexuality represented disrespect
and HIV risk, but also involved a greater choice for women
in terms of love, intimacy and pleasure. Lees argued that HIV
prevention research needs to move beyond risk to understand
women’s sexual lives more broadly, in order to understand how
they may adopt new HIV prevention technology.
Mitzy Gafos from the Medical Research Council conducted
qualitative research with MDP 301 participants in a
predominately rural area of KwaZulu-Natal, South Africa. She
explored the meanings of the microbicide gel with reference to
the traditional concept of ‘love medicines,’16 which are perceived
as a way for women to control the course of a relationship, at the
same time as being highly stigmatised within these communities.
Gafos’ analysis suggested that womenmade a distinction between
microbicide gels and the love medicines to avoid the stigma and
warned researchers against invoking such traditional practices to
‘sell’ microbicides.
The criminalisation of both HIV transmission and
homosexuality in various African countries was an important
focal point of M2012, and was explored in a symposium with
speakers from South Africa, Kenya and Australia. Brian
Kanyemba of the Desmond Tutu HIV Foundation in South
Africa told the conference that homosexuality is criminalised
in 38 African countries, undermining the effectiveness of the
HIV response.17 Kanyemba contrasted HIV prevention in South
Africa, where same-sex marriage is recognised and gay men
and lesbians protected by a Bill of Rights, with countries such
as Zimbabwe, Zambia, Malawi, Uganda and Kenya, where
there are legal penalties, and noted the resulting diversion of
funds, human rights abuses and disengagement from prevention
services by this vulnerable population. He also identiﬁed
criminalisation of homosexuality as a major barrier to
effective uptake of biomedical prevention strategies such as
microbicides and PrEP.
A symposium on the HIV prevention needs of HIV-positive
women reﬂected the concern about the possibility of women
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being excluded from prevention discoveries. Discussions
focussed on the development of new prevention tools for
HIV-positive women, access to existing tools and the other
issues that impact on HIV-positive women’s ability to protect
themselves, their partners and their children. Technologies that
might be beneﬁcial, such as therapeutic vaccines and
nonantiretroviral-based microbicides, were described.18,19
Jane Bruning from Positive Women Inc. (New Zealand)
outlined the various forms of female condom and the
different properties they offer,20 leading to a lively discussion
of the lack of access to this under-used female-controlled
technology and the need for a global strategic commitment.
Lucy Ghati from the National Empowerment Network of People
Living with HIV/AIDS in Kenya provoked impassioned debate
about the impacts of treatment-as-prevention on HIV-positive
women,21 with some arguing it would improve access while
other saying that it increased the burden of responsibility and had
coercive potential.
A rectal microbicides symposium blended science with
advocacy, with Ian McGowan from the University of
Pittsburgh School of Medicine outlining the past and
anticipated research trajectory of these agents,22 and
advocates Kadiri Audu from the International Center for
Advocacy on Right to Health and Jim Pickett from the AIDS
Foundation, Chicago, discussing the advocacy agenda.23,24
An understanding of anal health and anal sex practices was
recognised as being an essential underpinning for development
in this area.
Ethical challenges in taking prevention research forward
The ethics of HIV prevention research was a prominent topic at
M2012. Key ethical challenges identiﬁed were the standard of
prevention to be applied in new trials, now that there were
products available that had preventive efﬁcacy, and post-trial
access to effective products. In the standard of prevention
symposium, Ruth Macklin from Albert Einstein College of
Medicine, Jeremy Sugarman from Johns Hopkins Berman
Institute of Bioethics and Catherine Hankins from UNAIDS
outlined the differences in current ethical guidelines on this
issue.25–27 Morenike Ukpong from Obafemi Awolowo
University in Nigeria advocated for effective community
participation and described the pitfalls of consultation that
happens too late in the development of a protocol in
communities that have low research literacy and limited
capacity to contribute meaningfully.28 In the post-trial access
symposium, Ruth Macklin outlined the rationale for post-trial
access, arguing that trial participants have a particular moral
claim to products they helped to test. The implementation
difﬁculties of ensuring post-trial access were discussed at
length with panellists and the audience, with Salim Abdool
Karim from CAPRISA explaining the regulatory issues that had
held up access to tenofovir gel for trial participants after the
successful conclusion of CAPRISA 004.4
Adherence is the key to effectiveness
Understanding adherence in HIV prevention trials was a
recurring theme of M2012, discussed at several plenary
sessions, symposia and proffered paper sessions. In a
symposium session titled ‘Making sense of the PrEP Trial
Results’, Amy Corneli from FHI 360 noted that the apparent
lack of an effect may be entirely due to adherence.29 Douglas
Taylor also from FHI 360 outlined the limitations of traditional
measures of adherence, such as self-report and pill or applicator
count data and suggested that antiretroviral-based products
may allow for more objective measures of adherence.30
Corneli provided information on methods that had been used
to support adherence in recent trials.29 Both Corneli and Richard
Hayes (London School of Hygiene and Tropical Medicine),
in his plenary session,31 emphasised the need for standardised
measures of adherence to aid comparison of ﬁndings across
trials.
A symposium session addressed novel approaches to
measuring adherence. Richard Cone described the Medication
Event Monitoring System, which is widely used in therapeutic
research, and four novel methods to test for vaginal secretions
on applicators.32 Although the use of ultraviolet light proved
easy for participants, fast and reliable for record keeping and
analysis, and allowed for rapid identiﬁcation of poorly adherent
participants, it was not a sufﬁcient measure in isolation. Ariane
van der Straten from RTI International, noted that improved
adherence measurement requires a combination of self-report,
electronic monitoring devices, biomarkers and other objective
measures such as applicator tests and directly observed
therapy.33 The overall message was that more studies need to
be conducted to validate novel measures of adherence, even if
there is currently no gold standard.
New results from early phase trials
Several presentations focussed on recent Phase I and II
microbicide trials. Ian McGowan reported on MTN-007, a
Phase I randomised, double-blind, placebo-controlled rectal
safety and acceptability study of tenofovir 1% gel.34
Participants were randomised 1 : 1 : 1 : 1 to receive a reduced
glycerin tenofovir 1% gel, a hydoxyethylcellulose placebo gel, a
2% nonoxynol-9 gel or no treatment. The study concluded that
the reduced glycerin formula of 1% tenofovir was safe and well
tolerated.
Nicola Richardson-Harman from Alpha StatConsult LLC
described the dose–response relationship in RMP-01, the ﬁrst
randomised, double-blind, placebo-controlled Phase I
antiretroviral rectal microbicide trial.35 A vaginal gel, UC781,
was applied topically (0.1% v. 0.25% v. placebo; 1 : 1 : 1). Their
analysis demonstrated that tissue UC781 levels and ex vivo
infectibility data enable dose–response correlations. The study
was important in that it demonstrated the feasibility and
allowed comparisons of microbicide efﬁcacy between drugs,
compartments and application methods, without the dependence
on baseline infectivity data or frequency exposure.35
Recognition of outstanding achievement
Two conference awards were presented on the closing day of
M2012. Anna Forbes was awarded the Omololu Falobi Award
for Excellence in HIV Prevention Research Community
Advocacy for her signiﬁcant contributions over a long career
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dedicated to fostering civil society engagement in women’s
rights, and HIV care, treatment and prevention. Lut Van
Damme from FHI 360 and Gita Ramjee from the Medical
Research Council, who have had major roles in many of the
key microbicide trials, were honoured with the conference
Lifetime Achievement award. In his nominating speech, 2010
recipient Henry Gabelnick from CONRAD spoke of their
enormous contribution and determination in the face of the
many obstacles that clinical trials must deal with.
The future of HIV prevention research
Several sessions throughout M2012 provided insight into the
challenges the ﬁeld of microbicide research faces in conducting
trials. Angela Crook from the Medical Research Council
Clinical Trials Unit (proffered paper session)36 and Richard
Hayes (plenary session)31 both noted that it will be
increasingly difﬁcult to justify a placebo arm in trials, with
products like tenofovir gel providing promise for HIV
prevention. Without a placebo arm, a much larger sample
size will be required to reach adequate power, which has
signiﬁcant implications for resourcing. Crook used the
example of comparing a single-dose tenofovir regimen to a
two-dose before-and-after regimen to demonstrate the feasibility
of noninferiority microbicide trials despite the large sample size
required.36
It is apparent that the ﬁeld of HIV prevention and prevention
research is going to face serious shortfalls in funding in the
coming years. Debrework Zewdie from The Global Fund to
Fight AIDS, Tuberculosis and Malaria addressed this issue in
the closing plenary session.37 The key message was that the
ﬁeld of microbicides needs to look to innovative ﬁnancing and
the private sector. She also pointed out the signiﬁcant delay
to implementation from the results of male circumcision
and prevention of mother-to-child transmission trials, and
challenged the microbicide community to be prepared for
faster realisation in the future. This reinforced Milly Katana’s
plenary session, where she urged consideration of issues
of access now, rather than waiting until trial results were
released.38
The future of HIV prevention conferences
The Conference concluded with a joint presentation by Gina
Brown from the US National Institutes of Health Ofﬁce of AIDS
Research and Stephen Becker from the Bill and Melinda Gates
Foundation, representing the two bodies that have provided most
of funding for the Microbicides series of conferences over the
past 12 years. They announced the intention of the funders to
bring together vaccines, microbicides, oral PrEP and other HIV
prevention modalities in a new conference series, effectively
drawing the Microbicides series to a close. This new biennial
global HIV prevention conference series is likely to commence
in 2014. Discussion following their presentation emphasised
the need to maintain a strong interdisciplinary focus, particularly
involving community, advocacy and social science, to ensure
that the unique ﬂavour of the Microbicides series was
maintained.
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Investigator/research staff questionnaire 
(supplanted draft) 
1. How many phase IIB or Phase III HIV prevention trials have you been involved in? 
Please list.
 
Response 
Count
 
3
 answered question 3
 skipped question 7
2. Which HIV prevention intervention/s have you been involved in testing?
 
Response 
Percent
Response 
Count
PrEP 40.0% 4
HIV vaccine 20.0% 2
Microbicide 80.0% 8
PrEP/microbicide  0.0% 0
Treatment-as-prevention 10.0% 1
Other (please specify) 
 
10.0% 1
 answered question 10
 skipped question 0
2 of 8
3. What was your role in the trial or trials?
 
Response 
Percent
Response 
Count
Principal investigator 80.0% 8
Senior member of research team 40.0% 4
Community liaison officer  0.0% 0
Other (please specify) 
 
1
 answered question 10
 skipped question 0
4. What research ethics guidelines were used?
 
Response 
Percent
Response 
Count
National guidelines of host country 33.3% 3
CIOMS (Council for International 
Organisations of Medical Sciences) 33.3% 3
Declaration of Helsinki 88.9% 8
UNAIDS 33.3% 3
Nuffield Council on Bioethics 11.1% 1
NBAC (National Bioethics Advisory 
Commission)  0.0% 0
HPTN 11.1% 1
Other (please specify) 
 
22.2% 2
 answered question 9
 skipped question 1
3 of 8
5. Did your research strictly adhere to the research ethics guidelines used?
 
Response 
Percent
Response 
Count
Yes, with no likely deviation 80.0% 8
Yes, but compliance with the 
provision to ensure access to a 
proven product uncertain
30.0% 3
No, some deviations have been 
negotiated
 0.0% 0
Comment (optional) 
 
1
 answered question 10
 skipped question 0
6. Where did you obtain ethics approval for your trial?
 
Response 
Percent
Response 
Count
In the host country 10.0% 1
In the sponsoring country  0.0% 0
In both host and sponsoring 
countries
90.0% 9
Please name ethics committees used 
 
6
 answered question 10
 skipped question 0
4 of 8
7. Did you discuss distribution of research benefits with local communities?
 
Response 
Percent
Response 
Count
No 10.0% 1
Yes, in planning stages 20.0% 2
Yes, in recruitment stages 20.0% 2
Yes, in planning and recruitment 
stages
50.0% 5
Comment (optional) 
 
1
 answered question 10
 skipped question 0
8. Is antiretroviral therapy provided to seroconverters?
 
Response 
Percent
Response 
Count
No 25.0% 2
Not sure  0.0% 0
Yes, through government 
programs
50.0% 4
Yes, through international donor 
programs
12.5% 1
Yes, directly linked to the research 
program
12.5% 1
(please list any special provisions that assist in antiretroviral access) 
 
6
 answered question 8
 skipped question 2
5 of 8
9. Is antiretroviral therapy provided to HIV positive volunteers who are screened out?
 
Response 
Percent
Response 
Count
No 33.3% 3
Yes, through government 
programs
33.3% 3
Yes, through international donor 
programs
22.2% 2
Yes, directly linked to the research 
program
11.1% 1
(please list any special provisions that assist in antiretroviral access) 
 
6
 answered question 9
 skipped question 1
10. Does the trial offer ancillary medical benefits to participants?
 
Response 
Percent
Response 
Count
No 20.0% 2
Yes, sufficient to ensure smooth 
running of the research
30.0% 3
Yes, to treat conditions uncovered 
through the research processes
10.0% 1
Yes, to the degree possible on 
the basis of need
40.0% 4
 answered question 10
 skipped question 0
6 of 8
11. Which benefits does the trial offer participants?
 
Response 
Percent
Response 
Count
Male condoms (limited numbers) 10.0% 1
Male condoms (free, unlimited) 90.0% 9
Female condoms (limited numbers) 10.0% 1
Female condoms (free, unlimited 
numbers) 40.0% 4
STI testing/treatment 100.0% 10
Hormonal contraception (limited 
options) 10.0% 1
Hormonal contraception 
(comprehensive options) 30.0% 3
HPV vaccination  0.0% 0
Hepatitis B vaccination 10.0% 1
Male circumcision for 
participants/partners
 0.0% 0
Cervical screening 70.0% 7
Treatment of cervical dysplasia 30.0% 3
Referrals to local services for non-
trial related illness/injury 80.0% 8
Comment (optional) 
 
6
 answered question 10
 skipped question 0
7 of 8
12. Are benefits provided to partners or families of participants?
 
Response 
Percent
Response 
Count
No 62.5% 5
Yes 37.5% 3
Comment (optional) 
 
4
 answered question 8
 skipped question 2
13. Does your trial contribute infrastructure to the host country?
 
Response 
Percent
Response 
Count
No 22.2% 2
Yes (please specify) 
 
77.8% 7
 answered question 9
 skipped question 1
14. Will this infrastructure contribute to meeting health needs or research capacity of 
the community post-trial?
 
Response 
Percent
Response 
Count
No 22.2% 2
Yes (please specify) 
 
77.8% 7
 answered question 9
 skipped question 1
8 of 8
15. Does the trial sponsor limit benefits that are made available to participants?
 
Response 
Percent
Response 
Count
No 42.9% 3
Yes 57.1% 4
Comment (optional) 
 
5
 answered question 7
 skipped question 3
16. Are you satisfied with the benefits that the trial provides to participants?
 
Response 
Percent
Response 
Count
No  0.0% 0
Yes 75.0% 6
Partially 25.0% 2
Unsure  0.0% 0
Comment (optional) 
 
1
 answered question 8
 skipped question 2
1 of 31
Investigator/research staff questionnaire (final) 
1. How many phase IIB or phase III biomedical HIV prevention trials have you been 
involved in? (Please include trials you are CURRENTLY involved in as well as those 
completed.)
 
Response 
Percent
Response 
Count
One 29.4% 5
More than one 70.6% 12
 answered question 17
 skipped question 0
2. Which HIV prevention intervention have you been involved in testing?
 
Response 
Percent
Response 
Count
PrEP 20.0% 1
HIV vaccine  0.0% 0
Male circumcision 40.0% 2
Microbicide 40.0% 2
PrEP/microbicide  0.0% 0
Treatment-as-prevention  0.0% 0
STI treatment as HIV prevention  0.0% 0
Diaphragm  0.0% 0
Please specify approximate start date of trial 
 
2
 answered question 5
 skipped question 12
2 of 31
3. What was your role in the trial or trials?
 
Response 
Percent
Response 
Count
Principal investigator 100.0% 5
Senior member of research team  0.0% 0
Community liaison officer  0.0% 0
Other (please specify) 0
 answered question 5
 skipped question 12
3 of 31
4. Did you consult any ethical guidelines in designing your trial? If so, which guidelines 
did you consult? (Tick as many as apply.)
 
Response 
Percent
Response 
Count
National guidelines of host country 20.0% 1
National guidelines of sponsoring 
country
40.0% 2
National guidelines of researcher's 
institution
40.0% 2
CIOMS (Council for International 
Organisations of Medical Sciences) 20.0% 1
Declaration of Helsinki 100.0% 5
UNAIDS 20.0% 1
Nuffield Council on Bioethics  0.0% 0
NBAC (National Bioethics Advisory 
Commission)  0.0% 0
HPTN (HIV Prevention Trials 
Network)  0.0% 0
US Federal regulations (the 
Common rule) 40.0% 2
ICH-GCP (International Conference 
on Harmonization Good Clinical 
Practice
80.0% 4
Other (please specify) 
 
20.0% 1
 answered question 5
 skipped question 12
4 of 31
5. At what stage(s) did you consult ethical guidelines?
 
Response 
Percent
Response 
Count
I did not consult ethical guidelines  0.0% 0
Other members of the research 
team consulted ethical guidelines, 
but I did not
 0.0% 0
In planning stages 60.0% 3
In planning stages and 
throughout the research process 
as required
80.0% 4
Comment (optional) 0
 answered question 5
 skipped question 12
6. Was antiretroviral therapy provided to participants who seroconverted during the 
trial?
 
Response 
Percent
Response 
Count
No 20.0% 1
Yes, through government 
programs
40.0% 2
Yes, through NGO programs 20.0% 1
Yes, through international donor 
programs
40.0% 2
Yes, directly linked to the research 
program
 0.0% 0
Not sure  0.0% 0
Please list any special provisions that assisted in antiretroviral access 
 
1
 answered question 5
 skipped question 12
5 of 31
7. Are you aware of any ways in which your trial deviated from the research ethics 
guidelines you consulted?
 
Response 
Percent
Response 
Count
No 20.0% 1
No, but compliance with the 
provision to ensure access to a 
proven product is uncertain
40.0% 2
Yes, some deviations were 
negotiated
40.0% 2
Comment (optional) 
 
1
 answered question 5
 skipped question 12
8. Where did you obtain ethics approval for your trial? Tick as many as apply.
 
Response 
Percent
Response 
Count
In the host country 100.0% 5
In the sponsoring country 80.0% 4
In the country of the researcher's 
academic institution
40.0% 2
Please name ethics committees used 
 
3
 answered question 5
 skipped question 12
6 of 31
9. Did you negotiate the care that would be provided within the trial with communities 
affected by the trial?
 
Response 
Percent
Response 
Count
No 60.0% 3
Yes, in planning stages  0.0% 0
Yes, in recruitment stages  0.0% 0
Yes, in planning and recruitment 
stages
 0.0% 0
Yes, in planning and recruitment 
stages and through out the trial as 
required
40.0% 2
Comment (optional) 
 
1
 answered question 5
 skipped question 12
7 of 31
10. Was antiretroviral therapy provided to participants who seroconverted during the 
trial?
 
Response 
Percent
Response 
Count
No  0.0% 0
Yes, through government 
programs
40.0% 2
Yes, through NGO programs 20.0% 1
Yes, through international donor 
programs
40.0% 2
Yes, directly linked to the research 
program
 0.0% 0
Not sure  0.0% 0
Please list any special provisions that assist in antiretroviral access 
 
2
 answered question 5
 skipped question 12
8 of 31
11. Was antiretroviral therapy provided to volunteers found HIV positive at screening 
who were therefore ineligible to participate?
 
Response 
Percent
Response 
Count
No  0.0% 0
Yes, through government 
programs
40.0% 2
Yes, through non-government 
programs
20.0% 1
Yes, through international donor 
programs
40.0% 2
Yes, directly linked to the research 
program
 0.0% 0
Please list any special provisions that assist in antiretroviral access 
 
1
 answered question 5
 skipped question 12
9 of 31
12. Did the trial offer medical/prevention services to participants?
 
Response 
Percent
Response 
Count
No  0.0% 0
Yes, limited to conditions that 
would impact on the research 
findings (such as STIs)
40.0% 2
Yes, limited to conditions that 
would impact on the research (such 
as STIs) and conditions that are 
exacerbated by HIV (such as 
cervical dysplasia, TB)
 0.0% 0
Yes, unlimited (except by site 
capacity) 60.0% 3
Comment (please specify) 
 
1
 answered question 5
 skipped question 12
10 of 31
13. Which benefits did the trial offer participants? Tick all that apply.
 
Response 
Percent
Response 
Count
Counselling 100.0% 5
Male condoms 100.0% 5
Female condoms 20.0% 1
STI testing 80.0% 4
STI treatment 100.0% 5
Oral contraceptive pill 40.0% 2
Injectable contraception 40.0% 2
Contraceptive implants 20.0% 1
HPV vaccination  0.0% 0
Hepatitis B vaccination 20.0% 1
Male circumcision for 
partners/participants
40.0% 2
Cervical screening 20.0% 1
Treatment of cervical dysplasia  0.0% 0
Comment (optional) 
 
2
 answered question 5
 skipped question 12
11 of 31
14. Were health services offered to partners or families of participants?
 
Response 
Percent
Response 
Count
No 60.0% 3
Yes 40.0% 2
Comment (optional) 
 
2
 answered question 5
 skipped question 12
15. Did your trial contribute infrastructure to the host country, e.g.the training of health 
care workers, establishment of clinical facilities?
 
Response 
Percent
Response 
Count
No  0.0% 0
Yes (please specify) 
 
100.0% 5
 answered question 5
 skipped question 12
16. Did the trial sponsor have policies regarding health/prevention services that were 
made available to participants?
 
Response 
Percent
Response 
Count
No 50.0% 2
Yes 50.0% 2
Comment (optional) 0
 answered question 4
 skipped question 13
12 of 31
17. How did sponsors' policies affect the care/prevention services offered to 
participants?
 
Response 
Percent
Response 
Count
Sponsors did not have policies 25.0% 1
Sponsors' policies affected 
care/prevention services 
positively (increased or 
improved service range 
available)
50.0% 2
Sponsors' policies affected 
care/prevention services 
negatively (limited or decreased 
service range available)
25.0% 1
Comment (optional) 
 
1
 answered question 4
 skipped question 13
18. Were you satisfied that the trial adequately met its responsibilities to provide 
benefits and services to participants?
 
Response 
Percent
Response 
Count
No  0.0% 0
Yes 100.0% 5
Partially  0.0% 0
Unsure  0.0% 0
Comment (optional) 
 
1
 answered question 5
 skipped question 12
13 of 31
19. Thank you for completing this questionnaire. Please tick the box below to exit
 
Response 
Percent
Response 
Count
Exit now 100.0% 5
 answered question 5
 skipped question 12
20. This questionnaire will now ask a series of questions about the first trial you were 
involved in, then ask a series about the most recent trial you were involved in. What was 
the FIRST phase IIb or phase III HIV prevention intervention you were involved in testing?
 
Response 
Percent
Response 
Count
PrEP 20.0% 2
Male circumcision  0.0% 0
HIV vaccine 10.0% 1
Microbicide 30.0% 3
PrEP/microbicide  0.0% 0
Treatment-as- prevention  0.0% 0
STI treatment for HIV prevention 20.0% 2
Diaphragm 20.0% 2
Please list approximate start date of trial 
 
9
 answered question 10
 skipped question 7
14 of 31
21. What was your role in the FIRST phase IIb or III HIV trial you were involved in?
 
Response 
Percent
Response 
Count
Principal investigator 55.6% 5
Senior member of research team 44.4% 4
Community Liaison officer  0.0% 0
Other (please specify) 
 
3
 answered question 9
 skipped question 8
15 of 31
22. Did you consult any research ethics guidelines in the FIRST HIV prevention trial you 
were involved in? If so, whcih guidelines did you consult? Tick all that apply.
 
Response 
Percent
Response 
Count
National guidelines of host country 54.5% 6
National guidelines of sponsoring 
country
54.5% 6
National guidelines of researcher's 
institution
54.5% 6
CIOMS (Council for International 
Organisations of Medical Sciences) 27.3% 3
Declaration of Helskini 63.6% 7
UNAIDS 36.4% 4
Nuffield Council on Bioethics 9.1% 1
NBAC (National Bioethics Advisory 
Commission)  0.0% 0
HPTN (HIV Prevention Trials 
Network) 27.3% 3
US Federal regulations (the 
Common Rule) 54.5% 6
ICH-GCP (International Conference 
on Harmonization Good Clinical 
Practice)
54.5% 6
Other (please specify) 
 
2
 answered question 11
 skipped question 6
16 of 31
23. Where did you obtain ethics approval for the FIRST HIV prevention trial in which you 
were involved? Tick all that apply.
 
Response 
Percent
Response 
Count
In the host country 83.3% 10
In the sponsoring country 58.3% 7
In the country of the 
researcher's academic institution
91.7% 11
Please name ethics committees used 
 
7
 answered question 12
 skipped question 5
24. Did you negotiate the care that would be provided within the trial with communities 
affected by the trial for the FIRST HIV prevention trial in which you were involved?
 
Response 
Percent
Response 
Count
No 9.1% 1
Yes, in planning stages 54.5% 6
Yes, in recruitment stages 18.2% 2
Yes, in planning and recruitment 
stages
36.4% 4
Comment (optional) 
 
3
 answered question 11
 skipped question 6
17 of 31
25. In the FIRST HIV prevention trial in which you were involved, was antiretroviral 
therapy provided to participants who seroconverted during the trial?
 
Response 
Percent
Response 
Count
No 50.0% 6
Yes, through government programs 41.7% 5
Yes, through NGO programs 8.3% 1
Yes, through international donor 
programs
8.3% 1
Yes, directly linked to the research 
program
8.3% 1
Not sure 16.7% 2
Please list any special provisions that assisted in antiretroviral access 
 
6
 answered question 12
 skipped question 5
26. In the FIRST HIV prevention trial in which you were involved, was antiretroviral 
therapy provided to volunteers found HIV positive at screening and therefore ineligible?
 
Response 
Percent
Response 
Count
No 66.7% 8
Yes, through government programs 33.3% 4
Yes, through NGO programs 8.3% 1
Yes, through international donor 
programs
8.3% 1
Yes, directly linked to the research 
program
8.3% 1
 answered question 12
 skipped question 5
18 of 31
27. Did the FIRST HIV biomedical prevention trial you were involved in offer 
medical/prevention services to participants?
 
Response 
Percent
Response 
Count
No  0.0% 0
Yes, limited to conditions that 
would impact on the research 
findings (such as STIs)
54.5% 6
Yes, limited to conditions that 
would impact on the research (such 
as STIs) and conditions that are 
exacerbated by HIV (such as 
cervical dysplasia, TB)
9.1% 1
Yes, unlimited (except by site 
capacity) 36.4% 4
Comment (please specify) 
 
1
 answered question 11
 skipped question 6
19 of 31
28. Which health/prevention services were offered to participants in the FIRST HIV 
prevention trial in which you were involved? Tick as many as apply.
 
Response 
Percent
Response 
Count
Counselling 100.0% 12
Male condoms 100.0% 12
Female condoms 41.7% 5
STI testing 83.3% 10
STI treatment 100.0% 12
Oral contraceptive pill 50.0% 6
Injectable contraception 33.3% 4
Contraceptive implants 8.3% 1
HPV vaccination 8.3% 1
Hepatitis B vaccination 16.7% 2
Male circumcision for 
partners/participants
8.3% 1
Cervical screening 50.0% 6
Treatment of cervical dysplasia  0.0% 0
Referrals to local services for non-
trial related illness/injury 83.3% 10
 answered question 12
 skipped question 5
20 of 31
29. In the FIRST HIV prevention trial you were involved in, were health services offered to 
partners or families of participants?
 
Response 
Percent
Response 
Count
No 58.3% 7
Yes 41.7% 5
Comment (optional) 
 
2
 answered question 12
 skipped question 5
30. Did the FIRST HIV prevention trial you were involved with contribute infrastructure to 
the host country, e.g. training of health care workers, establishment of clinical facilities?
 
Response 
Percent
Response 
Count
No 16.7% 2
Yes 83.3% 10
Please specify 
 
4
 answered question 12
 skipped question 5
21 of 31
31. In the FIRST prevention trial in which you were involved, did the trial sponsor have 
policies regarding health/prevention services that were made available to participants?
 
Response 
Percent
Response 
Count
No 18.2% 2
Yes 81.8% 9
Comment (optional) 
 
2
 answered question 11
 skipped question 6
32. How did sponsors' policies affect the care/prevention services offered to 
participants in your FIRST biomedical prevention trial?
 
Response 
Percent
Response 
Count
Sponsors did not have policies 10.0% 1
Sponsors' policies affected 
care/prevention services 
positively (increased or 
improved service range 
available)
90.0% 9
Sponsors' policies affected 
care/prevention services 
negatively (limited or decreased 
service range available)
 0.0% 0
Comment (optional) 
 
2
 answered question 10
 skipped question 7
22 of 31
33. In the FIRST HIV prevention trial in which you were involved, were you satisfied that 
the trial adequately met its responsibilities to provide benefits and services to 
participants?
 
Response 
Percent
Response 
Count
No  0.0% 0
Yes 58.3% 7
Partially 41.7% 5
Unsure  0.0% 0
Comment (optional) 
 
4
 answered question 12
 skipped question 5
23 of 31
34. This next section of the survey asks you about the MOST RECENT phase IIb or phase 
III biomedical HIV prevention intervention you have been involved in testing. What was 
the MOST RECENT phase IIb or phase III biomedical HIV prevention intervention you were 
involved in testing?
 
Response 
Percent
Response 
Count
PrEP 50.0% 6
Male circumcision 16.7% 2
HIV vaccine 16.7% 2
Microbicide 8.3% 1
PrEP/microbicide 8.3% 1
Treatment-as- prevention  0.0% 0
STI treatment  0.0% 0
Diaphragm  0.0% 0
Please specify approximate start date of trial (year) 
 
7
 answered question 12
 skipped question 5
35. What was your role in the MOST RECENT phase IIb or III biomedical HIV prevention 
trial you were involved in?
 
Response 
Percent
Response 
Count
Principal investigator 50.0% 5
Senior member of research team 50.0% 5
Community Liaison officer  0.0% 0
Other (please specify) 
 
3
 answered question 10
 skipped question 7
24 of 31
36. Did you consult any research ethics guidelines in the MOST RECENT HIV prevention 
trial you were involved in? If so, which guidelines did you consult? Tick all that apply.
 
Response 
Percent
Response 
Count
National guidelines of host 
country
81.8% 9
National guidelines of sponsoring 
country
63.6% 7
National guidelines of 
researcher's institution
81.8% 9
CIOMS (Council for International 
Organisations of Medical Sciences) 27.3% 3
Declaration of Helsinki 72.7% 8
UNAIDS 63.6% 7
Nuffield Council on Bioethics  0.0% 0
NBAC (National Bioethics Advisory 
Commission)  0.0% 0
HPTN (HIV Prevention Trials 
Network) 45.5% 5
US Federal regulations (the 
Common Rule) 72.7% 8
ICH-GCP (international 
Conference on Harmonization 
Good Clinical Practice)
81.8% 9
Other (please specify) 
 
1
 answered question 11
 skipped question 6
25 of 31
37. At what stage(s) in planning did you consult ethical guidelines? Tick as many as 
apply.
 
Response 
Percent
Response 
Count
I did not consult guidelines  0.0% 0
Other members of the research 
team consulted guidelines, but I did 
not
 0.0% 0
In planning stages 36.4% 4
In planning stages, and 
throughout the trial as required
100.0% 11
Comment (optional) 
 
1
 answered question 11
 skipped question 6
38. Where did you obtain ethics approval for your MOST RECENT trial? Tick all that apply.
 
Response 
Percent
Response 
Count
In the host country 91.7% 11
In the sponsoring country 66.7% 8
In the country of the researcher's 
academic institution
83.3% 10
Please name ethics committes used 
 
7
 answered question 12
 skipped question 5
26 of 31
39. Did you consult with communities affected by the trial about the care/prevention 
services that would be provided within the trial in your MOST RECENT biomedical HIV 
prevention study?
 
Response 
Percent
Response 
Count
No  0.0% 0
Yes, in planning stages 36.4% 4
Yes, in recruitment stages 27.3% 3
Yes, in planning and recruitment 
stages
81.8% 9
Yes, during the trial 90.9% 10
Comment (optional) 0
 answered question 11
 skipped question 6
27 of 31
40. In the MOST RECENT biomedical HIV prevention trial in which you were involved, was 
antiretroviral therapy provided to participants who seroconverted during the trial?
 
Response 
Percent
Response 
Count
No  0.0% 0
Yes, through government 
programs
66.7% 8
Yes, through NGO programs 33.3% 4
Yes, through international donor 
programs
25.0% 3
Yes, directly linked to the research 
program
33.3% 4
Not sure  0.0% 0
Please list any special provisions that assisted in antiretroviral access 
 
3
 answered question 12
 skipped question 5
28 of 31
41. Which health/prevention services were offered to participants in the MOST RECENT 
biomedical HIV prevention trial in which you were involved? Tick as many as apply.
 
Response 
Percent
Response 
Count
Counselling 100.0% 12
Male condoms 100.0% 12
Female condoms 66.7% 8
STI testing 91.7% 11
STI treatment 91.7% 11
Oral contraceptive pill 58.3% 7
Injectable contraception 58.3% 7
Contraceptive implants 8.3% 1
HPV vaccination 8.3% 1
Hepatitis B vaccination 41.7% 5
Male circumcision for 
partners/participants
33.3% 4
Cervical screening 58.3% 7
Treatment of cervical dysplasia 16.7% 2
Referrals to local services for 
non-trial related illness/injury 100.0% 12
 answered question 12
 skipped question 5
29 of 31
42. Did the MOST RECENT HIV biomedical prevention trial you were involved in offer 
medical/prevention services to participants?
 
Response 
Percent
Response 
Count
No  0.0% 0
Yes, limited to conditions that 
would impact on the research 
findings (such as STIs)
41.7% 5
Yes, limited to conditions that 
would impact on the research (such 
as STIs) and conditions that are 
exacerbated by HIV (such as 
cervical dysplasia, TB)
16.7% 2
Yes, unlimited (except by site 
capacity) 41.7% 5
Comment (please specify) 
 
2
 answered question 12
 skipped question 5
43. In the MOST RECENT HIV prevention trial you were involved in, were health/prevention 
services offered to partners or families of participants?
 
Response 
Percent
Response 
Count
No 41.7% 5
Yes 58.3% 7
Comment (optional) 
 
1
 answered question 12
 skipped question 5
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44. Did the MOST RECENT HIV prevention trial you have been involved in contribute 
infrastructure to the host country, e.g.the training of health care workers, establishment 
of clinical facilities?
 
Response 
Percent
Response 
Count
No 16.7% 2
Yes (please specify) 
 
83.3% 10
 answered question 12
 skipped question 5
45. In the MOST RECENT prevention trial in which you were involved, did the trial sponsor 
have policies regarding health/prevention services that were made available to 
participants?
 
Response 
Percent
Response 
Count
No 16.7% 2
Yes 83.3% 10
Comment (optional) 
 
1
 answered question 12
 skipped question 5
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46. How did sponsors' policies affect the care/prevention services offered to 
participants in your MOST RECENT biomedical prevention trial?
 
Response 
Percent
Response 
Count
Sponsors did not have policies 10.0% 1
Sponsors' policies affected 
care/prevention services 
positively (increased or 
improved service range 
available)
90.0% 9
Sponsors' policies affected 
care/prevention services 
negatively (limited or decreased 
service range available)
 0.0% 0
Comment (optional) 
 
2
 answered question 10
 skipped question 7
47. In the MOST RECENT HIV prevention trial in which you were involved, were you 
satisfied that the trial adequately met its responsibilities to provide benefits and 
services to participants?
 
Response 
Percent
Response 
Count
No  0.0% 0
Yes 100.0% 12
Partially  0.0% 0
Unsure  0.0% 0
Comment (optional) 0
 answered question 12
 skipped question 5
1 of 31
Investigator/research staff questionnaire (final) 
1. How many phase IIB or phase III biomedical HIV prevention trials have you been 
involved in? (Please include trials you are CURRENTLY involved in as well as those 
completed.)
 
Response 
Percent
Response 
Count
One 29.4% 5
More than one 70.6% 12
 answered question 17
 skipped question 0
2. Which HIV prevention intervention have you been involved in testing?
 
Response 
Percent
Response 
Count
PrEP 20.0% 1
HIV vaccine  0.0% 0
Male circumcision 40.0% 2
Microbicide 40.0% 2
PrEP/microbicide  0.0% 0
Treatment-as-prevention  0.0% 0
STI treatment as HIV prevention  0.0% 0
Diaphragm  0.0% 0
Please specify approximate start date of trial 
 
2
 answered question 5
 skipped question 12
2 of 31
3. What was your role in the trial or trials?
 
Response 
Percent
Response 
Count
Principal investigator 100.0% 5
Senior member of research team  0.0% 0
Community liaison officer  0.0% 0
Other (please specify) 0
 answered question 5
 skipped question 12
3 of 31
4. Did you consult any ethical guidelines in designing your trial? If so, which guidelines 
did you consult? (Tick as many as apply.)
 
Response 
Percent
Response 
Count
National guidelines of host country 20.0% 1
National guidelines of sponsoring 
country
40.0% 2
National guidelines of researcher's 
institution
40.0% 2
CIOMS (Council for International 
Organisations of Medical Sciences) 20.0% 1
Declaration of Helsinki 100.0% 5
UNAIDS 20.0% 1
Nuffield Council on Bioethics  0.0% 0
NBAC (National Bioethics Advisory 
Commission)  0.0% 0
HPTN (HIV Prevention Trials 
Network)  0.0% 0
US Federal regulations (the 
Common rule) 40.0% 2
ICH-GCP (International Conference 
on Harmonization Good Clinical 
Practice
80.0% 4
Other (please specify) 
 
20.0% 1
 answered question 5
 skipped question 12
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5. At what stage(s) did you consult ethical guidelines?
 
Response 
Percent
Response 
Count
I did not consult ethical guidelines  0.0% 0
Other members of the research 
team consulted ethical guidelines, 
but I did not
 0.0% 0
In planning stages 60.0% 3
In planning stages and 
throughout the research process 
as required
80.0% 4
Comment (optional) 0
 answered question 5
 skipped question 12
6. Was antiretroviral therapy provided to participants who seroconverted during the 
trial?
 
Response 
Percent
Response 
Count
No 20.0% 1
Yes, through government 
programs
40.0% 2
Yes, through NGO programs 20.0% 1
Yes, through international donor 
programs
40.0% 2
Yes, directly linked to the research 
program
 0.0% 0
Not sure  0.0% 0
Please list any special provisions that assisted in antiretroviral access 
 
1
 answered question 5
 skipped question 12
5 of 31
7. Are you aware of any ways in which your trial deviated from the research ethics 
guidelines you consulted?
 
Response 
Percent
Response 
Count
No 20.0% 1
No, but compliance with the 
provision to ensure access to a 
proven product is uncertain
40.0% 2
Yes, some deviations were 
negotiated
40.0% 2
Comment (optional) 
 
1
 answered question 5
 skipped question 12
8. Where did you obtain ethics approval for your trial? Tick as many as apply.
 
Response 
Percent
Response 
Count
In the host country 100.0% 5
In the sponsoring country 80.0% 4
In the country of the researcher's 
academic institution
40.0% 2
Please name ethics committees used 
 
3
 answered question 5
 skipped question 12
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9. Did you negotiate the care that would be provided within the trial with communities 
affected by the trial?
 
Response 
Percent
Response 
Count
No 60.0% 3
Yes, in planning stages  0.0% 0
Yes, in recruitment stages  0.0% 0
Yes, in planning and recruitment 
stages
 0.0% 0
Yes, in planning and recruitment 
stages and through out the trial as 
required
40.0% 2
Comment (optional) 
 
1
 answered question 5
 skipped question 12
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10. Was antiretroviral therapy provided to participants who seroconverted during the 
trial?
 
Response 
Percent
Response 
Count
No  0.0% 0
Yes, through government 
programs
40.0% 2
Yes, through NGO programs 20.0% 1
Yes, through international donor 
programs
40.0% 2
Yes, directly linked to the research 
program
 0.0% 0
Not sure  0.0% 0
Please list any special provisions that assist in antiretroviral access 
 
2
 answered question 5
 skipped question 12
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11. Was antiretroviral therapy provided to volunteers found HIV positive at screening 
who were therefore ineligible to participate?
 
Response 
Percent
Response 
Count
No  0.0% 0
Yes, through government 
programs
40.0% 2
Yes, through non-government 
programs
20.0% 1
Yes, through international donor 
programs
40.0% 2
Yes, directly linked to the research 
program
 0.0% 0
Please list any special provisions that assist in antiretroviral access 
 
1
 answered question 5
 skipped question 12
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12. Did the trial offer medical/prevention services to participants?
 
Response 
Percent
Response 
Count
No  0.0% 0
Yes, limited to conditions that 
would impact on the research 
findings (such as STIs)
40.0% 2
Yes, limited to conditions that 
would impact on the research (such 
as STIs) and conditions that are 
exacerbated by HIV (such as 
cervical dysplasia, TB)
 0.0% 0
Yes, unlimited (except by site 
capacity) 60.0% 3
Comment (please specify) 
 
1
 answered question 5
 skipped question 12
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13. Which benefits did the trial offer participants? Tick all that apply.
 
Response 
Percent
Response 
Count
Counselling 100.0% 5
Male condoms 100.0% 5
Female condoms 20.0% 1
STI testing 80.0% 4
STI treatment 100.0% 5
Oral contraceptive pill 40.0% 2
Injectable contraception 40.0% 2
Contraceptive implants 20.0% 1
HPV vaccination  0.0% 0
Hepatitis B vaccination 20.0% 1
Male circumcision for 
partners/participants
40.0% 2
Cervical screening 20.0% 1
Treatment of cervical dysplasia  0.0% 0
Comment (optional) 
 
2
 answered question 5
 skipped question 12
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14. Were health services offered to partners or families of participants?
 
Response 
Percent
Response 
Count
No 60.0% 3
Yes 40.0% 2
Comment (optional) 
 
2
 answered question 5
 skipped question 12
15. Did your trial contribute infrastructure to the host country, e.g.the training of health 
care workers, establishment of clinical facilities?
 
Response 
Percent
Response 
Count
No  0.0% 0
Yes (please specify) 
 
100.0% 5
 answered question 5
 skipped question 12
16. Did the trial sponsor have policies regarding health/prevention services that were 
made available to participants?
 
Response 
Percent
Response 
Count
No 50.0% 2
Yes 50.0% 2
Comment (optional) 0
 answered question 4
 skipped question 13
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17. How did sponsors' policies affect the care/prevention services offered to 
participants?
 
Response 
Percent
Response 
Count
Sponsors did not have policies 25.0% 1
Sponsors' policies affected 
care/prevention services 
positively (increased or 
improved service range 
available)
50.0% 2
Sponsors' policies affected 
care/prevention services 
negatively (limited or decreased 
service range available)
25.0% 1
Comment (optional) 
 
1
 answered question 4
 skipped question 13
18. Were you satisfied that the trial adequately met its responsibilities to provide 
benefits and services to participants?
 
Response 
Percent
Response 
Count
No  0.0% 0
Yes 100.0% 5
Partially  0.0% 0
Unsure  0.0% 0
Comment (optional) 
 
1
 answered question 5
 skipped question 12
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19. Thank you for completing this questionnaire. Please tick the box below to exit
 
Response 
Percent
Response 
Count
Exit now 100.0% 5
 answered question 5
 skipped question 12
20. This questionnaire will now ask a series of questions about the first trial you were 
involved in, then ask a series about the most recent trial you were involved in. What was 
the FIRST phase IIb or phase III HIV prevention intervention you were involved in testing?
 
Response 
Percent
Response 
Count
PrEP 20.0% 2
Male circumcision  0.0% 0
HIV vaccine 10.0% 1
Microbicide 30.0% 3
PrEP/microbicide  0.0% 0
Treatment-as- prevention  0.0% 0
STI treatment for HIV prevention 20.0% 2
Diaphragm 20.0% 2
Please list approximate start date of trial 
 
9
 answered question 10
 skipped question 7
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21. What was your role in the FIRST phase IIb or III HIV trial you were involved in?
 
Response 
Percent
Response 
Count
Principal investigator 55.6% 5
Senior member of research team 44.4% 4
Community Liaison officer  0.0% 0
Other (please specify) 
 
3
 answered question 9
 skipped question 8
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22. Did you consult any research ethics guidelines in the FIRST HIV prevention trial you 
were involved in? If so, whcih guidelines did you consult? Tick all that apply.
 
Response 
Percent
Response 
Count
National guidelines of host country 54.5% 6
National guidelines of sponsoring 
country
54.5% 6
National guidelines of researcher's 
institution
54.5% 6
CIOMS (Council for International 
Organisations of Medical Sciences) 27.3% 3
Declaration of Helskini 63.6% 7
UNAIDS 36.4% 4
Nuffield Council on Bioethics 9.1% 1
NBAC (National Bioethics Advisory 
Commission)  0.0% 0
HPTN (HIV Prevention Trials 
Network) 27.3% 3
US Federal regulations (the 
Common Rule) 54.5% 6
ICH-GCP (International Conference 
on Harmonization Good Clinical 
Practice)
54.5% 6
Other (please specify) 
 
2
 answered question 11
 skipped question 6
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23. Where did you obtain ethics approval for the FIRST HIV prevention trial in which you 
were involved? Tick all that apply.
 
Response 
Percent
Response 
Count
In the host country 83.3% 10
In the sponsoring country 58.3% 7
In the country of the 
researcher's academic institution
91.7% 11
Please name ethics committees used 
 
7
 answered question 12
 skipped question 5
24. Did you negotiate the care that would be provided within the trial with communities 
affected by the trial for the FIRST HIV prevention trial in which you were involved?
 
Response 
Percent
Response 
Count
No 9.1% 1
Yes, in planning stages 54.5% 6
Yes, in recruitment stages 18.2% 2
Yes, in planning and recruitment 
stages
36.4% 4
Comment (optional) 
 
3
 answered question 11
 skipped question 6
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25. In the FIRST HIV prevention trial in which you were involved, was antiretroviral 
therapy provided to participants who seroconverted during the trial?
 
Response 
Percent
Response 
Count
No 50.0% 6
Yes, through government programs 41.7% 5
Yes, through NGO programs 8.3% 1
Yes, through international donor 
programs
8.3% 1
Yes, directly linked to the research 
program
8.3% 1
Not sure 16.7% 2
Please list any special provisions that assisted in antiretroviral access 
 
6
 answered question 12
 skipped question 5
26. In the FIRST HIV prevention trial in which you were involved, was antiretroviral 
therapy provided to volunteers found HIV positive at screening and therefore ineligible?
 
Response 
Percent
Response 
Count
No 66.7% 8
Yes, through government programs 33.3% 4
Yes, through NGO programs 8.3% 1
Yes, through international donor 
programs
8.3% 1
Yes, directly linked to the research 
program
8.3% 1
 answered question 12
 skipped question 5
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27. Did the FIRST HIV biomedical prevention trial you were involved in offer 
medical/prevention services to participants?
 
Response 
Percent
Response 
Count
No  0.0% 0
Yes, limited to conditions that 
would impact on the research 
findings (such as STIs)
54.5% 6
Yes, limited to conditions that 
would impact on the research (such 
as STIs) and conditions that are 
exacerbated by HIV (such as 
cervical dysplasia, TB)
9.1% 1
Yes, unlimited (except by site 
capacity) 36.4% 4
Comment (please specify) 
 
1
 answered question 11
 skipped question 6
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28. Which health/prevention services were offered to participants in the FIRST HIV 
prevention trial in which you were involved? Tick as many as apply.
 
Response 
Percent
Response 
Count
Counselling 100.0% 12
Male condoms 100.0% 12
Female condoms 41.7% 5
STI testing 83.3% 10
STI treatment 100.0% 12
Oral contraceptive pill 50.0% 6
Injectable contraception 33.3% 4
Contraceptive implants 8.3% 1
HPV vaccination 8.3% 1
Hepatitis B vaccination 16.7% 2
Male circumcision for 
partners/participants
8.3% 1
Cervical screening 50.0% 6
Treatment of cervical dysplasia  0.0% 0
Referrals to local services for non-
trial related illness/injury 83.3% 10
 answered question 12
 skipped question 5
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29. In the FIRST HIV prevention trial you were involved in, were health services offered to 
partners or families of participants?
 
Response 
Percent
Response 
Count
No 58.3% 7
Yes 41.7% 5
Comment (optional) 
 
2
 answered question 12
 skipped question 5
30. Did the FIRST HIV prevention trial you were involved with contribute infrastructure to 
the host country, e.g. training of health care workers, establishment of clinical facilities?
 
Response 
Percent
Response 
Count
No 16.7% 2
Yes 83.3% 10
Please specify 
 
4
 answered question 12
 skipped question 5
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31. In the FIRST prevention trial in which you were involved, did the trial sponsor have 
policies regarding health/prevention services that were made available to participants?
 
Response 
Percent
Response 
Count
No 18.2% 2
Yes 81.8% 9
Comment (optional) 
 
2
 answered question 11
 skipped question 6
32. How did sponsors' policies affect the care/prevention services offered to 
participants in your FIRST biomedical prevention trial?
 
Response 
Percent
Response 
Count
Sponsors did not have policies 10.0% 1
Sponsors' policies affected 
care/prevention services 
positively (increased or 
improved service range 
available)
90.0% 9
Sponsors' policies affected 
care/prevention services 
negatively (limited or decreased 
service range available)
 0.0% 0
Comment (optional) 
 
2
 answered question 10
 skipped question 7
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33. In the FIRST HIV prevention trial in which you were involved, were you satisfied that 
the trial adequately met its responsibilities to provide benefits and services to 
participants?
 
Response 
Percent
Response 
Count
No  0.0% 0
Yes 58.3% 7
Partially 41.7% 5
Unsure  0.0% 0
Comment (optional) 
 
4
 answered question 12
 skipped question 5
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34. This next section of the survey asks you about the MOST RECENT phase IIb or phase 
III biomedical HIV prevention intervention you have been involved in testing. What was 
the MOST RECENT phase IIb or phase III biomedical HIV prevention intervention you were 
involved in testing?
 
Response 
Percent
Response 
Count
PrEP 50.0% 6
Male circumcision 16.7% 2
HIV vaccine 16.7% 2
Microbicide 8.3% 1
PrEP/microbicide 8.3% 1
Treatment-as- prevention  0.0% 0
STI treatment  0.0% 0
Diaphragm  0.0% 0
Please specify approximate start date of trial (year) 
 
7
 answered question 12
 skipped question 5
35. What was your role in the MOST RECENT phase IIb or III biomedical HIV prevention 
trial you were involved in?
 
Response 
Percent
Response 
Count
Principal investigator 50.0% 5
Senior member of research team 50.0% 5
Community Liaison officer  0.0% 0
Other (please specify) 
 
3
 answered question 10
 skipped question 7
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36. Did you consult any research ethics guidelines in the MOST RECENT HIV prevention 
trial you were involved in? If so, which guidelines did you consult? Tick all that apply.
 
Response 
Percent
Response 
Count
National guidelines of host 
country
81.8% 9
National guidelines of sponsoring 
country
63.6% 7
National guidelines of 
researcher's institution
81.8% 9
CIOMS (Council for International 
Organisations of Medical Sciences) 27.3% 3
Declaration of Helsinki 72.7% 8
UNAIDS 63.6% 7
Nuffield Council on Bioethics  0.0% 0
NBAC (National Bioethics Advisory 
Commission)  0.0% 0
HPTN (HIV Prevention Trials 
Network) 45.5% 5
US Federal regulations (the 
Common Rule) 72.7% 8
ICH-GCP (international 
Conference on Harmonization 
Good Clinical Practice)
81.8% 9
Other (please specify) 
 
1
 answered question 11
 skipped question 6
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37. At what stage(s) in planning did you consult ethical guidelines? Tick as many as 
apply.
 
Response 
Percent
Response 
Count
I did not consult guidelines  0.0% 0
Other members of the research 
team consulted guidelines, but I did 
not
 0.0% 0
In planning stages 36.4% 4
In planning stages, and 
throughout the trial as required
100.0% 11
Comment (optional) 
 
1
 answered question 11
 skipped question 6
38. Where did you obtain ethics approval for your MOST RECENT trial? Tick all that apply.
 
Response 
Percent
Response 
Count
In the host country 91.7% 11
In the sponsoring country 66.7% 8
In the country of the researcher's 
academic institution
83.3% 10
Please name ethics committes used 
 
7
 answered question 12
 skipped question 5
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39. Did you consult with communities affected by the trial about the care/prevention 
services that would be provided within the trial in your MOST RECENT biomedical HIV 
prevention study?
 
Response 
Percent
Response 
Count
No  0.0% 0
Yes, in planning stages 36.4% 4
Yes, in recruitment stages 27.3% 3
Yes, in planning and recruitment 
stages
81.8% 9
Yes, during the trial 90.9% 10
Comment (optional) 0
 answered question 11
 skipped question 6
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40. In the MOST RECENT biomedical HIV prevention trial in which you were involved, was 
antiretroviral therapy provided to participants who seroconverted during the trial?
 
Response 
Percent
Response 
Count
No  0.0% 0
Yes, through government 
programs
66.7% 8
Yes, through NGO programs 33.3% 4
Yes, through international donor 
programs
25.0% 3
Yes, directly linked to the research 
program
33.3% 4
Not sure  0.0% 0
Please list any special provisions that assisted in antiretroviral access 
 
3
 answered question 12
 skipped question 5
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41. Which health/prevention services were offered to participants in the MOST RECENT 
biomedical HIV prevention trial in which you were involved? Tick as many as apply.
 
Response 
Percent
Response 
Count
Counselling 100.0% 12
Male condoms 100.0% 12
Female condoms 66.7% 8
STI testing 91.7% 11
STI treatment 91.7% 11
Oral contraceptive pill 58.3% 7
Injectable contraception 58.3% 7
Contraceptive implants 8.3% 1
HPV vaccination 8.3% 1
Hepatitis B vaccination 41.7% 5
Male circumcision for 
partners/participants
33.3% 4
Cervical screening 58.3% 7
Treatment of cervical dysplasia 16.7% 2
Referrals to local services for 
non-trial related illness/injury 100.0% 12
 answered question 12
 skipped question 5
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42. Did the MOST RECENT HIV biomedical prevention trial you were involved in offer 
medical/prevention services to participants?
 
Response 
Percent
Response 
Count
No  0.0% 0
Yes, limited to conditions that 
would impact on the research 
findings (such as STIs)
41.7% 5
Yes, limited to conditions that 
would impact on the research (such 
as STIs) and conditions that are 
exacerbated by HIV (such as 
cervical dysplasia, TB)
16.7% 2
Yes, unlimited (except by site 
capacity) 41.7% 5
Comment (please specify) 
 
2
 answered question 12
 skipped question 5
43. In the MOST RECENT HIV prevention trial you were involved in, were health/prevention 
services offered to partners or families of participants?
 
Response 
Percent
Response 
Count
No 41.7% 5
Yes 58.3% 7
Comment (optional) 
 
1
 answered question 12
 skipped question 5
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44. Did the MOST RECENT HIV prevention trial you have been involved in contribute 
infrastructure to the host country, e.g.the training of health care workers, establishment 
of clinical facilities?
 
Response 
Percent
Response 
Count
No 16.7% 2
Yes (please specify) 
 
83.3% 10
 answered question 12
 skipped question 5
45. In the MOST RECENT prevention trial in which you were involved, did the trial sponsor 
have policies regarding health/prevention services that were made available to 
participants?
 
Response 
Percent
Response 
Count
No 16.7% 2
Yes 83.3% 10
Comment (optional) 
 
1
 answered question 12
 skipped question 5
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46. How did sponsors' policies affect the care/prevention services offered to 
participants in your MOST RECENT biomedical prevention trial?
 
Response 
Percent
Response 
Count
Sponsors did not have policies 10.0% 1
Sponsors' policies affected 
care/prevention services 
positively (increased or 
improved service range 
available)
90.0% 9
Sponsors' policies affected 
care/prevention services 
negatively (limited or decreased 
service range available)
 0.0% 0
Comment (optional) 
 
2
 answered question 10
 skipped question 7
47. In the MOST RECENT HIV prevention trial in which you were involved, were you 
satisfied that the trial adequately met its responsibilities to provide benefits and 
services to participants?
 
Response 
Percent
Response 
Count
No  0.0% 0
Yes 100.0% 12
Partially  0.0% 0
Unsure  0.0% 0
Comment (optional) 0
 answered question 12
 skipped question 5
